$\underline{https://www.fluoridefreepeel.ca/fois-reveal-that-health-science-institutions-around-the-world-have-no-record-of-sars-cov-2-isolation-purification/$

Los FOI revelan que las instituciones de salud/ciencia de todo el mundo (220 y contando) no tienen registro de aislamiento/purificación SARS-COV-2, en cualquier lugar, nunca

Video Introducción:

Evidencia oficial de que la Virología es Pseudociencia. Christine Massey

10 de junio de 2023:

https://www.bitchute.com/video/gvu4NbieSuVb/

Versión en polaco:



[Vete aquí por FOIs en otros virus imaginarios, aquí para FOIs en experimentos de control de virus y aquí para FOIs sobre si las bacterias han sido mostradas a la enfermedad de la CAUSA.]

Una persona cuerda mezclaría una muestra de paciente (que contiene varias fuentes de material genético y nunca ha demostrado contener ningún supuesto virus) con células renales de mono transfecto, suero bovino fetal y medicamentos tóxicos, entonces afirmar que el brebaje resultante es el aislamiento SARS-COV-2 y la enviaría a nivel internacional para su uso en investigación crítica (incluyendo la vacuna y el desarrollo de pruebas)?

Porque ese es el tipo de negocio fraudulento de monos que se desmayó como aislamiento de virus por equipos de investigación de todo el mundo.

Sólo uno de los muchos ejemplos se muestra a continuación. Esto es de un estudio citado por el Departamento de Salud de Australia como un documento que llevó al aislamiento del SARS-CoV-2 en la cultura. (Puedes detectar el oxymoron en esa cita?)

2.1 Cell culture of SARS-CoV-2 and electron microscopy

Vero/hSLAM cells (African green monkey kidney cells transfected to express the human signaling lymphocytic activation molecule (SLAM; also known as CDw150)¹ were grown at 37°C, 5% CO₂ in maintenance media consisting of 10mL Earle's minimum essential medium (EMEM), 7% fetal bovine serum (FBS) (Bovogen Biologicals, Keilor East, AUS) 2mM L-glutamine, 1 mM sodium pyruvate, 1500mg/L sodium bicarbonate, 15 mM HEPES and 0.4mg/ml geneticin to 95% confluency in 25cm² flasks. Prior to use for isolation, maintenance media was removed from the flask and 500μL of respiratory swab inoculum was overlaid on the cell monolayer. The flask was returned to the 37°C incubator to allow the virus to adsorb for 1 hour before addition of 10 mL viral culture media (EMEM as above but FBS reduced to 2%). Flasks were monitored for viral cytopathic effect and 140μL aliquots of supernatant removed every 48 hours to assess virus burden by TaqMan real-time RT-PCR. First passage culture grown virus isolate was subsequently shipped nationally and internationally in packaging compliant with UN 2814 Category A shipping requirements using credentialed, specialised courier services under the appropriate Australian government export approvals processes and receiving country import permissions.

Si eres nuevo en el tema de aislamiento/purificaciónvirus, te recomiendo encarecidamente que empieces leyendo la Declaración y corroborando las pruebas.

Colegas de todo el mundo y yo (Christine) han estado presentando Libertad de Información a instituciones de varios países que buscan registros que describen el aislamiento/purificación del supuesto virus COVID-19 de cualquier muestra no adulterada tocada de un paciente enfermo.

La razón: sin que se haya realizado el paso crucial del aislamiento/purificación (de muchos pacientes, seguidos de caracterización, secuenciación y experimentos controlados), no hay manera de afirmar científicamente que el supuesto coronavirus de la "novel" (culpado a medidas generalizadas de muerte/enfermiza/afirmación) realmente existe.

Sin que este paso haya sido realizado y seguido de caracterización, secuenciación y experimentos controlados, todas las afirmaciones de este supuesto virus no son más que especulaciones salvajes respaldadas sólo por ciencia fraudulenta, pruebas fraudulentas y diagnósticos basados en fraudes. (He hecho numerosas entrevistas sobre este tema, que se pueden encontrar cerca de la parte inferior de esta página.)

Las solicitudes presentadas por mi colega en Nueva Zelanda y yo (y muchos de los demás remitentes) **no** se han limitado a los registros de aislamiento realizados por la institución respectiva, o limitado a los registros escritos por la institución respectiva, sino que estaban abiertos a cualquier registro que descisó el aislamiento/purificación del virus COVID-19 (también conocido como el aislamiento/purificación de la SARS-COV-2) realizado por cualquier persona, nunca, en cualquier parte del planeta.

Hasta ahora (26 de noviembre de 2023) 53 instituciones canadienses han dado sus respuestas: Agencia de Salud Pública del Canadá (y otra de la Agencia de Salud Pública del Canadá, esta es la supuesta variante del Reino Unido, alias B.1.1.7-Aka Apha; y otra de la Agencia de Salud Pública de Canadá de cualquier presunto virus/variante, y otra de la Agencia de Salud Pública de Canadá de nuevo a cambio de un supuesto virus en todos los países) de la enfermedad Health Canadade la salud de Canadá (v otro de Health Canada), el Consejo Nacional de Investigación de Canadá, Organización de Vacunciones y Enfermedades Infecciosas-InteracCentro de la Comunidad (VIDO-InterVac), Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Patented Medicine Prices Review Board Canada, Royal Canadian Mounted Police (RCMP), Public Health Ontario, Ontario Ministry of Health (y otro del Ministerio de Salud de Ontario, Red de Salud Universitaria, Ontario Ministerio de Medicina General y Policía Provincial de Ontario, Alberta Ministry of Health, Alberta Premier Jason Kenney, su Oficina y Consejo Ejecutivo, el Servicio de Policía de Calgary, Institut National de San Publique du Quebec (otra de la policía pública de Ontario (otra de la policía pública de Alberta, Alberta Premier Jason Kenney, su oficina y Consejo Ejecutivo, Servicio de Policía de Calgary, Institut National de San Pedro de Publique du Ouebec (aotra de la Pública PúblicaSalud Ouebec). British Columbias Ministerio de Salud (re-la variante del Reino Unido) (otra del Ministerio de Salud de Columbia Británica), British Columbias Centre for Disease Control, British Columbia-s Provincial Health Authority (2, 1 re-SARS-COV-2, 1 re the alega "B.1.1.7" alias "Alpha variant" (también conocido como alias variante de Reino Unido), Vancouver Coastal Health Authority (re-B.1.1.7-aka .& Community Services, Departamento de New Brunswicks/Ministerio de Salud, Universidad McGill, Universidad de Ottawa, Universidad de Waterloo, Universidad de Dalhousie, Universidad de Guelph, Universidad de Columbia Británica, la Ciudad de Toronto, Policía de Toronto (y otra de la Policía de Toronto), Halton Region, (Ontario), (Ontario), la (Ontario), (Ontario); (Kingston, Frontenac, Lennox y Addington, Ontario, re-Ay4)), . . . , (y otro de), (Ontario) (otro de), (Ontario) (Ontario) () (y otro de de), (Ontario), (Ontario), (Ontario), la , , la (otra de), , y (Toronto) (nota que investigadores de las últimas 4 instituciones habían afirmado públicamente haber sido el virus, al igual que VIDO-Intervac).

Todas las instituciones no han proporcionado ni citar ni 1 registro que describe el aislamiento de la supuesta "virus COVID-19" directamente de una muestra de paciente que no fue adulterada primero con otras fuentes de material genético. (Es otras fuentes son típicamente de riñón de mono, también conocido como las células de Vero y suero bovino fetal).

(Y, hasta donde sabemos, nadie en el planeta ha purificado nunca el supuesto virus, incluso de una cultura celular.

En sus respuestas, numerosas instituciones han dejado explícitamente claro que el aislamiento/purificación simplemente nunca se hace en virología, y que el aislamiento en la virología significa exactamente lo contrario de lo que significa en inglés cotidiano. Esto también se evidencia en todos los documentos de aislamiento de los virus que hemos visto, para cualquier supuesto virus.



Para una

idea de lo que realmente está pasando:

<u>Funcionarios canadienses de salud pública no tienen registro de</u> aislamiento/purificación SARS-COV-2 realizado en cualquier lugar, víspera r

(Nota: **Sébastien Grammond**, un hombre que actúa como juez de la Corte Federal aquí en Canadá, ha inventado una falsa confirmación de que **el** virus SARS-CoV-2 es real. Basado en cero ciencia válida y a pesar de saber que las 138 instituciones enumeradas en **mi declaración jurada** no habían logrado citar ni siquiera 1 ejemplo del supuesto virus que había sido purificado de cualquier muestra de pacientes en el planeta. Por qué perder el tiempo en la ciencia o la lógica cuando puede simplemente aceptar la *invitación del Fiscal General de Canadá para tomar nota judicial de que el virus es real?* Suena perfectamente legal. Las creencias generalizadas son mucho mejores que revisar los hechos pertinentes.)

PLEASE COMPARTE THESE DOCUMENTS FAR Y WIDE

Al 4 de diciembre de 2023: **220 instituciones y oficinas en 40 países** han respondido hasta ahora, así como algunos autores del estudio de aislamiento de la OSARS-COV-2, y ninguno ha proporcionado o citado ningún registro que describa el aislamiento/purificación real de la SARS-COV-2. Todas las respuestas en nuestra colección están disponibles en esta página.

Lista de ficheros Excel 220 instituciones:

 $\underline{https://www.fluoridefreepeel.ca/wp\text{-}content/uploads/2023/11/Institution\text{-}list\text{-}for-website.xls}$

La carpeta de Google donde todos los documentos del FOI al 14 de julio de 2022 se agrupan por país (en su mayor parte) y se compilan en 11 pdfs (Exposiciones 1 4; Exhibit 4 tiene 8 partes):

Aquí está mi **declaración** detallada **con respecto a la colección mundial del FOI y la naturaleza no científica de la virología** (14 páginas), que se notaria, fechada el 2 de diciembre de 2022 (me estaba apresurando a hacer algunas ediciones de última hora antes de imprimir y dirigí al notario; por favor perdone las tejas): https://www.fluoridefreepeel.ca/wp-content/uploads/2022/12/2022-12-02-Christine-virus-FOIs-declaration-notarized-1.pdf

A continuación (y <u>aquí</u>) hay una declaración actualizada y simplificada de 1 página notariada re el virus FOIs. Habla por sí mismo. Siéntete libre de compartirlo.

Declaration

my name is christine; i communicate in everyday English not legalese; i do not consent to contract or joinder or grant power of attorney or act as surety or trustee; my home is at Brampton, Ontario; i am fully competent to make this declaration and do so voluntarily; statements herein are based on my own knowledge/experience; the following is true:

- i have worked professionally as a biostatistician with a master's degree in biostatistics earned at the Dalla Lana School of Public Health, University of Toronto;
- i have filed "freedom of information" (FOI) "requests" for all studies/reports in the
 possession/custody/control of "health"/"science" institutions ("ministries of health",
 universities, public health units, etc) that describe purification of the alleged "SARSCOV-2" by anyone anywhere from the bodily fluid/tissue/excrement of any diseased
 man/woman; such is necessary for valid sequencing and scientific proof of a "virus";
- i required that if any record held by the institution in question matched my
 "request" but was currently available to "the public" elsewhere, i be given enough
 detail so that i could identify and access it;
- i filed FOI "requests" for same and for scientific proof of existence of dozens of other alleged "viruses" including "HPV", and collected FOI responses obtained by others;
- 5. as of June 23, 2023, as documented/shown on my own website, 52 Canadian institutions and 164 institutions in 39 other countries have been queried about "SARS-COV-2" and all failed to provide or cite even 1 responsive record, thus demonstrating inability to prove existence; queries for other "viruses" also yielded no responsive records; all of this documentation is freely available to anyone;
- these failures align with all of the many "virus" studies i reviewed virologists
 haven't implemented scientific method and successfully shown "virus" existence,
 rather they engage in pseudoscience, logical fallacies, assumptions;

autographed on June 23, 2

by: christine: a woman often referred to as "Christine Massey".

Aquí está mi boletín de noticias Substack donde publico las últimas respuestas de la FOI: https://christinemasseyfois.substack.com/.

Si desea recibir actualizaciones de correo electrónico con nuevas respuestas de FOI, hágamelo saber en christinem.fluoridefreepeel.ca o cmssyc.gmail.com.

La lista que se muestra a continuación estaba actualizada al 5 de octubre de 2021; ahora es mucho más larga.

1	Country / Region	Institution
2	Australia	University of Western Australia
3	Australia	ACT Government (Government of the Australian Capital Territory) / Canberra Health Services (CHS)
4	Australia	Commonwealth Scientific and Industrial Research Organisation – CSIRO
5	Australia	Department of Health
6	Australia	New South Wales Ministry of Health
7	Australia	Peter Doherty Institute for Infection and Immunity
8	Australia	South Australia Minister for Health and Wellbeing
9	Australia	Western Australia Minister & Dept of Health
10	Brazil	Anvisa (Brazilian Health Regulatory Agency)
11	Brazil	Ministry of Health
12	Britain	Health and Safety Executive
13	British Isles	Isle of Man Department of Health and Social Care
14	Canada	Aylmer Police Services
15	Canada	Centre for Disease Control, British Columbia
16	Canada	City of Toronto, Ontario
	Canada	Department of Health & Community Services, Newfoundland Labrador
18	Canada	Halton Region
	Canada	Hastings Prince Edward Public Health
	Canada	Health Canada
	Canada	Institut National de Sante Publique du Quebec
	Canada	Institutes of Health Research
	Canada	Kingston, Frontenac, Lennox and Addington Public Health, Ontario (re "any variant")
	Canada	McGill University
	Canada	Ministry of Health, British Columbia
	Canada	Ministry of Health, Ontario
	Canada Canada	Mount Sinai Hospital, Toronto, Ontario National Research Council
	Canada	Natural Sciences and Engineering Research Council of Canada
	Canada	New Brunswick Department of Health
_	Canada	Peterborough Police Service
	Canada	Peterborough Public Health
	Canada	Provincial Health Services Authority, British Columbia
_	Canada	Region of Durham Public Health Department, Ontario
_	Canada	Region of Peel, Ontario
_	Canada	Sunnybrook Health Sciences Centre, Toronto, Ontario
		Toronto Police Service
_	Canada	
_	Canada	University of Ottawa
	Canada	University of Toronto
_	Canada	Vancouver Coastal Health Authority, British Columbia (re "the UK variant")
_	Canada	Grey Bruce Health Services
_	Canada	Grey Bruce Health Unit
_	Canada	McMaster University
_	Canada	Public Health Agency of Canada
_	Canada	Public Health Ontario (aka Ontario Agency for Health Protection and Promotion)
	Canada	Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) at University of
	Czech Republic	Ministry of Health
	Czech Republic	Univerzita Karlova Statens Serum Institut
	Denmark England	Pennine Acute NHS Trust
	England	Public Health England
	England	Salford Royal NHS Foundation Trust
		Centre for Disease Prevention and Control
_	Europe	
_	India	Indian Council of Medical Research
_	Italy	Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani"
		Ministry of Health, Welfare and Sport
_	Netherlands New Zealand	Associate Minister of Health Hon Jenny Salesa

58	New Zealand	Associate Minister of Health Hon Peeni Henare
59	New Zealand	Associate Minister of Health Julie Anne Genter
60	New Zealand	Bay of Plenty District Board
61	New Zealand	Department of the Prime Minister and Cabinet
62	New Zealand	Institute of Environmental Science and Research - ESR
63	New Zealand	Ministry of Health
64	New Zealand	University of Auckland
65	New Zealand	University of Otago
66	Norway	Norwegian Ministry of Health and Cares Services & subordinate agency t
67	Phillipines	Research Institute for Tropical Medicine, Department of Health
68	Portugal	Ministry of Health
69	Republic of Columbia	Ministry of Health & Social Protection
70	Republic of Ireland	National Virus Reference Laboratory, University College Dublin
71	Republic of Serbia	Ministry of Health
72	Republic of South Africa	Governmental COVID-19 Advisory Committee
73	Republic of South Africa	Minister of Co-operative Governance and Traditional Affairs
74	Republic of South Africa	National Department of Health
75	Republic of South Africa	National Institute for Communicable Diseases
76	Republic of South Africa	President
77	Scotland	Public Health Scotland
78	Slovenia	Department of Health
79	Slovenia	University of Ljubljana - Faculty of Medicine and Institute of Microbiolog
80	Slovenia	Univerzitetni klinični center Ljubljana UKCLJ (University Medical Centre L
81	Slovenia	National Laboratory for Health, Environment and Food (Nacionalnega lab
82	Spain	Ministry of Health
83	Sweden	Public Health Authority (Folkhälsomyndigheten)
84	Ukraine	Ministry of Health
85	United Kingdom	Cabinet Office
	United Kingdom	Department of Health and Social Care

87	United Kingdom	Government Office for Science
88	United Kingdom	House of Commons
89	United Kingdom	House of Lords
90	United Kingdom	Imperial College London
91	United Kingdom	Medicines and Healthcare Products Regulatory Agency
92	United Kingdom	Prime Minister's Office
93	United Kingdom	University of Warwick
94	United States of America	Agency for Toxic Substances and Disease Registry
95	United States of America	Arkansas Department of Health
96	United States of America	California Department of Public Health
97	United States of America	Centers for Disease Control and Prevention
98	United States of America	Commonwealth of Massachusetts Department of Health
99	United States of America	Commonwealth of Massachusetts Office of the Governor
100	United States of America	Commonwealth of Virginia Department of General Services
101	United States of America	Department of Health and Human Services
102	United States of America	Metro Public Health Department, Nashville, Tennessee
103	United States of America	Michigan Department of Health and Human Services
104	United States of America	Montgomery County, Pennsylvania
105	United States of America	National Institute of Allergy and Infectious Diseases - NIAID
106	United States of America	New York State Department of Health
107	United States of America	Oregon Health Authority
108	United States of America	Oregon Health & Science University
109	United States of America	Pennsylvania Department of Health
110	United States of America	Washington DC Department of Health
111	Uruguay	Clemente Stable Biological Research Institute, Ministry of Education and Culture
112	Uruguay	University of the Republic (UdelaR) Faculty of Chemistry
113	Uruguay	Ministry of Public Health
114	Wales	Public Health Wales

(Sí, conocemos las muchas publicaciones en las que los autores dicen haber sido el virus. Hemos mirado numerosos estudios de este tipo y aún no hemos visto uno donde realmente lo hicieron. Afirmar haber hecho algo y realmente hacerlo a veces son dos cosas diferentes, incluso en la ciencia revisada por pares.

Y sí, somos conscientes de los muchos supuestos genomas publicados. SARS-COV-2. Estos fueron fabricados de hecho, no descubiertos.

Y sí, sabemos que se han publicado fotos EM, supuestamente del virus, sin embargo una foto de algo no te dice cuál es la cosa, de dónde vino o qué hace. Uno tiene que examinar los métodos utilizados para .aislar el virus / obtener dichas fotos / obtener supuestos genomas, y es cuando absolutamente **todo** se desmorona con el COVID-19 (y la virología en general).

Notas:

Global Research publicó toda la colección del FOI (al 04 de agosto de 2021) en su sitio web. Las páginas web de GRs se pueden traducir a 51 idiomas diferentes activando el menú "Tratar Web" desplegando el menú en el banner superior de la página principal: https://www.globalresearch.ca/foi-reveal-health-science-institutions-around-world-have-no-record-sars-2-isolation-purification-anywhere-ever/5751969

Cualquiera es bienvenido a publicar estos documentos en otros sitios. Por favor, hazlo. Sólo les pedimos que también citen esta página web en particular porque aquí es donde añadimos todas las nuevas FOIs que obtenemos. Es importante que la gente sepa dónde puede encontrar la colección más actualizada y completa.

Y si obtienes o te encuentras con nuevas respuestas que no están en nuestra colección, por favor reenvíelos para que podamos agregarlos a la colección.

Aquí hay una **pequeña URL** que redirdia a esta página web: http://tinyurl.com/norecordfound

Respuestas de la FOI de instituciones en los Estados Unidos, India, República de Sudáfrica, Nueva Zelanda, Australia, Reino Unido, Inglaterra, Escocia, Gales, Irlanda, Dinamarca, Noruega, Finlandia, Países Bajos, Suecia, España, CDC, Europeo, Eslovenia, República Checa, Ucrania, Colombia, Uruguay, Italia, Portugal, Brasil, República de Colombia, Argentina, Ilse of Man, Phillipines, etc., además de correos electrónicos del Instituto Alemanias Robert Koch (RKI) y varios autores de aislamiento de virus.

Un gran **agradecimiento** a todas las personas que ahora han compartido amablemente las respuestas adicionales de que obtuvieron reislamiento/purificación/existencia de .SARS-COV-2. Algunos prefieren permanecer en el anonimato, otros se nombran a continuación.

Vale, aquí vamos. A continuación se presentan las respuestas SARS-COV-2 FOI de 150 instituciones fuera de Canadá.

La **Organización Mundial de la Salud** no respondió a mi consulta del tipo FOI enviada el 22 de febrero de 2022 en busca de ningún registro que describiera cualquier supuesto **SARS-COV-2** - siendo encontrado en el fluido corporal/tejido de cualquier persona en la Tierra y purificado, por cualquier persona, en cualquier lugar, siempre... para que se secuenciara, secara y se estudie con experimentos controlados (también conocido como ciencia):

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/W.H.O.O.-request-SARS-COV-2-purification.pdf}$

request to W.H.O. re: "SARS-COV-2" purification

Christine Massey <cmssyc@gmail.com> To: informationrequest@who.int Tue, Feb 22, 2022 at 2:38 PM

February 22, 2022

Hello,

Description of Requested Records:

All studies and/or reports from anywhere in the world describing the purification of the alleged "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants") directly from a sample taken from a diseased human, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum).

Clarification of Request:

Please note that I am not requesting studies/reports where researchers failed to purify the suspected "virus" and instead:

- cultured something, and/or
- performed an amplification test (i.e. PCR), and/or
- · fabricated a "genome" from millions of sequences (allegedly) detected in an impure substance, and/or
- produced electron microscopy images of unpurified things.

I am already aware that according to virus theory a "virus" requires host cells in order to replicate, and am not requesting records that describe replication of a 'virus' without host cells. Nor am I requesting records that describe a strict fulfillment of Koch's Postulates, or records that describe a suspected "virus" floating in a vacuum, or private patient information.

I simply request records that describe purification (separation of the alleged virus from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things).

Please note that my request includes any study/report matching the above description, authored by anyone, anywhere.

If any records match the above description of requested records and are currently available in the public domain, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible.

Format:

Pdf documents sent to me via email; I do not wish for anything to be shipped to me.

Contact Information:

Last name: Massey First name: Christine

Location: Peterborough, Ontario, Canada

Email: cmssyc@gmail.com

Thank you in advance and best wishes, Christine Massey, M.Sc.

28 de noviembre de 2022:

Un colega en Japón exigió a la gente de **la Organización Mundial de la Salud** proporcionar/citar cualquier registro del imaginario **SARS-COV-2** que se encuentra y purificó de cualquier persona enferma en el planeta, para que se secuenciara, secara y estudiara con experimentos controlados aka ciencia. Pero, en cambio, la dirigieron a una página web inútil sobre una base de datos global de medidas públicas de salud y social aplicadas durante la pandemia imaginaria:


 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2023/02/WHO-Nov-2022-PACKAGE-redacted.pdf}{}$





Como próximo enlace verás un registro de SARS-COV-2 aislamiento/purificación. Centros para el Control y la Prevención de Enfermedades y la Agencia para Sustancias Tóxicas y el Registro de Enfermedades (CDC/ATSDR), fechados el 2 de noviembre de 2020, obtenidos por Michael S. en NZ:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/USA-CDC-Virus-Isolation-Response-Scrubbed.pdf}{\\$



Page 2

If you are not satisfied with the response to this request, you may administratively appeal by writing the Deputy Agency Chief FOIA Officer, Office of the Assistant Secretary for Public Affairs, U.S. Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Ave Suite 729H, Washington, D.C. 20201. You may also transmit your appeal via email to FOIARequest@psc.hhs.gov. Please mark both your appeal letter and envelope "FOIA Appeal." You appeal must be postmarked or electronically transmitted by Monday, February 1, 2021.

Sincerely,

Roger Andoh CDC/ATSDR FOIA Officer Office of the Chief Operating Officer (770) 488-6399 Fax: (404) 235-1852

#20-02166-FOIA

El 1 de marzo de 2021, una vez más, el CDC dejó claro a mi colega en Nueva Zelanda que todavía no tienen registros de aislamiento de SARS-COV-2 realizados por

cualquiera, en cualquier parte del planeta, nunca... sólo no con tantas palabras. En cambio, los CDC implicaban absurdamente que el aislamiento de la "SARS-COV-2" requeriría la replicación de un virus sin celdas huéspedes y por lo tanto es imposible. https://www.fluoridefreepeel.ca/wp-content/uploads/2021/03/CDC-March-1-2021-SARS-COV-2-Isolation-Response-Redacted.pdf

Page 3—

For information about the SARS-CoV-2 genome sequence, see the NIH GenBank website (https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/), which includes over 44,000 sequences as of December 7, 2020.

On February 21, 2021, you requested the following information:

Can you please clarify if you have any records of the separation of SARS-COV-2 from everything else (known as isolation and purification)? A simple yes or no will do regarding the answer. Please use the Merrian-Webster dictionary's common definition of isolation. I will provide the definitions below:



The SME states the following:

The definition of "isolation" provided in the request is outside of what is possible in virology, as viruses need cells to replicate, and cells require liquid food. However, the SARS-CoV-2 virus may be isolated from a human clinical specimen by culturing in cell culture, which is the definition of "isolation" as used in microbiology, and as indicated in the previous round of response in the resources provided.

3 de marzo de 2021: CDC de nuevo no proporcionó/cita ningún registro que desclinara el aislamiento/purificación de SARS-COV-2 por nadie en ninguna parte de la nada... PERO ya no lo diría simplemente (como lo hicieron el 2 de noviembre); en cambio le dieron a mi colega en Nueva Zelanda alguna canción y baile y citaron su propio estudio fraudulento (por Harcourt et al.):

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/03/CDC- marzo-3-2021-SARS-COV-2-purification-FOI-response.pdf



Public Health Service

Centers for Disease Control and Prevention (CDC) Atlanta GA 30333 March 3, 2021



This letter is our final response to your attached Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of March 1, 2021, assigned #21-00795-FOIA.

For administrative convenience and to fully respond to your request, program staff have provided the following information below with corresponding web links.

SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Active infection with SARS-CoV-2 is detected by <u>diagnostic tests</u>. Currently there are two types of diagnostic tests – molecular tests that detect the virus's genetic material and antigen tests that detect specific proteins on the surface of the virus. For current data showing the total number of SARS-CoV-2-positive cases and deaths, visit the <u>CDC COVID-19 Data Tracker</u>, which shows cases and deaths in the United States broken down by state and county, daily trends in the number of cases by state, and other parameters.

Evidence of SARS-CoV-2 infection can be found in a study entitled, Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, which includes electron microscopy images of SARS-CoV-2 in infected lung and upper airway tissues as well as staining of lung and upper airway tissues using an antibody against SARS-CoV-2. The specimens analyzed in this study were from patients with common signs and symptoms associated with COVID-19, including fever, cough, and shortness of breath. All patients had abnormal findings on chest radiographs. There are other similar studies publicly available online. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's PubMed entry.

The SARS-CoV-2 virus may be isolated from human clinical specimens by culturing in cells. In January 2020, CDC isolated the SARS-CoV-2 virus from a clinical specimen from the first confirmed case of COVID-19 in the United States. There are other similar studies published describing the isolation and characterization of SARS-CoV-2 from human clinical specimens. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's <u>PubMedentry</u>. There are also several <u>publications</u> documenting SARS-CoV-2 infection and transmission among presymptomatic and asymptomatic individuals.

For information about the SARS-CoV-2 genome sequence, see the NIH GenBank website (https://www.nebi.nlm.nih.gov/genbank/sars-cov-2-seqs/), which includes over 44,000 sequences as of December 7, 2020.

If you need any further assistance or would like to discuss any aspect of the records provided please contact either our FOIA Requester Service Center at 770-488-6399 or our FOIA Public Liaison at 770-488-6277.

7 de junio de 2021: Los CDC admitieron que no tienen registro de "SARS-COV-2" purificación de una muestra de paciente a través de la maceración, filtración y uso de una ultracentrifugadora, por cualquier persona, en cualquier lugar, jamás: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/06/CDC-FOIA-request-response-no-records-SARS-COV-2-purification.pdf

1 de septiembre de 2021:

Otra respuesta FOIA de **los CDC**, donde no proporcionaron o citar ni siquiera 1 registro del supuesto **virus COVID-19**, **alias .SARS-COV-2**, **o cualquier "variantes"** que haya sido purificado de cualquier muestra de pacientes en el planeta, por cualquier persona, en cualquier lugar, nunca:

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/CDC-Sept-1-PACKAGE-redacted.pdf}$

The SARS-CoV-2 virus may be isolated from human clinical specimens by culturing in

8 de septiembre de 2021: Otra respuesta FOIA de la repuración de **CDC** del fantasma .SARS-COV-2 . Esta vez, los CDC citaron un artículo en el que los autores ni siquiera afirmaron haber purificado a sí mismos ningún "virus", y en su lugar declaró falsamente que: *SARS-CoV-2 estaba aislado en las células de Vero* ... (8). [oximoron]. [La referencia CDC-s no 8 es el infame estudio Harcourt et al.]. https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/Sept-8-2021-CDC-package.pdf

Centers for Disease Control and Prevention (CDC) Atlanta GA 30333

September 8, 2021

Ms. Christine Massey

Via email: cmssyc@gmail.com

Dear Ms. Massey:

This letter is our final response to your attached Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of August 16, 2021, assigned #21-01986-FOIA.

The National Center for Immunization and Respiratory Diseases provides the link to the following study that is responsive to your request.

https://wwwnc.cdc.gov/eid/article/26/8/20-1246_articleI

If you need any further assistance or would like to discuss any aspect of the records provided please contact either our FOIA Requester Service Center at 770-488-6399 or our FOIA Public Liaison at 770-488-6277.

Roger Andoh

CDC/ATSDR FOIA Officer

Office of the Chief Operating Officer

(770) 488-6399 Fax: (404) 235-1852

Enclosure

21-01986-FOIA

26 de octubre de 2021:

UU. Los Centros para el Control y la Prevención de Enfermedades una vez más no proporcionaron o citar ni siquiera 1 registro de la purificación de la OCV-2, por parte de cualquier persona, en cualquier parte del planeta:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/11/CDC-2021-10-23-SARS-CO-V-2-v3-BS-redacted.pdf

enters for Disease Cont and Prevention (CDC) October 26, 2021

This letter is our final response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of September 20, 2021, assigned #21-02310-FOIA, for

This is a formal request for access to general records, made under the Freedom of Information Act.

Please note: this request is very similar to another request CDC/ATSDR responded to in March, 2021 where I had specified purification via maceration, filtration and use of an ultracentrifuge.

My request also includes the language of 'variants' to ensure that records would match all related alleged SARS-COV-2 viruses.

Description of Requested Records:

All studies and/or reports in the possession, custody or control of Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1,", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), directly from a sample taken from a diseased human where the patient sample was nog first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum).

Please note that I am not requesting studies/reports where researchers failed to purify the suspected "virus" and instead:

- cultured an unpurified sample or other unpurified substance, and/or
 performed an amplification test (i.e. a PCR test) on all the RNA from a patient sample or from a cell culture, or on genetic material from any unpurified substance, and/or
 fabricated a "genome" by editing/assembling/aligning sequences detected in the total RNA from a patient sample or from a cell culture or from any unpurified substance, and/or
- and/or produced electron microscopy images of unpurified things.

For further clarity, please note I am already aware that according to virus theory a "virus" requires host cells in order to replicate, and I am **not** requesting records describing the **replication** of a "virus" without host cells.

Page 2—

Further, I am not requesting records that describe a suspected "virus" floating in a vacuum; I am simply requesting records that describe its purification (separation from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things).

Please also note that my request is **not limited** to records that were authored by CDC/ATSDR or that pertain to work done at by CDC/ATSDR. Rather, my request includes any record matching the above description, for example (but not limited to): any published peer-reviewed study authored by anyone, anywhere, ever that has been downloaded or printed by CDC/ATSDR and relied on as

If any records match the above description of requested records and are currently available to the public elsewhere, please provide enough information about each record so that I may identify and access each one with certainty (i.e. titl e the public may access it). Please provide URLs where possible.

For administrative convenience and to fully respond to your request, program staff have provided the following information below with corresponding web links.

SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Active infection with SARS-CoV-2 is detected by diagnostic tests. Currently there are two types of diagnostic tests—nolecular tests that detect the virus's genetic material and antigen tests that detect specific proteins on the surface of the virus. For current data showing the total number of SARS-CoV-2-positive cases and deaths, visit the CDC COVID-19 Data Tracker, which shows cases and deaths in United States broken down by state and county, daily trends in the number of cases by state, and other parameters.

Evidence of SARS-CoV-2 infection can be found in a study entitled, Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, which includes electron microscopy images of SARS-CoV-2 in infected lung and upper airway tissues as well as staining of lung and upper airway tissues using an antibody against SARS-CoV-2.

The specimens analyzed in this study were from patients with common signs and symptoms associated with COVID-19, including fever, cough, and shortness of breath. All patients had abnormal findings on

There are other similar studies publicly available online. To aid in locating other related studies, pleass see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's <u>PubMed</u>

The SARS-CoV-2 virus, whether the original strain or variants of the virus, may be isolated from human clinical specimens by culturing in cells. In January 2020, CDC isolated the SARS-CoV-2 virus from a clinical specimen from the first confirmed case of COV1D-19 in the United States. There are other similar studies published describing the isolation and characterization of SARS-CoV-2 from human clinical specimens. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's PubMed entry. There are also several publications documenting SARS-CoV-2 infection and transmission among pre-symptomatic and asymptomatic individuals.

For information about the SARS-CoV-2 genome sequence, see the NIH GenBank website (https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/), which includes over 1 million sequences

1 de abril de 2022:

UU. Los Institutos Nacionales de Salud no proporcionaron ni citaron ni un registro de la supuesta "SARS-COV-2" (o cualquier supuesto "variante") de haber sido purificado del fluido corporal/espelado/excremento de cualquier paciente en el planeta, por cualquier persona, en cualquier lugar, cuando respondiera a una solicitud de registros bajo la custodia de los CDC, y ellos extraña e inexactamente declararon que la solicitud era "impropper". Carta completa:

Pdf: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/CDC-2022-PACKAGE-redacted.pdf



DEPARTMENT OF HEALTH & HUMAN SERVICES

National Institutes of Health Freedom of Information Office Building 31, Room 5B-35 31 Center Drive, MSC 2107 Bethesda, Maryland 20892-2107 phone: (301) 496-5633 fax: (301) 402-4541



This responds to your September 8, 2021, Freedom of Information Act (FOIA) request addressed to the FOIA Office, National Institutes of Health, (NIH) and received on the same day. You requested a copy of all studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) describing the purification of the "COVID-19 virus".

Please be advised that your request is improper as defined by FOIA given that you have not specified where (named office or institute) or what (i.e. named grant number, report, etc) you would like searched at the NIH. Considering the omission of the aforementioned information necessary for a proper search to be conducted, the NIH cannot process your request as it is written. In good faith, we provide the following information that may prove useful to you.

Much of the information on the isolation of the virus from the diseased host, which requires growth in cell culture, is already publicly available. Viruses do not replicate outside of a host or in a pure culture (devoid of other cells). Koch's postulates were formed prior to the identification of viruses as the causative agents of some diseases and also pre-date modern microbiological techniques, including the ability to isolate viruses from hosts. As such, Koch's postulates have limitations when evaluating viruses and do not adequately account for the way viruses are isolated and propagated given that viruses are obligate intracellular parasites.

SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Active infection with SARS-CoV-2 is detected by <u>diagnostic tests</u>. Currently there are two types of diagnostic tests – molecular tests that detect the virus's genetic material and antigen tests that detect specific proteins on the surface of the virus. For current data showing the total number of SARS-CoV-2-positive cases and deaths, visit the <u>CDC COVID-19 Data Tracker</u>, which shows cases and deaths in the United States broken down by state and county, daily trends in the number of cases by state, and other parameters.

17 de noviembre de 2022:

Los CDC no pudieron proporcionar/citar ningún registro de la supuesta SARS-COV-2 siendo purificada incluso de un cultivo celular, en cambio citaron estudios y páginas web irrelevantes:

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/11/CDC-purified-from-cell-culture-PACKAGE-redacted.pdf}$

SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Active infection with SARS-CoV-2 is detected by <u>diagnostic tests</u>. Currently there are two types of diagnostic tests – molecular tests that detect the virus's genetic material and antigen tests that detect specific proteins on the surface of the virus. For current data showing the total number of SARS-CoV-2-positive cases and deaths, visit the <u>CDC COVID-19 Data Tracker</u>, which shows cases and deaths in the United States broken down by state and county, daily trends in the number of cases by state, and other parameters.

Evidence of SARS-CoV-2 infection can be found in a study entitled, Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, which includes electron microscopy images of SARS-CoV-2 in infected lung and upper airway tissues as well as staining of lung and upper airway tissues using an antibody against SARS-CoV-2. The specimens analyzed in this study were from patients with common signs and symptoms associated with COVID-19, including fever, cough, and shortness of breath. All patients had abnormal findings on chest radiographs. There are other similar studies publicly available online. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's PubMed entry.

The SARS-CoV-2 virus may be isolated from human clinical specimens by culturing in cells. In January 2020, CDC <u>isolated the SARS-CoV-2 virus</u> from a clinical specimen from the first confirmed case of COVID-19 in the United States. There are other similar studies published describing the isolation and characterization of SARS-CoV-2 from human clinical specimens. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's <u>PubMed entry</u>. There are also <u>several publications</u> documenting SARS-CoV-2 infection and transmission among presymptomatic and asymptomatic individuals.

For information about the SARS-CoV-2 genome sequence, see the NIH GenBank website (https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/), which includes over 44,000 sequences as of December 7, 2020.

20/21 de octubre de 2022:

Las personas de **los CDC** fueron desafiadas a proporcionar/citar pruebas científicas de la existencia del **supuesto SARS-COV-2 o del supuesto VIH** basado en experimentos controlados usando partículas purificadas. No podían, ya que ninguno existe, por lo que en cambio proporcionaron vínculos inútiles para el VIH, ni siquiera pretendían mostrar experimentos controlados. Para SARS-COV-2 dieron los mismos párrafos que le han estado dando a la gente durante el último año más o menos, con enlaces a estudios y páginas web más inútiles.

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/11/CDC-SARS-COV-2-HIV-scientific-proof-PACKAGE-redacted.pdf

Program provides the following public links as responsive to your request:

- •HIV Research
 - o https://www.cdc.gov/hiv/research/index.html
- HIV Lab Testing Info
 - o https://www.cdc.gov/hiv/testing/laboratorytests.html
- General HIV Diagnosis/Testing
 - o https://www.cdc.gov/hiv/testing/index.html.
- HIV Fact Sheets
 - o https://www.cdc.gov/hiv/library/factsheets/index.html
- HIV Reports
 - o https://www.cdc.gov/hiv/library/reports/index.html
 - o https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
- 25 Notable HIV and AIDS Reports Published in CDC's Morbidity and Mortality Weekly Report (MMWR)
 - o https://www.cdc.gov/mmwr/hiv_aids20.html
- Recent MMWRs on HIV
 - o https://www.cdc.gov/hiv/library/reports/mmwr.html
- Early MMWRs on AIDS:
 - o https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5021a1.htm
 - o https://www.cdc.gov/mmwr/preview/mmwrhtml/june 5.htm

16 de diciembre de 2022:

UU. Los Centros para el Control y la Prevención de Enfermedades no pudieron proporcionar ningún registro de la supuesta proteína de pico SARS-COV-2 que se encuentra en alguien y se purificó (en lugar de que se la proteína de Spike en un laboratorio y luego se estudiara, como si eso reflejara algo que estaba pasando en personas reales); y así respondieron como si se tratara otro FOI con respecto al virus falso, y proporcionó los mismos párrafos inútiles que han estado dando a las personas durante el último año o así:https://www.fluoridefreepeel.ca/wp-content/uploads/2022/12/CDC-no-purified-spike-protein-PACKAGE-to-Dec-16-redacted.pdf

14 de febrero de 2023:

protein-PACKAGE-redacted-2023-02-14.pdf

Una vez más, la gente de **los EE.UU. Los Centros para el Control y la Prevención** de **Enfermedades** no pudieron proporcionar ningún registro de la **supuesta proteína de pico SARS-COV-2** que se encuentra en alguien y se purificó. (Especícimente descarto estudios en los que se creó en un laboratorio la proteína "recombinant" se creó en un laboratorio para ser estudiado, porque esos estudios no pueden proporcionar ninguna evidencia de la supuesta proteína de pico de SARS-COV-2, que realmente existen en personas con el diagnóstico de convidado fraudulento, o personas que recibieron las vacunas falsas de ARNm, o cualquier persona en absoluto):https://www.fluoridefreepeel.ca/wp-content/uploads/2023/02/CDC-spike-



Centers for Disease Control and Prevention (CDC) Atlanta GA 30333 February 14, 2023

Ms. Christine Massey

Via email: cmssyc@gmail.com

Dear Ms. Massey:

This letter is in response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of December 22, 2022, for

Greetings Roger,

I require access to general records, as per your duty under the Freedom of Information Act;

description of required records:

all studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) describing the alleged "SARS-COV-2 spike protein" being found in any people (i.e in the bodily fluid/tissue/excrement of someone diagnosed with the alleged "COVID-19" or someone who received a so-called "COVID-19 vaccine") and purified (as per standard laboratory practices for the purification of very small things), with purification of particles confirmed via EM imaging (the EM image(s) must be available and provided);

note that i do not require or want studies/reports where researchers did something with recombinant (lab-created) so-called "SARS-COV-2 spike protein" that had to be created in order to study "it", or studies/reports where the alleged protein was allegedly detected indirectly (i.e. with a nonspecific antibody test);

this FOI is not limited to records that were authored by the CDC or ATSDR or that pertain to work done at/by the CDC or ATSDR; rather, it includes any record matching the above description, authored by anyone, anywhere, ever;

if any records match the above description of requested records and are currently available to the public elsewhere, please provide enough information about each record so that i may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it); provide URLs where possible;

A search of our records failed to reveal any documents pertaining to your request.

21 de marzo de 2023:

Roger Andoh, actuando como Oficial de la FOIA en la Oficina del Director de Operaciones, **los CDC** confesaron que los CDC ni siquiera tienen un estudio en el que los autores hicieron cualquiera de los siguientes:

- 1) se probó la supuesta **proteína** de **pico** en la sangre de personas vacunadas y "invaccinadas", y comparó los resultados para buscar evidencia de que las quackcines de ARNmRN hacen que los cuerpos creen la proteína
- 2) comparó los niveles **de** anticuerpos para las personas vacunadas y las personas inyectadas con otras toxinas (es decir, otras charlas), para evaluar **la especificidad de**

los anticuerpos. https://www.fluoridefreepeel.ca/wp-content/uploads/2023/03/CDC-spike-protein-comparisons-PACKAGE-redacted.pdf

A search of our records failed to reveal any documents pertaining to your request.

You may contact our FOIA Public Liaison at 770-488-6246 for any further assistance and to discuss any aspect of your request. Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services, National Archives and Records Administration, 8601 Adelphi Road-OGIS, College Park, Maryland 20740-6001, e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.

If you are not satisfied with the response to this request, you may administratively appeal to the Deputy Agency Chief FOIA Officer, Office of the Assistant Secretary for Public Affairs, U.S. Department of Health and Human Services, via the online portal at https://requests.publiclink.hhs.gov/App/Index.aspx, Please mark both your appeal letter and envelope "FOIA Appeal." Your appeal must be electronically transmitted by June 14, 2023.

Sincerely,

Roger Andoh

CDC/ATSDR FOIA Officer Office of the Chief Operating Officer

(770) 488-6399 Fax: (404) 235-1852

#23-00723-FOIA

2 de marzo de 2023: **EE. Los Centros para el Control de Enfermedades** pueden probar la existencia de **la proteína de pico SARS-COV-2**

Roger Andoh, actuando como Oficial de la FOIA en la Oficina del Director Operativo, **CDC** y **el Registro de Sustancias Tóxicas y Enfermedades**, confesó que estas instituciones tienen cero pruebas de la existencia de la supuesta proteína de pico SARS-COV-2, esta vez a mi colega Louis Stephen.

Además, en esta respuesta, Roger evadió:

- una solicitud de prueba de reclamaciones en relación con los llamados anticuerpos SARS-COV-2.
- una solicitud de documentación que explique por qué es necesario utilizar el ARNA sintético en lugar de natural (supuesto) en convid jabs,
- una solicitud de documentación que explique por qué es necesario usar células renales de mono para (supuestamente pero no realmente) en el crecimiento de un virus que supuestamente infecta los pulmones humanos, etc.:

https://www.fluoridefreepeel.ca/wp-content/uploads/2023/04/CDC-spike-antibodies-why-Vero-etc-PACKAGE-redacted.pdf

For number 1, a search of our records failed to reveal any documents pertaining to the spike protein as you describe.

For numbers 2 and 3, although CDC cannot answer every hypothetical question and questions are not permissible under FOIA, CDC does offer the following link that discusses how COVID-19 Vaccines work: <u>Understanding How COVID-19 Vaccines Work | CDC.</u>

Number 4 of your request is an inappropriate FOIA request written as questions with 4 subparts containing 6 separate questions.

[Alguien amablemente envió otra respuesta de la FOI de los CDC de fecha 30 de diciembre de 2020 en el supuesto 2003-SARS-COV-1 y todos los coronavirus de frío común. Los CDC no tienen registro de haber sido aislado :

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2020/12/CDC-isolation-FOI-reply-any-coronavirus.pdf}]$

13 de septiembre de 2022:

Un hombre o mujer anónimo en la Oficina de Registros Públicos de la **Universidad de Carolina del Norte en Chapel Hill** proporcionó documentos inútiles que no contienen evidencia científica del supuesto **SARS-COV-2**, y confesó que no hay otros documentos relevantes para la solicitud:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/09/UNC-Chapel-Hill-PACKAGE-redacted.pdf}{PACKAGE-redacted.pdf}$

Fwd: Re: Create a new password for the UNC-Chapel Hill public records portal Tue, Sep 13, 2022 at 1:17 PM To: Christine Massey <cmssyc@gmail.com> This is their response. Sent from ProtonMail for iOS ------ Forwarded message ------ From: Public Records Officepublic Records Officepublicrecordsoffice@email.unc.edu Date: On Tue, Sep 13, 2022 at 1:16 PM Subject: Fwd: Re: Create a new password for the UNC-Chapel Hill public records portal Public Records Info <info@publicrecords.unc.edu> Thank you for your message. The University has provided all records responsive to this request. Sincerely, Public Records Office From Date: Tuesday, September 13, 2022 at 11:19 AM To: Public Records Info <info@publicrecords.unc.edu> Subject: Re: Create a new password for the UNC-Chapel Hill public records portal Some people who received this message don't often get email from healingque@protonmail.com. Learn why this is important Thank you for your quick response. The documents provided do not contain any scientific evidence of a physical particle found in humans. Nothing in them fits the description of a virus. Please go over the request again and if you have them provide the document showing evidence of its existence. If UNC does not have such records, please let me know. Once again thank you so much for your time,

Sent with Proton Mail secure email.

----- Original Message ----On Sunday, September 11th, 2022 at 10:10 AM, UNC-Chapel Hill Public Records Office <info@publicrecords.unc.edu> wrote:

10 de diciembre de 2021:

UU. El Departamento de Trabajo / Administración de Seguridad y Salud Ocupacional (OSHA) admitió que no tienen registro describiendo la purificación de ningún virus de COVID-19 (también conocido como "SARS-COV-2", incluyendo cualquier supuesta muestra de pacientes en el planeta, por cualquiera, jamás:

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/OSHA-PACKAGE-redacted.pdf}$



December 10, 2021

Ms. Christine Massey

Peterborough, Ontario Canada

RE: Freedom of Information Act Request No. 2022-F-01464

Dear Ms. Massey:

This is a final response to your Freedom of Information Act (FOIA) request to the Occupational Safety and Health Administration (OSHA) dated November 8, 2021, seeking documents concerning the "purification" of SARS-CoV-2. Your request was assigned to the OSHA Directorate of Technical Support and Emergency Management for a response.

You have asked for documentation in OSHA's possession, "...describing the purification of any 'COVID-19 virus' (aka 'SARS-COV-2', including any alleged 'variants' i.e. 'B.1.1.7', 'B.1.351', 'P.1')" In your request, you defined "purification" to mean, "... separation of the alleged 'virus' from everything else in the patient sample...."

A search of OSHA's records did not locate any documents that meet the criteria of your request. Therefore, under FOIA we are providing you a no records response. Please be aware that OSHA did not extend the search for documents outside of the Agency for any responsive records, as you requested. This is beyond the scope of FOIA requirements.

If you have questions about our response, please contact Robert B. Turnage at (202) 693-2036 or turnage.robb@dol.gov.

Although we believe we have fulfilled your FOIA request, you have the right to appeal this decision with the Solicitor of Labor within 90 days from the date of this letter. The appeal must state, in writing, the grounds for the appeal, including any supporting statements or arguments. The appeal should also include a copy of your initial request and a copy of this letter.

If you appeal, you may mail your appeal to: Solicitor of Labor, U.S. Department of Labor, Room N-2420, 200 Constitution Avenue, NW, Washington, DC 20210 or fax your appeal to (202) 693-5538. Alternatively, you may email your appeal to foiaappeal@dol.gov; appeals submitted to any other email address will not be accepted. The envelope (if mailed), subject line (if emailed), or fax cover sheet (if faxed), and the letter indicating the grounds for appeal, should be clearly marked: "Freedom of Information Act Appeal."

In addition to filing an appeal, you may contact the Department's FOIA Public Liaison, Thomas G. Hicks, Sr., at (202) 693-5427 or hicks.thomas@dol.gov for assistance in resolving disputes.

3 de septiembre de 2021: Fauics **National Institute of Allergy and Infectious Diseases** (**NIAID**) / **National Institutes of Health**, en respuesta a una solicitud de registros que demuestre que NIAID o NIH tiene una muestra física de SARS-CoV-2 purificado: Conmeja aislamiento/purificación con el crecimiento del virus imaginario en el cultivo celular,

- proporciona comentarios irrelevantes y distractor re Koch.s Postulados,
- cita estudios y páginas web inútiles e irrelevantes, y ordenador inventado genomas, y
 confirma que la virología no es una ciencia.

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/NIAID-NIH-Sept-3-2021.pdf



Public Health Service

National Institutes of Health Freedom of Information Office Building 31, Room 58-35 31 Center Drive, MSC 2107 Bethesde, Meryland 20892-2107 phone: (301) 496-5633 fax: (301) 402-4541

Via Email:

September 3, 2021



Re: FOIA Case Number: 56905

Dear

This is our final response to your Freedom of Information Act (FOIA) request addressed to National Institutes of Health (NIH), dated August 18, 2021, and received in this office on the same day. You requested copies of public records that demonstrates the NIAID or NIH has a physical sample of the isolated and purified SARS-CoV-2 virus, to produce any and all evidence of this External Standard or Certified Reference Material (CRM) for calibration of RT-PCR test kits and any or all documentation and evidence of whether the Whole Genome Sequencing (WGS) occurred from the isolate, as well as evidence and information on the current modality/test being used to determine and identify the difference from the original SARS-CoV-2 virus and the "Delta Variant" and/or other variants with all evidence and documentation demonstrating the initial discovery of the other variants.


Please be advised that your request is improper as defined by FOIA given that you have not specified where (named office or institute) or what (i.e. named grant number, report, etc) you would like searched at the NIH. Considering the omission of the aforementioned information necessary for a proper search to be conducted, the NIH cannot process your request as it is written. In good faith, we provide the following information that may prove useful to you.

Much of the information on the isolation of the virus from the diseased host, which requires growth in cell culture, is already publicly available. Viruses do not replicate outside of a host or in a pure culture (devoid of other cells). Koch's postulates were formed prior to the identification of viruses as the causative agents of some diseases and also pre-date modern microbiological techniques, including the ability to isolate viruses from hosts. As such, Koch's postulates have limitations when evaluating viruses and do not adequately account for the way viruses are isolated and propagated given that viruses are obligate intracellular parasites.

11 de marzo de 2022:

UU. El Departamento de Salud y Servicio Humano confirma que Vivek Murthy, el hombre que actúa como "Ourgeno General", no tiene antecedentes que describan a nadie en la Tierra en el hallazgo y purifican al supuesto "SARS-COV-2" (el presunto virus COVID-19), o cualquier supuesta variante de la misma, de los fluidos corporales de cualquier persona enferma humana.

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/03/HHS-Surgeon-General-PACKAGE-redacted.pdf





Assistant Secretary for Public Affairs Washington, D.C. 20201

Case No. 2022-00537-FOIA-PHS

March 11, 2022

Sent via email: Christine Massey cmssyc@gmail.com

Dear Christine Massey:

This letter is the final response to your March 07, 2022, Freedom of Information Act (FOIA) request. Specifically, you requested the following records: "(See attached)

All studies / reports in the possession, custody or control of the man who acts as "Surgeon General" in the Department of Health and Human Services, Vivek H. Murthy, that describe anyone on Earth finding and purifying (i.e. via via filtration, ultracentrifugation and chromatography) the alleged "SARS-COV-2" (the alleged "COVID-19" virus), or any alleged variant thereof, directly from the bodily fluids of any diseased human where the bodily fluids were not first combined with any other source of genetic material (i.e. a human or animal cell line; fetal bovine serum)".

A representative from the Office of the Assistant Secretary for Health (OASH) conducted a search and reports there are no records responsive to your request: "We have no studies or reports of which we have custody or control over related to this topic, thus no records to share".

While we believe an adequate search of the appropriate files was conducted for the records requested, you have the right to appeal this finding that no responsive records exist within OASH. By filing an appeal, you preserve your rights under FOIA and give the agency a chance to review and reconsider your request and the agency's decision.

Please mark the correspondence, "Freedom of Information Act Appeal." Your appeal must be transmitted within 90 days from the date of receipt of this letter to:

Ms. Carol Maloney
Deputy Agency Chief FOIA Officer
U.S. Department of Health and Human Services
Office of the Assistant Secretary for Public Affairs
HHS.ACFO@hhs.gov

If you would like to discuss our response before filing an appeal to attempt to resolve your dispute without going through the appeals process, you may contact the HHS FOIA Public Liaison for assistance at:

HHS FOIA/PA Public Liaison FOI/Privacy Acts Division

19 de agosto de 2021:

UU. El Departamento de Salud y Servicios Humanos citó estudios y páginas web inútiles e irrelevantes, y fabricado engenados en respuesta a una solicitud de FOIA para los registros que demuestra que el Departamento de Salud y Servicios Humanos de los Estados Unidos tiene una muestra física del virus SARS-CoV-2 aislado y purificado.

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/08/US-Health-and-Human-Services-response-redacted.pdf



Christine Massey <cmssyc@gmail.com>

Fwd: HHS FOIA Request 2021-01625-FOIA-OS

Mon, Aug 23, 2021 at 6:05 PM

To: "christinem@fluoridefreepeel.ca" <christinem@fluoridefreepeel.ca>

You can add to your list. From US Department of Human and Health Services.

------ Forwarded message -----From: Taylor, Natasha <foiarequest@hhs.gov>
Date: Thu, Aug 19, 2021 at 4:50 PM
Subject: HHS FOIA Request 2021-01625-FOIA-OS

To:

RE: 2021-01625-FOLA-OS

Mr.

Dear Mr.

This is in response to your Freedom of Information Act (FOIA) request, dated: August 18, 2021, concerning "Records that demonstrates the US Department of Health and Human Services has a physical sample of the isolated and purified SARS-CoV-2 virus including the following: 1) Any and all evidence of this External Standard or Certified Reference Material (CRM) for calibration of RT-PCR test kits and any or all documentation; 2) Evidence of whether the Whole Genome Sequencing (WGS) occurred from the isolate; 3) Evidence and information on the current modality/test being used to determine and identify the difference from the original SARS-CoV-2 virus and the "Delta Variant" and/or other variants with all evidence and documentation demonstrating the initial discovery of the other variants. (Date Range for Record Search: From 10/1/2019 To 8/18/2021)".

We received your request on August 18, 2021.

For administrative convenience and to fully respond to your request, program staff have provided the following information below with corresponding web links.

SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Active infection with SARS-CoV-2 is detected by diagnostic tests. Currently there are two types of diagnostic tests — molecular tests that detect the virus's genetic material and antigen tests that detect specific proteins on the surface of the virus. For current data showing the total number of SARS-CoV-2-positive cases and deaths, visit the CDC COVID-19 Data Tracker, which shows cases and deaths in the United States broken down by state and county, daily trends in the number of cases by state, and other parameters.

Evidence of SARS-CoV-2 infection can be found in a study entitled, Pathology and Pathogenesis of SARS-CoV-2
Associated with Fatal Coronavirus Disease, which includes electron microscopy images of SARS-CoV-2 in infected lung and upper airway tissues as well as staining of lung and upper airway tissues using an antibody against SARS-CoV-2.

The specimens analyzed in this study were from patients with common signs and symptoms associated with COVID-19, including fever, cough, and shortness of breath. All patients had abnormal findings on chest radiographs.

There are other similar studies publicly available online. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's PubMed entry.

The SARS-CoV-2 virus may be isolated from human clinical specimens by culturing in cells. In January 2020, CDC isolated the SARS-CoV-2 virus from a clinical specimen from the first confirmed case of COVID-19 in the United States. There are other similar studies published describing the isolation and characterization of SARS-CoV-2 from human clinical specimens. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's PubMed entry. There are also several publications documenting SARS-CoV-2 infection and transmission among pre-symptomatic and asymptomatic individuals.

24 de junio de 2021 Respuesta FOIA:

El **Instituto Nacional de Alergia y Enfermedades Infecciosas** (NIAID) de Anthony Fauics no proporcionó/cita ningún registro de la purificación de un paciente de una muestra de pacientes por cualquier persona, en cualquier lugar.

NIAID me remitió al estudio de los CDC anti-ciencia de Harcourt et al., incluso después

de que les aconseje los CDC de <u>junio 7, 2021</u>. He apelado al Enlace Público de NIAID. Las comunicaciones entre yo y NIAID se proporcionan aquí:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/06/NIAID-FOIA-package-redacted.pdf

We have previously queried our Division of Clinical Research for records responsive to similar requests. Your request is properly directed to the Centers for Disease Control and Prevention (CDC) as they are the ones who did the isolation: https://www.cdc.gov/coronavirus/2019-ncov/lab/grows-virus-cell-culture.html

See publication: https://wwwnc.cdc.gov/eid/article/26/6/20-0516 article

You can submit a request to the CDC at the following link: https://www.cdc.gov/od/foia/index.htm
If you disagree with their no records determination, you should properly avail yourself of the appeal rights described in their final response to you.

If you are not satisfied with the processing and handling of this request, you may contact the NIAID FOIA Public Liaison:

NIAID FOIA Public Liaison

El estudio de los CDC citado por NIAID no purificó nada de una muestra de un paciente. Es el mismo estudio que el Dr. Thomas Cowan escribió sobre 2020 (<u>sólo envenenado Monkey Kidney Cells "Grew" el "Virus" (</u>en <u>inglés</u>), donde también abordó la naturaleza fraudulenta de los autores.

First, in the section titled "Whole Genome Sequencing," we find that rather than having isolated the virus and sequencing the genome from end to end, that the CDC "designed 37 pairs of nested PCRs spanning the genome on the basis of the coronavirus reference sequence (GenBank accession no. NC045512)."

To me, this computer-generation step constitutes scientific fraud. Here is an equivalency: A group of researchers claim to have found a unicorn because they found a piece of a hoof, a hair from a tail, and a snippet of a horn. They then add that information into a computer and program it to re-create the unicorn, and they then claim this computer re-creation is the real unicorn. Of course, they had never actually seen a unicorn so could not possibly have examined its genetic makeup to compare their samples with the actual unicorn's hair, hooves and horn.

The researchers claim they decided which is the real genome of SARS-CoV-2 by "consensus," sort of like a vote. Again, different computer programs will come up with different versions of the imaginary "unicorn," so they come together as a group and decide which is the real imaginary unicorn.

Anteriormente, en 2020, Ron Bublitz ya había preguntado a **EE. Instituto Nacional de Alergia y Enfermedades Infecciosas (NIAID), Institutos Nacionales de Salud (NIH),** la pregunta que se muestra a continuación. Su correspondencia se publica en el siguiente enlace, junto con la respuesta evasiva proporcionada por el Jefe de la Sección NIH/NIAID para la Correspondencia Controlizada y la Subdivisión de Investigación Pública, Asuntos Legislativos y Corresponsales. Pdf mostrando el texto y una foto de los correos electrónicos reales: https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/NIAID-reply-to-Ron-Bublitz-re-SARS-COV-2-isolation.pdf

To: NIAID NEWS (NIH/NIAID)

Subject: a basic and serious question.

I see that you have released images of the electron microscope view of C19 virus. I would like to know how you are certain that is the virus? How was it isolated? Have you followed Koch's Postulates in order to be completely certain that is the pathogen that causes disease?

Ron amablemente proporcionó una captura de pantalla de sus comunicaciones con NIAID, que se muestra a continuación.



Tenga en cuenta que **NIH/NIAID** no respondió a ninguna de las preguntas de Ron **Bublitz** y se limitó a citar <u>el mismo estudio de los CDC</u> de Harcourt et al. mencionado anteriormente que se inmiscuyó en el típico enfoque fraudulento de la empresa "monkey" a la llamada "aislamiento" como se muestra en la imagen de pantalla a continuación).

Cell Culture, Limiting Dilution, and Virus Isolation

We used Vero CCL-81 cells for isolation and initial passage. We cultured Vero E6, Vero CCL-81, HUH 7.0, 293T, A549, and EFKB3 cells in Dulbecco minimal essential medium (DMEM) supplemented with heat-inactivated fetal bovine serum (5% or 10%) and antibiotics/antimycotics (GIBCO, https://www.thermofisher.com 12). We used both NP and OP swab specimens for virus isolation. For isolation, limiting dilution, and passage 1 of the virus, we pipetted 50 µL of serum-free DMEM into columns 2-12 of a 96-well tissue culture plate, then pipetted 100 µL of clinical specimens into column 1 and serially diluted 2-fold across the plate. We then trypsinized and resuspended Vero cells in DMEM containing 10% fetal bovine serum, 2× penicillin/streptomycin, 2× antibiotics/antimycotics, and 2× amphotericin B at a concentration of 2.5 × 10⁵ cells/mL. We added 100 μL of cell suspension directly to the clinical specimen dilutions and mixed gently by pipetting. We then grew the inoculated cultures in a humidified 37°C incubator in an atmosphere of 5% CO2 and observed for cytopathic effects (CPEs) daily. We used standard plaque assays for SARS-CoV-2, which were based on SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) protocols (9,10).

10 de **junio** de 2022: Julia Spiegel, mujer que actúa como Secretaria Adjunta de Asuntos Jurídicos bajo **Gavin Newsom**, el hombre que actúa en **la Oficina del Gobernador de California**, confesó a Kristen Welch que no tienen antecedentes describiendo cualquier supuesto "**SARS-COV-2**" (o "variante) siendo encontrado en el fluido corporal/tejido de nadie en la Tierra y purificado... por cualquier persona, en cualquier lugar, siempre... para que se secuencia, se cara a ser secuenciado, se cara a lo que se caracteriza y se estudia con experimentos controlados (también conocido como

"ciencia):https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/Gavin-Newson-acting-as-Gov-California-PACKAGE-redacted.pdf

GOVERNOR GAVIN NEWSOM • SACRAMENTO, CALIFORNIA 95814 • (916) 445-2841

There are no records responsive to your request in the custody of the Governor's Office.

Thank you for contacting the Governor's Office.

Sincerely,

0

JULIA SPIEGEL
Deputy Legal Affairs Secretary

27 de enero de 2022:

El Departamento de Salud del estado de Washington proporcionó la ubicación de registros supuestamente -pero-no-receptivo a un FOI para estudios en los que se encontró el supuesto SARS-COV-2 en el líquido corporal/tejido de personas enfermas y purificado.

Instalación 1 es la comedia de ciencia fisita que no tiene nada que ver con la purificación o un virus, titulado "SARS-CoV-2 Sequencing and Variants" en el estado de Washington.

Comienza: La secuenciación de la próxima generación es un conjunto de métodos de laboratorio que los científicos utilizan para escanear un genoma viral para determinar la secuencia del genoma de un virus.

Cuidado con la secuela que vence el 25 de julio de 2022.

El departamento también confesó que su laboratorio: "No ha intentado aislar el SARS-CoV-2 de ningún espécimen o matriz". La PHL tampoco ha aislado en su poder el virus SARS-CoV-2 viable. El WAPHL realiza pruebas diagnósticas basadas en PCR... La secuenciación de la próxima generación se realiza en muestras positivas de pacientes SARS-CoV-2 usando material genómico extraído, no aislados de virus.

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/06/Washington-State-DOHinstall-1-PACKAGE-redacted.pdf

Subject Fw: DOH Public Records Center :: D000656-012522

christinem@fluoridefreepeel.ca <christinem@fluoridefreepeel.ca>

Date 2022-01-28 02:50 PM



Hello Christine.

I live in Washington State. I submitted a public records request to the WA State Department of Health for the studies and/or reports purification of the SARS COV 2 virus as per your example.

"The Washington State Public Health Lab (PHL) provided the following statement in response to your request, "The WAPHL has not attempted to isolate SARS-CoV-2 from any specimen or matrix. Nor does the PHL have in its possession isolated viable SARS-CoV-2 virus. The WAPHL performs diagnostic testing that is PCR based and does not require virus isolation. Next generation sequencing is performed on SARS-CoV-2 positive patient samples using extracted genomic material, not virus isolates."

You will receive the next installment on or before July 25, 2022 and will continue to receive installments until your request has been

Should you no longer need this information, please contact our office by responding directly to this email.

Sincerely,

Washington State Department of Health Disease Control and Health Statistics Public Records

Please see their email below.

Thank you for all you are doing to bring truth to light!

Be Well,

- Forwarded Message -

From: WA State DOH Records Center <washingtondoh@govga.us>

Sent: Thursday, January 27, 2022, 04:03:09 PM PS Subject: DOH Public Records Center :: D000656-012522

--- Please respond above this line ---



Reference # D000656-012522

The Department of Health received a public records request from you on January 25, 2022. You requested the following:

"This is a formal request for access to general records, made under the Freedom of Information Act.

25 de noviembre de 2021:

Kate Wilson, en funciones para el Departamento de Salud del Condado de

Multnomah, Portland, Oegon, confirmó que una búsqueda exhaustiva no arrojó ningún registro de nadie en la Tierra que hubiera encontrado y purificado el supuesto "SARS-COV-2" (a través de maceración, filtración y ultracentrifugación) de cualquier líquido corporal/tejido de cualquier persona enferma, en cualquier lugar, nunca: https://www.fluoridefreepeel.ca/wp-content/uploads/2023/04/Multnomah-County-Oregon-PACKAGE-redacted.pdf

Re: Public Records request to Multnomah County, Oregon re: "SARS-COV-2" purification

From Kate W. Yeiser < Kate. Yeiser @multco.us> Tο Date Thursday, November 25th, 2021 at 6:11 AM Thank you for your patience as we conducted a search of any research with these very specific criteria. After reviewing what scientific materials identified through a request to county health leadership and a subsequent full data query of county communications, we can now confirm that we have no records responsive to your request. Best, Kate On Thu, Nov 11, 2021 at 12:20 AM 🖶 External Sender - Be Suspicious of Attachments, Links, and Requests for Payment or Login Information. November 11, 2021 To Kate Willson Multnomah County Health Department Portland, Oregon Submitted via email to: kate.willson@multco.us Dear Ms. Willson. This is a formal request for access to general records, made under Oregon's Public Records Law. Description of Requested Records: All studies and/or reports in the possession, custody or control of Multnomah County Government describing the purification of any "SARS-COV-2" (including any "variant" of "SARS-COV-2") said to have caused disease in

11 de marzo de 2022:

La Universidad de Illinois confirmó para Natalia Litbarg, MD, que: los custodios de la

humans (via maceration, filtration and use of an ultracentrifuge; also referred to at times by some people as

universidad que, debido a la naturaleza de su trabajo podrían haber tenido registros que describen a alguien en la Tierra encontrando al supuesto **SARS-COV-2** en los fluidos corporales de un huésped enfermo y purificando, no pudo identificar ningún registro de este tipo:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/Universidad-de-Illinois-PACKAGE.pdf}{}$

Other than your submission of a date range, this request is identical to your previous request dated and received in my office on February 17, 2022. Based on the above terms and wording that you have used, our office has shared your request with University records custodians who, because of nature of their work, may have had responsive records. Utilizing the word and terms you provided, those University records custodians cannot identify responsive records.

You have a right, under the law, to seek a review of this response by the Public Access Counselor (PAC) in the Office of the Attorney General. The PAC may be reached by phone at 877-299-3642, by email to public.access@ilag.gov, or by postal mail at the Public Access Bureau, 500 S. 2nd Street, Springfield, Illinois 62706. You also have the right to seek judicial review under section 11 of this Act.

If you have any questions or would like to discuss how to narrow the scope of your request, please contact me at 217-333-6400.

Sincerely,

Kirsten Ruby Senior Associate Director and Chief Records Officer

18 de mayo de 2022:

Jorge Pérez, el hombre que actúa como Oficial Adjunto de Salud, Investigación de Salud Pública del **Condado de Los Ángeles**, confesó a <u>Kristen Welch</u> que no hay registros de que el supuesto **SARS-COV-2** se encuentre en el fluido corporal/tejido de alguien y purificado... por cualquiera, en cualquier lugar, nunca... pero aparentemente está de acuerdo con el hecho de que los virólogos no tienen una variable independiente para usar en cualquier experimento de virus y él piensa que el condado tiene el derecho de aterrorizar a la gente con su "-doctrine":

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/06/Los-Angeles-County-Dept-PH-PACKAGE-redacted.pdf}{}$

After a diligent search, the Department has determined that there are no responsive records to your request.

In providing you with this response, the County is not waiving any rights, defenses, or claims of privilege, exception or exemption under the CPRA or any other statutes. The County reserves its right to assert all applicable privileges, <u>doctrines</u>, and exemptions.

Sincerely,

Jorge Perez

Jorge Perez, Deputy Health Officer Public Health Investigation COR ID No 221787

doctrine =


a <u>belief or set of beliefs</u> held and taught by a Church, political party, or other group.

a stated <u>principle of government policy</u>, mainly in foreign or military affairs.

They pretend they have a "right" to lie & terrorize.

13 de abril de 2022:

El Ministerio de Salud de la República de Trinidad y Tobago confirmó para Chetawayo La Borde que *el COVID-19 no ha sido aislado y purificado:* https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/Trinidad-and-Tobago-PACKAGE.pdf









Requested Information	Legal Advice	Document(s)/Information to be released
Has COVID-19 been isolated and purified? Please provide data.	The Applicant may be furnished with the information requested and as shown in the third column, as same constitutes official information pursuant to Section 11 of the Freedom of Information Act, Chapter 22:02 and same is not exempted from disclosure pursuant to Part IV of the Act,	"COVID-19 has not been isolated and purified."
3. Please provide detailed info on all individuals that have taken any of the COVID-19 vaccines since March 30th 2021 till (sic) present in Trinidad and Tobago and their health status if they are alive or dead regardless of cause of death.	Please advise the Applicant that the MoH is not in possession of the information requested.	"The MoH is not in possession of the information requested."

Sincerely

/f/ Permanent Secretary Ministry of Health.

PERMANENT SECRETARY MINISTRY OF HEALTH

Suiza:

Noviembre 2021: Oficina Federal de Salud Pública (FOPH)

Enero de 2022: Instituto de Virología e Inmunología (IVI)

Ambos no proporcionaron o citaron, para el hombre inquisición, incluso 1 registro de .SARS-COV-2- siendo encontrado en los fluidos corporales de cualquier humano enfermo y purificado (lo que sería necesario para que pudiera secuenciarse, caracterizar y estudiar con experimentos controlados para determinar si realmente existe): https://www.fluoridefreepeel.ca/wp-

Am 25.01.2022 um 08:45 schrieb eliane.brogini@babs.admin.ch:

Sehr geehrter Herr

Besten Dank für Ihr Gesuch um Einsicht in Akten gemäss Bundesgesetz über das Öffentlichkeitsprihzip der Verwaltung. Wir verfügen über keine amtlichen Dokumente, die den von Ihnen beschriebenen Anforderungen entsprechen.

Freundliche Grüsse, Eliane Brogini

Betreff: AW: WG: BGÖ-Gesuch um Einsicht in Akten - gereinigtes Virus - Labor Spiez

Von: <eliane.brogini@babs.admin.ch>

Datum: 28.01.2022, 14:57 An: @gmx.ch>

Kopie (CC): <labor-spiez@babs.admin.ch>, <claudia.geiger@babs.admin.ch>

Sehr geehrter Herr

Vielen Dank für Ihre Anfrage und für Ihr Interesse an den Aufgaben und Tätigkeiten des Labor Spiez.

Das Bundesamt für Bevölkerungsschutz hat keine amtlichen Dokumente erstellt, die den von Ihnen beschriebenen Anforderungen (Ziffer 2) entsprechen.

In der wissenschaftlichen Fachliteratur gibt es hingegen inzwischen eine Vielzahl von Publikationen, in denen die Isolierung von SARS-Cov-2-Viren beschrieben worden ist. Nur als Beispiel finden Sie in der Anlage eine Publikation aus Nature, einer der weltweit angesehensten Zeitschriften für Naturwissenschaften (Wölfel, R., Corman, V.M., Guggemos, W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465-469 (2020).

Wir weisen Sie darauf hin, dass Sie nach Artikel 13 BGÖ die Möglichkeit haben, innerhalb von 20 Tagen nach Erhalt dieser Mitteilung schriftlich einen Schlichtungsantrag an die Schlichtungsbehörde zu stellen (Eidgenössischer Datenschutz- und Öffentlichkeitsbeauftragter EDÖB, Feldeggweg 1, 3003 Bern; www.edoeb.admin.ch) und unsere oben dargelegte Haltung überprüfen zu lassen.

Für allfällige Fragen stehen wir gerne zur Verfügung.

Freundliche Grüsse, Eliane Brogini

Betreff: Ihr Gesuch vom 17. Oktober 2021 - Einsicht in Akten - gereinigtes Virus - Antwort

Von: <lorenz.overhage@bag.admin.ch>

Datum: 23.11.2021, 11:34 **An:** @gmx.ch>

Sehr geehrter Herr

zurückkommend auf Ihr Zugangsgesuch vom 17. Oktober 2021 nach Öffentlichkeitsgesetz (BGÖ; SR 152.3) darf ich Ihnen mitteilen, dass beim BAG keine Dokumente zum gewünschten Inhalt vorhanden sind.

Wir betrachten Ihr Gesuch als erledigt und weisen Sie darauf hin, dass Sie gestützt auf Art. 13 BGÖ die Möglichkeit haben, unsere Antwort durch die Schlichtungsstelle überprüfen zu lassen, indem Sie innerhalb von 20 Tagen nach Empfang dieser Mitteilung schriftlich einen Schlichtungsantrag stellen (Eidgenössischer Datenschutz- und Öffentlichkeitsbeauftragter EDÖB, Feldeggweg 1, 3003 Bern, www.edoeb.admin.ch).

Lorenz Overhage

MLaw

Eidgenössisches Departement des Innern EDI Bundesamt für Gesundheit BAG Abteilung Recht

16 de marzo de 2022:

Larry Stinson, quien actúa como Director de Operaciones para la llamada "no con fines de lucro" Peterborough Public Health (PPH), confirmó que PPH y Thomas Piggott. el hombre que actúa como Oficial Médico de Salud, no tienen antecedentes describiendo a nadie en la Tierra encontrando y purificando cualquier supuesto SARS, H5N1, H1N1, MERS, Ebola, o SARS-COV-2 "virus" de los fluidos corporales de cualquier enfermo humano, nunca... o cualquier estudio que en la opinión de Thomas demuestre la existencia de cualquiera de esos supuestos virus A pesar de la afirmación de Thomas de haber vivido todos estos supuestos brotes:

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/Peterborough-PH-SARS-H5N1H1N1-Ebola-SCV2-PACKAGE-redacted.pdf

On February 16, 2022, Thomas Piggott, the man who acts as Medical Officer of Health, Peterborough Public Health tweeted the following claim:

I've lived through SARS in 2003, we quickly forgot. I've lived through H5N1 in 2005 & since, we quickly I've lived through H1N1 in 2009, we quickly forgot. I've lived through MERS in 2012, we quickly forgot. I've lived through Ebola in 2014, we quickly forgot.

Massey, Christine Re Proof Alleg Outbreaks File No 2022-03 Mar 16 2022.pdf

Description of Requested Records:

All studies / reports in the possession, custody or control of Thomas Piggott or anyone else acting at Peterborough Public Health, that describe anyone on Earth finding and purifying (i.e. via via filtration, ultracentrifugation and chromatography) any of the 5 alleged "viruses" listed above by Thomas Piggott directly from the bodily fluids of any diseased human where the bodily fluids were <u>not</u> first combined with any other source of genetic material (i.e. a human or animal cell line; fetal bovine serum).

Please note that I do not require and do not want studies/reports where researchers failed to purify an alleged "virus" from a sick human's bodily fluid and instead

- cultured an unpurified substance (i.e. bodily fluid) in a malnourished cell line, added toxic drugs, watched for cytopathic effects and called that "virus isolation", and/or
 performed an unreliable amplification test (i.e. a PCR test), that can only detect sequences and not "viruses"
- on the soup of genetic material extracted from a patient's bodily fluid or from monkey/cow/human cell culture
- supernatant, and/or fabricated an in silico (computer) sequence ("genome") from millions of sequences unreliably detected in the soup of total RNA extracted from a patient's bodily fluid or from a monkey/cow/human cell cul produced electron microscopy images of unpurified particles in a monkey/cow/human cell culture

p.s. To clarify: where I wrote "animal experiments will be accepted" - this applies to experimental proof of disease

Also, please add "SARS-COV-2" to the list of alleged viruses for which I require records of purification, since Thomas Piggott claims to have lived through "COVID-19" also

Peterborough Public Health has no records in relation to your request. Local public health is are responsible for adherence to the Health Protection and Promotion and implementation Public Health Standards and related protocols as set by the Ministry of Health. Scientific ad Public Health Ontario. We do not work directly with patient samples related SARS-COV-2 of

If you have any questions, I can be contacted at Istinson@peterboroughpublichealth.ca, or 743-1000, extension 253

25 de agosto de 2021:

Peterborough Public Health y (extro-out) Oficial Médico Dr. Rosana Salvaterra confirma que no tienen registros que describan la purificación de la supuesta "SARS-COV-2", "VIH", también el virus de inmunodeficiencia humana, el virus del Oep B o el virus de la ApC de cualquier muestra de pacientes en el planeta, por cualquiera, en cualquier lugar. Lo que significa que tienen cero pruebas de su existencia.https://www.fluoridefreepeel.ca/wp-content/uploads/2021/08/Peterborough-PH-PH-HIV-Hep-Hep-C-SARSCOV2-package-redacted.pdf

3 de enero de 2022:

Sarah B. Kotler, J.D. (abogado), Director de la División de Libertad de Información, EE.UU. La Administración de Alimentos y Medicamentos (FDA, por sus siglas en se negó a responder formalmente a mi solicitud de FOIA que le entregó por correo electrónico... pero también indicó que la FDA no tiene registro que describa la purificación de cualquier muestra pacientes en la Tierra, por cualquiera, en cualquier lugar, nunca. Tampoco respondió a mi pregunta de qué hará con el conocimiento de que nadie en el planeta tiene ninguna prueba del virus, a pesar de ser un servidor público que trabaja para una agencia que ha estado estampiendo todo tipo de dispositivos, inyecciones, etc. También me llamó "Rude", mientras que parece bastante contenta de aceptar el fraude mundial y las violaciones del Código de

Nuremberg: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/FDA-PACKAGE-redacted.pdf

FOIA request to FDA re: "SARS-COV-2" purification Kotler, Sarah <Sarah.Kotler@fda.hhs.gov> To: Christine Massey <cmssyc@gmail.com> Mon, Jan 3, 2022 at 7:15 AM Our regulation (which I cited below) gives you the option of (1) mailing or (2) faxing your request. We also have the online portal, which is the fastest method right now due to mail delays and the fact that our office remains closed, and we are limited in our ability to retrieve mail or faxes. In any event, the information you are seeking about "purification" would not even be with FDA. I would suggest you submit your request to the CDC based on the information at SARS-CoV-2 Viral Culturing at CDC | CDC. Instructions for submitting a request to that agency are at: Freedom of Information Act Importance to CDC Mission | CDC Thank you, Sarah B. Kotler, J.D. Director, Division of Freedom of Information

20 de agosto de 2022:

US FDA 301-796-8976

El Centro de Control y Prevención de Enfermedades de Maine fue pedido registros del supuesto SARS-COV-2 siendo encontrado y purificado de cualquier muestra clínica en la Tierra, y respondió con insueltos de los fabricantes.https://www.fluoridefreepeel.ca/wp-content/uploads/2022/09/Maine-CDC-PACKAGE-redacted.pdf

HETL uses the FDA EUA OPTI-SARS Covid-19 Real time PCR test and the Hologic Aptima SARS-CoV-2 assay for qualitative detection of SARS-CoV-2 RNA from human clinical specimens. Attached are the manufacturers' Instructions For Use documents.

28 de julio de 2022:

Algante hombre o mujer anónima que trabaja en el Departamento de Regulación y Deontología de la Agencia Nacional para la Seguridad de Medicamentos y Productos Sanitarios, Francia alias LáAgence Nationale de Sécurité du Médicament et des produits de santé (ANSM) respondió a mi FOI para obtener registros de cualquiera en la Tierra encontrando y purificando el hipotizado virus convicioso de cualquier fluido/tejido corporal de cualquier persona en el planeta. Según la traducción de mi colega Marc Grayás, este hombre o mujer indicó que la ANSM no está autorizada a verificar la existencia de supuestos virus a menos que sea necesario en el contexto de una solicitud relativa a un fármaco o un microorganismo, que según ellos no es el caso de su actividad de "pandemic". Los documentos solicitados no existen dentro de la ANSM y la ciencia no entra en el ámbito de competencia de la ANSM. Qué bueno saberlo. https://www.fluoridefreepeel.ca/wp-content/uploads/2022/08/France-ANSM-PACKAGE-redacted.pdf



Direction Réglementation et Déontologie Pôle juridique et droits des usagers Saint-Denis, le 28 Juillet 2022

Réf: 22V147

Madame,

Par courrier électronique en date du 13 mai 2022, vous avez souhaité disposer d'une copie de toutes les études et/ou rapports en possession, sous la garde ou sous le contrôle de l'ANSM décrivant la purification du présumé "virus COVID-19" (plus précisément "SARS-COV-2", y compris toute "variante" présumée) directement à partir d'un échantillon prélevé sur un humain malade, où l'échantillon du patient n'a d'abord été combiné avec aucune autre source de matériel génétique.

A cet égard, je suis en mesure de vous apporter les éléments de réponse suivants.

En vertu des dispositions combinées des articles L. 300-2 et L. 311-1 du code des relations entre le public et l'administration (CRPA), le document sollicité revêt le caractère de document administratif, communicable à tout tiers qui en fait la demande.

Précisément, l'article L. 311-1 du CRPA précité dispose que, sous réserve des dispositions des articles L. 311-5 et L. 311-6, les administrations mentionnées à l'article L. 300-2 sont tenues de communiquer aux personnes qui en font la demande les documents administratifs qu'elles détiennent, qui émanent d'elles ou qui lui ont été adressés.

L'ANSM (Agence nationale de sécurité du médicament et des produits de santé), établissement public placé sous la tutelle du ministère chargé de la Santé, est une agence d'évaluation et de décision, dont les missions sont d'offrir un accès équitable à l'innovation pour tous les patients et de garantir la sécurité des produits de santé tout au long de leur cycle de vie.

A ce titre, la compétence de l'ANSM, prévue à l'article L. 5311-1 du code de la santé publique, s'exerce sur les médicaments, les matières premières à usage pharmaceutique, les dispositifs médicaux et dispositifs médicaux de diagnostic in vitro, les produits biologiques à effet thérapeutique (produits sanguins labiles, organes, tissus, cellules, produits de thérapies génique et cellulaire, lait maternel), les micro-organismes et toxines, les produits cosmétiques et les produits de tatouage.

L'ANSM n'est en revanche pas habilitée à évaluer la purification seule d'un virus, sauf si cette évaluation est nécessaire dans le cadre d'une demande concernant un médicament ou un mirco-organisme, ce qui n'est pas le cas en l'espèce.

Madame Christine MASSEY
Peterborough, Ontario, Canada

143/147 boulevard Anatole France - F-93285 Saint-Denis Cedex - Tel: +33 (0)1 55 87 30 00 - www.ansm.sante.fr

Enero de 2022:

El Ministerio de Salud / Instituto de Salud Pública de Bucarest y el Centro Nacional de Vigilancia y Control de Enfermedades Transmisibles no

proporcionaron/citaron ningún registro de los supuestos "SARS-COV-2" que se habían encontrado en los fluidos corporales de cualquier paciente de la Tierra y purificados, de modo que se podía secuenciar, caracterizar y estudiar con experimentos controlados... y así demostrar que existían: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/Romania-PACKAGE-red-redacted.pdf

MINISTERUL SĂNĂTĂTII Institutul National de Sanatate Publică INTRARE IESIRE Ziua 28 Lune 20 22



MINISTERUL SĂNĂTĂȚII INSTITUTUL NAȚIONAL DE SĂNĂTATE PUBLICĂ NATIONAL INSTITUTE OF PUBLIC HEALTH

Str. Dr. Leonte nr. 1-3, 050463, Bucureşti, ROMÂNIA Tel: (401) 021 318 36 20, director (401) 021 318 36 19, fax (401) 021 312 34 26 e-mail: directie.generala@insp.gov.ro

CĂTRE	
E-mail	

Spre informare, Ministerul Sănătății Direcția Relații cu Presa, Afaceri Europene și Relații Internaționale

Ca urmare a adresei dumneavoastră, înregistrată la INSP cu nr 1469/27.01.2022, vă transmitem, mai jos, link-urile pe care le puteți accesa în vederea obținerii informațiilor solicitate respectiv, dovezile științifice privind izolarea virusului în cultură.

Stelzer-Braid S, Walker GJ, Aggarwal A, Isaacs SR, Yeang M, Naing Z, Ospina Stella A, Turville SG, Rawlinson WD. Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes. Pathology. 2020 Dec;52(7):760-763. doi: 10.1016/j.pathol.2020.09.012. Epub 2020 Oct 8. PMID: 33131800; PMCID: PMC7543926.

Francis R, Le Bideau M, Jardot P, Grimaldier C, Raoult D, Bou Khalil JY, La Scola B. High-speed large-scale automated isolation of SARS-CoV-2 from clinical samples using miniaturized co-culture coupled to high-content screening. Clin Microbiol Infect. 2021 Jan;27(1):128.e1-128.e7. doi: 10.1016/j.cmi.2020.09.018. Epub 2020 Sep 23. PMID: 32979576; PMCID: PMC7510445.

- https://www.edc.gov/coronavirus/2019-ncov/lab/grows-virus-cell-culture.html https://www.nejm.org/doi/full/10.1056/nejmoa2001017
- Zhou, P., Yang, XL., Wang, XG. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). https://doi.org/10.1038/s41586-020-2012-7

Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, et al. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States. Emerg Infect Dis. 2020;26(6):1266-1273. https://doi.org/10.3201/eid2606.200516

Agosto de 2022:

Los CDC de Taiwán no proporcionaron o citaron a <u>Michael S.</u> ninguna prueba científica de la existencia del supuesto "pero vamos" afrontarlo, estrictamente en silico . SARS-COV-2:

https://www.www.fluoridefreepeel.ca/wp-content/uploads/2022/09/Taiwan-CDC-existence-PACKAGE-redacted.pdf

正 本 檔 號: 保存年限:

發文日期:中華民國111年8月15日 發文字號:疾管檢驗字第1110060731號

主旨:署長信箱民眾意見-信件編號:202207250000004-This is a

Freedom of Information Act Request. Ple

Thank you for your email dated July 25, 2022. Our reply to your inquiry is as follows:

At present, the laboratory diagnosis of SARS-CoV-2 can be divided into three types. They are viral nucleic acid detection, antigen detection and virus culture and isolation.

We are unable to provide laboratory records of virus-related testing.

If you have further questions regarding COVID-19, you can visit Taiwan CDC's website at http://www.cdc.gov.tw.
Best regards,

Taiwan Centers for Disease Control

剔本: cdcwwwod@cdc.gov.tw

\$T

绞

第1頁 共1頁

Enero de 2022:

Los CDC de Taiwán confirmaron para Michael S. en NZ que no han purificado el supuesto "SARS-COV-2" de ningún espécimen de paciente o cultura del virus, y se han basado exclusivamente en pruebas de PCR fraudulentas sin sentido para detectar el virus imaginario:

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/2022-01-17-Taiwan-CDC-SARS-COV-2-v3-redacted.pdf

Thank you for your email dated January 9, 2022. Our reply to your inquiry is as follows:

We did not purify SARS-CoV2 viruses from original specimens or virus culture. In Taiwan CDC the SARS-CoV2 is detected by using real-time RT-PCR.

If you have further questions regarding COVID-19, you can visit Taiwan CDC's website at http://www.cdc.gov.tw.

Best regards,

Taiwan Centers for Disease Control

副本:cdcwwwod@cdc.gov.tw

22 de abril de 2022:

El Departamento de Salud e Higiene Mental de de confirmó que no tienen antecedentes describiendo la purificación de cualquier supuesto "SARS-COV-2" (incluyendo cualquier supuesto "variantes") de una muestra tocada de un humano enfermo, por cualquier persona, en cualquier lugar, nunca: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/NYC-Dept-of-Health-and-Mental-Hygiene-PACKAGE-redacted.pdf

4 de marzo de 2022:

El Departamento de Salud e Higiene Mental de la ciudad de Nueva York negó repentinamente una solicitud de Louis Stephen que había incluido lo siguiente: La información que solicito es: 1) Prueba de aislamiento o de aislamiento del virus SARS-COV-2.

:訂

:

裝

con esta explicación:

Su solicitud no describe razonablemente los registros que usted está solicitando: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/NYC-Dept-Health-and-Mental-Hygiene-PACKAGE-redacted.pdf

The NYC DOMH never contacted me for clear direction on how they wanted the request to be described for their search. Obviously, they can't fulfill my request so they skirted around it!

Let me know your thoughts.

Kind regards,

Lou
Sent Irom Yahoo Mail on Android

----- Forwarded Message ---
On Friday, March 4, 2022, 10:52:48 AM EST, Bernadette O'Donnell

bodonnell1@health.nyc.gov> wrote:

Dear Louis

The New York City Department of Health and Mental Hygiene (DOHMH) denies your Freedom of Information Law request with the above-referenced control number: Pursuant to Public Officers Law § 89(3)(a), a request for records must be "reasonably described." As written, your request does not reasonably describe the records you are requesting from DOHMH. Without a clear description of the records you seek, we are unable to conduct a search of

21 de marzo de 2022:

El Departamento de Salud y Hospitales de la Ciudad *de* Nueva York dice: de Véase la página 3:https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/New-York-City-Dept-of-Health-Hospitals-PACKAGE-redacted.pdf

FOIL request to NYC Depts of Health & MH/Hospitals re: "SARS-COV-2" purification

HHCFOIL <HHCFOIL@nychhc.org>

Mon, Mar 21, 2022 at 1:43

To: Christine Massey <cmssyc@gmail.com>

the agency's records to determine whether we are able to respond to your request.

Cc: "recordsaccess@health.nyc.gov" <recordsaccess@health.nyc.gov>, HHCFOIL <HHCFOIL@nychhc.org>

Dear Ms. Massey,

Our research department conducted a diligent search for all the prospective COVID protocols for purification methods/description of SARS-Cov2 and couldn't find any responsive records to your FOIL request. The facility research teams at Health + Hospitals have confirmed that they did not perform any purification methods of the virus. Also, please note that H+H does not do research lab benchwork.

Therefore we are closing this FOIL request.

Sincerely,

Vanita Yogeshwar

Records Access Officer

NYC Health + Hospitals

30 de marzo de 2022:

Oficina del Alcalde de la Ciudad de Nueva York: En respuesta a una solicitud de

registros que describe el aislamiento/purificación del supuesto "SARS-COV-2" de una muestra tocada de un humano enfermo, la oficina del Alcalde reveló que:

Después de realizar una búsqueda, la Oficina del Alcalde no ha encontrado ningún registro que responda a su solicitud:

Pdf: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/NYC-Office-of-Mayor-PACKAGE-redacted.pdf



THE CITY OF NEW YORK OFFICE OF THE MAYOR NEW YORK, NY 10007

March 30, 2022

Dear Christine Massey:

This letter is a response to your request pursuant to the Freedom of Information Law received on November 4, 2021, for the following records:

All studies and/or reports in the possession, custody or control of the Office of the Mayor describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), directly from a sample taken from a diseased human where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum). Please note that I am not requesting studies/reports where researchers failed to purify the suspected "virus" and instead: - cultured an unpurified sample or other unpurified substance, and/or performed an amplification test (i.e. a PCR test), and/or - fabricated a "genome", and/or produced electron microscopy images of unpurified things. I am already aware that according to virus theory a "virus" requires host cells in order to replicate, and am not requesting records that describe replication of a "virus" without host cells. Nor am I requesting records that describe a strict fulfillment of Koch's Postulates, or records that describe a suspected "virus" floating in a vacuum, or private patient information. I simply request records that describe purification (separation of the alleged "virus" from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things). Please note that my request includes any study/report matching the above description, authored by anyone, anywhere.

After conducting a search, the Mayor's Office has not found any records responsive to your request under FOIL. You may appeal this determination in writing within thirty days by addressing such an appeal to FOIL Appeal@cityhall.nyc.gov.

Sincerely,

Jeffrey Lowell

Records Access Officer

23 de octubre de 2021:

El Asesor General Adjunto de **la Universidad** de **Clemson, Carolina del Sur**, confirmó para el solicitante que la Universidad no tiene ningún registro de la purificación de la SARS-COV-2, a pesar de que su Departamento de Ingeniería Ambiental y Ciencias de la Tierra recibió recientemente \$900,000 para estudiar el supuesto virus: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/11/Clemson-University-2021-10-23-SARS-COV-2-v3-redacted.pdf

Robert Wilkins <bertw@clemson.edu></bertw@clemson.edu>	Sat, Oct 23, 2021 at 5:43 AM
Cc: Amy McKinney Josey <amjosey@clemson.edu></amjosey@clemson.edu>	
Good afternoon	
I hope you are doing well. Your FOIA request below was forwarded to me for response. I have departments. The University does not have records responsive to your request.	directed your below request to the appropriate
I hope you have a nice weekend.	
Best regards,	
Robert W. Wilkins	
Assistant General Counsel	
Clemson University	
207 Sikes Hall	
Clemson, SC 29634	

15 de octubre de 2021:

La Oficina del Gobernador de Illinois confirmó que no localizaron estudios que descubrise el aislamiento y el análisis del supuesto virus COVID-19, alias SARS-COV-2.

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/11/Illinois-Officer-ofgobernador-Oct-15-2021.jpg

OFFICE OF THE GOVERNOR

207 STATE HOUSE SPRINGFIELD, ILLINOIS 62706

JB PRITZKER GOVERNOR

October 15, 2021

VIA EMAIL

michelleturney1771@att.net

Re: FOIA Request # 2021-268

Dear Ms. Turney:

This letter is in response to your narrowed Illinois Freedom of Information Act ("FOIA") request received on October 7, 2021 seeking:

All records of scientific laboratory studies analyzing and identifying the SARS-CoV-2 virus from an isolated sample extracted from a human being, am unable to find proof of the above.

Please be advised that after conducting a search, the Governor's Office has located no records responsive to your request.

To the extent you consider this response to be a denial of your FOIA request, you have the right to a denial reviewed by the Office of the Illinois Attorney General, 500 S. 2nd Street, Springfield, Illinois 62706, (877) 299-3642, publicaccess@atg.state.il.us.

If you choose to submit a request for review, you must do so within 60 days after the date of this response letter. The request for review must be in writing, signed by you, and include a copy of your FOIA request and this office's response. 5 ILCS 140/9.5(a). In addition, you have the right to seek judicial review of this response. 5 ILCS 140/11(a), (b).

If you have any questions or need additional information, please contact me.

Sincerely,

Gonard France

Shannon I. Leonard, FOIA Officer Office of Illinois Governor JB Pritzker

24 de septiembre de 2021:

El gobernador de Wisconsin y el Departamento de Servicios de Salud confirmaron para Charles R. Haeuser que no tienen antecedentes en relación con el aislamiento/purificación del presunto virus COVID-19 (o en lo que respecta a la seguridad y/o aprobación de las llamadas "vaccines"). (El DHS proporcionó accesorios con respecto a Wisconsin.s.COVID-19 Community Outreach Grant; haga clic aquí para

verlos o descargarlos.)

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/11/Wisconsin-Gobern-and-Dept-de-Health-Services-PACKAGE-redacted.pdf

RE: Your August 14, 2021 Public Records Requests

Dear Mr. Haeuser:

This is in response to your public records requests received by the Department of Health Services on August 14, 2021. You requested:

- All studies and/or reports in the possession, custody or control of the State of Wisconsin,
 Department of Health Services, Governor of the State of Wisconsin, Any contracted employees
 or Laboratories contracted by The State of Wisconsin, Department of Health Services or its duly
 appointed entities describing the purification (i.e. via filtration and ultracentrifugation) of any
 "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351",
 "P.1") directly from a sample taken from a diseased human, where the patient sample was not
 first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells;
 fetal bovine serum).
- [A]ny/all internal documents that refer to, or indicate who authorized the total amount and any
 and all records regarding research done into the use of the word vaccine, the safety of any
 vaccine and any records that the Department of Health Services has that show an approval of
 any "vaccine or inoculation" that was approved by the FDA for safe, ethical use on anyone,
 anywhere.

DHS has no responsive records to the first two bullets of your request. It should also be

29 de septiembre de 2021:

Metro Departamento de Salud Pública, Nashville, Tennessee aconsedió que "no existe tal registro", o esta oficina no mantiene registros (s) que respondan a una solicitud de Irucka Embry re purificación de la supuesta "SARS-COV-2" o la coincidencia completa de secuencias genómicas de los virus de las víctimas del presunto virus en Metro Nashville y Wuhan, China.

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/10/Metro-PHD-Nashville-Tennessee-redacted-PACKAGE.pdf

- Copies of public record(s) responsive to your request are:

 Attached;
 Available for pickup at the following location:

 2500 Charlotte Avenue, First Floor, Suite 115 (Medical Records); or
 Being delivered via: USPS First-Class Mail Belectronically Other: _______.
- X Your request is denied on the following grounds:
- Your request was not sufficiently detailed to enable identification of the specific requested record(s). You need to provide additional information to identify the requested record(s).
- Questions which seek information rather than the reproduction of record(s) does not require a response under TPRA.
- X No such record(s) exists, or this office does not maintain record(s) responsive to your request.

18 de agosto de 2021:

El Departamento de Servicios de Salud de Arizona confirmó para Timothy Martin que no tienen antecedentes describiendo aislamiento/purificación de ninguna muestra de

pacientes en el planeta, y <u>confunden</u> tales con los datos privados/protegidos/identificados de salud:



August 18, 2021

Sent Via Electronic Mail

Timothy C. Martin

Re: Response-August 16, 2021 Public Records Request

Dear Mr. Martin:

On behalf of the Arizona Department of Health Services ("ADHS"), I am responding to your August 16, 2021 public records request (the "Request"). In your Request, you ask for communicable disease related information, specifically records "describing the isolation of a SARS-CoV-2 virus, directly from a sample taken from a diseased patient, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; liver cancer cells, lung cells from a lung cancer patient)."

In response to your Request, ADHS does not have any records "describing the isolation of a SARS-CoV-2 virus, directly from a sample taken from a diseased patient, where the patient sample was not first combined with any other source of genetic material." Please note that available deidentified COVID-19 data, including case data, may be reviewed at: https://www.azdhs.gov/covid19/data/index.php. You may also wish to check with the Centers for Disease Control and Prevention for information that may be useful to you. See https://www.cdc.gov/coronavirus/2019-ncov/index.html.

In addition, even if ADHS had records responsive to your Request, A.R.S. § 36-664(A) states: "[a] person who obtains communicable disease related information in the course of providing a health service or obtains that information from a health care provider pursuant to an authorization shall not disclose or be compelled to disclose that information except as authorized by state or federal law...." (Emphasis added). See also A.R.S. §§ 36-661(5), (14), (21), 36-664(C), 36-665 and 36-666(A)(2) (it is a class 3 misdemeanor to disclose communicable disease related information in violation of A.R.S. Title 36, Chapter 6, Article 4); May 29, 2020 Under Advisement Ruling issued in Maricopa County Superior Court Case No. CV2020-005385; January 29, 2021 Minute Entry issued in Maricopa County Superior Court Case No. CV2020-012030.

Douglas A. Ducey | Governor Cara M. Christ, MD, MS | Director

150 N. 18th Ave., Suite 200, Phoenix, AZ 85007-2670 P | 602-542-1020 F | 602-364-1150 W | azhealth.gov

Health and Wellness for all Arizonans


53647409.1

4 de febrero de 2022:

El Departamento de Salud de Florida finalmente admitió a Beatriz Scova que no

tienen registro de la purificación de la SARS-COV-2:

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/Florida-Dept-Health-etc-PACKAGE-UPDATED.pdf



13 de junio de 2022:


Rosemary Hewig, en calidad de "Esq"., Oficial de Acceso a los Registros,

Departamento de Salud del Estado de Nueva York, aseguró a Louis que todavía están buscando diligentemente registros que demuestren la existencia de **SARS-COV-2** y que sólo necesitarán hasta el 17 de agosto de 2022 para responder a su FOI de fecha 4 de enero de 2022:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/NY-State-DOH-June-13-PACKAGE-redacted.pdf}{PACKAGE-redacted.pdf}$

Rosemary parece haber olvidado sus respuestas anteriores a mi amigo Bill Huston y yo

en la que confesó que la gente que dirige NYS DoH no tiene ningún registro que indique que .SARS-COV-2 ha sido aislado, abajo.



Empire State Plaza, Corning Tower, Albany, NY 12237 health.ny.gov

9 de diciembre de 2021:

10 meses cortos es todo lo que el **Departamento de Salud del Estado de Nueva York**

tardó en proporcionarle a William Huston una lista sin sentido de variantes imaginarias de la SARS-COV-2 en respuesta a su solicitud de registros que indican que el virus ha sido aislado. Y, el 25 de febrero de 2022, finalmente concluyeron su búsqueda de registros de "diligent" para responder a mi solicitud de purificación de fecha 5 de noviembre de 2021, y confirmaron que no encontraron registros: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/NYS-Dept-Health-WH-CM-PACKAGE-redacted.pdf



KATHY HOCHUL Governor MARY T. BASSETT, M.D., M.P.H. Acting Commissioner

KRISTIN M. PROUD
Acting Executive Deputy Commissioner

December 9, 2021

William Huston Terra Vigilate P.O. Box 22 Endicott, NY 13761

FOIL #: 21-02-073

Dear Mr. Huston:

This letter responds to your Freedom of Information Law (FOIL) request of February 1, 2021, in which you requested "[r]ecords which indicate that the virus* which purportedly causes COVID-19 disease, has been isolated. (* Known by various names, including SARS-nCoV, SARS-COV-2, 2019-nCoV, SARS2-nCoV-19, HCoV-19, etc)."

Please be advised that the culture and isolation of SARS-CoV-2 virus is a time-consuming process and a high biohazard procedure, that can only be performed in a certified biosafety level 3 (BSL-3) laboratory. Very few clinical laboratories can perform this procedure as most do not have BSL-3 facilities. The New York State Department of Health's Wadsworth Center ("Wadsworth") does have BSL-3 laboratories and as of November 12, 2021, has performed cultures on a total of 306 specimens from COVID patients, randomly selected throughout the pandemic. Due to the cost and labor-intensive nature of the procedure, it is only performed on a small fraction of samples. From these 306 specimens, the SARS-CoV-2 virus has been isolated 194 times.

The lineage of the harvested viruses from the cultures is determined by analyzing the entire genomic viral sequence following next generation sequencing. This is also a costly and time-consuming procedure, only performed on a small percentage of samples. For 85 of the inoculated samples that grew, the virus lineage (variant type) is not known at this time as the sequence analysis has not been performed.

Further, variants are only assigned a Greek letter by the World Health Organization when they are determined to be Variants of Interest or Variants of Concern. Thus, there have been numerous variants identified that do not have a Greek letter designation. For the 109 samples that have been cultured and sequenced at Wadsworth, the lineage and variant classifications identified are shown in the table below:

SARS-CoV-2 Lineage	Greek letter designation	Number of Different Samples That Grew
B.1	N/A	34
B.1.1.207	N/A	5
B.1.1.348	N/A	2
B.1.1.519	N/A	1

Please be advised that the New York State Department of Health does not maintain records responsive to your request.

Should you feel that you have been unlawfully denied access to records, you may appeal such denial in writing within 30 days to the Records Access Appeals Officer, Division of Legal Affairs, Empire State Plaza, 2438 Corning Tower, Albany, New York 12237-0026.

If you require additional information or wish to discuss this matter further, please do not hesitate to contact me at (518) 474-8734.

Sincerely,

Rosemarie Hewig

Rosemarie Hewig, Esq. Records Access Officer

30 de septiembre de 2021: **El Departamento de Salud del Estado de Nueva York** aconsedió **a** <u>William Huston</u> que tienen cero registros que indican que el supuesto SARS-CoV-2 es la causa de la COVID-19.<u>https://www.fluoridefreepeel.ca/wp-content/uploads/2021/10/NY-State-DH-no-records-Sept-30-2021.pdf</u>



HOWARD A. ZUCKER, M.D., J.D. Commissioner

KRISTIN M PROUD
Acting Executive Deputy Commissioner

September 30, 2021

William Huston Terra Vigilate P.O. Box 22 Endicott, NY 13761

Governor

FOIL #: 21-02-070

Dear William Huston:

This letter responds to your Freedom of Information Law (FOIL) request of February 1, 2021, in which you requested "[r]ecords which indicate that the virus known as SARS-CoV-2 (a/k/a, 2019-nCoV, HCoV-19, SARSnCoV- 19, SARS-nCoV-2, and SARS2-nCoV-19) is the cause of Coronavirus Disease-2019 (COVID-19)."

The New York State Department of Health does not maintain records responsive to your request. Please be advised, the Department follows the findings and directives issued by the Centers for Disease Control and Prevention (CDC). Information responsive to your request can be found on the CDC's website at the following link:

https://www.cdc.qov/coronavirus/2019-ncov/your-health/about-covid-19/basics-covid-19.html

Should you feel that you have been unlawfully denied access to records, you may appeal such denial in writing within 30 days to the Records Access Appeals Officer, Division of Legal Affairs, Empire State Plaza, 2438 Corning Tower, Albany, New York 12237-0026.

If you require additional information or wish to discuss this matter further, please do not hesitate to contact me at (518) 474-8734.

Sincerely,

Rosemarie Hewig

Rosemarie Hewig, Esq. Records Access Officer

RH/bae

Empire State Plaza, Coming Tower, Albany, NY 12237 health.ny.gov

Mayo 25 de 2022:

Rector Prof. Dr. Piotr Ponikowski, del **Departamento Médico de la Universidad de Wroclaw, Polonia,** confirmó que la universidad no tiene registro de que el supuesto SARS-COV-2 esté aislado, punto.

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/06/Ponikowski-U-of-Wroclaw-Poland-Med-dept-scaled.jpg



Uniwersytet Medyczny

im. Piastów Śląskich we Wrocławiu

Rektor

DKO-1.0147.15.2022

Wrocław, 25 maja 2022 r.

Szanowny Pan

ZAWIADOMIENIE

Na podstawie art. 14 ust. 1 ustawy z dnia 6 września 2001 r. o dostępie do informacji publicznej (Dz. U. 2022, poz. 902), po rozpoznaniu Pana wniosku z dnia 13 maja 2022 r. dotyczącego informacji, czy Uniwersytet Medyczny we Wrocławiu posiada dokumentację na temat izolacji wirusa Sars-Cov-2 informuję, że Uniwersytet Medyczny we Wrocławiu nie poslada dokumentacji na temat izolacji wirusa Sars-Cov-2.

Z wyrazami poważania

Translation into English:

"Pursuant to Article 14 (1) of the Act of September 6, 2001 on disclosing public information (Jurnals of Law 2022, item 902 after examin your application of May, 13, 2022 regarding information wheather University of Wroclaw-Poland has documentation on the Isolation of the Sars-Cov-2 virus; informs that University of Wroclaw has not documentation on Isolation of Sars-Cov-2 virus"



ul. Marcinkowskiego 2-6, 50-368 Wrocław tel.: +48 71/784-10-56

e-mail: bip@umw.edu.pl, magdalena.krystyniak@umw.edu.pl

10 de mayo de 2022:

Bélgicas Sciensano (Instituto Belgano para la Salud) coordina un Grupo de Evaluación de Riesgos - encargado de evaluar los riesgos para la salud pública en un contexto nacional e internacional, valida los procedimientos en el contexto de la Comisión de y - (p3). Así que naturalmente confirmó para Max De Cleyn que nunca han encontrado y purificado el supuesto virus del fluido corporal / tejido de cualquier

paciente y no saben quién podría tener: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/05/Bélgica-Sciensano-PACKAGE-redacted.pdf

From: Dieter Van Cauteren < Dieter. Van Cauteren @sciensano.be>

Date: Tue, May 10, 2022 at 2:41 PM

Subject: RE: Access to Info Request: records re PURIFICATION OF "SARS-COV-2"

To: maxdecleyn@gmail.com <maxdecleyn@gmail.com>

Cc: legaloffice <legaloffice@sciensano.be>

Dear Mr DE CLEYN

We have received your request for information of 18 April. This request was made under the law on the publicity of the administration.

We understood you request concerns records that describe purification directly from a primary clinical sample from a patient.

We do not perform such purification within Sciensano, we can detect the viral genome in the primary sample, or isolate the virus (when we know it is positive) in cell culture.

We do not know where such purification information would be available, you may contact the National Reference Center at the UZ/KU Leuven with this question.

Sincerely

Dieter Van Cauteren

31 de marzo de 2021:

El Instituto Nacional de Enfermedades Infecciosas de Japón respondió que los investigadores hicieron análisis genéticos y análisis de antígenos cuando se le preguntó un colega anónimo, cómo aislar el virus.

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/05/Japan-Inst-of-Infect-Dis-PACKAGE-redacted.pdf}$



国立感染症研究所 Info 事務担当窓口です。

お問い合わせいただいた件につきまして該当研究部より回答いただきましたので 下記をご参考いただけると幸いです。

- 1. ウイルスの種類を確認するため、遺伝子解析あるいは抗原解析を行っています。
- 2. 分離方法に関する最新の情報を英文誌に公表しています。

https://bmjopenrespres.bmj.com/content/8/1/e000830.long

以上、よろしくお願いします。

国立感染症研究所 Info 担当事務受付窓口

Instituto Nacional de Enfermedades Infecciosas de Japón

Esto es lo que le dije acerca de las 2 letras que se muestran a continuación:

La primera foto... es de este tuit (la propia cuenta del solicitante): https://twitter.com/un4yRFGlfQRAIZD/status/1422586472616513541

El Instituto Nacional de Enfermedades Infecciosas dice que no tienen documentos para la evidencia científica, los artículos, etc. sobre la existencia de SARS-CoV-2. El segundo es de este tuit (izgato):

https://twitter.com/dhBGGFoCRYyPo4u/status/1470999015534006274

Aquí el Instituto Nacional de Enfermedades Infecciosas dice que no tienen documentos para la evidencia científica, los artículos, etc. sobre la existencia de SARS-CoV-2, muestras físicas y los registros de aislamiento viral.

(El lado derecho de la foto es la petición sobre el virus de la gripe.

Tampoco tienen documentos, muestras físicas.)


Para su información, este es el artículo del aislamiento viral SARS-CoV-2 por el Instituto Nacional de Enfermedades Infecciosas, Japón. Aquí introducen el nuevo tipo de células de Vero que han...

https://www.pnas.org/content/117/13/7001

Aquí hay un pdf que contiene las 3 letras:

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/Japan-Natl-Inst-of-Infec-Dis.pdf





18 de marzo de 2022: En respuesta a una solicitud de registros que describen el aislamiento/depurificación del supuesto SARS-COV-2 de una muestra torida de un paciente enfermo, el Instituto Finlandés para la Salud y el Bienestar (THL) declaró lo siguiente: El término "aislado" se ha utilizado en un sentido diferente en la solicitud de información que está bien establecido en la ciencia y que el aislamiento de cualquier

virus en el sentido de la solicitud de información no es posible en absoluto. Pdf:





Hi Christine

I sent Freedom of information request to finnish health authority (THL) and go the (expected) answer. You can see them below.

Their response:

Hey.

We have examined your request for information on 16.3.2022.

The right of access to information pursuant to Chapter 3 of the Act on Public Access to the Activities of Public Authorities (621/1999, hereinafter "the Public Access to Information Act") applies to information entered in the documents of public authorities. According to section 5 (3) (3) of the Public Access to Information Act, documents obtained for the authority's internal training, information retrieval or other comparable internal use are not considered to be documents of the authority. For example, scientific literature and libraries collected by the authority for its own activities are therefore not documents of the authority that would be provided in response to requests for information under the Public Access to Information Act. As the right of access under Chapter 3 of the Public Access to Information Act is only information contained in existing documents, new documents (such as bibliographies) are in principle produced in response to

Link to the Publicity Act; https://www.finlex.fi/fi/laki/aiantasa/1999/19990621#L1P5

THL has examined whether it is in possession of authority documents, the subject of your request for a reply. No such documents have been found. Given that the term 'isolate' has been used in a different sense in the request for information than is well established in science and that 'isolating' any virus within the meaning of the request for information is not at all possible, it is likely that the entire file does not exist at all.

If you wish, you have the right to have the matter confirmed by an authority. If you would like the matter to be referred to an authority for confirmation, you can report it by replying to this message.

Regards, Tuuli Karppinen Lawyer Department of Health and Welfare

My request sent to finnish Department of Health and Welfare (THL) is as you recommended it to be done:

Aihe: Tietojen saantipyyntö: SARS-COV-2:n ja sen varianttien eristämiseen liittyvät lähteet

Marjo Loisa Terveyden ja hyvinvoinnin laitos Viestintä ja vaikuttaminen -yksikkö Viestintäjohtaja PL 30 00271 Helsinki

Lähetetty sähköpostitse osoitteeseen: marjo.loisa@thl.fi

Tämä on julkisuuslain nojalla tehty virallinen pyyntö. https://oikeusministerio.fi/esite-julkisuuslaista

https://www.finlex.fi/fi/laki/ajantasa/1999/19990621#L4

Kuvaus pyydetyistä lähteistä:

Kaikki Terveyden ja hyvinvoinnin laitoksen (THL) hallussa tai tiedossa olevat lähteet, jotka kuvaavat sars-cov-2-viruksen eristämistä (mukaan lukien kaikki oletetut variantit) suoraan sairaalta potilaalta otetusta näytteestä, jossa potilasnäytettä ei ole ensin yhdistetty muuhun geneettisen materiaalin lähteeseen (esim. apinan munuaissoluihin, maksasyöpäsoluihin, naudan sikiön seerumiin jne).

Pyydän huomioimaan, että käytän "eristämistä" sanan arkipäiväisessä merkityksessä, eli asian (asioiden) -tässä tapauksessa sars-covid-2 viruksen (tai sen varianttien) erottamiseen kaikesta muusta. En siis pyydä lähteitä, joissa "sars-cov-2:n eristämisellä" viitataan:

22 de septiembre de 2021:

El Instituto de Salud y Bienestar de Finlandia respondió a una solicitud de evidencia de que el supuesto SARS-COV-2 había sido purificado y demostrado que causaba síntomas en humanos, con un documento sobre los efectos citopáticos en células de mono hambrientas y envenenadas. El solicitante notificó posteriormente a la Junta

Nacional de Investigación de la Investigación de la investigación, pero la Junta insistió en que una investigación preliminar sería inapropiada. Porque la ciencia. https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/Finland-Inst-for-Health-and-Welfare-THL-PACKAGE-redacted.pdf

Elektronimikroskooppikuvia koronaviruksesta on runsaasti löydettävissä erilaisista kuvapankeista, esim. https://www.niaid.nih.gov/news-events/novel-coronavirus-sarscov2-images.

Tämän linkin kautta pääsette tarkastelemaan SARS-CoV-2 -viruksen rakennetta: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164637/pdf/367 1260.pdf

Teillä on mahdollisuus saattaa asia viranomaisen ratkaistavaksi ilmoittamalla siitä sähköpostitse THL:n kirjaamoon kirjaamo@thl.fi, jolloin saatte asiasta valituskelpoisen hallintopäätöksen.

Ystävällisin terveisin

Hanna Kaarre

toimeksi saaneena

17 de septiembre de 2021: **El Laboratorio Nacional de Salud Pública de Lituania** proporcionó a Arturas Bartasius documentos PCR inútiles y confirmó que *el* [oximoron], *microscopía electrónica y purificación de virus (filtración, ultracentrifo, cromatografía) NVSPL no se realiza*. https://www.fluoridefreepeel.ca/wp-content/uploads/2021/10/Lithuania-NATIONAL-PUBLIC-HEALTH-CARE-LABORATORY-PACKAGE-uned.pdf

NACIONALINĖ VISUOMENĖS SVEIKATOS PRIEŽIŪROS LABORATORIJA

Biudžetinė įstaiga, Žolyno g. 36, LT-10210 Vilnius, tel. (8 5) 270 9229, faks. (8 5) 210 4848 el. p. nyspi@nyspi.lt. www.nyspi.lt Duomenys kaupiami ir saugomi Juridiniu asmenu registre, kodas 195551983

Artūrui Bartašiui

El. p. bartasius.arturas@yahoo.com

2021-09-Nr.

I 2021-09-17 Nr. (08 16.1.17 Mr)2-

113823

Nacionaliniam visuomenės sveikatos centrui prie Sveikatos apsaugos ministerijos

DÉL ARTŪRO BARTAŠIAUS PAKLAUSIMO PERSIUNTIMO

Nacionalinė visuomenės sveikatos priežiūros laboratorija (toliau - NVSPL) išnagrinėjusi piliečio Artūro Bartašiaus paklausimą teikia SARS-CoV-2 nustatymui polimerazės grandininės reakcijos metodu šiuo metu naudojamų reagentų aprašus ir instrukcijas. Šiuos reagentus naudoja NVSPL ir kitos SARS-CoV-2 PGR tyrimus atliekančios Lietuvos laboratorijos.

Atkreipiame dėmesį, kad SARS-CoV-2 viruso išskyrimas ląstelių kultūrose, elektroninės mikroskopijos tyrimas bei viruso išgryninimas (filtravimas, ultracentrifugavimas, chromatografija) NVSPL neatliekamas.

Pridedama:

1. TagPath COVID-19 CE-IVD RT-PCR Kit, 1egz.

2.Allplex SARS-CoV-2 Assay, 1egz.

Direktoriaus pavaduotoja,

laikinai einanti direktoriaus pareigas

Rosita Marija Balčienė

Svajūnė Muralytė, tel. +37067180340, el. p. svajune.muralyte@nvspl.lt

Creo que/esperar que este pdf contiene detalles de una respuesta de la República de Bulgaria..... ., y ese diagnóstico se ha basado en pruebas PCR y antigénicas sin sentido:https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/Bulgaria-excertsfrom-website.pdf

ОТГОВОРЪТ



Министерство на Здравеопазването

РЕПУБЛИКА БЪЛГАРИЯ, Министерство на здравеопазването Главен секретар

Документ, регистриран от: (следват лични данни на вносителите)

Относно: Заявление за достъп до обществена информация, регистрирано в Министерство на здравеопазването с вх. № 93-00-55 от 01.03.2021 г.

Уважаеми (еди кои си)

Във връзка с Ваше заявление за достъп до обществена информация, регистрирано в Министерството на здравеопазването с вх. № 93-00-55 от 01.03.2021 г. и на основание чл. 33 от Закона за достъп до обществена информация, Ви информирам, че Министерството на здравеопазването не разполага със заявената от Вас информация и няма данни за нейното местонахождение.

С уважение, ХРИСТИНА ГЕТОВА, ГЛАВЕН СЕКРЕТАР

гр. София, пл. "Света Неделя" № 5 тел. +359 2 9301 171, +359 2 981 01 11, факс: +359 2 981 18 33 e-mail: mailto:press@mh.government.bg / https://www.mh.government.bg/bg

На друго запитване от други хора до Me3e-то с вх. № 93-00-207/130821 да представят научни доказателства за ползите от маските, официалният отговор на Me3e-то гласи (цитат): "В заключение Ви информирам, че Me3e-то не разполага с документи от научни изследвания за ползите от маските."

2021 (Ene. 9 o septiembre. 1, no estoy seguro de cuál): **El Ministerio de Salud de Serbia** le dijo a la ASSOCIATION OF .PARENTS OF MISSING BABIES OF SERBIA. que no tienen registros de aislamiento del presunto/imaginario virus COVID-19, o de cualquiera de los otros datos solicitados. La traducción al inglés y la declaración jurada firmadas incluyeron:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/11/Serbia-Ministry-of-Health-WITH-AFFIDAVIT-AND-TRANSLATION.pdf



УДРУЖЕЊЕ "РОДИТЕЉИ НЕСТАЛИХ БЕБА СРБИЈЕ"

ул. Едварда Грига 1/9 улаз I Београд-Ресник

Поштовани,

На основу Закона о слободном приступу информацијама од јавног значаја ("Службени гласник РС" бр. 120/04; 54/07; 104/09 и 36/10) и Ваших захтева за приступ информацијама од јавног значаја број: 416-21/1, 417-21/2 и 418-21/3 од 28.08.2021. године, заведени у Министарству здравља под бројем: 500-01-1144/2021-16, а који се односе на достављање информација о научној студији која недвосмислено доказује способност и максималну поузданост РСК и RT/РСК метода у детекцији SARS-COV2 узрочника, односно научну студију која недвосмислено доказује "златни стандард" са највећим степеном осетљивости и највећим степеном специфичности РСК и RT/РСК метода у детекцији SARS-COV2 узрочника; научни доказ о постојању-изоловању вируса SARS-COV2; сертификате произвођача личне заштитне опреме прописаних у члану 17. став 10а Закона о заштити становништва од заразних болести и заштитних маски прописаних у члану 2. Уредбе о мерама за спречавање и сузбијање заразне болести ЦОВИД-19 са научним истраживањима и научним доказом да наведена заштитна опрема и заштитне маске пружају заштиту од преноса вируса SARS-COV2, као и научна истраживања и научне доказе који гарантују да наведена заштитна опрема и заштите маске не изазивају нежељена дејства по живот и здравље људи, као и на остале информације наведене у захтевима, обавештавамо Вас да Министарство здравља не поседује тражене информације.

С поштовањем,

ДРЖАВНИ СЕКРЕТАР пр Миреад Берлек

Mayo y agosto de 2021: **La Universidad de Salud y Ciencia** de **Oregon** no proporcionó ni citó ni siquiera 1 registro que describe la purificación del supuesto virus COVID-19 (también conocido como una muestra de pacientes, por cualquier persona en el planeta, para el solicitante.

Good morning,

Thank you for your patience as we worked through your detailed March 29, 2021, public records request. Your request was forwarded to OHSU researchers who were noted to be actively working on COVID-related research. A number of researchers responded and OHSU hereby offers to you the following published information for your review:

 Attached article "The S1 protein of SARS-CoV2 crosses the blood-brain barrier in mice" published in the Nature Neuroscience dated Nov. 19, 2020.

Further, please see attached links of published research which may be useful to you:

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.

Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, Gumber S, Nekorchuk M, Busman-Sahay K, Strongin Z, Harper JL, Tharp GK, Pellegrini KL, Kirejczyk S, Zandi K, Tao S, Horton TR, Beagle EN, Mahar EA, Lee MYH, Cohen J, Jean SM, Wood JS, Connor-Stroud F, Stammen RL, Delmas OM, Wang S, Cooney KA, Sayegh MN, Wang L, Filev PD, Weiskopf D, Silvestri G, Waggoner J, Piantadosi A, Kasturi SP, Al-Shakhshir H, Ribeiro SP, Sekaly RP, Levit RD, Estes JD, Vanderford TH, Schinazi RF, Bosinger SE, Paiardini M. Cell. 2021 Jan 21;184(2):480-475.e21. doi: 10.1016/j.cell.2020.11.007. Epub 2020 Nov 10. PMID: 33278358 Free PMC article.

Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques.

21 de junio de 2021.

A través de la Dra. Fabio Franchi, autor de la COVID-19. La catástrofe causada por el virus que no está allí, Dr. Maria Rosaria Capobianchi, Directora de Virología, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (Instituto Nacional de Enfermedades Infecciosas Lazzaro Spallanzani), Italia no proporcionó ni citó ni citó ni siquiera 1 registro de la purificación del supuesto virus COVID-19 alias .SARS-COV-2.

Respuesta de la FOI y Dr. La respuesta de Franquis (incluyendo adjuntos) está aquí, con traducciones al inglés:

https://www.fluoridefreepeel.ca/italys-national-institute-of-infectious-dis-diseases-lazzaro-spallanzani-has-no-record-of-sars-cov-2-isolation-purification-by-anyone-aywhere-everever/

Da: Capobianchi Maria Rosaria < maria.capobianchi

Inviato: lunedi 21 giugno 2021 20:57

A: Direzione Sanitaria INMI Lazzaro Spallanzani <dirsan@inmi.it>

Oggetto: R: istanza accesso agli atti

In merito a quanto richiesto dall'Avvocato Rodaro, si rappresenta quanto segue.

Il richiedente usa il termine isolamento a sproposito.

In Virologia con il termine isolamento virale si intende la messa in coltura di un campione biologico e la verifica della moltiplicazione del virus su un substrato di cellule vive permissive, coltivate in vitro. L'isolamento si può ottenere anche in animali da esperimento, ma non è questo il caso.

Le cellule inoculate, in parallelo con un controllo non inoculato, vengono monitorate nel tempo per vedere se il virus cresce, la qual cosa è evidente come effetto citopatico, come presenza di particelle virali in microscopia elettronica, oppure, più comunemente, misurando nel tempo la quantità di genomi virali rilasciati dalle cellule in maniera progressivamente incrementale, come risultato della replicazione del virus. Non esistono altre accezioni del termine "Isolamento virale".

29 de octubre de 2021?

El Ministerio de Salud de Italia no proporcionó ni citó ningún estudio o informe (evidencia) (o página web citando tales) para el aislamiento/depurificación del presunto virus Sars-Cov-2 o cualquier supuesta variante, para el solicitante: <a href="https://www.www.fluoridefreepeel.ca/wp-content/uploads/2021/11/Italia-Ministry-of-talia-ministry-of-talia-

Health-PACKAGE-redacted.pdf



DIREZIONE GENERALE DELLA PREVENZIONE SANITARIA Ufficio 1 – Affari Generali e Segreteria Tecnico Viale Giorgio Ribotta, 5 – 00144 Roma

0049278-29/10/2021-DCPRE-

e p.c.

ALL'UFFICIO DI GABINETTO gab@postacert.sanita.it

AL SEGRETARIATO GENERALE SEGGEN


BUFFONATIEDI STATO

Registro - classif:DGPREV/I/ I.8.e.c.3

AL RESPONSABILE DELLA TRASPARENZA

SEDE

Oggetto: Istanza di accesso civico generalizzato



In merito, si rappresenta che il Decreto Legislativo 14 marzo 2013, n. 33, all'art. 5 (Accesso civico a dati e documenti), prevede al comma 2 che "chiunque ha diritto di accedere ai dati e ai documenti detenuti dalle pubbliche amministrazioni, ulteriori rispetto a quelli oggetto di pubblicazione ai sensi del presente decreto, nel rispetto dei limiti relativi alla tutela di interessi giuridicamente rilevanti secondo quanto previsto dall'articolo 5-bis"ma, come chiarito dall'ANAC 1, "resta escluso che per rispondere a tale richiesta – l'amministrazione sia tenuta a formare o raccogliere o altrimenti procurarsi informazioni che non siano già in suo possesso, pertanto, l'amministrazione non ha l'obbligo di rielaborare i dati ai fini dell'accesso generalizzato, ma solo consentire l'accesso ai documenti nei quali siano contenute le informazioni già detenute e gestite dall'amministrazione

Ciò posto, in un'ottica di leale collaborazione e trasparenza, Le segnaliamo la pagina dell'Istituto Superiore di Sanità (ISS) sulle varianti² ed, in particolare, l'ultima survey sull'argomento³ nonché, sul sito web di questo Ministero, la pagina con le domande frequenti (Frequently Asked Questions -FAQ) e le risposte sulle varianti⁴.

Distinti saluti

Il Direttore generale F.to Dott. Giovanni Rezza*

?InheritRedirect-true&redirect=%2Fconsulta-1-ocument!%3Fstart%3D2%28q%3D%2522Determinazione%2520n %25201309%2522%26sort%3Dddm Dataclu0 String sortable-

https://www.iss.it/cov19-cosa-fa-iss-varianti

31 de agosto de 2021: El **Instituto de Investigación de Medicina Tropical**, Departamento de Salud, Phillipines. Respuesta de artículo y FOI: CCH FOI Bombshell: DOH no se compromete a no Evidence SARS-CoV-2 Aislado. Sin embargo, el Gobierno bloqueó a la nación debido a los virus que aún no se ha probado que existe.

https://covidcalltohumanity.org/2021/08/31/cch-foi-bombshell-doh-admits-noevidence-sars-cov-2-isolated-yet-government-locked-down-nation-due-to-virus-sinais-has-vet-to-exist/

Respuesta de la FOI se respaldó aquí:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/Phillipines-Department-de-Health-response-Ago-31-2021.pdf

^{*} Firma autografa sostituita a mezzo stampa ai sensi dell'art.3, comma 2, del D.lgs. n.39/1993

ANAC, Linee guida 1309/2016 https://www.anticorruzione.it/-/determinazione-n.-1309-del-28/12/2016-rif.-

https://www.lss.tl/documents/201260/Relazione-tecnica-quick-survey+variant1+settembre+2021+versione+finale.pdf/0043 0078-505f-082f-20e6-6ad2a6312c687t=1633703643180

https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioFaqNuovoCoronavirus.jsp?lingua=italiano&id=250

Real-time PCR technology is reliant on the ability of the thermocycling machine's camera to correctly detect successive exponential increases in the fluorescence intensity against erratic fluorescence signals that behave as background noise. As such, the primary determinant whether a person is classified as positive L Documents and/or communications regarding the is the presence of the viral RNA target in their sample. Certified Reference Material In the context of the PCR procedure, the "CRM" referred here may pertain (CRM) being used by DOH and its authorized testing centers to to the "positive" control that is incorporated as part of the components of determine whether a person is the real-time PCR kit. The primary function of a positive template control is positively infected with SARSto serve as a validity checkpoint to detect general failures or errors assumed CoV-2 to be related to all samples belonging to the same run; that is to say that if a positive control fails, then all samples belonging to the same run are retested. The final outcome of each tested sample is tied to the performance of the positive control The real-time RT-PCR test for SARS-CoV-2 does not "isolate" the virus but rather detects short target sequences of the virus in clinical samples. If these target sequences are detected in clinical samples, these can be amplified and detected through the test. The positive control material included in the PCR kit is likewise not a whole virus but rather nucleic acid fragments taken from the virus or synthesized, and that which serve as the basis for (1) comparing if a clinical sample that is tested is positive for the virus; and (2) provide supporting information that the assay is working. As originally stated, the four criteria known as "Koch's postulates" are: (1) The microorganism must be found in diseased but not healthy individuals; II. Documents, lab results. (2) The microorganism must be cultured from the diseased individual; (3) and/or communications Inoculation of a healthy individual with the cultured microorganism must including but not limited to recapitulated the disease; and finally (4) The microorganism must be rescientific articles demonstrating, isolated from the inoculated, diseased individual and matched to the using procedures that satisfy original microorganism. Koch's Postulates, that this (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775492/). Certified Reference Material is

Agosto 2021: **Massachusetts Departamento de Salud** Informes de **Salud** No Documentos Responsables a FOIA Solicitud de Información sobre Aislable Purificada de SARS-COV-2/COVID-19 Virus & Delta Variant Formando Basis para todas las Restricciones Estatales COVID por Ramola Dharmaraj:

Las respuestas de Massachusetts en el artículo anterior también se respaldan en los siguientes enlaces:

11 de agosto de 2021

La Oficina del Gobernador del Commonwealth de Massachusetts le dijo a Ramola Dharmaraj *que no tenemos registros* - reislamiento del virus SARS-COV-2/COVID-19: https://www.fluoridefreepeel.ca/wp-

<u>content/uploads/2021/09/COMMONWEALTH-OF-MASSACHUSETTS-OFFICE-OF-THE-GOVERNOR-Response-Letter.--Dharmaraj.pdf</u>

25 de agosto de 2021

Estado Libre Asociado de Massachusetts Departamento de Salud: El .

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/Commonwewealth-of-Massachusetts-Deptof-Health-package.pdf

Clarification 2: Isolate means "to separate something from other things with which it is connected or mixed"—Cambridge Dictionary definition.

Clarification 3: This request is not for information on something procured by means of 1) Culturing something,

- Nasally swabbing something from any randomly sick (with some other disease) or healthy person,
- Amplifying something via PCR Test (Which its inventor Dr. Kary Mullis has clearly stated is not to be used to diagnose any disease),
- 4) the Sequencing of something,
- 5) or the Computer-Generated Sequencing of something.

The Department has no responsive records to your request.

Noviembre 08, 2021:

Otra confesión sin registros de Gillian Haney, director de la División de Vigilancia, Análisis e Informática (DSAI), Oficina de Enfermedades Infecciosas y Ciencias de la Laboratorio del **Departamento de Salud Pública de Massachusetts:**https://www.fluoridefreepeel.ca/wp-content/uploads/2023/11/Massachusetts-Dept-of-Public-Health-Nov-2021.pdf



The Commonwealth of Massachusetts

Executive Office of Health and Human Services
Department of Public Health
Bureau of Infectious Disease and Laboratory Sciences
305 South Street, Jamaica Plain, MA 02130

CHARLES D. BAKER Governor KARYN E. POLITO Lieutenant Governor Division of Surveillance, Analytics and Informatics (DSAI) Tel: (617) 983-6801 Fax: (617) 983-6813 MARYLOU SUDDERS Secretary

MARGRET R. COOKE Acting Commissioner
Tel: 617-624-6000

November 08, 2021



Re: Public Record Request BIDLS-2021-221

This letter is in regard to the above referenced public record request received by the Massachusetts Department of Public Health (the "Department" or "DPH") on October 28, 2021. This request has been assigned a tracking number: BIDLS-2021-221. Specifically, you requested:

All studies and/or reports in the possession, custody or control of the Massachusetts Department of Public Health describing the purification of the often mentioned "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants") directly from a sample taken from a diseased human, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum).

Please note that I am not requesting studies/reports where researchers failed to purify the suspected "virus" and instead:

- · cultured something, and/or
- · performed an amplification test (i.e. a PCRtest), and/or
- fabricated a genome from sequences detected in an impure substance, and/or
- · produced electron microscopy images of unpurified things.

The Department has no records responsive to your request.

To the extent you are seeing scientific information about the SARS-CoV-2 virus and COVID-19, the US Centers for Disease Control and Prevention makes COVID-19

2 de septiembre de 2021: El **Departamento de Servicios Generales de la**

Commonwealth de Virginia proporcionó registros supuestamente receptivos que contenían cero descripciones de la purificación de cualquier muestra de pacientes en el planeta, por cualquier persona, en cualquier lugar. Los registros supuestamente (pero no realmente) sensibles son 1): el CDC 2019-Novel Coronavirus (2019-nCoV) Panel de Diagnóstico RT-PCR en Tiempo Real, y 2) ThermoFisher TaqPathTM COVID-19 Combo Kit Procedimiento para la detección de la ENT de 2019-nCoV por RTPCR. https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/Virginia-Dept-de-General-Services-PACKAGE-redacted.pdf



Joseph F. Damico Director

Sandra Gill, Deputy Director Matthew James, Deputy Director
 VIRGINIA
 1100 Bank Street

 Department of General Services
 Richmond, Verginitie 23219

 Phone (804) 371-8305
 FAX (804) 371-8305

September 2, 2021

Dear

I am responding to your request for information received by the Department of General Services (DGS) via email on August 26, 2021. In your request you asked for in brief, all studies and/or reports in possession, custody or control of the Division of Consolidated Laboratory Services describing the purification of any COVID-19 virus.

Please find attached documents responsive to your request.

I hope this information is helpful. Thank you for your inquiry.

Dena Potter
Director of Communications

Commonwealth of Virginia
Department of General Services
Division of Consolidated Laboratory Services
Richmond, Virginia

CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel

I. PURPOSE/APPLICATION:

A. This procedure is for the qualitative detection of nucleic acid from the 2019novel Coronavirus (nCoV), termed severe acute respiratory syndrome

1 de septiembre de 2021: El **Departamento de Salud de Pensilvania** confirmó que no tienen registro de purificación de SARS-COV-2 de cualquier muestra de pacientes en el planeta, por cualquiera, en cualquier lugar:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/Pennsylvania-Dept-of-Health-PACKAGE-redacted.pdf}{}$



September 1, 2021

King of Prussia, PA

ladymohan@yahoo.com

RE: Right to Know Law Request DOH-RTKL-COV-150-2021

Dear M

This letter acknowledges receipt by the Pennsylvania Department of Health (Department) of your written request for records under the Pennsylvania Right-to-Know Law (RTKL), 65 P.S. §§ 67.101-67.3104. The Department received your request on August 25, 2021. You requested:

[A]ny records that describe the isolation of a "COVID-19 virus" (aka "SARS-COV-2") from an unadulterated sample taken from a diseased human, where the patient sample was not first combined with any other source of genetic material. Isolate meaning a thing is separated from all other material surrounding it. I am NOT REQUESTING white papers where "isolation" of SARS-CoV-2 refers to: the culturing of something, performance of an amplification test (PCR) or the sequencing of something.

Your request is denied, as the Department is not in possession of records responsive to your request.

As a courtesy, the Department provides the following information: The Department interprets your request to seek records for the isolation of intact virus/viral particles of SARS-CoV-

Please be advised that the Department's molecular test processing is not isolating live virus or viral particles. The Department is isolating SARS-CoV-2 genetic material extracted from virus/viral particles in the patient specimen. That extracted genetic material is used in PCR reactions for the detection of the presence of SARS-CoV-2 genetic material in that extract.

The Department's Bureau of Laboratories utilizes COVID PCR assays which have received authorized EUAs from the FDA:

- (1) The CDC COVID RT-PCR assay described int the most recent approved update; and
- (2) The Thermofisher COVID multiplex RT-PCR panel assay.

30 de agosto de 2021: **El condado** de **Montgomery, Pensilvania** confirma que no tienen registro de la purificación de la SARS-COV-2 de cualquier muestra de pacientes en el planeta, por cualquier persona, en cualquier lugar, o cualquier prueba de su existencia:

MONTGOMERY COUNTY BOARD OF COMMISSIONERS


VALERIE A. ARKOOSH, MD, MPH, CHAIR KENNETH E. LAWRENCE, JR., VICE CHAIR JOSEPH C. GALE, COMMISSIONER



OFFICE OF THE SOLICITOR

MONTGOMERY COUNTY COURTHOUSE • PO Box 311 Norristrown, Pa 19404-0311 610-278-3033 FAX: 610-278-3069 • TDD: 610-631-1211 WWW.MONTCOPA.ORG

August 30, 2021



Re: Right-to-Know Request No. 0R21-553

Dear M

On August 26, 2021, the open-records officer of Montgomery County received your written request for information. The County is responding to your request under the Pennsylvania Right-To-Know Law, 65 P.S. §§ 67.101, et seq. (RTKL). You asked for the following:

"...I am seeking any records that describe the isolation of a "COVID-19 virus" (aka "SARS-COV-2") from an unadulterated sample taken from a diseased human, where the patient sample was not first combined with any other source of genetic material. Isolate meaning a thing is separated from all other material surrounding it.

Note: I am NOT REQUESTING CDC website referral information or white papers where "isolation" of SARS-CoV-2 refers to:

- · the culturing of something
- performance of an amplification test (PCR) or
- the sequencing of something.

To clarify, I am requesting via disclosure all white papers / solid scientific evidence proving that:

- the SARS-CoV-2 virus causes the illness that matches the characteristics of all of the deaths attributed to COVID-19;
- that said virus has been properly purified / isolated from human beings, reproduced and then shown to cause said Covid-19 / SARS-COV-2 in human beings..."

Under the RTKL, a written response to your request was due on or before September 2, 2021.

13 de agosto de 2021: El Asesor General y el Oficial de FOI del **Departamento de Salud de Washington DC** confirmaron al solicitante que el Departamento no tiene registro describiendo la purificación de ningún virus de la COVID-19 (también conocido como SARS-COV-2, incluyendo cualquier supuesto "variantes", es decir. B.1.1.7, B.1.351, P.1 a) directamente de una muestra de un paciente. Comunicación completa:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/08/Washington-DCH-DC-DC-FOIA-01-R.08-11-11-2021-redacted-package.pdf

Your Freedom of Information Act (FOIA) request seeks "studies and/or reports ... describing the **purification** of any "**COVID-19 virus**" (aka "SARS-COV-2", including alleged variants" [Bolding in original]

FOIA Response

The Government of the District of Columbia has posted COVID-19 documents, data, and information on https://coronavirus.dc.gov/.

When I conferred with the Director of the Department of Health regarding your FOIA request, I was advised that the Department of Health has not been involved in any research or day-to-day activities related to purification of SARS-CoV-2. No letters, reports, or documents (other than your FOIA request) regarding a purification process have been received by the Director of the Department of Health.

Agosto 2021: **El Departamento de Salud y Servicios Humanos** de **Michigan** confirmó que no tienen antecedentes que describan la purificación del virus (incluyendo cualquier supuesta "variantes") de cualquier muestra de pacientes en el planeta, por cualquier persona, en cualquier lugar.

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/Michigan-Dept-of-Health-and-Human-Services-package.pdf}$



RE: Public Records Request, Reference # H012477-080421.

Dear Mr

This notice is issued in response to your request, legally received by the Michigan Department of Health and Human Services (Department) on August 05, 2021, requesting information under the Freedom of Information Act (FOIA), MCL 15.231 et seq.

Your request is denied.

To the best of the Department's knowledge, information, and belief, this Department does not possess or maintain records under the description you provided or by other names reasonably known to the Department.

As to the denial, the Department is obligated to inform you that under MCL 15.240 §10 the following remedies are available:

- Appeal this decision in writing to the Legal Affairs Administration of the Department of Health and Human Services, PO Box 30195, Lansing, MI 48909. The writing must specifically state the word "appeal" and must identify the reason or reasons you believe the denial should be reversed. The Department must respond to your appeal within ten days of receipt. Under unusual circumstances, the time for response to your appeal may be extended by ten business days.
- File an action in the appropriate court within 180 days after the date of the final determination to deny the request. If you prevail in such an action, the court is to award reasonable attorney fees, costs, disbursements, and possible damages.

The Department's FOIA policies and procedures are available at Policies and Procedures.

Sincerely,

Ruth O'Connor Bureau of Legal Affairs

18 de agosto de 2021: **El Departamento de Salud Pública de California** confirmó para Kim Leonoudakis que no tienen registro de que SARS-COV-2 (incluyendo a cualquier "variantes" haya sido purificado de cualquier muestra de pacientes en el planeta y ningún análisis de la supuesta variante de la supuesta "Delta": https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/California-DPH-FOIA-P013439080421.pdf

20 de mayo de 2022:

El Departamento de Salud Pública de California admitió a Kristen Welch que no tienen registro de ningún supuesto "SARS-COV-2" (o escaritano) que haya sido encontrado y purificado de la fluididad/tejida/excremento de cualquier humano enfermo en el planeta (para que sea secuenciado, caracterizado y estudiado con experimentos

controlados) por cualquier persona, en cualquier lugar, nunca.

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/05/California-Dept-of-Public-Health-Kristen-PACKAGE-redacted.pdf



May 19, 2022

RE: Public RecordsAct Request, Reference # P015815-051222

Dear Kristin Welch.

On May 12, 2022,the California Department of Public Health (CDPH) received your request for thefollowing records under the Public Records Act:

FOIA REQUEST PERTAINING TO THE SARS-COV-2 VIRUS

PLEASE SEE THE ATTACHED FOIA REQUEST

CDPHdoes not have existing documents responsive to this request. However, you may find relevant information toyour inquiry at the following link: https://testing.covid19.ca.gov/covidnet/.

Further, additional papers about the isolation of SARS-CoV-2 are available through the NIH at the following link: https://www.ncbi.nlm.nih.gov/sars-cov-2/

This concludes our response to this request.

Thank you,

Christa Daley

To monitor the progress, update this request, or download responsive records, please log into the <u>Public Records Center</u>.

24 de agosto de 2021:

El Departamento de Salud Pública de California confirmó para Robin que no tienen registro de que el virus (incluyendo a los "variantes" haya sido purificado de cualquier muestra de pacientes en el planeta, por cualquier persona, en cualquier lugar. https://www.fluoridefreepeel.ca/wp-content/uploads/2021/08/California-Dept-Public-Health-P013542-081421-redacted.pdf

culture or from any unpurified substance, and/or

Produced electron microscopy images of unpurified things in a cell culture.

Clarification of Request

For further clarity, please note I am already aware that according to virus theory a "virus" requires host cells in order to replicate, and I am not requesting records describing the replication of a "virus" without host cells.

Further, I am not requesting private patient information, or records that describe a suspected "virus" floating in a vacuum; I am simply requesting records that describe its purification (i.e. separation from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things).

Please note that my request includes any study/report matching the above description, for example (but not limited to) any published peer-reviewed study authored by anyone, anywhere.

If any records match the above description of requested records and are currently available in the public domain, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible.

If there are any fees for searching or copying these records, please inform me if the cost will exceed \$5. However, I would also like to request a waiver of all fees in that the disclosure of the requested information is in the public interest and will contribute significantly to the public's understanding of "COVID-19". This information is not being sought for commercial purposes.

The California Public Records Act requires a response within ten business days. If access to the records I am requesting will take longer, please contact me with information about when I might expect copies.

If you deny any or all of this request, please cite each specific exemption you feel justifies the refusal to release the information and notify me of the appeal procedures available to me under the law.

Format

Electronic files conveyed to me via email, preferably in PDF format; I do not wish for anything to be shipped to me.

CDPH has completed a diligent search and has determined that it is not in possession of records that are responsive to your request. For this reason, this concludes CDPH's response to your request, which will now be closed.

Sincerely,

Taylor St. Mary AGPA CID/DCDC

To monitor the progress, update this request, or download responsive records, please log into the Public Records Center.

9 de agosto de 2021: El **Departamento de Salud de Arkansas** Asesor General Adjunto asesor al Dr. James W. Smith que el Departamento no tiene registro describiendo la purificación de cualquier "SARS-COV-2" (incluyendo cualquier escariants) de cualquier muestra de pacientes en el planeta, por cualquiera, nunca, a través de la filtración y la ultracentrifugación. Sin embargo, proporcionó 2 correos electrónicos en busca de COVID 19 en aguas residuales. Dr. Smith hará un seguimiento para solicitar que la respuesta sea proporcionada en una carta formal, firmada y fechada con un número de archivo. Correspondeción completa:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/08/Arkanas-Dept-of-Health-no-records-email-response-Aug-9-redacted.pdf

Después de que una serie de solicitudes de Libertad de Información a partir de abril de 2020 no lograron dar una respuesta satisfactoria, Ricardo Maarman (trabaje junto al <u>Dr. Faiez Kirsten</u>) desafió al **gobierno sudafricano** en el Tribunal Superior del Cabo Occidental en mayo de 2021 a proporcionar pruebas del virus que supuestamente justifica las devastadoras medidas de bloqueo del gobierno.

(Más específicamente, Ricardo desafió al Presidente, al Departamento Nacional de Salud, al Comité Asesor Gubernamental COVID-19 y al Ministro de Gobernanza Cooperativa y Asuntos Tradicos. Y la declaración jurada respondida fue escrita principalmente por el Director Ejecutivo interino del Instituto Nacional de Enfermedades Transmisibles de Sudáfrica.)

El gobierno no proporcionó pruebas o incluso pruebas convincentes, y en las páginas 29 de su <u>declaración jurada de respuesta</u> (empezando en la página 31 del pdf) reveló que se han basado en un enfoque "bien establecido" pero no científico al aislamiento de los virus.

- 86.1. Protocols for isolation and culturing of "physical virus" are now well established. There are many clear review manuscripts to support this statement. It is not done routinely for diagnosis, as it will be impractical and will not be conducive to patient management.
- 86.2. The nature of the SARS COV-2 has been established not only through RT-PCR in sequencing but also in electron microscopy.
- 86.5. There have been significant advances with new diagnostic methodologies and sequencing, and further associations are made:
 - 86.5.1. A nucleic acid sequencing belonging to a putative pathogen should be present in most cases of an infectious disease.
- 86.6. The nature of the micro-organism inferred from the available sequence should be consistent with the known biological characteristic of that group or organisms.

La declaración jurada del gobierno de SA implica ingenieritamente que los postulados de Kochs (o una variación por lo tanto) se han cumplido por el supuesto virus, cuando en realidad ninguno de ellos lo ha sido. No contiene ninguna mención de la **purificación** de las partículas que se han mostrado en imágenes EM (dentro de cultivos celulares, nunca purificados o en muestras de pacientes) supuestamente como el virus, o la caracterización o secuenciación de partículas purificadas, o cualquier experimento controlado que implique partículas purificadas.

Y la discusión del gobierno de SA sobre los criterios Bradford-Hill se pasa por alto el hecho de que estos criterios **presuponen** la existencia y la medición válida del factor potencialmente causal bajo investigación, cuando la realidad es que ninguna prueba ha sido o podría haber sido validada para las partículas nunca purificadas, nunca caracterizadas, nunca secuenciadas, supuestamente son el virus.

La jueza dictabió que el asunto **no** es **urgente** y le dio por **marcha** al asunto. Ricardo seguirá adelante con esto. El aviso de moción, <u>transcripción</u> de <u>la audiencia</u>, , otra documentación y entrevistas sobre este caso se publican en un sitio web dedicado: https://www.showusthevirus.info.

The applicant has not made a case for urgency.

5852/2020_2021.05.27

1...

2 RULING

Consequently the matter is struck off the roll. The applicant has got another course which the applicant, if he wishes, can take. That is my ruling.

Pertaining to costs, each party will pay its own costs.

10

NZIWENI, AJ

JUDGE OF THE HIGH COURT

Un **documento judicial** de **Lisboa** fechado el 19 de mayo de 2021 se publica en el sitio web de <u>Andre Dias, PhD</u> (según lo informado por Celia Farber en "The Truth Barrier", **celiafarber.substack.com**).

La URL <u>del</u> documento de la corte es <u>https://andre-dias.net/wp-content/uploads/Fwd-Sentenca.pdf</u> (y lo hemos respaldado en <u>https://www.fluoridefreepeel.ca/wp-content/uploads/2021/06/Portuguese-court-ruling.pdf</u>).

Según Ms. Farberás publicó la entrevista por correo electrónico del 28 de junio de 2021 con Dias, que es un experto en modelado de la enfermedad pulmonar, el fallo de la corte se refiere a una petición ciudadana al Ministerio de Salud, equivalente a una Solicitud de Libertad de Información... que terminó en la corte con consultas epidemiológicas y estadísticas, y el tribunal también formalizó que el ministerio no tiene datos ni referencias sobre la existencia del virus.

Sra. Farber aconseja que una traducción al inglés del fallo de la corte está en marcha y será compartida en su sitio web una vez que se prepare. A continuación se muestra una captura de pantalla del documento original que muestra algunas de las preguntas que se habían planteado al Ministerio de Salud de Portugal, para la que aparentemente no tenían respuestas.

1 - Cópia de publicação científica, revista por pares (peer-review), referente ao estudo sobre o grau de infeção provocada nos humanos, pelo vírus SARS-Cov2, responsável pela doença Covid-19, a partir de uma amostra não adulterada retirada de um humano doente;

II - Cópia de publicação científica, revista por pares (peer review), referente ao estudo sobre o grau de infecção nos humanos provocada pelo SARS-Cov2 obtida por via empírica e que prove que foram cumpridos os postulados de Koch/Evans (1976), indicando a data e o(s) autor(es) que realizaram o isolamento e purificação do vírus em laboratório;

III - Cópia da publicação científica, revista por pares (peer review). relativamente ao teste RT-PCR (polimerase chain reaction, ou, em português, reação em cadeia da polimerase) como ferramenta de diagnóstico fiável para identificar a infecção por vírus SARS-Cov2 em humanos, i.é, se o teste RT-PCR identifica a presença do RNA viral e a presença do referido vírus infeccioso;

Julio 2021: **El Ministerio de Salud de Brasil** proporcionó/citado cero registros de la purificación de la FOI, Marcella Picone. El Ministerio alegó inicialmente que la solicitud (que el resto del mundo entendía muy bien) no estaba clara, pero también admitió que la información inexistente. En su segunda respuesta a la Sra. Picone explicaron que han estado siguiendo una investigación realizada por otros países. Véase ps 2, 13, 14. Respuestas completas:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/07/Brasil-Ministry-of-Health-package.pdf

Plataforma Integrada de Ouvidoria e Acesso à Informação Detalhes da Manifestação

que corresponda a descrição acima, por exemplo ('mas não limitado a) qualquer estudo revisado por pares publicado de autoria de qualquer pessoa, em qualquer lugar. Observe também que, apesar do fato de que a purificação é uma etapa essncial(mas não suficiente) para provar a existência de um vírus causador de doenças.

Portanto, no interesse da transparência e de acordo com os propósitos da legislação, se algum registro corresponder a descrição acima dos registros solicitados e estiver atualmente disponível em outro local, forneça informações suficientes sobre cada registro para que eu possa identificar e acessar cada um certeza (ou seja título, autor, data, periódico). Forneça url sempre que possível. Grata desde já

Aguardo retomo.

Proposta de melhoria:

Município do local do fato:

UF do local do fato:

Local:

Não há anexos originais da manifestação.

Não há anexos complementares.

Não há textos complementares.

Não há envolvidos na manifestação.

Campos Adicionais Não há campos adicionais. Dados das Respostas Tipo de Data/Hora Teor da Resposta Decisão Compromisso Anexos Resposta 22/07/2021 A presente demanda não Resposta Informação Conclusiva 15:42 dispõe de clareza de dados Inexistente para que seja possível compreender a informação requerida pela interessada. porquanto solicita: SOLICITO TODOS OS ESTUDOS E OU, RELATÓRIOS EM POSSE OU CONTROLE, MINISTÉRIO DA SAÚDE E

FIOCRUZ OU QUALQUER

La **Agencia Reguladora de la Salud de Brasil** (**Anvisa**) es una charla de la FDA. En su respuesta de la FOI a Marcella Picone, explicaron que no tienen registro de la purificación de la SARS-COV-2 y no están obligados por ley, por lo tanto no es (en sus

mentes) su obligación asegurarse de que el virus realmente existe. Comunicación completa:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/07/Brazil-ANVISA-package.pdf}{}$



DESPACHO Nº 268/2021/SEI/GGTPS/DIRE3/ANVISA

Processo nº 25351.920427/2021-18

Interessado: CGTAI

Assunto: Recurso de 1º Instância Fala.BR NUP nº 25072018642202185

A questão feita pelo protocolo SAT é genérica e solicita informação não disponível em âmbito da GGTPS:

> "Solicito,todos os estudos e / ou relatórios em posse, custódia ou controle da Anvisa, FIOCRUZ, MINISTERIO DA SAUDE E MINISTERIO da CIENCIA descrevendo a purificação de qualquer "virus COVID-19" (também conhecido como "SARS-COV-2", incluindo quaisquer alegadas "variantes", ou seja, "B.1.1.7", B.1.351", P.1") diretamente de uma amostra retirada de um ser humano doente, onde a amostra do paciente não foi combinada primeiro com qualquer outra fonte de material genético (ou seja, células de rim de macaco aka Células Vero; soro fetal de bovino). Observe que não estou solicitando estudos / relatórios em que os pesquisadores não conseguiram purificar o "vírus" suspeito (separe o suposto "vírus" de tudo o mais na amostra do paciente) e, em vez disso: cultivou uma amostra não purificada ou outra substância não purificada, e / ou realizou um teste de amplificação (ou seja, um teste de PCR) no RNA total de uma amostra de paciente ou de uma cultura de células, ou no material genético de qualquer substância não purificada, e / ou fabricou um genoma com base em seguências detectadas por PCR no RNA total de uma amostra de paciente ou de uma cultura de células ou de qualquer substância não purificada, e / ou produziu imagens de microscopia eletrônica de coisas não purificadas em uma cultura de células. Esclarecimento de Pedido Para maior clareza, observe que já estou ciente de que, de acordo com a teoria do virus, um "virus" requer células hospedeiras para se replicar e não estou solicitando registros que descrevam a replicação de um "virus" sem células hospedeiras. Além disso, não estou solicitando registros que descrevam um "virus" suspeito flutuando no vácuo; Estou simplesmente solicitando registros que descrevem sua punificação (separação de tudo o mais na amostra do paciente, de acordo com as práticas laboratoriais padrão para a purificação de outras coisas muito pequenas). Observe que minha solicitação inclui qualquer estudo / relatório que corresponda à descrição acima, por exemplo (mas não limitado a) qualquer estudo revisado por pares publicado de autoria de qualquer pessoa, em qualquer lugar. Observe também que, apesar do fato de que a purificação é uma etapa essencial (mas não suficiente) para provar a existência de um "virus" causador de doenças. Portanto, no interesse da transparência e de acordo com os propósitos da legislação, se algum registro corresponder à descrição acima dos registros solicitados e estiver atualmente disponível ao público em outro lugar, forneça informações suficientes sobre cada registro para que eu possa identificar e acessar cada um um com certeza (ou seja, título, autor (es), data, periódico, onde o público pode acessá-lo). Forneça URLs sempre que possível. Grata desde já. Aguardo retorno."

Diante do questionamento genérico e de informação não disponível nessa GEVIT/GGTPS a resposta encaminhada foi:

> Prezado (a) Senhor(a), Com base nas informações fornecidas pela Gerência De Produtos Diagnósticos De Uso In Vitro (GEVIT), área técnica afeta ao assunto questionado, informamos que a informação solicitada não está disponível na Gerência de Produtos para diagnóstico in vitro da Anvisa. Informações a cerca de purificação de virus não são informações requeridas para registro de

https://sei.anvisa.gov.br/sei/controlador.php?acac=documento imprimir web&acac origem=arvore visualizar&id documento=1718195&infra sis... 1/2


22/07/2021

SEVANVISA - 1537031 - Despecho

produto para diagnóstico de Covid, de acordo com o disposto na RDC 36/2015. Ademais, não temos produtos registrados com a finalidade de identificação de variantes de interesse do virus sars-cov 2. Em atendimento ao disposto no art. 11, § 4o, da Lei 12.527/11, informamos que o requerente poderá registrar recurso na Plataforma Integrada de Ouvidoria e Acesso à Informação - Fala.BR, no prazo de 10 (dez) dias, contado da ciência da decisão, que será avaliado pelo GerênciaGeral de Tecnologia de Produtos para Saúde (GGTPS). Para mais esclarecimentos, a Anvisa também disponibiliza a sua Central de Atendimento, por meio do 0800 642 9782 (dias úteis, das 7h30 às 19h30) e por meio eletrônico, no Fale Conosco: (http://www.anvisa.gov.br/ institucional/faleconosco/ FaleConosco.a sp) Atenciosamente, Agência Nacional de Vigilância Sanitária

A resposta foi adequada, visto que a GEVIT/GGTPS não pode disponibilizar informação que não detém. Neste sentido, indefiro o recurso apresentado.

En el siguiente enlace (del <u>sitio web</u> del periodista de investigación ganadora Torsten Engelbrecht y coautor del libro <u>Virus Mania</u>) es un correo electrónico del <u>Dr. Michael Laue</u>, Jefe del Laboratorio Consultor de Microscopía Electron Diagnóstica de Patógenos Infeciosos en **Alemania Robert Koch Institut (RKI)**, un instituto *dentro* de *la cartera del* y responsable control y prevención de enfermedades: https://www.torstenengelbrecht.com/wp-content/uploads/RKI-noSARSCoV2purification-1.pdf



El enlace para el resumen de Turonova et al., proporcionado por el Dr. Laue en el correo electrónico de arriba, está <u>aquí;</u> el texto completo del documento está aquí: <u>Análisis estructural in situ de spike SARS-CoV-2 revela flexibilidad mediada por tres bisos</u>)

El **punto** de **partida** para este trabajo es un llamado aislado SARS-COV-2 llamado .MUC-IMB1 (denominado simplemente como "MUC-1" en los <u>materiales de soporte</u> de papel). Turonova y al. crédito G. Dobler del Instituto de Microbiología de la Bundeswehr por proporcionarles este "aislado".

Contacté con el Dr. Gerhard Dobler para confirmar detalles sobre el programa "MUC-1" (que pasa por varios nombres diferentes, incluyendo Alemania/BavPat1/2020), y resulta que MUC-1 es otro resultado de la metodología mono-negocio citada en la parte superior de esta página. (Los correos electrónicos y más detalles se publican aquí: MUC-1 alias MUC-IMB1: a más Corman/Drosten fraude empresarial de monos.) MUC-1 no está aislado/purificado, ni se demostró que contuviera ningún virus.

También en el sitio web de Torsten Engelbrecht se encuentran enlaces a las respuestas de los autores de los autores de los estudios SARS-COV-2, comenzando con el documento Zhu et al citado anteriormente por el Dr. Michael Laue. **Ninguno** proporcionó ninguna evidencia o repuración de seguridad de la propagación del virus. Se copia y pega de la página de inicio de Torstenés:

Na **Zhu et al.** (*NEJM*): [Veremos] una imagen de partículas de virus sedimentados, no de purificadas. (<u>ver Email</u>).

Leo L. M. Poon; Malik Peiris (*Medicina de la Naturaleza*): La imagen es el virus que brota de una célula infectada. No es un virus purificado (<u>ver Email</u>).

Sharon R. Lewin y otros. (*The Medical Journal of Australia*): La extracción de ácido nucleico se realizó en el material aislado recuperado de las células infectadas. Este material no fue centrifugado, por lo que no se purificó a través de gradiente de sacarosa para tener una banda de densidad como tal. Las imágenes EM se obtuvieron directamente de material de cultivo celular (ver Email).

Myung-Guk Han et al. (Osong Public Health and Research Perspectives): No pudimos estimar el grado de purificación porque no purificamos y concentramos el virus cultivado en las células (ver Email).

Wan Beom Park et al. (*Journal of Korean Medical Science*): "No obtenemos un micrograma electrónico que mostréis el grado de purificación" (<u>ver Email</u>).

13 de enero de 2021: **El Ministerio de Salud y Servicios de Cuidado de Noruega** no proporcionó o citó ningún registro de aislamiento de la muestra de un paciente sintomático, donde la muestra no fue adulterada con material genético adicional, por nadie, por cualquier persona en ninguna parte, para el solicitante Martiens Bekker. Solicitud y respuesta con traducción al inglés:

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/06/Noruega-Ministry-of-Health-cites-no-records.pdf}$

Fra: Riise Øystein [mailto: Oystein. Riise@hod.dep.no] Sendt: onsdag 13. januar 2021 14:37 Til: @vinje.kommune.no > Emne: krav om innsyn
Hei,
Vi viser til din henvendelse om krav om innsyn fra en innbygger i din kommune.
Slik vi forstår henvendelsen gjelder det dokumentasjon på om SARS-CoV-2 forårsaker sykdommen covid-19.
Departementet vil vise til Folkehelseinstituttets hjemmesider på norsk og engelsk <u>Folkehelseinstituttet - FHI</u> :
Det finnes også informasjon på nettsidene til det europeiske smittevernbyrået <u>Homepage European Centre for Disease Prevention and Control (europa.eu)</u> og WHO <u>Technical guidance (who.int)</u> .
Med vennlig hilsen

25 de abril de 2021: la **Dirección de Salud de Noruega** (que depende del Ministerio de Salud y Servicios de Atención) no proporcionó ni citó ni siquiera 1 registro de la purificación de un paciente de una muestra de paciente, por cualquier persona, en cualquier lugar, y proporcionó una excusa tonta en su lugar:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/06/Norwegian-Directorate-of-Health.pdf



This message has been automatically translated: Norwegian -> English.

Christine Massey <cmssyc@gmail.com>

Public Administration Act request for freedom of information to the Norwegian Directorate of Health

Torunn Janbu <Torunn.Janbu@helsedir.no>
To: "cmssyc@gmail.com" <cmssyc@gmail.com>

Sun, Apr 25, 2021 at 2:09 PM

Thank you for the inquiry dated 16 April 2021.

The Norwegian Directorate of Health does not own, store or control documents with information about patients.

Torunn Janbu

Department Director Department of Specialist Health Services

Quality and course division

The Norwegian Directorate of Health

Mobile 97735457

Mayo, 2021 **Uruguays Clemente Stable Biological Research Institute** (en el Ministerio de Educación y Cultura) y la **Facultad de Química de la Universidad de la República** no proporcionaron/no se citaron registros de la purificación SARS-COV-2, por parte de cualquier persona en cualquier lugar, para la solicitante María Bettina Galo. Ambas respuestas:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/05/Uruguay-Clemente-Stable-Biol-Research-Inst-Min-Edu-and-Culture-Faculty-of-Chem-Uof-Repub-no-records.pdf





Montevideo, 25 de mayo de 2021.

Consejo Directivo del Instituto de Investigaciones Biológicas Clemente Estable

ASUNTO: la solicitud de acceso a información pública, presentada por la Sra. María Bettina Gallo, al amparo de la Ley 18.381 de Acceso a la Información Pública.


OBJETO: La Sra. María Bettina Gallo determina el objeto de la solicitud en su derecho a conocer acerca de ".Todos los estudios y / o informes en posesión, custodia o control de los informes y registros que describan la purificación de cualquier "virus COVID-19" (incluidos "B.1.1.7", "B.1.351", "P.1" y cualquier otra "variante") (mediante maceración, filtración y uso de una ultracentrifuga; también a veces por algunas personas como "aislamiento"), directamente de una muestra tomada de un ser humano enfermo, donde la muestra del paciente NO SE combinó primero con ninguna otra fuente de material genético (es decir, células de riñón de mono, también conocidas como células Vero; suero fetal bovino)"

FUNDAMENTO LEGAL: El acceso a la información pública es un derecho de todas las personas, con arreglo al artículo 3º de la Ley 18.381.

Que la Unidad Ejecutora 011 "Instituto de Investigaciones Biológicas Clemente Estable" es un sujeto obligado por la Ley 18.831 a brindar información que se sea considerada pública con arreglo a los artículos 4 y 5 de la citada.

Que en aplicación del principio de informalismo a favor del administrado el Consejo Directivo de la Unidad Ejecutara va a procesar la presente solicitud ya que la misma debió presentarse por escrito en la forma establecida por el artículo 13 de la Ley 18.381.

INFORME: De acuerdo a lo hasta aquí expresado el Consejo Directivo de la Unidad Ejecutora 011 "Instituto de Investigaciones Biológicas Clemente Estable" informa que no se trabaja con el virus vivo y que no se realizó la purificación del virus COVID en ninguna de sus variantes.





7 de junio de 2021: **El Ministerio de Salud Pública de Uruguay** no proporcionó o citó a la solicitante María Bettina Galo ningún registro de la muestra de un paciente purificado de una muestra de paciente, por cualquier persona, en cualquier lugar, nunca, y afirmó que no pueden entender la petición:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/06/Uruguay-Ministry-of-Public-Health-of-Res-377-2021.pdf

RESULTANDO: que la peticionante solicita información sobre: i) todos los estudios y/o informes en posesión, custodia o control de los Centros para el Control y la Prevención de Enfermedades del M.S.P. y/o privados integrantes o no del Grupo Asesor Científico Honorario (GACH), sin excepción, a cargo de la pandemia Covid-19, UDELAR, Facultad de Ciencias, Facultad de Quimica, Facultad de Medicina y el Departamento de Genética de la Facultad de Medicina, la Agencia para Sustancias y cualquier otra dependencia público o privado, o público-privada (Laboratorios de investigación); y ii) información sobre cada registro que describan la purificación de cualquier "virus- COVID -19" para poder identificar y acceder a cada uno con certeza;

CONSIDERANDO: I) que en merito a lo informado por la División Servicios Jurídicos, corresponde acceder a lo peticionado con excepción de la información solicitada que no se ajusta a los requisitos normativos, debiendo existir una descripción clara de la información requerida, así como cualquier dato que facilite su localización, rigiendo para ello lo dispuesto en el artículo 13 de la Ley Nº 18.381 de 17 de octubre de 2008;

II) que de acuerdo a lo dispuesto por el artículo 16 de la citada disposición legal, el acto que resuelva la petición debe emanar del jerarca máximo del Inciso o quien posea facultades delegadas al efecto; <u>ATENTO</u>: a lo precedentemente expuesto y a lo establecido por Resolución Ministerial Nº 38:991 de 22 de enero de 1991;

Una vez más, el **Ministerio de Salud Pública de Uruguay** fue preguntado por la depuración de María Bettina Galo re-SARS-COV-2. La respuesta: "No somos conscientes de que el SARS COV 2 ha sido cultivado - a pesar de que Bettina hadn-t preguntó por "cultivation", que es lo contrario de purificar cualquier cosa. Véase la página 20:https://www.fluoridefreepeel.ca/wp-content/uploads/2021/08/Uruguay-Respuesta-MSP-SOBRE-COVID-EFECTOS-ADVEROS-DOCUMENTO-Maria-Bettina-1.pdf

18. El Sars-Cov2 ha sido Aislado, Secuenciado y Purificado según método científico para elementos pequeños en Uruguay? Si la respuesta es Sí, indicar por favor por quién, documentación al respecto, publicación, corroborado por pares (quiénes)

No tenemos conocimiento que en el país se haya cultivado el SARS CoV 2 ya que exige condiciones de bioseguridad con las cuales el país no cuenta.

13 de enero de 2023:

La Autoridad de Salud de Oregon rechazó la divulgación de todos los registros inéditos re 21 consultas re imaginaria.

Un colega buscó registros que contenían información sobre la **supuesta** investigación de la **Autoridad** de **Salud** de **Oregón** sobre el virus imaginario, desde 21 ángulos diferentes; Jeanne Windham, una mujer que actúa como Coordinadora del Proceso de Registros Públicos y Litigios Internos, insistió en que toda la *información obtenida por la Autoridad de Salud de Oregón o un administrador de salud pública local en el curso de una investigación de enfermedad o brote de enfermedad reportable... es confidencial bajo la ley estatal.... que suena sólo un poco pescado, especialmente considerando que los casos de comunicación están fraudulentamente clasificados como tales basados en*

(como los llama David Icke) y que no puede detectar ninguna enfermedad, reportable o de otra manera, y que la supuesta enfermedad de reportables ha sido nunca mostrada que existe, junto con el virus. https://www.fluoridefreepeel.ca/wp-content/uploads/2023/05/Oregon-Health-Authority-many-issues-PACKAGE-redacted.pdf

Re: Public Records Requests - Records Related to SARS-CoV2 Outbreak Pursuant to ORS 433.001, 433.004 and 433.006 (2022-0033)

Dear

This will confirm our telephone conversation of Friday, January 7, 2022, wherein I advised that Oregon Health Authority received your various public records requests related to the SARS-CoV-2 outbreak. Information related to COVID-19 can be found here. Except for the data Oregon Health Authority publishes, information obtained by Oregon Health Authority or a local public health administrator in the course of a reportable disease or disease outbreak investigation, including records of testing performed by the OSPHL from patient samples, is confidential under state law, and not subject to disclosure under the Oregon Public Records Act. See ORS 433.008(1). There is no exception under ORS 433.008(2) that would permit Oregon Health Authority, in its discretion, to provide you with the information you are seeking. That being said, the lab recommends that citizens explore the NCBI Pubmed COVID-19 website, which has over 187,000 published research articles and over 6,700 clinical trials investigating SARS-CoV-2. The information available on this site is growing with new articles added frequently. I hope this is helpful.

Jeanne Windham

Public Records and Internal Litigation Process Coordinator
OREGON HEALTH AUTHORITY

30 de marzo de 2021: **La Autoridad de Salud** de **Oregón** confirmó que no tienen ningún registro de la purificación de ninguna muestra de pacientes en el mundo: Vea la redacción completa de la solicitud y respuesta: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/05/Oregon-HA-marzo-2021-request-response.pdf

On Tuesday, March 30, 2021 1:28 PM, Windham Jeanne <JEANNE.WINDHAM@dhsoha.state.or.us> wrote:

VIA EMAIL ONLY -March 30, 2021

Re: Public Records Request - Studies/Reports Related to Purification of Any "SARS-COV-2 Causing Disease in Humans (2021-

Good Afternoon

This will confirm Oregon Health Authority received your March 29, 2021 public records request for "All studies and/or reports in the possession, custody or control of the Oregon Health Authority (OHA) describing the purification of any "SARS-COV-2" (including any "variant" of "SARS-COV-2") said to have caused disease in humans (via maceration, filtration and use of an ultracentrifuge; also referred to at times by some people as "isolation"), directly from a sample taken from a diseased human, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum)." There are no responsive records to your request. This will complete your request.

Jeanne Windham

Public Records and Internal Litigation Process Coordinator OREGON HEALTH AUTHORITY
Fiscal and Operations Division
500 Summer St. NE, E-20
Salem, OR 97301
(971) 345-1688
jeanne.windham@dhsoha.state.or.us
http://www.oregon.gov/OHA

22 de mayo de 2021: **Ministerio de Salud y Protección Social, República de Colombia** admite que no tienen registro de la depuración de la muestra de un paciente de una muestra de pacientes. Carta completa:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/06/FOI-Colombia-no-records-package.pdf

Fecha: 22-05-2021 Página 1 de 2

Bogotá D.C.,



ASUNTO: Derecho de Petición. Rad 202142400025922

Respetada

En atención al radicado del asunto, en el que solicita "Todos los registros en posesión, custodia o control del Ministerio de Salud y Protección Social de la República de Colombia que describan el aislamiento de un virus SARS-COV-2 y / o cualquiera de sus variantes, directamente de una muestra tomada de un paciente enfermo, donde no so combinó la muestra del paciente primero con ninguna otra fuente de material genético (es decir, células de riñón de mono, también conocidas como células Vero; suero fetal bovino)", para lo cual este Ministerio se permite precisar lo siguiente:

Conforme al Decreto 4107 de 2011 el Ministerio de Salud y Protección Social tiene como objetivo, dentro del marco de sus competencias, formular, adoptar, dirigir, coordinar, ejecutar y evaluar la política pública en materia de salud, salud pública, y promoción social en salud, y participar en la formulación de las políticas en materia de pensiones, beneficios económicos periódicos y riesgos profesionales, lo cual se desarrollará a través de la institucionalidad que comprende el sector administrativo.

De otra parte, informarle que conforme a nuestras competencias no contamos con registros que describan el aislamiento de un virus SARS-COV-2 y / o cualquiera de sus variantes, directamente de una muestra tomada de un paciente enfermo, donde no se combinó la muestra del paciente primero con ninguna otra fuente de material genético.

Cordialmente.

Leonardo Arregoces Castillo

Director de Medicamentos y Tecnologías en Salud


Elaboró: Lhernandea

Carrera 13 Nº 32 - 76 - Código Postal 110311, Bogotá D.C

31 de enero de 2022:

El Consejo Indio de Investigación Médica (ICMR, el organismo de ápice en la India para la formulación, coordinación y promoción de la investigación biomédica) confirmó que el solicitante no tiene registro de que se encuentre en los fluidos corporales de cualquier humano enfermo y purificado (lo cual sería necesario para que pueda secuenciarse, caracterizarse y estudiarse con experimentos controlados para determinar si realmente existe):


https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/ICMR-Jan-2022.pdf



14 de febrero de 2022:

ICMR confirmó para otro solicitante que no tiene una muestra física de SARS-COV-2 purificado:

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/ICMR-Feb-2022.jpg



7 de diciembre de 2021:

No hay una metodología para purificar el SARS-COV-2 directamente de los especímenes clínicos de los pacientes hasta que el virus se aísle utilizando métodos in vitro o in vivo, dijo que ningún hombre o mujer coherente nunca. Sin embargo, esta es la última respuesta del **Consejo Indio de Investigación Médica** (órgano de la India para la formulación, coordinación y promoción de la investigación biomédica) a una solicitud de registros de purificación.

Y, considerando los aspectos de bioseguridad, los registros de los especímenes clínicos, aislados de SARS-COV-2 en posesión, custodia o control del ICMR-Instituto Nacional de Virología. Mkaay.

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/ICMR-Dec-2021-CantPurifyWinSIsolating.pdf}{CantPurifyWinSIsolating.pdf}$



आई सी एम आर - राष्ट्रीय विषाण विज्ञान संस्थान

भारतीय आयुर्विज्ञान अनुसंधान परिषद

स्यारस्य एवं परिवार कल्याण नंत्रानय, भारत सरकार

I C M R - NATIONAL INSTITUTE OF VIROLOGY

Indian Council of Medical Research

20 - ए. डा. आबेडकर मार्ग, पोस्ट बॉक्स संख्या 11, पूर्ण - 411 001, मारत. 20-A. Dr. Ambedkar Road, Post Box No. 11, Pune 411 001, India Tel. NIV Camp +91-020-26127301, 26006290, Fax: 26122669, 26126643 / NIV Pashan +91-020-26006390 Fax: No. 25871895 / 25870640 E-mail: director.niv@scmr.gov/in Website: www.niv.co.in

No. 1/8/2005/RTI/Admn./XVII-2009

Of December, 2021

To



Sub.: Online Application under Right to Information Act 2005 Ref.: Registration No. NIOVP/R/E/21/00083 dated 06/11/2021

This is in reference to your above online application no. NIOVP/R/E/21/00083 dated 6th November, 2021 seeking information under Right to Information Act 2005. The information sought by you is furnished below.

Please provide all studies and/or reports in the possession, custody or control of ICMR or NIV or other affiliated bodies /agencies describing the purification of the alleged "COVID-19 virus" (aka "SARS-CoV-2", including any alleged "variants") directly from a sample taken from a diseased human, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; Fetal Bovine Serum).

As per our knowledge, there is no methodology available to purify SARS-CoV-2 directly from the clinical specimens of the patient until the virus is solated using in vitro or in viv methods Considering the biosecurity aspects, the records of the clinical specimens, isolates of SARS-CoV-2 in possession, custody or control of ICMR-National Institute of Virology, Pune cannot be shared publicly.

The Appellate Authority in respect of the information furnished above is, Prof. Priya Abraham, Director, ICMR-National Institute of Virology, Pune. If you are not satisfied with this reply, you may appeal within 30 days of receipt of this letter.

Thanking you,

Yours sincerely,

Senti Canan Dr. Deepti Parashar

CPIO & Scientist-E

विश्व खारथ्य संघटन राष्ट्रीय शीताचार केन्ट पोलिओ, खसरा एवं रुबेला के लिए रेफरल प्रयोगशाला



WORLD HEALTH ORGANIZATION Collaborating Centre for Emerging Viral infections National Influenza Centre

Referral Lab for Polio, Measles and Rubelta

3 de mayo de 2021: Consejo Indio de Investigación Médica (ICMR, el organismo de ápice en la India para la formulación, coordinación y promoción de la investigación biomédica) no ha proporcionado/cita ningún registro de la purificación de la lecena (quien pidió mantener su nombre y archivo privado); en su lugar citaron un ejemplo típico de fraude de "monkey-business"" - exactamente lo que el solicitante había pedido

que no recibiera.

Tenga en cuenta que el ICRM ha afirmado fraudulentamente haber aislado el virus y el escarián imaginario del Reino Unido, de haber estado rastreando el virus en toda la India, ha desarrollado una charla COVID-19, comparte derechos de propiedad en la quackcine y es miembro de la <u>red de mano de</u> obra <u>de salud</u> global de la OMS.

El 1 registro citado por ICMR es una correspondencia titulada "Primer aislamiento del SARS-CoV-2 de muestras clínicas en la India" publicada en la Revista de Investigación Médica de la India, una revista publicada para el ICRM. De acuerdo con la correspondencia. Los laboratorios designados de pruebas COVID-19... refirieron los especímenes ... al Consejo Indio de Investigación Médica-Instituto Nacional de Virología (ICMR-NIV), Pune, después de Tres de los autores están afiliados al ICRM.

Respuesta completa de los ICMR:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/05/India-Council-Medical-Research-request-repro-redacted.pdf}{}$

| | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 05/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft. Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadaw, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Rephy :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Oupta
 | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status BEQUEST DISPOSED OF Date of action 08/05/2021 Rephy > For all the queries a research article has been published in the year 2020. Ref. Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Oupts | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CQ) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CQ) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy > For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta
 | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 03/05/2021 Rephy > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (OPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref. Prasad Sarkale, Savita Patel, Pragya Yadaw, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (OPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DESPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedits Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:> For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS).
 | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref. Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 05/05/2021 Repty :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RE-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Reply:> For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RE-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 03/05/2021 Rephy > For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Putel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Repty:> For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RE-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/03/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Presad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by
observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status BEQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DSPOSED OF Date of action 03/05/2021 Rephy: For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (OPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (OPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta |
|--|---|---|---|--|--
--	--	--	--
--	--	--	--
--	--	--	--
--	--	--	--
--	--	--	--
--	--	--	--
--	--		
Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DESPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries. SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase	Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Partel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase	Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Pated, Pragya Yadaw, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase	Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-91 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DSPOSED OF Date of action 08/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref. Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DESPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DESPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries. SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta
 | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :> For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority inclain Council of Medical Research Status REQUEST DEPOSED OF Date of action 03/05/2021 Repty:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS).
 | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-91 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Repty :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Partel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Repty:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Putel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref. Prasad Sarkale, Savita Putel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-91 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RE-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref. Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25,/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Repty > For all the queries a research article has been published in the year 2020. Ref. Prasad Sarkale, Savita Putel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries> SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DSPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RE-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref. Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DEPOSED OF 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Putel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DSPOSED OF Date of action 08/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-91 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DSPOSED OF Date of action 08/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref. Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing
cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DSPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Enter Registration Number Name Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta |
| Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF. Date of action 05/05/2021 Rephy For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ) values in real-time reverse transcription-polymerase | Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action Date of action Os/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadev, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft. Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF. Date of action 05/05/2021 Repty: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patet, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). Dr Nivedita Gupta
 | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patet, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 08/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 08/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta
 | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF. Date of action 05/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action Reply: For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedtts Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action Date of action Status REQUEST DISPOSED OF. Date of action Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadaw, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS).
 | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action Reply: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action Reply: - For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 03/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Partel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 05/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft - Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 03/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 02/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects
(CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopethic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 2s/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2022 Reply > For all the queries a research article has been published in the year 2020. Reft- Presed Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). Dr Nivedita Gupta | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 02/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Sarka Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta |
| Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF. Date of action 05/05/2021 Rephy For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ) values in real-time reverse transcription-polymerase | Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action Date of action Os/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadev, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft. Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF. Date of action 05/05/2021 Repty: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patet, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). Dr Nivedita Gupta
 | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patet, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 08/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 08/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta
 | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF. Date of action 05/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action Reply: For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedtts Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action Date of action Status REQUEST DISPOSED OF. Date of action Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadaw, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS).
 | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action Reply: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action Reply: - For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 03/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Partel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 05/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft - Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 03/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 02/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects
(CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopethic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 2s/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2022 Reply > For all the queries a research article has been published in the year 2020. Reft- Presed Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). Dr Nivedita Gupta | Name Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 02/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Sarka Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta |
| Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF. Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ) values in real-time reverse transcription-polymerase | Date of filing 25/04/2021 Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action Os/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadev, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft. Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF. Date of action 05/05/2021 Repty: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft - Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patet, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). Dr Nivedita Gupta
 | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patet, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Partel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta
 | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF. Date of action 05/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action Reply:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedits Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action Sephy: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Dute of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action Reply: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action Reply: - For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 05/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 03/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Partel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 05/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft - Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 03/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 02/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Refr Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and
cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopethic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 03/05/2022 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Presed Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). Dr Nivedita Gupta | Date of filing 25/04/2021 Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 02/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Sarka Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta |
| Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF. Date of action 08/05/2021 Rephy: For all the queries a research article has been published in the year 2020. Reft. Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF. Dute of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadev, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action OS/OS/2021 Reply: For all the queries a research article has been published in the year 2020. Reft: Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action OS/OS/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Refr Prasad Sarkale, Savita Patet, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and mext-generation sequencing (NGS). Dr Nivedita Gupta
 | Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytoparthic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Partel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Partel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Public Authority Indian Council of Medical Research Status REQUEST DESPOSED OF Date of action 08/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Refr Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta | Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta
 | Public Authority indian Council of Medical Research Status REQUEST DEPOSED OF. Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft: Prasad Sarkale, Savita Partel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta | Public Authority Indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedits Gupta | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action REPLY: For all the queries a research article has been published in the year 2020. Reft: Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). | Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will amswer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Partel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 0s/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft- Presed Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF. Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Reply > For all the queries a research article has been published in the year 2020. Reft - Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority indian Council of Medical Research Status REQUEST DEPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Repty:- For all the queries a research article has been published in the year 2020. Refr-Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in
real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopethic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 08/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Public Authority Indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft- Presed Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Public Authority indian Council of Medical Research Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Sarka Pated, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta |
| Status REQUEST DESPOSED OF Date of action 03/05/2021 Rephy :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase | Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CI) values in real-time reverse transcription-polymerase | Status REQUEST DISPOSED OF Date of action Os/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action OS/DS/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Status BEQUEST DISPOSED OF Date of action OS/OS/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta
 | Status Date of action 08/05/2021 Rephy: For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopethic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Status REQUEST DISPOSED OF Date of action 03/05/2021 Repty :- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Status REQUEST DISPOSED OF Date of action O3/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Status REQUEST DEPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Status REQUEST DESPOSED OF Date of action 03/05/2021 Rephy :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta
 | Status REQUEST DISPOSED OF Date of action OS/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Status Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Status REQUEST DISPOSED OF Date of action 08/05/2021 Rephy > For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta | Status REQUEST DEPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupts | Status Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Status REQUEST DEPOSED OF Date of action REPLY:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). | Status BEQUEST DISPOSED OF Date of action 03/05/2021 Rephy :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action 05/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, sindian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action O3/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action OS/OS/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Status REQUEST DISPOSED OF Date of action OS/OS/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action OS/05/2021 Repty :- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries. SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action O3/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries. SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Status REQUEST DISPOSED OF Date of action OS/OS/2021 Reply > For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, anticle will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries. SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action OS/OS/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status BEQUEST DISPOSED OF Date of action 03/05/2021 Rephy: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, SavIta Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action OS/OS/2021 Rephy: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain
reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status BEQUEST DISPOSED OF Date of action 03/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopethic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Status REQUEST DISPOSED OF Date of action OS/OS/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Status REQUEST DISPOSED OF Date of action 03/05/2021 Rephy :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Status REQUEST DISPOSED OF Date of action Os/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (CQ values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta |
| Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Brillian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase | Date of action 03/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CI) values in real-time reverse transcription-polymerase | Date of action 05/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CI) values in real-time reverse transcription-polymerase | Date of action 03/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft: Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action 03/05/2021 Reply: For all the queries a research article has been published in the year 2020. Ref:-Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action O3/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of action 08/05/2021 Reply: For all the queries a research article has been published in the year 2020. Ref:-Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta
 | Date of action 08/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopethic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of action O3/05/2021 Repty :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta
 | Date of action O\$/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). Dr Nivedita Gupta | Date of action 08/05/2021 Reply > For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta | Date of action 03/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta | Date of action 05/05/2021 Reply: For all the queries a research article has been published in the year 2020. Ref: Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and sext-generation sequencing (NGS). | Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action 05/05/2021 Reply: For all the queries a research article has been published in the year 2020. Ref:-Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action 03/05/2021 Reply: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action 08/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Date of action 03/05/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action 03/05/2021 Repty:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries. SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action 03/05/2021 Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action 03/05/2021 Repty:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries. SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action 03/05/2021 Reply: For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Date of action OS/OS/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, and Sarkule of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPES) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action 03/05/2021 Repty:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries. SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action OS/OS/2021 Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action 03/05/2021 Rephy: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, SavIta Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action 08/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron
microscopy and next-generation sequencing (NGS). | Date of action 03/05/2021 Rephy > For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopethic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Date of action Os/os/2021 Reply: For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, and Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of action 03/05/2021 Rephy:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Date of action Os/os/2021 Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta |
| Rephy:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's)and cycle threshold (CQ) values in real-time reverse transcription-polymerase | Reply:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CI) values in real-time reverse transcription-polymerase | Reply:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-\$1 cells by observing cytopathic effects (CPE's) and cycle threshold (CI) values in real-time reverse transcription-polymerase | Rephy:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, SavIta Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Reply :- For all the queries a research article has been published in the year 2020. Reft:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta
 | Rephy :- For all the queries a research article has been published in the year 2020. RefPrasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopethic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Rephy :- For all the queries a research article has been published in the year 2020. Ref:Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta
 | Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Rephy:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta | Reply:- For all the queries a research article has been published in the year 2020. Ref Prassad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedits Gupta | Reply:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Reply:- For all the queries a research article has been published in the year 2020. Reft Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Rephy:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Reply:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-seneration sequencing (NGS). | Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Rephy:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Reply:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, and India, and Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkule, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPES) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Reply:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Reply:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Putel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation
sequencing (NGS). | Rephy:- For all the queries a research article has been published in the year 2020. Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopethic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Reply:- For all the queries a research article has been published in the year 2020. Reft- Prasad Sarkale, Savita Patel, Praya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Rephy:- For all the queries a research article has been published in the year 2020. Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta |
| Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase | Ref:- Prasad Sarkale, Savita Partel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CI) values in real-time reverse transcription-polymerase | Ref:- Prasad Sarkale, Savita Pated, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CI) values in real-time reverse transcription-polymerase | Ref:- Prasad Sarkale, Savita Putel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (OPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:-Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta
 | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Ref:- Prasad Sarkale, Savita Putel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta
 | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPEs) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Putel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Ref:-Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Presed Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries: SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Ref:-Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CI) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Putel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS).
 | Ref:-Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-61 cells by observing cytopathic effects (CPE's) and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's) and cycle threshold (CX) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Ref Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (Ct) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | Ref:- Prasad Sarkale, Savita Patel, Pragya Yadav, et al., First isolation of SARS-Cov-2 from clinical samples in India, Indian Journal of Medical Research. This article will answer your queries:- SARS-Cov-2 was successfully isolated and characterized from clinical samples in India using Vero CCL-81 cells by observing cytopathic effects (CPE's)and cycle threshold (CC) values in real-time reverse transcription-polymerase chain reaction (RT-PCR), electron microscopy and next-generation sequencing (NGS). Dr Nivedita Gupta | | |
| | | cines reaction (vi-r-c.s), execution microscopy and next-generation sequencing (vi-cs). | Dr Nieedita Gupta | Dr Nivedita Gupta | |
 | | | | |
 | | | | | Dr Nivedita Gupta
 | Dr Nissellin Guette | | | Dr Nivedita Gupta | Dr Nivedita Gupta
 | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Minnellin Guerte | |
 | | | Dr Nivedita Gupte | Dr Nivedita Gupta | Dr Nivedita Gupta
 | Dr Nivedita Gupta | | | |
| Dr Nivedita Gupta | De Minadite Guete | | | 7 man and the Co. | CP10 Details :- Phone: 013-26588980 | CP10 Details :- Phone: 01.1-26588980
 | CPIO Details :- Phone: 011-26588980 | FROM: 0.1-20385980 | F1000E.011-03300300 | 71000.00.70 | | |
 | - Thomas Wall And | F10000 012-0000000 | Phone: 0.1-20588980 | CP10 Details :- |
 | St messie supe | Dr Nivedits Gupts | Dr Nivedita Gupta | | The state of the s | CONTRACTOR OF THE PROPERTY OF |
 | of meeting stapes | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta
 | No. of the control of | | 25.00 (25.00) | CDIO Details | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phonic: 011-26588980
 | CP10 Details :- Phonic: 011-26588980 |
| | OP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 82 63 | | | 100
 | ngupta@icree.org.in | ngupta@icme.org.in | ngupta@icrrr.org.in | ngupta@icme.org.in | ngupta@icrm.org.in
 | ngupts@icmr.org.in | ngupta@icmr.org.in | ngupta@icmr.org.in | |
 | 10 miles | | 8 6 | |
 | | | | |
 | | | 100 | 87 (5) | 100
 | 89 (8) | | 87 (6 | |
| CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-2658980 ngupta@icmr.org.in | CPIO Details :- Phone: 011-26588980 ngupta@icrn.org.in | ngupta@icres.org.in | ngupta@icmr.cog.in | ngupta@icror.org.in | ngupta@icnw.org.in
 | | | | |
 | | | | ngupta@icrre.org.in | ngupta@icmr.cog.in
 | ngupta@icrre.org.in | ngupta@icrecorg.in | ngupta@icmr.cog.in | ngupta@icre.org.in | ngupta@icres.org.in
 | ngupta@icre.org.in | ngupta@icmr.org.in | ngupta@icrre.org.in | ngupta@icmr.org.in | ngupta@icrec.org.in
 | ngupta@icnr.org.in | ngupta@icmr.org.in | ngupta@icnr.org.in | ngupta@icrrr.org.in | ngupta@icres.org.in
 | ngupta@icrrr.ong.in | ngupta@icre.org.in | ngupta@icre.org.in | ngupta@icrre.org.in |
| CP10 Details :- Phone: 011-26588980
ngupta@icru.org.in | CPIO Details :- Phone: 011-2658990 ngupta@icrer.org.in Or Seminan Panda | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Or Saminan Pande | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icre.org.in Or Saminan Panda | ngupta@icmr.org.in Or Semiren Pande | ngupta@icmr.org.in Or Samiran Pande
 | Or Samiran Panda | Or Samiran Panda | Or Samiran Panda | Or Saminen Panda | Or Saminen Panda
 | Or Samiran Panda | Or Samiran Panda | Or Samiran Panda | ngupta@icrre.org.in Or Saminen Pande | ngupta@icrvr.org.in
Or Seminen Pande
 | ngupta@icre.org.in Or Saminen Pande | ngupta@icrur.org.in Or Samiran Panda | ngupta@icrre.org.in Or Samiran Panda | ngupta@icmr.cog.in Or Semiran Pande | ngupta@icmr.org.in Or Semiran Pande
 | ngupta@icmr.org.in Dr Semiran Pande | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icrrr.org.in Or Seminan Pende
 | ngupta@icmr.org.in Or Semiran Pande | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icmr.org.in Or Samiran Pande | ngupta@icnv.org.in Or Saminan Panda | ngupta@icrur.org.in Or Samiran Panda
 | ngupta@icnr.org.in Or Samiran Panda | ngupta@icmr.org.in Dr Semiran Pande | ngupta@icre.cog.in Or Saminan Panda | ngupta@icmr.cog.in Or Semiran Pande |
| CP1O Details :- Phone: 011-26588980 ngupta@icnr.cog.in Or Seminan Pande | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | ngupta@icmr.cog.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@fcre.org.in Or Samiran Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icnr.org.in Or Saminan Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icror.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | Dr Seminan Panda First Appellate Authority Details :- Phone: 011-26588395 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | Dr Seminen Pande First Appellate Authority Details :- Phone: 011-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrec.org.in Or Saminen Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icrec.org.in Or Seminan Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icrec.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icror.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrre.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588395 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icrnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995
 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrur.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588895 |
| CP1O Details :- Phone: 011-26588980 ngupta@icnrc.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588955 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 pendas.lng@icmr.gov.in | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Or Saminan Panda First Appellate Authority Details :- Phone: 011-26588995 pendas.hq@icmr.gov.in | ngupta@icrer.cog.in Or Samiran Pande First Appellate Authority Details:- Phone: 01.1-26588305 pendes.hq@icrer.gov.in | ngupta@icre.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icre.gov.in | ngupta@icnr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 013-26588895 pendas.hg@icnr.gov.in | ngupta@icror.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588305 pandas.htq@icror.gov.in
 | Dr Seminan Panda First Appellate Authority Details :- Phone: 011-36588955 pandas.ht@licmr.gov.in | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 pendas.hq@lcmr.gov.in | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 pendas.hq@lcmr.gov.in | Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icmr.gov.in | Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 pendes.hq@icmr.gov.in
 | Or Seminar Pende First Appellate Authority Details:- Phone: 011-26588895 pendes.lng@lcmr.gov.in | Dr Seminen Pande First Appellate Authority Details :- Phone: 011-26588895 pandes.hq@icnsc.gov.in | Or Seminan Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icns.gov.in | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icmr.gov.in | ngupta@icrec.org.in Or Semiran Panda First Appellate Authority Details:- Phone: 011-26588895 pendes.hq@icrec.gov.in
 | ngupta@icrec.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icrec.gov.in | ngupta@icror.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.ing@icror.gov.in | ngupta@icre.org.in Or Samicra Panda First Appellate Authority Details:- Phone: 013-25588995 pendas.lq@icre.gov.in | ngupta@icnn.org.in Or Saminan Panda First Appellate Authority Details:- Phone: 011-26588305 pandas.hq@icnn.gov.in | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-36588305 pandas.hq@icrer.gov.in
 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 01.1-36588305 pandas.hq@icrer.gov.in | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 013-26588895 pendes.hq@lcmr.gov.in | ngupta@icmr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@lcmr.gov.in | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 013-26588895 pendas.hq@icmr.gov.in | ngupta@icnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendas.lng@icnr.gov.in
 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 01.1-26588205 pandas.hq@icrer.gov.in | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 013-26588895 pendas.hq@icmr.gov.in | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details:- Phone: 01.1-26588895 pandes.hq@icmr.gov.in | ngupta@icnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icns.gov.in | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 01.1-26588895 pandas.htq@icnr.gov.in
 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandes.hq@icnr.gov.in | ngupta@icner.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 0136588355 pandas.hq@icne.gov.in | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588305 pandas.hq@icnr.gov.in | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588895 pandas.hq@fcmr.gov.in |
| CP10 Details :- Phome: 011-26588980 ngupta@icrre.org.in Or Samiran Panda First Appellate Authority Details :- Phome: 011-26588895 pendas.hq@icrre.gov.in | CPIO Details :- Phone: 01.1-26588980 ngupta@icmr.org.in Or Saminan Panda Phone: 01.1-26588995 pandas.hq@icmr.gov.in [Nodal Officer Details :- | CPIO Details :- Phone: 011-26588980 ngupta@icrn.org.in Or Samiran Panda Phone: 011-26588995 pandas.hq@icrn.gov.in [Nodad Officer Details :- | ngupta@icres.org.in Or Samiran Panda Phone: 011-26588895 pendas.hq@icres.gov.in [Nostal Officer Details :-] | ngupta@fcmr.org.in Or Semiren Panda Phome: 01-26588895 pandas.hq@fcmr.gov.in [Notial Officer Details.] | ngupta@icnr.org.in Or Semiran Panda Phone: 011-26588895 pandas.lng@icnr.gov.in [Nodad Officer Dettails :- | ngupta@icres.org.in Dr Seminen Panda Phome: 011-26588895 pandas.hq@icres.gov.in [Nortal Officer Dettails.]
 | First Appellate Authority Details :- Dr Seminen Pands Phone: 011-26588895 pands.hq@icmc.gov.in [Noctal Officer Details :- | First Appellate Authority Details :- Dr Seminan Panda Phone: 011-26588805 pandas.hq@icmr.gov.in [Nostal Officer Details :-] | First Appellate Authority Details :- Dr Seminan Panda Phone: 011-26588805 pandas.hq@icmr.gov.in [Nostal Officer Details :-] | Or Seminan Panda Phone: 011-26588895 pandas.hq@icmc.gov.in [Nostal Officer Details.] | Or Semiran Panda Phone: 011-26588895 pandas.hq@icmc.gov.in [Nostal Officer Details.]
 | First Appellate Authority Details :- Dr Samiran Panda Phone: 013-26588895 pandas.hq@lcmr.gov.in [Nodal Officer Details :-] | First Appellate Authority Details :- Dr Samiran Panda Phone: 011-26588895 pandas.hq@icmr.gov.in [Nodal Officer Details :- | Or Seminar Panda Phone: 011-26588895 pendes.hq@icmc.gov.in [Nodal Officer Dettails :-] | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 01-26588895 pandas.hq@icnr.gov.in [Notial Officer Details :- | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 01.1-26588895 pandas.hq@icmr.gov.in
 | ngupta@icnrc.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icnrc.gov.in [Notial Officer Details :- | ngupta@icrec.org.in Dr Seminan Pande Phome: 01.1-26588895 pandas.hq@icrec.gov.in [Nodal Officer Dettails :- | ngupta@fcre.org.in Or Semiren Pande First Appellate Authority Details :- Phone: 011-26588895 pandes.hq@icmr.gov.in [Nodal Officer Details :- | rgupta@icmr.org.in Or Seminen Pande Phone: 011-26588895 pendes.hq@icmr.gov.in [Nodad Officer Details :-] | ngupta@icres.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@icres.gov.in [Nosted Officer Details :-]
 | ngupta@icres.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@icres.gov.in (Nostal Officer Details :-) | Ingupta@icmr.org.in Or Seminan Penda Phone: 011-26588895 pandas.ing@icmr.gov.in (Nodad Officer Details :-) | regupta@icrre.org.in Dr Seminen Pende Phone: 013-26588895 pendes.hq@icrre.gov.in [Nodal Officer Details :-] | Ingupta@icmr.org.in Or Semiran Panda Phone: 013-26588895 pandas.lng@icmr.gov.in (Nodad Officer Dettails :-) | ngupta@icrre.org.in Or Semiren Pande Phone: 011-26588895 pandes.hg@icrer.gov.in [Nodal Officer Details >-]
 | ngupta@icrer.org.in Or Samiran Pande Phone: 011-26588895 pendas.hq@icrer.gov.in [Nodal Officer Details :-] | Ingupta@icmr.org.in Or Semiran Panda Phone: 013-26588895 pandas.lng@icmr.gov.in (Nodad Officer Dettails :-) | ngupta@icrer.org.in Or Semiran Pande Phone: 01-26588895 pendes.hq@icrer.gov.in [Nosted Officer Details :-] | mgupta@icnr.org.in Dr Semiren Pende Phome: 011-26588895 pandas.hq@icnr.gov.in [Nodal Officer Details.] | ngupta@icrer.org.in Dr Seminan Pande Phome: 011-36588895 pandas.hq@icrer.gov.in [Nodal Officer Details.]
 | ngupta@icnr.org.in Dr Semiren Pende Phone: 011-26588895 pandas.hq@icnr.gov.in [Noctal Officer Details.] | ngupta@icrer.org.in Dr Samiran Panda Phone: 011-26588895 pendas.hq@icrer.gov.in [Nostal Officer Details :-] | ngupta@icnr.org.in Dr Semiran Panda Phone: 01-26588895 pandas.hq@icnr.gov.in [Nodal Officer Details] | mgupta@icrec.org.in Or Samiran Panda Phone: 011-26588895 pendes.hq@icrec.gov.in [Nodal Officer Details :- |
| CP10 Details :- Phone: 011-26588980 ngupta@fcmr.org.in Or Samiran Panda Phone: 011-2658895 pandas.hq@fcmr.gov.in [Notal Officer Details :- | CPIO Details :- Phone: 013-26588980 ngupta@icmr.org.in Or Samiran Panda Phone: 013-26588995 pandas.hq@icmr.gov.in [Notal Officer Details :- Telephone Number 013-26589980 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icmr.gov.in [Nodal Officer Details :- Telephone Number 011-2658990 | ngupta@icres.org.in Or Samiran Panda Phome: 011-26588895 pendas.hq@icres.gov.in [Nodal Officer Details :- Telephone Number 011-26588980 | ngupta@fcmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.htg@fcmr.gov.in [Notial Officer Details :- O11-26588980 | ngupta@icnrc.org.in | Ingupta@icres.org.in Dr Semiran Panda Dr Semiran Panda Phome: 011-26588895 pendas.hq@icres.gov.in [Nostal Officer Detrails >- Telephone Number 011-26588990
 | Dr Semiran Panda Phone: 011-26588895 pendes.hq@icmr.gov.in [Noxted Officer Detrails >- Telephone Number 011-26588990 | First Appellate Authority Details :- Dr Seminan Panda Phone: 011-26588895 pendas.hq@icmr.gov.in [Noded Officer Details :- O11-26588980 | First Appellate Authority Details :- Phone: 01.26588895 pendas.hq@icmr.gov.in [Nodal Officer Details :- O1.26588980 | Or Seminan Pande Phone: 011-26588895 pandes.hq@icmr.gov.in [Notal Officer Details >- Telephone Number 011-26588980 | Or Semiran Pande Phone: 011-26588895 pandes.hq@icmr.gov.in [Notial Officer Details >- Telephone Number 011-26588980
 | Dr Semiran Panda Phone: 01.26588895 pendas.hq@lcnr.gov.in | First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@icmr.gov.in [Nodad Officer Details :- Vision Number 011-26588990 | Or Samiran Panda Phone: 011-26588895 pendes.hq@icmr.gov.in [Nodal Officer Details > Telephone Number 011-26588980 | mgupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588395 pandas.hg@icmr.gov.in [Notial Officer Details :- O11-26588980 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icmr.gov.in [Nodal Officer Details :- Telephone Number 011-26588980
 | mgupta@fcnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@fcmr.gov.in [Notial Officer Details :- O11-26588980 | Ingupta@icmr.org.in Dr Saminan Panda Dr Saminan Panda Phome: 011-26588895 pandas.hq@icmr.gov.in [Noxtal Officer Detrails :- Telephone Number 011-26588980 | ngupta@fcre.cog.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icmr.gov.in [Nodal Officer Details :- O11-26588980 | Ingusta@icres.org.in Dr Seminer Pande | ngupta@icres.org.in Or Semican Panda Phone: 011-26588895 pendas.hq@icres.gov.in [Nodal Officer Details :-] Telephone Number 011-26588980
 | ngupta@icres.org.in Or Seminan Panda Phone: 011-26588895 pendas.hq@icres.gov.in [Nodal Officer Details :- Telephone Number 011-26588980 | Ingupta@icrre.org.in Or Samiran Panda Phone: 01:26588895 pandas.hq@icrre.gov.in [Nodal Officer Details :- Telephone Number 01:26588980 | rgupta@icre.org.in Dr Samiran Panda Phone: 011-26588895 pendas.hq@icre.gov.in [Nodal Officer Details :- Telephone Number - 011-26588980 | Ingupta@icmr.org.in Or Semiran Panda Phone: 011-26588895 pandas.hq@icmr.gov.in [Nodal Officer Details :- Telephone Number 011-26588980 | ngupta@icrec.org.in Or Samiran Panda Phone: 011-26588895 pandas.hq@icrec.gov.in [Nodal Officer Details :- Telephone Number 011-2658990
 | ngupta@icrer.org.in Or Semiran Panda Phone: 01-26588895 pandas.hq@icrer.gov.in [Nodal Officer Details :- Telephone Number 01-26588980 | Ingupta@icmr.org.in Or Semiran Panda Phone: 011-26588895 pandas.hq@icmr.gov.in [Nodal Officer Details :- Telephone Number 011-26588980 | ngupta@icnr.org.in Or Semiran Panda Phone: 011-26588895 pandas.hq@icnr.gov.in [Nodal Officer Details :- Telephone Number 011-26588990 | Ingusta@icns.org.in Dr Samiran Panda | ngupta@icnr.org.in Dr Seminen Pande Phome: 011-26588895 pendas.hq@icnr.gov.in [Nodas Officer Details >- Telephone Number 011-26588990
 | Ingupta@icnr.org.in Dr Semiren Pande Phone: 01-26588895 pandas.hq@icnr.gov.in [Noxtal Officer Detrails > Telephone Number 011-26588990 | ngupta@icrer.org.in Or Semiran Panda Phone: 01-26588895 pandas.hq@icrer.gov.in [Nodul Officer Details :- Telephone Number 012-26588980 | Ingusta@icns.org.in Dr Samiran Panda Dr Samiran Panda Phome: 01-26588895 pandas.hq@icns.gov.in [Nodal Officer Details > Telephone Number 011-26588980 | mgupta@icre.org.in Or Seminan Panda Phone: 011-26588805 pendas.hq@icre.gov.in [Nodad Officer Details :- Telephone Number 011-26588980 |
| CP1O Details :- Phone: 013-26588980 ngupta@icmr.org.in Or Seminan Pande | CPIO Details :- Phome: 011-2658980 ngupta@icnr.org.in Or Samiran Panda | CPIO Details :- Phome: 011-26588980 ngupta@icnr.org.in Or Samiran Pande | ngupta@icrur.org.in Or Samiran Panda | ngupta@icmr.org.in Or Semiran Panda | ngupta@icrur.org.in Or Samiran Panda | ngupta@icrrr.org.in Or Samiran Panda
 | Or Semiran Panda | Or Samiran Panda | Or Samiran Panda | Or Samiran Panda | Or Samiran Panda
 | Dr Samiran Panda | Or Samiran Panda | Or Samiran Panda | ngupta@icrre.org.in Or Saminen Pande | ngupta@icrvr.org.in
Or Seminen Pande
 | ngupta@icre.org.in Or Saminen Pande | ngupta@icrur.org.in Or Samiran Panda | ngupta@icrre.org.in Or Samiran Panda | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icnr.org.in Or Samiran Panda
 | ngupta@icrur.org.in Or Samiran Panda | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icrrr.org.in Or Seminan Pende
 | ngupta@icmr.org.in Or Samiran Pande | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icrur.org.in Or Samiran Panda | ngupta@icrrr.org.in Or Samiran Panda | ngupta@icnr.org.in Or Saminan Panda
 | ngupta@icre.org.in Or Samiran Panda | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icre.cog.in Or Saminan Panda | ngupta@icmr.cog.in Or Semiran Pande |
| CP10 Details :- Phone: 011-26588980 ngupta@fcmr.org.in Or Samiran Panda Phone: 011-2658895 pandas.hq@fcmr.gov.in [Notal Officer Details :- | CPIO Details :- Phone: 01.1-26588980 ngupta@icmr.org.in Or Saminan Panda Phone: 01.1-26588995 pandas.hq@icmr.gov.in [Nodal Officer Details :- | CPIO Details :- Phone: 011-26588980 ngupta@icrn.org.in Or Samiran Panda Phone: 011-26588995 pandas.hq@icrn.gov.in [Nodad Officer Details :- | ngupta@icres.org.in Or Samiran Panda Phone: 011-26588895 pendas.hq@icres.gov.in [Nostal Officer Details :-] | ngupta@fcmr.org.in Or Semiren Panda Phome: 01-26588895 pandas.hq@fcmr.gov.in [Notial Officer Details.] | ngupta@icnr.org.in Or Semiran Panda Phone: 011-26588895 pandas.lng@icnr.gov.in [Nodad Officer Dettails :- | ngupta@icres.org.in Dr Seminen Panda Phome: 011-26588895 pandas.hq@icres.gov.in [Nortal Officer Dettails.]
 | First Appellate Authority Details :- Dr Seminen Pands Phone: 011-26588895 pands.hq@icmc.gov.in [Noctal Officer Details :- | First Appellate Authority Details :- Dr Seminan Panda Phone: 011-26588805 pandas.hq@icmr.gov.in [Nostal Officer Details :-] | First Appellate Authority Details :- Dr Seminan Panda Phone: 011-26588805 pandas.hq@icmr.gov.in [Nostal Officer Details :-] | Or Seminan Panda Phone: 011-26588895 pandas.hq@icmc.gov.in [Nostal Officer Details.] | Or Semiran Panda Phone: 011-26588895 pandas.hq@icmc.gov.in [Nostal Officer Details.]
 | First Appellate Authority Details :- Dr Samiran Panda Phone: 013-26588895 pandas.hq@lcmr.gov.in [Nodal Officer Details :-] | First Appellate Authority Details :- Dr Samiran Panda Phone: 011-26588895 pandas.hq@icmr.gov.in [Nodal Officer Details :- | Or Seminar Panda Phone: 011-26588895 pendes.hq@icmc.gov.in [Nodal Officer Dettails :-] | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 01-26588895 pandas.hq@icnr.gov.in [Notial Officer Details :- | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 01.1-26588895 pandas.hq@icmr.gov.in
 | ngupta@icnrc.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icnrc.gov.in [Notial Officer Details :- | ngupta@icrec.org.in Dr Seminan Pande Phome: 01.1-26588895 pandas.hq@icrec.gov.in [Nodal Officer Dettails :- | ngupta@fcre.org.in Or Semiren Pande First Appellate Authority Details :- Phone: 011-26588895 pandes.hq@icmr.gov.in [Nodal Officer Details :- | rgupta@icmr.org.in Or Seminen Pande Phone: 011-26588895 pendes.hq@icmr.gov.in [Nodad Officer Details :-] | ngupta@icres.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@icres.gov.in [Nosted Officer Details :-]
 | ngupta@icres.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@icres.gov.in (Nostal Officer Details :-) | Ingupta@icmr.org.in Or Seminan Penda Phone: 011-26588895 pandas.ing@icmr.gov.in (Nodad Officer Details :-) | regupta@icrre.org.in Dr Seminen Pende Phone: 013-26588895 pendes.hq@icrre.gov.in [Nodal Officer Details :-] | Ingupta@icmr.org.in Or Semiran Panda Phone: 013-26588895 pandas.lng@icmr.gov.in (Nodad Officer Dettails :-) | ngupta@icrre.org.in Or Semiren Pande Phone: 011-26588895 pandes.hg@icrer.gov.in [Nodal Officer Details >-]
 | ngupta@icrer.org.in Or Samiran Pande Phone: 011-26588895 pendas.hq@icrer.gov.in [Nodal Officer Details :-] | Ingupta@icmr.org.in Or Semiran Panda Phone: 013-26588895 pandas.lng@icmr.gov.in (Nodad Officer Dettails :-) | ngupta@icrer.org.in Or Semiran Pande Phone: 01-26588895 pendes.hq@icrer.gov.in [Nosted Officer Details :-] | mgupta@icnr.org.in Dr Semiren Pende Phome: 011-26588895 pandas.hq@icnr.gov.in [Nodal Officer Details.] | ngupta@icrer.org.in Dr Seminan Pande Phome: 011-36588895 pandas.hq@icrer.gov.in [Nodal Officer Details.]
 | ngupta@icnr.org.in Dr Semiren Pende Phone: 011-26588895 pandas.hq@icnr.gov.in [Noctal Officer Details.] | ngupta@icrer.org.in Dr Samiran Panda Phone: 011-26588895 pendas.hq@icrer.gov.in [Nostal Officer Details :-] | ngupta@icnr.org.in Dr Semiran Panda Phone: 01-26588895 pandas.hq@icnr.gov.in [Nodal Officer Details] | mgupta@icrec.org.in Or Samiran Panda Phone: 011-26588895 pendes.hq@icrec.gov.in [Nodal Officer Details :- |
| CP10 Details :- Phone: 011-26588980 ngupta@fcmr.org.in Or Samiran Panda Phone: 011-2658895 pandas.hq@fcmr.gov.in [Notal Officer Details :- | CPIO Details :- Phone: 01.1-26588980 ngupta@icmr.org.in Or Saminan Panda Phone: 01.1-26588995 pandas.hq@icmr.gov.in [Nodal Officer Details :- | CPIO Details :- Phone: 011-26588980 ngupta@icrn.org.in Or Samiran Panda Phone: 011-26588995 pandas.hq@icrn.gov.in [Nodad Officer Details :- | ngupta@icres.org.in Or Samiran Panda Phone: 011-26588895 pendas.hq@icres.gov.in [Nostal Officer Details :-] | ngupta@fcmr.org.in Or Semiren Panda Phome: 01-26588895 pandas.hq@fcmr.gov.in [Notial Officer Details.] | ngupta@icnr.org.in Or Semiran Panda Phone: 011-26588895 pandas.lng@icnr.gov.in [Nodad Officer Dettails :- | ngupta@icres.org.in Dr Seminen Panda Phome: 011-26588895 pandas.hq@icres.gov.in [Nortal Officer Dettails.]
 | First Appellate Authority Details :- Dr Seminen Pands Phone: 011-26588895 pands.hq@icmc.gov.in [Noctal Officer Details :- | First Appellate Authority Details :- Dr Seminan Panda Phone: 011-26588805 pandas.hq@icmr.gov.in [Nostal Officer Details :-] | First Appellate Authority Details :- Dr Seminan Panda Phone: 011-26588805 pandas.hq@icmr.gov.in [Nostal Officer Details :-] | Or Seminan Panda Phone: 011-26588895 pandas.hq@icmc.gov.in [Nostal Officer Details.] | Or Semiran Panda Phone: 011-26588895 pandas.hq@icmc.gov.in [Nostal Officer Details.]
 | First Appellate Authority Details :- Dr Samiran Panda Phone: 013-26588895 pandas.hq@lcmr.gov.in [Nodal Officer Details :-] | First Appellate Authority Details :- Dr Samiran Panda Phone: 011-26588895 pandas.hq@icmr.gov.in [Nodal Officer Details :- | Or Seminar Panda Phone: 011-26588895 pendes.hq@icmc.gov.in [Nodal Officer Dettails :-] | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 01-26588895 pandas.hq@icnr.gov.in [Notial Officer Details :- | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 01.1-26588895 pandas.hq@icmr.gov.in
 | ngupta@icnrc.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icnrc.gov.in [Notial Officer Details :- | ngupta@icrec.org.in Dr Seminan Pande Phome: 01.1-26588895 pandas.hq@icrec.gov.in [Nodal Officer Dettails :- | ngupta@fcre.org.in Or Semiren Pande First Appellate Authority Details :- Phone: 011-26588895 pandes.hq@icmr.gov.in [Nodal Officer Details :- | rgupta@icmr.org.in Or Seminen Pande Phone: 011-26588895 pendes.hq@icmr.gov.in [Nodad Officer Details :-] | ngupta@icres.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@icres.gov.in [Nosted Officer Details :-]
 | ngupta@icres.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@icres.gov.in (Nostal Officer Details :-) | Ingupta@icmr.org.in Or Seminan Penda Phone: 011-26588895 pandas.ing@icmr.gov.in (Nodad Officer Details :-) | regupta@icrre.org.in Dr Seminen Pende Phone: 013-26588895 pendes.hq@icrre.gov.in [Nodal Officer Details :-] | Ingupta@icmr.org.in Or Semiran Panda Phone: 013-26588895 pandas.lng@icmr.gov.in (Nodad Officer Dettails :-) | ngupta@icrre.org.in Or Semiren Pande Phone: 011-26588895 pandes.hg@icrer.gov.in [Nodal Officer Details >-]
 | ngupta@icrer.org.in Or Samiran Pande Phone: 011-26588895 pendas.hq@icrer.gov.in [Nodal Officer Details :-] | Ingupta@icmr.org.in Or Semiran Panda Phone: 013-26588895 pandas.lng@icmr.gov.in (Nodad Officer Dettails :-) | ngupta@icrer.org.in Or Semiran Pande Phone: 01-26588895 pendes.hq@icrer.gov.in [Nosted Officer Details :-] | mgupta@icnr.org.in Dr Semiren Pende Phome: 011-26588895 pandas.hq@icnr.gov.in [Nodal Officer Details.] | ngupta@icrer.org.in Dr Seminan Pande Phome: 011-36588895 pandas.hq@icrer.gov.in [Nodal Officer Details.]
 | ngupta@icnr.org.in Dr Semiren Pende Phone: 011-26588895 pandas.hq@icnr.gov.in [Noctal Officer Details.] | ngupta@icrer.org.in Dr Samiran Panda Phone: 011-26588895 pendas.hq@icrer.gov.in [Nostal Officer Details :-] | ngupta@icnr.org.in Dr Semiran Panda Phone: 01-26588895 pandas.hq@icnr.gov.in [Nodal Officer Details] | mgupta@icrec.org.in Or Samiran Panda Phone: 011-26588895 pendes.hq@icrec.gov.in [Nodal Officer Details :- |
| CP10 Details :- Phone: 011-26588980 ngupta@fcmr.org.in Or Samiran Panda Phone: 011-2658895 pandas.hq@fcmr.gov.in [Notal Officer Details :- | CPIO Details :- Phone: 01.1-26588980 ngupta@icmr.org.in Or Saminan Panda Phone: 01.1-26588995 pandas.hq@icmr.gov.in [Nodal Officer Details :- | CPIO Details :- Phone: 011-26588980 ngupta@icrn.org.in Or Samiran Panda Phone: 011-26588995 pandas.hq@icrn.gov.in [Nodad Officer Details :- | ngupta@icres.org.in Or Samiran Panda Phone: 011-26588895 pendas.hq@icres.gov.in [Nostal Officer Details :-] | ngupta@fcmr.org.in Or Semiren Panda Phome: 01-26588895 pandas.hq@fcmr.gov.in [Notial Officer Details.] | ngupta@icnr.org.in Or Semiran Panda Phone: 011-26588895 pandas.lng@icnr.gov.in [Nodad Officer Dettails :- | ngupta@icres.org.in Dr Seminen Panda Phome: 011-26588895 pandas.hq@icres.gov.in [Nortal Officer Dettails.]
 | First Appellate Authority Details :- Dr Seminen Pands Phone: 011-26588895 pands.hq@icmc.gov.in [Noctal Officer Details :- | First Appellate Authority Details :- Dr Seminan Panda Phone: 011-26588805 pandas.hq@icmr.gov.in [Nostal Officer Details :-] | First Appellate Authority Details :- Dr Seminan Panda Phone: 011-26588805 pandas.hq@icmr.gov.in [Nostal Officer Details :-] | Or Seminan Panda Phone: 011-26588895 pandas.hq@icmc.gov.in [Nostal Officer Details.] | Or Semiran Panda Phone: 011-26588895 pandas.hq@icmc.gov.in [Nostal Officer Details.]
 | First Appellate Authority Details :- Dr Samiran Panda Phone: 013-26588895 pandas.hq@lcmr.gov.in [Nodal Officer Details :-] | First Appellate Authority Details :- Dr Samiran Panda Phone: 011-26588895 pandas.hq@icmr.gov.in [Nodal Officer Details :- | Or Seminar Panda Phone: 011-26588895 pendes.hq@icmc.gov.in [Nodal Officer Dettails :-] | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 01-26588895 pandas.hq@icnr.gov.in [Notial Officer Details :- | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 01.1-26588895 pandas.hq@icmr.gov.in
 | ngupta@icnrc.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icnrc.gov.in [Notial Officer Details :- | ngupta@icrec.org.in Dr Seminan Pande Phome: 01.1-26588895 pandas.hq@icrec.gov.in [Nodal Officer Dettails :- | ngupta@fcre.org.in Or Semiren Pande First Appellate Authority Details :- Phone: 011-26588895 pandes.hq@icmr.gov.in [Nodal Officer Details :- | rgupta@icmr.org.in Or Seminen Pande Phone: 011-26588895 pendes.hq@icmr.gov.in [Nodad Officer Details :-] | ngupta@icres.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@icres.gov.in [Nosted Officer Details :-]
 | ngupta@icres.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@icres.gov.in (Nostal Officer Details :-) | Ingupta@icmr.org.in Or Seminan Penda Phone: 011-26588895 pandas.ing@icmr.gov.in (Nodad Officer Details :-) | regupta@icrre.org.in Dr Seminen Pende Phone: 013-26588895 pendes.hq@icrre.gov.in [Nodal Officer Details :-] | Ingupta@icmr.org.in Or Semiran Panda Phone: 013-26588895 pandas.lng@icmr.gov.in (Nodad Officer Dettails :-) | ngupta@icrre.org.in Or Semiren Pande Phone: 011-26588895 pandes.hg@icrer.gov.in [Nodal Officer Details >-]
 | ngupta@icrer.org.in Or Samiran Pande Phone: 011-26588895 pendas.hq@icrer.gov.in [Nodal Officer Details :-] | Ingupta@icmr.org.in Or Semiran Panda Phone: 013-26588895 pandas.lng@icmr.gov.in (Nodad Officer Dettails :-) | ngupta@icrer.org.in Or Semiran Pande Phone: 01-26588895 pendes.hq@icrer.gov.in [Nostal Officer Details :-] | mgupta@icnr.org.in Dr Semiren Pende Phome: 011-26588895 pandas.hq@icnr.gov.in [Nodal Officer Details.] | ngupta@icrer.org.in Dr Seminan Pande Phome: 011-36588895 pandas.hq@icrer.gov.in [Nodal Officer Details.]
 | ngupta@icnr.org.in Dr Semiren Pende Phone: 011-26588895 pandas.hq@icnr.gov.in [Noctal Officer Details.] | ngupta@icrer.org.in Dr Samiran Panda Phone: 011-26588895 pendas.hq@icrer.gov.in [Nostal Officer Details :-] | ngupta@icnr.org.in Dr Semiran Panda Phone: 01-26588895 pandas.hq@icnr.gov.in [Nodal Officer Details] | mgupta@icrec.org.in Or Samiran Panda Phone: 011-26588895 pendes.hq@icrec.gov.in [Nodal Officer Details :- |
| CP10 Details :- Phone: 011-26588980 ngupta@fcmr.org.in Or Samiran Panda Phone: 011-2658895 pandas.hq@fcmr.gov.in [Notal Officer Details :- | CPIO Details :- Phone: 01.1-26588980 ngupta@icmr.org.in Or Saminan Panda Phone: 01.1-26588995 pandas.hq@icmr.gov.in [Nodal Officer Details :- | CPIO Details :- Phone: 011-26588980 ngupta@icrn.org.in Or Samiran Panda Phone: 011-26588995 pandas.hq@icrn.gov.in [Nodad Officer Details :- | ngupta@icres.org.in Or Samiran Panda Phone: 011-26588895 pendas.hq@icres.gov.in [Nostal Officer Details :-] | ngupta@fcmr.org.in Or Semiren Panda Phome: 01-26588895 pandas.hq@fcmr.gov.in [Notial Officer Details.] | ngupta@icnr.org.in Or Semiran Panda Phone: 011-26588895 pandas.lng@icnr.gov.in [Nodad Officer Dettails :- | ngupta@icres.org.in Dr Seminen Panda Phome: 011-26588895 pandas.hq@icres.gov.in [Nortal Officer Dettails.]
 | First Appellate Authority Details :- Dr Seminen Pands Phone: 011-26588895 pands.hq@icmc.gov.in [Noctal Officer Details :- | First Appellate Authority Details :- Dr Seminan Panda Phone: 011-26588805 pandas.hq@icmr.gov.in [Nostal Officer Details :-] | First Appellate Authority Details :- Dr Seminan Panda Phone: 011-26588805 pandas.hq@icmr.gov.in [Nostal Officer Details :-] | Or Seminan Panda Phone: 011-26588895 pandas.hq@icmc.gov.in [Nostal Officer Details.] | Or Semiran Panda Phone: 011-26588895 pandas.hq@icmc.gov.in [Nostal Officer Details.]
 | First Appellate Authority Details :- Dr Samiran Panda Phone: 013-26588895 pandas.hq@lcmr.gov.in [Nodal Officer Details :-] | First Appellate Authority Details :- Dr Samiran Panda Phone: 011-26588895 pandas.hq@icmr.gov.in [Nodal Officer Details :- | Or Seminar Panda Phone: 011-26588895 pendes.hq@icmc.gov.in [Nodal Officer Dettails :-] | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 01-26588895 pandas.hq@icnr.gov.in [Notial Officer Details :- | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 01.1-26588895 pandas.hq@icmr.gov.in
 | ngupta@icnrc.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 pandas.hq@icnrc.gov.in [Notial Officer Details :- | ngupta@icrec.org.in Dr Seminan Pande Phome: 01.1-26588895 pandas.hq@icrec.gov.in [Nodal Officer Dettails :- | ngupta@fcre.org.in Or Semiren Pande First Appellate Authority Details :- Phone: 011-26588895 pandes.hq@icmr.gov.in [Nodal Officer Details :- | rgupta@icmr.org.in Or Seminen Pande Phone: 011-26588895 pendes.hq@icmr.gov.in [Nodad Officer Details :-] | ngupta@icres.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@icres.gov.in [Nosted Officer Details :-]
 | ngupta@icres.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 pendes.hq@icres.gov.in (Nostal Officer Details :-) | Ingupta@icmr.org.in Or Seminan Penda Phone: 011-26588895 pandas.ing@icmr.gov.in (Nodad Officer Details :-) | regupta@icrre.org.in Dr Seminen Pende Phone: 013-26588895 pendes.hq@icrre.gov.in [Nodal Officer Details :-] | Ingupta@icmr.org.in Or Semiran Panda Phone: 013-26588895 pandas.lng@icmr.gov.in (Nodad Officer Dettails :-) | ngupta@icrre.org.in Or Semiren Pande Phone: 011-26588895 pandes.hg@icrer.gov.in [Nodal Officer Details >-]
 | ngupta@icrer.org.in Or Samiran Pande Phone: 011-26588895 pendas.hq@icrer.gov.in [Nodal Officer Details :-] | Ingupta@icmr.org.in Or Semiran Panda Phone: 013-26588895 pandas.lng@icmr.gov.in (Nodad Officer Dettails :-) | ngupta@icrer.org.in Or Semiran Pande Phone: 01-26588895 pendes.hq@icrer.gov.in [Nostal Officer Details :-] | mgupta@icnr.org.in Dr Semiren Pende Phome: 011-26588895 pandas.hq@icnr.gov.in [Nodal Officer Details.] | ngupta@icrer.org.in Dr Seminan Pande Phome: 011-36588895 pandas.hq@icrer.gov.in [Nodal Officer Details.]
 | ngupta@icnr.org.in Dr Semiren Pende Phone: 011-26588895 pandas.hq@icnr.gov.in [Noctal Officer Details.] | ngupta@icrer.org.in Dr Samiran Panda Phone: 011-26588895 pendas.hq@icrer.gov.in [Nostal Officer Details :-] | ngupta@icnr.org.in Dr Semiran Panda Phone: 01-26588895 pandas.hq@icnr.gov.in [Nodal Officer Details] | mgupta@icrec.org.in Or Samiran Panda Phone: 011-26588895 pendes.hq@icrec.gov.in [Nodal Officer Details :- |
| CP1O Details :- Phone: 011-26588980 ngupta@icnrc.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588955 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | ngupta@icmr.cog.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@fcre.org.in Or Samiran Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icnr.org.in Or Saminan Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icror.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | Dr Seminan Panda First Appellate Authority Details :- Phone: 011-26588395 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | Dr Seminen Pande First Appellate Authority Details :- Phone: 011-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrec.org.in Or Saminen Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icrec.org.in Or Seminan Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icrec.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icror.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrre.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588395 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icrnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995
 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrur.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588895 |
| CP1O Details :- Phone: 011-26588980 ngupta@icnrc.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588955 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | ngupta@icmr.cog.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@fcre.org.in Or Samiran Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icnr.org.in Or Saminan Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icror.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | Dr Seminan Panda First Appellate Authority Details :- Phone: 011-26588395 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | Dr Seminen Pande First Appellate Authority Details :- Phone: 011-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrec.org.in Or Saminen Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icrec.org.in Or Seminan Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icrec.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icror.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrre.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588395 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icrnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995
 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrur.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588895 |
| CP1O Details :- Phone: 011-26588980 ngupta@icnrc.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588955 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | ngupta@icmr.cog.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@fcre.org.in Or Samiran Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icnr.org.in Or Saminan Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icror.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | Dr Seminan Panda First Appellate Authority Details :- Phone: 011-26588395 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | Dr Seminen Pande First Appellate Authority Details :- Phone: 011-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrec.org.in Or Saminen Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icrec.org.in Or Seminan Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icrec.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icror.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrre.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588395 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icrnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995
 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrur.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588895 |
| CP1O Details :- Phone: 011-26588980 ngupta@icnrc.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588955 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | ngupta@icmr.cog.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@fcre.org.in Or Samiran Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icror.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | Dr Seminan Panda First Appellate Authority Details :- Phone: 011-26588395 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | Dr Seminen Pande First Appellate Authority Details :- Phone: 011-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrec.org.in Or Saminen Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icrec.org.in Or Seminan Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icrec.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icror.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrre.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588395 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icrnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995
 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrur.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588895 |
| CP1O Details :- Phone: 011-26588980 ngupta@icnrc.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588955 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995 | ngupta@icmr.cog.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@fcre.org.in Or Samiran Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icror.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | Dr Seminan Panda First Appellate Authority Details :- Phone: 011-26588395 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | Dr Seminen Pande First Appellate Authority Details :- Phone: 011-26588895 | Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrec.org.in Or Saminen Panda First Appellate Authority Details > Phone: 011-26588895 | ngupta@icrec.org.in Or Seminan Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icrec.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icror.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrre.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588395 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395
 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Semiran Penda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icrnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588995
 | ngupta@icrer.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icmr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 013-26588895 | ngupta@icnr.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icrur.org.in Or Semiran Panda First Appellate Authority Details :- Phone: 011-26588895
 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@fcmr.org.in Or Samiran Panda First Appellate Authority Details :- Phone: 011-26588895 | ngupta@icnr.org.in Dr Samiran Panda First Appellate Authority Details :- Phone: 011-26588395 | ngupta@icmr.org.in Or Samiran Panda First Appellate Authority Details:- Phone: 011-26588895 |
| CP1O Details :- Phone: 011-26588980 ngupta@icnr.cog.in Or Seminan Pande | CPIO Details :- Phone: 011-2658990 ngupta@icrer.org.in Or Seminan Panda | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Or Saminan Pande | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icre.org.in Or Saminan Panda | ngupta@icmr.org.in Or Semiren Pande | ngupta@icmr.org.in Or Samiran Pande
 | Or Samiran Panda | Or Samiran Panda | Or Samiran Panda | Or Saminen Panda | Or Saminen Panda
 | Or Samiran Panda | Or Samiran Panda | Or Samiran Panda | ngupta@icrre.org.in Or Saminen Pande | ngupta@icrvr.org.in
Or Seminen Pande
 | ngupta@icre.org.in Or Saminen Pande | ngupta@icrur.org.in Or Samiran Panda | ngupta@icrre.org.in Or Samiran Panda | ngupta@icmr.cog.in Or Semiran Pande | ngupta@icmr.org.in Or Semiran Pande
 | ngupta@icmr.org.in Dr Semiran Pande | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icrrr.org.in Or Seminan Pende
 | ngupta@icmr.org.in Or Semiran Pande | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icmr.org.in Or Samiran Pande | ngupta@icnv.org.in Or Saminan Panda | ngupta@icrur.org.in Or Samiran Panda
 | ngupta@icnr.org.in Or Samiran Panda | ngupta@icmr.org.in Dr Semiran Pande | ngupta@icre.cog.in Or Saminan Panda | ngupta@icmr.cog.in Or Semiran Pande |
| CP1O Details :- Phone: 011-26588980 ngupta@icnr.cog.in Or Seminan Pande | CPIO Details :- Phone: 011-2658990 ngupta@icrer.org.in Or Seminan Panda | CPIO Details :- Phone: 011-26588980 ngupta@icmr.org.in Or Saminan Pande | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icre.org.in Or Saminan Panda | ngupta@icmr.org.in Or Semiren Pande | ngupta@icmr.org.in Or Samiran Pande
 | Or Samiran Panda | Or Samiran Panda | Or Samiran Panda | Or Saminen Panda | Or Saminen Panda
 | Or Samiran Panda | Or Samiran Panda | Or Samiran Panda | ngupta@icrre.org.in Or Saminen Pande | ngupta@icrvr.org.in
Or Seminen Pande
 | ngupta@icre.org.in Or Saminen Pande | ngupta@icrur.org.in Or Samiran Panda | ngupta@icrre.org.in Or Samiran Panda | ngupta@icmr.cog.in Or Semiran Pande | ngupta@icmr.org.in Or Semiran Pande
 | ngupta@icmr.org.in Dr Semiran Pande | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icrrr.org.in Or Seminan Pende
 | ngupta@icmr.org.in Or Semiran Pande | ngupta@icmr.org.in Dr Samiran Panda | ngupta@icmr.org.in Or Samiran Pande | ngupta@icnv.org.in Or Saminan Panda | ngupta@icrur.org.in Or Samiran Panda
 | ngupta@icnr.org.in Or Samiran Panda | ngupta@icmr.org.in Dr Semiran Pande | ngupta@icre.cog.in Or Saminan Panda | ngupta@icmr.cog.in Or Semiran Pande |
| CP10 Details :- Phone: 011-26588980
ngupta@icru.org.in | CPIO Details :- Phone: 011-2658980 ngupta@icmr.org.in | CPIO Details :- Phone: 011-26588980 ngupta@icrn.org.in | ngupta@icres.org.in | ngupta@icmr.cog.in | ngupta@icror.org.in | ngupta@icnw.org.in
 | | | | |
 | | | | ngupta@icrre.org.in | ngupta@icmr.cog.in
 | ngupta@icrre.org.in | ngupta@icrecorg.in | ngupta@icmr.cog.in | ngupta@icre.org.in | ngupta@icres.org.in
 | ngupta@icre.org.in | ngupta@icmr.org.in | ngupta@icrre.org.in | ngupta@icmr.org.in | ngupta@icrec.org.in
 | ngupta@icnr.org.in | ngupta@icmr.org.in | ngupta@icnr.org.in | ngupta@icrrr.org.in | ngupta@icres.org.in
 | ngupta@icrrr.ong.in | ngupta@icre.org.in | ngupta@icre.org.in | ngupta@icrre.org.in |
| CP10 Details :- Phone: 011-26588980 | OP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 82 63 | | | 100
 | ngupta@icros.org.in | ngupta@icror.org.in | ngupta@icre.org.in | ngupta@icmr.org.in | ngupta@icmr.org.in
 | ngupta@icrrr.org.in | ngupta@icrrc.org.in | ngupta@icre.org.in | |
 | 10 miles | | 8 6 | |
 | | | | |
 | | | 100 | 87 (5) | 100
 | 89 (8) | | 87 (6 | |
| CP10 Details :- Phone: 011-26588980 | OP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 82 63 | | | 100
 | ngupta@icmr.org.in | ngupta@icmr.org.in | ngupta@icme.org.in | ngupta@icmr.org.in | ngupta@icmr.org.in
 | ngupta@icmr.org.in | ngupta@icrus.org.in | ngupta@icms.org.in | |
 | 10 miles | | 8 6 | |
 | | | | |
 | | | 100 | 87 (5) | 100
 | 89 (8) | | 87 (6 | |
| CP10 Details :- Phone: 011-26588980 | OP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 82 63 | | | 100
 | ngupta@icrer.org.ln | ngupta@icmr.org.in | ngupta@icmr.org.in | ngupta@icrre.org.in | ngupta@icrrr.org.in
 | ngupta@icrur.org.in | ngupta@icmr.org.in | ngupta@icmr.org.in | |
 | 10 miles | | 8 6 | |
 | | | | |
 | | | 100 | 87 (5) | 100
 | 89 (8) | | 87 (6 | |
| CP10 Details :- Phone: 011-26588980 | OP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 82 63 | | | 100
 | neusta@icmcore.in | neurta@icmr.org.in | neurota@icmr.ore.in | neuntafficar.org.in | neurota@icros.com.in
 | neunta@icmr.com.in | neuma@icror.com.in | neurta@icmcore.in | |
 | 10 miles | | 8 6 | |
 | | | | |
 | | | 100 | 87 (5) | 100
 | 89 (8) | | 87 (6 | |
| CP10 Details :- Phone: 011-26588980 | OP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 82 63 | | | 100
 | | | The second secon | The second secon | The second secon | I I amenina and a second and a | I I I I I I I I I I I I I I I I I I I | Language Control of the Control of t | |
 | 10 miles | | 8 6 | |
 | | | | |
 | | | 100 | 87 (5) | 100
 | 89 (8) | | 87 (6 | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 710000 00700000 |
 | | 1 10 0 | 1 10 0 | and the same of th | |
 | 1 20 0 | | FINANCIA AL ANDROISE | Unio Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | CPID Details :- Phone: 01.1-26585980 | Phone: 011-20585960
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | From: 011-2058590
 | | | | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | F House and Proposition |
 | | 1 5 6 | | |
 | | 1 0 0 | 1 2 2 2 | FIRMS WAS ASSESSED. | Ono Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phome: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | O10 Details >- Phone: 011-26583980
 | O10 Details >- Phone: 011-26585/960 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | CP10 Details :- Phone: 011-26588980
 | Phone: 011-2038980 | | | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | 7 10000 101 20000 |
 | | | | |
 | | | 1 2 2 2 | F10000 004-200000000 | CPVD Details :- Phonic: 013-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | O'10 Details >- Phone: 011-26588980
 | Phone: 011-20588980 | CPIO Details :- Phone: 0.1-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | GP10 Details :- Phone: 011-26588980
 | Ght0 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | Phone: 011-20588980 | |
 | |
| | | | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980 | The state of the s | |
 | | | | 1 22 2 | 1 2 2 2
 | | | F TROOK VALANCESCO | CP10 Details 3- Phonic: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | ONO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | Phone: 0.1-26585980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Fhome: 011-26588980 | CPIO Details:- Phone: 011-26588980 | CP10 Details :- Phone: 0.11-26588980 | Phone: 0.1-20585960
 | The state of the s | | | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | |
 | | | | |
 | | | | # TRANSPORT TO A PROPERTY OF THE PROPERTY OF T | Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | U90 Details :- Phone: 011-26588980 | Phone: 011-20588980
 | CP10 Details :- Phone: 011-26588980 | GP00 Details :- Phone: 011-26588980 | ONO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980
 | ONO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | Fhone: 011-26588980
 | | | |
| | | | THE RELEASE OF THE PROPERTY OF | | CPIC Details >- Phone: 011-26588980 | Ono Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980
 | FROM: 0.1-20385980 | F1000E.011-03300300 | 71000.00.70 | | - Thomas Wall And
 | F10000 012-0000000 | Phone: 0.1-20588980 | Unit Details :- I Phone Of Lincolnian | | CONTRACTOR OF THE PROPERTY OF |
 | The state of the s | CONTRACTOR OF THE PROPERTY OF | | | | |
 | | | | | AND REAL PROPERTY.
 | THE RESERVE OF THE PROPERTY OF | | CPO Details :- Phone: 011-26588980 | CPO Details :- Phone: 011-26588980 | Uno Detaes :- Phone: 011-26588980 |
| | | | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CPIO Details :- Phone: 011-26588980 | FROM: 0.1-20385980 | F10006: UL1-C0300900 | 71000 017000000 | |
 | F House, Val. Woods and | Filose 012-02-0000 | Phone: 0.1-20588980 | CPIO Details :- Phone 011.765ssnan |
 | | 100 to 10 | 250000000000000000000000000000000000000 | | |
 | | 55782.557675 | | | 250000000000000000000000000000000000000
 | 200000000000000000000000000000000000000 | | | | CBIO Details :-
 | OPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phonic: 011-26588980 |
| | | | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CPIO Details :- Phone: 011-26588980 | FROM: UL1-20365960 | FTIONE: W.1-20000000 | , 7 TOOR 14.2 TOO 15.2 | The state of the s | THE PROPERTY OF THE PROPERTY O | F10000 (4.2-4003000)
 | Phone: 0.1-20588980 | CPIO Details :- Phone 011.765ssnan | | | 100 to 10 | 250000000000000000000000000000000000000
 | | | CDIO Distriction | | 55782.557675
 | | | 250000000000000000000000000000000000000 | 200000000000000000000000000000000000000 |
 | | | CBIO Details :- | OPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phonic: 011-26588980 |
| | | | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CPIO Details :- Phone: 011-26588980 | From: U.1-2008980 | FROME: U.1-(2-300-900) | , ribons 50,2-20040000 | The same of the sa | THOUSE WAS A CONTROL OF
 | France of Property Co. | Phone: 0.1-20588980 | CPIO Details :- Phone 011.765ssnan | | The state of the s | 100 to 10 | 250000000000000000000000000000000000000
 | | | | | 55782.557675
 | | | 250000000000000000000000000000000000000 | 200000000000000000000000000000000000000 |
 | | | CBIO Details :- | OPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phonic: 011-26588980 |
| | | | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CPIO Details :- Phone: 011-26588980 | FROM: U.1-2008980 | F100E: V44-49300300 | A THORE WAS A WOODS AND A STATE OF THE PARTY | The state of the s | F Thomas And a "Account of the Control of the Contr | F1900E 044-W0300300 | Phone: 011-2658980
 | CPIO Details :- Phone 011.765ssnan | | | 100 to 10 | 250000000000000000000000000000000000000 |
 | | CDIO Distriction | | 55782.557675 |
 | | 250000000000000000000000000000000000000 | 200000000000000000000000000000000000000 | |
 | | CBIO Details :- | OPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phonic: 011-26588980
 |
| | Of Miledia Oupla | Dr Nivedita Gupta | 553,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) (653,000 (653,000 (653,000 (653,000 (653,000 (653,000 (653,000) | 5000 02 02 02 02 02 02 02 02 02 02 02 02 | CP10 Details :- Phone: 013-26588980 | CP10 Details :- Phone: 011-26588980
 | CPIO Details :- Phone: 011-26588980 | FROM: UL1-20085980 | FTIOTIE: VL 4-VS 3000000 | | | | |
 | | | From: 011-2658980 | CP10 Details :- Phone of 1 Nevernon |
 | | | 100000000000000000000000000000000000000 | COUNTRY OF THE PROPERTY OF THE | CONTRACTOR OF THE PROPERTY OF | CROS DALATE | 57000 Sept. 100 |
 | | - CESTANO 1947-1947 | -3333500 Pelation | Control of the Contro | |
 | Transportation | CDIO Details | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980
 |
| | or missing dupin | Dr Nieedita Gupta | | 7 man and the Co. | The Committee of the Co | |
 | CONTRACTOR OF THE PARTY OF THE | CPIO Details :- | O'll Details > Phone of 1.26 septim | 010 Details >- Phone: 011-26588980 | O10 Details >- Phone: 011,76588980 | CPIO Details :-
 | | The second secon | | -0.0000 2010000000 | |
 | 2000 W 1000 200 1 | | | |
 | | | | | - 1000000000000000000000000000000000000
 | | 25.00 (25.00) | | The second secon | |
 |
| , or meete supre | | The Million Office Private | | 25(3) A (1) (3) (3) | |
 | THE PROGRAMMENT AND THE PR | CRIO Detroite : | CPIO Details :- | CP10 Details :- Phone of 1.7658000 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011,74508980
 | CP10 Details :- Phone 011 74555000 | CRIO Detroite : | | 100000000000000000000000000000000000000 | of mesons suppe
 | or investigations | or meeting supple | | 200000000000000000000000000000000000000 | 2000 1000 0000
 | | or meeting stapes | or meeting stapes | of means supe | or meeting supple
 | or meeting dupon | No. of the control of | | 2000 N 1000 N | The state of the s | | THE RESERVE OF THE PROPERTY OF |
 |
| Of Missian dupts | | De Mine ditte Guerte | | - (200 (100 (100 (100 (100 (100 (100 (100 | | 11 Transportation 1 Transporta |
 | CRIO Details - | CPIO Details to | CPIO Details :- Phone 011, 24500000 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011,74588980
 | CPIO Details :- Phone of 1. 245/2000 | CDIO Detribe | | 127 (2012) | or mestic dupie
 | or meeting dupos | Of Miseans dupas | | |
 | | of meeting stapes | or meeting duping | of missons dupts | or meeting dupts
 | or meeting dupin | No. of the control of | | 275 (27 TO 15 TO 1 | | CONSTRUCTION OF THE PROPERTY O | The state of the s | |
| of meeting supple | | De Minedite Guede | | - (200 (100 (100 (100 (100 (100 (100 (100 | | 11 Transportation 1 Transporta |
 | CRIO Details - | CPIO Details to | CPIO Details :- Phone 011, 24500000 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011,74588980
 | CPIO Details :- Phone of 1. 245/2000 | CDIO Detribe | | 127 (2012) | or mestic dupie
 | or aniesta supre | or meeting stapes | | THE CONTROL OF THE CO | |
 | of meeting stapes | or meeting stapes | of meeting supple | or meeting supple | or meeting dupon
 | No. of the control of | | 275 (27 TO 15 TO 1 | | CONSTRUCTION OF THE PROPERTY O | The state of the s | |
| | | De Mine dite Guete | | - CERTAL PART (CHERTAL CHERTAL | | |
 | CROO Details : | CPIO Details :- Phone on a passenger | CP10 Details :- Phone 011, NAMED III | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone (11,74508780)
 | CPIO Details :- Phone 013,365 FEBRUAR | CRIC Data Services | | 100000000000000000000000000000000000000 | of means supe
 | or meeting duping | or nineana dapia | | |
 | 0.000.000 | or revenue supre | or meeting duping | or meeting duping | or meeting dupin
 | or meeting dupin | NEW 2007 (1997) | | 0.000,000,000,000,000 | | | |
 | | | |
| or nivedita dupta | | The Million Distriction | | -3000000000000000000000000000000000000 | | The supplementary of the suppl |
 | CRIO Details - | CPIO Details to | CPIO Details :- Phone 011, 24500000 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone 011,74588980
 | CPIO Details in | CRIO Detroite | The state of the s | - 2000000 Page 10000 | of means supe | Or Assects dupts
 | or misecina dupra | | | | 0.0000000000000000000000000000000000000
 | of meeting stapes | Or Assects dupts | or meetra dupta | or misecità dupia | or wisecute dupts
 | No. of the Contract of the Con | 350000000000000000000000000000000000000 | 1200 Co. | | The second secon | The state of the s | CANADA MARIANTANA MARI |
| Dr Nivecità Gupta | | The left of the Process | | | | The second secon |
 | CRIO Datable is | CPIO Details :- | CP10 Details :- Phone: 011.74556990 | CP10 Details :- Phone: 013-26585980 | CP10 Details :- Phone 01.1.76588880
 | CPIO Details to | CBO Data E - | TO SERVICE AND ADDRESS OF THE PARTY OF THE P | - 2003000 Page 2003 | or means supe | Or Assectta Gupta
 | Dr Nivectità Guipta | | | | 30000000000000000000000000000000000000
 | or meetre supre | Or Ansectta Gupta | Of Nivedia Gupta | Of Nivecita Gupta | or meeting dupin
 | | | C1000 C000 Finance C000 | | Transmission of the Control of the C | The state of the s |
 |
| Dr Nivedita Gupta | | 1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 | Control of the Contro | | 76500 MEDIO 5 6 7 8 | The second of th | | CRIO Details :
 | CPIO Details :- Phone OT S MARROW | CP10 Details :- Physics 013, NASSESSES | CP10 Details :- Phone: 011-26588990 | CP10 Details :- Phone 011, 24508780 | CPIO Details :- Physic (11, MSP200)
 | CRIO Details : | Second Microsophia | | or meeting supple | Dr Nivedita Gupta
 | Dr Nivedita Gupta | | | |
 | or missing supra | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta | Of Needle dupts
 | | 2000 0000000000000000000000000000000000 | 2000 SCHOOL SCHO | | 100000000000000000000000000000000000000 | TOTAL PLANT BOOK AND
 | |
| Dr Nivedita Gupta | | 1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 (1 | Control of the Contro | | 76500 MEDIO 5 6 7 8 | The second of th | | CRIO Details :
 | CPIO Details :- Phone OT S MARROW | CP10 Details :- Physics 013, NASSESSES | CP10 Details :- Phone: 011-26588990 | CP10 Details :- Phone 011, 24508780 | CPIO Details :- Physic (11, MSP200)
 | CRIO Details : | Second Microsophia | | or meeting supple | Dr Nivedita Gupta
 | Dr Nivedita Gupta | | | |
 | or missing supra | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta | Of Needle dupts
 | | 2000 0000000000000000000000000000000000 | 2000 SCHOOL SCHO | | 100000000000000000000000000000000000000 | TOTAL PLANT BOOK AND
 | |
| Dr Nivecità Gupta | | The left of the Process | | | | The second secon |
 | CRIO Datable is | CPIO Details :- | CP10 Details :- Phone: 011.74556990 | CP10 Details :- Phone: 013-26585980 | CP10 Details :- Phone 01.1.76588880
 | CPIO Details to | CBO Data E - | TO SERVICE AND ADDRESS OF THE PARTY OF THE P | - 2003000 Page 2003 | or means supe | Or Assectta Gupta
 | Dr Nivectità Guipta | | | | 30000000000000000000000000000000000000
 | or meetre supre | Or Ansectta Gupta | Of Nivedia Gupta | Of Nivecita Gupta | or meeting dupin
 | | | C1000 C000 Finance C000 | | Transmission of the Control of the C | The state of the s |
 |
| | | De Mine dite Guete | | - (CONTRACTOR) | |
 | | CRIO Detroite :- | CPIO Details :- | CP10 Details :- Phone of 1.76588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011,74508980 | CP10 Details :- Phone 011 NASHMAN | CRIO Detroite : | | 127 (127 (127 (127 (127 (127 (127 (127 (
 | St America Gapta | or meeting duping | or nineana dapia | |
 | | 0.000.000.000 | or revenue supre | or meeting duping | or meeting duping
 | or meeting dupin | or meeting dupin | No. of the control of | | 275 (27 TO 15 TO 1 | |
 | The state of the s | |
| | | Dr Niverlite Gueta | 27-03-44-03-44-0 | | |
 | 112277760745075 | CRIO DataSci | CP10 Details :- | CP10 Details :- Phone 011,74506080 | CPIO Details :- Phone: 011-26588980
 | CPIO Details :- Phone: 011,26588980 | CPIO Details :- Phone 011, 26522000 | CDIO Datalle - | | 522(3) (3) (3) (3) (3)
 | | STATE STATE | Continuous angue | | 200 00 MCC00 50 MC
 | | 0.000.000.000.000 | | 357,000000000000000000000000000000000000 | Continue and the contin | Co. (miching supple
 | | 255.000.000.000 | | 0.0000000000000000000000000000000000000 | | |
 | | The state of the s | HELP CONSTRUCTION |
| | | Dr Niverlite Gueta | 27-03-44-03-44-0 | | |
 | 112277760745075 | CRIO DataSci | CP10 Details :- | CP10 Details :- Phone 011,74506080 | CPIO Details :- Phone: 011-26588980
 | CPIO Details :- Phone: 011,26588980 | CPIO Details :- Phone 011, 26522000 | CDIO Datalle - | | 522(3) (3) (3) (3) (3)
 | | STATE STATE | Continuous angue | | 200 00 MCC00 50 MC
 | | 0.000.000.000.000 | | 357,000000000000000000000000000000000000 | Continue and the contin | Co. (michina supra
 | | 255.000.000.000 | | 0.0000000000000000000000000000000000000 | | | |
 | | The state of the s | HELP CONSTRUCTION |
| , or meete supre | | The Million Office Private | | - (200 (100 (100 (100 (100 (100 (100 (100 | | 11 Transportation 1 Transporta |
 | CRIO Details - | CPIO Details to | CPIO Details :- Phone 011, 24500000 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011,74588980
 | CPIO Details :- Phone of 1. 245/2000 | CDIO Detribe | | 127 (2012) | or mestic copie
 | or investigations | or meeting supple | | |
 | | or meeting stapes | or meeting stapes | of means supe | or meeting supple
 | or meeting dupon | No. of the control of | | 275 (27 TO 15 TO 1 | | CONSTRUCTION OF THE PROPERTY O | The state of the s | |
| , or means cupts | | The Million State Country | 100000000000000000000000000000000000000 | - CED (CO. CO. CO. CO. CO. CO. CO. CO. CO. CO. | (C200) 180, (C200) 180, (C200) | 11 Maria
 | | CDIO Details - | CPIO Details :- | CPIO Details :- Phone: 011, 34500000 | CP10 Details :- Phone: 011-26588990
 | CP10 Details :- Phone 011.26588980 | CP10 Details :- Phone: 011, 26500000 | CONO Detroite | The second secon | - (20000000 Penedation) | or means super
 | or meeting dupos | or meeting duping | 252.00000000000000000000000000000000000 | |
 | - APS 25 CO. 10 APS 25 CO. | of meeting stapes | or meeting duping | of Airectia dupta | or meeting dupos
 | or meeting dupin | NEW 2007 (1997) | 350000000000000000000000000000000000000 | - CHESTER OF THE PROPERTY AND THE PROPER | | 15 Mar Wall (1995) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 | 12 No. 10 | |
| Dr Nivedita Gupta | | Parking the Street | | 17503000 National Nat | 1000 HEAD 1400 CO 100 C | 10 10 10 10 10 10 10 10 10 10 10 10 10 1 | The state of the s | CRIO Details - | CPIO Details :- Phone OT S MARRIED
 | CP10 Details :- Physics 013, NASSESSES | CP10 Details :- Phone: 011-26588990 | CP10 Details :- Phone: 011.24508980 | CPIO Details :- Physic (11, MSP200) | CRIO Details
 | Contract to the contract of th | - 2003000 (March 1997) | or amenia dupia | or reveals dupts | Dr Nivecitis dupts |
 | | | 2000 CCC 1 CCC 2 C | or meetre supre | Of Nivedita dupta | Of Nivedita Gupta
 | or reveals dupts | Dr Nivedita Gupta | | | CONT. CO. CO. CO. CO. CO. CO. CO. CO. CO. CO
 | | 1000 March 1997 - 1 | SERVED PLANTS FOR THE PARTY OF | |
| Dr Nivedita Gupta | | Parking the Street | | 17503000 National Nat | 1000 HEAD 1400 CO 100 C | 10 10 10 10 10 10 10 10 10 10 10 10 10 1 | The state of the s | CRIO Details - | CPIO Details :- Phone OT S MARRIED
 | CP10 Details :- Physics 013, NASSESSES | CP10 Details :- Phone: 011-26588990 | CP10 Details :- Phone: 011.24508980 | CPIO Details :- Physic (11, MSP200) | CRIO Details
 | Contract to the contract of th | - 2003000 (March 1997) | or amenia dupia | or reveals dupts | Dr Nivecitis dupts |
 | | | 2000 CCC 1 CCC 2 C | or meetre supre | Of Nivedita dupta | Of Nivedita Gupta
 | or reveals dupts | Dr Nivedita Gupta | | | CONT. CO. CO. CO. CO. CO. CO. CO. CO. CO. CO
 | | 1000 March 1997 - 1 | SERVED PLANTS FOR THE PARTY OF | |
| | | Dr Niverlite Gueta | | - (200 (100 (100 (100 (100 (100 (100 (100 | | 11 Transportation 1 Transporta |
 | CRIO Details - | CPIO Details to | CPIO Details :- Phone 011, 24500000 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011,74588980
 | CPIO Details :- Phone of 1. 245/2000 | CDIO Detribe | | 127 (2012) | Si differenti Supple
 | or meeting support | or means supe | | THE CONTROL OF THE CO | |
 | ST THESIA SUPE | or meeting suppor | of director supple | or mesms signs | Si different sugar
 | No. of the control of | | 275 (27 TO 15 TO 1 | | CONSTRUCTION OF THE PROPERTY O | The state of the s | |
| | or meeting dupts | Dr Nivedita Gupta | | | |
 | | CDIO Datalis :- | CPIO Details :- | CPIO Details :- Ot 1.76 Stepan | CP10 Details :- Phone: 011-26588980
 | CPIO Details :- Phone: 011.24538980 | CPIO Details :- | CDIO Data Sci | protection to the contract of | | - CON 22 Y ST (CON)
 | | | 250000000000000000000000000000000000000 | 100 March 1997 - 100 Ma | 1000 CO 1000 C | | - CONTROL - CONT |
 | | | | - CERTIFICATION CONTRACTOR | | 200 CA
 | 5000 400 00 PUC Secure | | | | | | |
| | or meeting dupos | Dr Nivedita Gupta | | Control of the Contro | COND DURANTE | CONC. Describer |
 | | | | |
 | | | CONC. D. L. C. | |
 | | | 100 CONT 100 | CONTRACTOR OF THE PROPERTY OF | CROS DALATE | 15 No. 10 | |
 | CHECKSON CONTRACTOR AND CONTRACTOR A | | | | | Contract and the Contract of t | COMPANIES.
 | CDAC Describes | The second secon | THE COLUMN TWO IS NOT THE PROPERTY OF THE PROP |
| | | | | | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 01.1-26588980
 | CP10 Details :- Phone: 011-26588980 | FROM: UL1-20085980 | FINORE 011-0000000 | FIRST VALUE OF THE PROPERTY OF | |
 | THOUSE VALUE AND ADDRESS OF THE PROPERTY OF TH | Phone: 011-2658980 | CP10 Details :- Phone (11.) MSM (12.) | | | 255 000 245 255 257 35
 | | | | CRIC Data To |
 | | 125 (A) 145 (A) 125 (A | | 25.00 (25.00) | 25 CONTRACTOR DE 27 CON | 1.00000.00000
 | | | CDIO Details | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 |
			CONTRACTOR OF THE PROPERTY OF			O'10 Details :- Phone: 011-26588980	O'10 Details :- Phone: 011-26588980	FROM: 0.1-2008090	FTIONE: W.1-20000000	, 7 TOOR 14.2 TOO 15.2	The state of the s	THE PROPERTY OF THE PROPERTY O	F10000 (4.2-4003000)	FROM: (41-2030000)	O'10 Details >		THE R. L. P. LEWIS CO., LANS ASSESSMENT	and the second s	The state of the s	CONTRACTOR OF THE PROPERTY OF			CONTRACTOR OF THE PROPERTY OF	CONTRACT OF THE PROPERTY OF TH					The state of the s	THE REAL PROPERTY AND ADDRESS OF THE PROPERTY ADDRESS OF THE PROPERTY AND ADDRESS OF THE PROPERTY ADDRESS OF THE PROPERTY AND ADDRESS OF THE PROPERTY ADDRESS	The state of the s		070 Details >- Phone: 011-26588380	CPIO Details :- Phone: 011-26588980	CP10 Details :- Phone: 011-26588980
			(P10 Details :- Phone: 011-26588980	CP10 Details :- Phone: 011,26588980																															
 | Thomas or a comment | Those was account. | 7.10000.000.000 | of thousand the artistic and a state of the | |
 | Financial Control of the Control of | The second of th | A CONTRACTOR OF THE PARTY OF TH | Phone: 011-24588980 | CP10 Details :- Phone: 013-26588980 | CPIO Details :- Phone: 013-24588880 | CPIO Details :- Phone: 013.2658880 | CP10 Details :- Phone: 013-26588980
 | CPIC Details >- Phone 011-2658280 | Phone: 011,76538980 | CP10 Details :- Phone: 011-26588980 | (Phone: 011,2658980) | CP10 Details :- Phone: 013-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | CPIO Details - Phone: 013.76588980 | CP10 Details :- Phone: 013-26588980
 | CP10 Details :- Phone: 01.1-26588980 | Phone 011-2658080 | | Tribute to Property | TOTAL STATE OF THE PARTY OF THE | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | |
 | | | | |
 | | | | # TRANSPORT TO A PROPERTY OF THE PROPERTY OF T | Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | U90 Details :- Phone: 011-26588980 | Phone: 011-20588980
 | CP10 Details :- Phone: 011-26588980 | GP00 Details :- Phone: 011-26588980 | ONO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980
 | ONO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | Fhone: 011-26588980
 | | | | | | |
| | | | CP10 Details :- Phone: 013-26588980 | CPIO Details :- Phone: 011-26588980 | |
 | The state of the s | | | | |
 | | The same of the sa | 4 Property on a representation 1 | Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | Phone: 011-26588980 | UPIO DESIRES >- Phone: 011-76588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | CP10 Details :- Phone: 011-26589980 | CP10 Details :- Phone: 013-26588980
 | (PiO Details :- Phone: 013-26588980 | CP10 Details :- Phone: 013-26588980 | CP10 Details :- Phone: 011-26588980 | From: 011-2658980 | | |
 | The same of the sa | The state of the s |
| | | | CPIO Details :- | CPIO Details - | |
 | FIRST CALL CONTROL OF THE PROPERTY OF THE PROP | FROM: UL1-2008090 | F10000 W.1-W.000990 | 7 TOTAL VI. 2-10-000-000 | | F House Was accounted
 | Filoso (4.2-2030) | FROM: U.1-(2000000) | to the tree property of | The Cartie Control of the Control of | CRIO Details - Phone M.S. Marketon | CRO Details:
 | CPIO Details to | CRIO Details to | | | CPIO Details to
 | CPIO Details to | CRO Details - | CPIO Details to | CPIO Details : | CRO Details
 | CRO Details - | CRIO Details - | CRIO Details :- | | FROM: ULT-120000000
 | F1000E VL1/2000000 | FT0008: VL1-43000000 |
| | | | CRIO Details: | CRIC Datality | | FTIONE: UL1-20300300
 | A LA CAMBRIA C. | Priorie: ULT-2008090 | F 100 to 10 to 200 to 2 | 71000 017000000 | 7.000.00 | F House, Val. Woods and | Filose 012-02-0000
 | C-10 C-10 C-10 C-10 C-10 C-10 C-10 C-10 | The first property of | Phone DATE SERVICE | CRIC Details - Phone OIL MESSER | CRIO Detroit :
 | CRIO Details : | CRIO Data Sc. | | | CRIC Data Re - CO S NEXTRAN
 | CRIO Details : Bloom 011 MSHIND | CRIO Detaile | CRIO Details : | CRIO Details : Record 013 MISSERIE | CRIO Detaile
 | CRIO Details - Bloom 011 Millers | CRIO Datalis - Phone: 011 NASSERSE | Figure 011 24588980 | | FROM: ULT-20000000
 | C 10 DWHILE - FROM THE STATE OF | M 10 00000 (L1 20000000) | | | | |
| | | | CP10 Details :- Phone 011-74588980 | CPIO Details :- | |
 | FINNE VALVAGORISM | Filtrate OLD Control | F1000E-04-2-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0- | - 100m 100 months |
 | F House Was accounted | Filode OLI-Design | FINAL VALVAGORIAN | | CPIC Details :- Blook of 1.24588888
 | CPIO Details :- | CPIO Details to | CPIO Details :- | CPIO Details :- Phone 011, NAMEDIA | CPRO Details to
 | | CPIO Details :- Phone of 1.24588980 | CPIO Details to | CPIO Details :- Phone 011.24588880 | CP10 Details in
 | CP10 Details :- Phone 011-36580900 | CPIO Details :- Phone 011.24588880 | CP10 Details :- Phone 011 NASHMEN | CPIO Details :- Phone 013,34588980 | CPIO Details :-
 | Phone of Landaum | | Filtration of the Control of the Con | FIRST VALUE OF THE PROPERTY OF | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | |
 | | | | |
 | | | | # TRANSPORT TO A PROPERTY OF THE PROPERTY OF T | Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | U90 Details :- Phone: 011-26588980 | Phone: 011-20588980
 | CP10 Details :- Phone: 011-26588980 | GP00 Details :- Phone: 011-26588980 | ONO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980
 | ONO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | Fhone: 011-26588980
 | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | - Thomas to a woodenstand |
 | | | | 1 22 22 | 1 22 22
 | | | | FINANCIAL TO A CONTROL OF THE CONTRO | Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | U90 Details :- Phone: 011-26588980 | UTO DESES >- FROM: 011-26585980
 | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CPIO Details:- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | Phone: 011-26585960
 | | | | | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phonic: 011-26588980 | The state of the s | |
 | | | | |
 | | 1 2 2 | F10000 VA P WARMSTON | Gro Details :- Phonic 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CPIO Details >- Phone: 011-26588980 | Phone: 011-26585980
 | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | CP90 Details :- Phone: 0.1-26588980 | OPIO Details :- Phone: 011-26588980 | GP10 Details :- Phone: 011-26588980
 | CP90 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | Fhone: 011-26585960
 | | | | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | F House and Proposition |
 | | 1 5 6 | | |
 | | 1 0 0 | 1 2 2 2 | FIRMS WAS ASSESSED. | Ono Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phome: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | O10 Details >- Phone: 011-26583980
 | O10 Details >- Phone: 011-26585/960 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | CP10 Details :- Phone: 011-26588980
 | Phone: 011-2038980 | | | |
| CP10 Details :- Phone: 011-26588980 | OP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 88 68 | | | 100
 | | 1 2 6 | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 1 62 75 | 1 12 17
 | 1 02 17 | | | |
 | 10 miles | | 8 6 | |
 | | | | |
 | | | 100 | 87 (5) | 100
 | 89 (8) | | 87 (6 | |
| CP10 Details :- Phone: 011-26588980 | OP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 88 68 | | | 100
 | | | 22 25 | 41 10 | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 | 26 | 22 02 | 22 6 | |
 | 10 miles | | 8 6 | |
 | | | | |
 | | | 100 | 87 (5) | 100
 | 89 (8) | | 87 (6 | |
| CP10 Details :- Phone: 011-26588980 | OP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 88 68 | | | 100
 | and the second s | | illanding | | and the same is | annual discount les
 | 1 I manufacture I | | | | 10 miles
 | | 8 6 | | |
 | | | | |
 | | 100 | 87 (5) | 100 | 89 (8)
 | | 87 (6 | |
| CP10 Details :- Phone: 011-26588980 | OP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 88 68 | | | 100
 | | 1 2 6 | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 1 62 75 | 1 12 17
 | 1 02 17 | | | |
 | 10 miles | | 8 6 | |
 | | | | |
 | | | 100 | 87 (5) | 100
 | 89 (8) | | 87 (6 | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phonic: 0.1-26588980 | 7.1000.007 |
 | | | | |
 | | | 1 2 2 2 | Filtrate VL P William VI | CP10 Details :- Phonic 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | Phone: 0.1-26383980
 | Phone: 011-2555960 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | GHO Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | FROM: 011-29585980 | | | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | THOUSE WAS A CONSTRUCTION |
 | | | | |
 | | | | FIRST NA 4" AND | Ono Detats :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details:- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CPO Detaes :- Phone: 011-26588980
 | C70 Details >- Phone: 011-26588980 | CP10 Details:- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980
 | CP10 Details:- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | Phone: 011-26585980 | |
 | |
| | | | CONTRACTOR OF THE PROPERTY OF | | CPIC Details :- Phone: 013-2658980 | O'10 Detaes :- Phone: 011-26588980 | CPO Detaes :- Phone: 011-26588980
 | FROM: 0.1-20385980 | F1000E.011-03300300 | 71000.00.70 | | - Thomas Wall And
 | F10000 012-0000000 | Phone: 0.1-20588980 | UNU Details :- I Phone M1. Modernin | | THE R. L. P. LEWIS CO., LANSING MICH.
 | and the second s | The state of the s | The state of the s | | | CONTRACTOR OF THE PROPERTY OF | and the second s | | |
 | | The state of the s | The state of the s | The state of the s | | UPO Details :- Phone: 011-26588980 | CPTO Details :- Phone: 011-26588980 | CPO Details :- Phone: 011-26588980
 |
| | Of Alledia dupa | Dr Nivedita Gupta | | 70000000000000000000000000000000000000 | CP10 Details :- Phone: 013-26588980 | CP10 Details :- Phone: 01.1-26588980
 | CPIO Details :- Phonis: 011-26588980 | From: U11-20065980 | FTIOTIE: UL1-2/2008/000 | CHOOSE WAS A CONSTRUCTION OF THE CONSTRUCTION | The same of the sa | T TROUBLE WAS A WOODSHIP TO THE TOTAL OF THE | THOUSE WAR PARAMETERS | Phone: 011-26585980
 | CP10 Details :- | CONTROL OF | | 12 P | 17 (17 (17 (17 (17 (17 (17 (17 (17 (17 (|
 | The state of the s | CONC. District. | The state of the s | | 0.0000000000000000000000000000000000000 | 000000000000000000000000000000000000000 | - CONTROL (CARDON CARDON CARON CARDON CARDON CARDON CARDON CARDON CARDON CARDON CARDON CARDON | Communication and the |
 | | Transportation and the second | CRIO Details | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 |
| | | | | | CP10 Details :- Phone: 013-24588980 | CP10 Details :- Phone: 01.1-26588980
 | CP10 Details :- Phone: 011-26588980 | FROM: UL1-20085980 | FINORE 011-0000000 | FIRST VALUE OF THE PROPERTY OF | |
 | THOUSE VALUE AND ADDRESS OF THE PROPERTY OF TH | Phone: 011-2658980 | CP10 Details :- Phone (11, NOSEMAN) | PROPERTY OF THE PROPERTY OF TH | | 25.500.000.000.000 |
 | | CONTRACTOR OF THE PROPERTY OF | CROS Districts | | | 125 (A) 145 (A) 125 (A
 | 22.00 (20.00) | 25.00 (25.00) | 200000000000000000000000000000000000000 | 1.00000.0000000000000000000000000000000 |
 | | CDIO Datalis - | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 |
| | | | CRIO Details: | CRIC Datality | | FTIONE: UL1-20300300
 | A LA CAMBRIA C. | Priorie: ULT-2008090 | F 100 to 10 to 200 to 2 | 71000 017000000 | 7.000.00 | F House, Val. Woods and | Filose 012-02-0000
 | C-10 C-10 C-10 C-10 C-10 C-10 C-10 C-10 | The first property of | Phone DATE SERVICE | CRIC Details - Phone OIL MESSER | CRIO Detroit :
 | CRIO Details : | CRIO Data Sc. | | | CRIC Data Re - CO S NEXTRAN
 | CRIO Details : Bloom 011 MSHIND | CRIO Detaile | CRIO Details : | CRIO Details : Record 013 MISSERIE | CRIO Detaile
 | CRIO Details - Bloom 011 Millers | CRIO Datalis - Phone: 011 NASSERSE | Figure 011 24588980 | | PROPERTY OF THE PROPERTY OF TH | C 10 DWHILE - FROM THE STATE OF | M 10 00000 (L1 20000000)
 |
| | | | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980 | |
 | | | | |
 | | | | and the second s | Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | UPO Detaes :- Phone: 011-26588980 | UTU DELEG :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 013-26588980 | (Pto Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 370 Decade - Phone: 011-26588980
 | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | - Thomas to a woodenstand |
 | | | | 1 22 22 | 1 22 22
 | | | | FINANCIAL TO A PARTICIPATION OF THE PARTICIPATION O | Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | U90 Details :- Phone: 011-26588980 | UTO DESES >- FROM: 011-26585980
 | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CPIO Details:- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | Phone: 011-26585960
 | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | - 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 |
 | | | | | 1 22 22
 | | | | FIRST WAR AND | Gro Details :- Phonic 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 013-26588980 | CP10 Details :- Phone: 011-26588980 | C70 Details :- Phone: 011-26588980
 | Phone: 011-26585960 | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | ONO Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980
 | Fhone: 011-20585980 | | | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phonic: 0.1-26588980 | - 110mm W-100mm |
 | | 1 2 2 | | |
 | | | 1 2 2 1 | F10000 VA 4-0400000000 | Ono Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | O10 Details :- Phone: 011-26585980
 | Ono Details :- Phone: 011-2638360 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | CP10 Details :- Phone: 011-26588980
 | Phone: 0.1-2638390 | | | | | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | 7 10000 101 20000 |
 | | | | |
 | | | 1 2 2 2 | F10000 004-200000000 | CPVD Details :- Phonic: 013-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | O'10 Details >- Phone: 011-26588980
 | Phone: 011-20588980 | CPIO Details :- Phone: 0.1-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | GP10 Details :- Phone: 011-26588980
 | Ght0 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | Phone: 011-20588980 | |
 | |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | |
 | | | | |
 | | | | # TRANSPORT TO A PROPERTY OF THE PROPERTY OF T | Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | U90 Details :- Phone: 011-26588980 | Phone: 011-20588980
 | CP10 Details :- Phone: 011-26588980 | GP00 Details :- Phone: 011-26588980 | ONO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980
 | ONO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phone: 011-26588980 | Fhone: 011-26588980
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | TO A STATE OF THE PARTY OF THE | CP10 Details :- Phone: 013-26588980 | CP10 Details :- Phone: 01.1-26588980 | CPIO Details :- Phone: 011-26588980 | FROM: 0.1-20385980 | F100000 UL1-C0300300 | 7 TOOR 0.12 TOOR 0.12 | The state of the s | The state of the s | Filose 042-0430300 | Phone: 0.1-20588980 | CP10 Details :- Phone of 1.74646999 | TOTAL BOARD STATE OF THE PROPERTY OF THE PROPE | | THE CONTRACTOR OF THE PROPERTY | 125000 Add 126000 A | | The state of the s | CONTRACTOR OF THE PROPERTY OF | AND | CONTRACTOR OF THE PROPERTY OF | 25000000000 | 0200776500000 | 125(G)V 245(1900) | TO CONTRACT OF THE PROPERTY OF | COLUMN DESCRIPTION OF THE PROPERTY OF THE PROP | | A CONTRACTOR OF THE PROPERTY O | CRIO Details | CP10 Details :- Phone: 011-26588980 | OPIO Details :- Phonic: 011-26588980 | CP10 Details :- Phonic: 011-26588980 |
| | or ansetria dupos | Dr Nivedita Gupta | 2000 March 1980 | Contraction of the Contraction o | CDMC Datable is | CDIO Datalle C | | The same and the s | A STATE OF THE PARTY OF THE PAR | MANA DESIGNATION OF THE PROPERTY OF THE PROPER | Unit Design > Phone: 011-26588980 | Flore (11.765000) | Those 011 Maries | | CDO Details | Company and the company of the compa | Section interest and | | | Section retires and I | | CONTRACTOR OF THE PROPERTY OF | 100 mark 100 mm 1 | | | CHECKEN THE TOP AND A TOP A TOP AND A TOP | CONTROL OF THE PROPERTY OF THE | | The second secon | Secon nucres and B | 10 mar 20 | CRIC Data Services | COND Detaile is | THE PARTY OF THE P | The state of the s |
| | | | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 01.1-26588980
 | CPIO Details :- Phone: 011-26588980 | FROM: UL1-2508980 | FT000E-01-2-0300000 | | | | |
 | | FIRST MARKET CO. | Fhone: 011-2658980 | CP10 Details > Bluese 011, NASSERIER | COLOR DE LA COLOR |
 | 100 to 10 | 250000000000000000000000000000000000000 | | CONTRACTOR OF THE PROPERTY OF | CONTRACTOR OF THE PROPERTY OF | | 553.00 (56.00 (60.00) |
 | | 230000000000000000000000000000000000000 | 200000000000000000000000000000000000000 | |
 | | CRIO Details | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | O'10 Details :- Phone: 011-26588980
 |
| | | | 102701100000000000000000000000000000000 | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CPIO Details :- Phonis: 011-26588980 | From: U11-20065980 | FTIOTIE: UL1-2/2008/000 | CHOOSE WAS A CONSTRUCTION OF THE CONSTRUCTION | The same of the sa | T TROUBLE WAS A WOODSHIP TO THE TOTAL OF THE | THOUSE WAR PARAMETERS | Phone: 011-26585980
 | CPIO Details :- Phone (11.74/Streen | | 100000000000000000000000000000000000000 | The second secon | | 110791110000000000000000000000000000000
 | | | | 17 DECEMBER 1997 |
 | | | The state of the s | The state of the s | 100000000000000000000000000000000000000 | | CBIO Details to
 | ONO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 |
| | | | CRIO Details - Phone: 011.24588980 | CPIO Details - Phone 011-24588980 | |
 | THOUGH WAS A CONTROL OF THE PARTY OF THE PAR | Thomas of the contract of the | F1000E-04-2-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0- | - 100m 100 months | | F House Was accounted | Filode OLI-Design
 | Service Contract Cont | The first property of | Phone 015,24588980 | CRIO Details - Phone: 011,24588980 | CPNO Details: - Phone: 011.74555980 | CPIO Details - Phone: 011-24588980
 | (PHO Details :- Phone: 011,24588980 | | | CRIO Details to | CPIO Details - Phone: 011.24588880
 | CRO Details - Phone 011-34588980 | CPIO Details :- Phone (11.7458898) | CPIO Details :- Phone: (III.) 26585780 | CRO Details - Phone 011-24588980 | CPIO Details - Phone: 011-34588980
 | CRIO Details - Phone 011, 2658990 | CRIO Details :- Phone: 011-34588980 | | THE RESERVE OF THE PERSON OF T | Service of the servic | Service of the servic |
| | | | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | THOUSE WAS ACCOUNTED. |
 | | | | |
 | | | | FINANCIA VA A V | Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CPIO Detaes :- Phone: 011-26588980
 | CPU Details :- Phone: 011-20588980 | CP10 Details :- Phone: 011-26588980 | Phone: 011-26585980 | The state of the s | |
 |
| | | | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980 | |
 | | | | |
 | | | | and the second s | Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | UPO Detaes :- Phone: 011-26588980 | UTU DELEG :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 013-26588980 | CPIO Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 013-26588980 | (Pto Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | CP10 Details :- Phone: 011-26588980 | 370 Decade - Phone: 011-26588980
 | | | |
| | | | | TO DESCRIPTION OF THE PERSON O | CP10 Details :- Phone: 013-26588980 | CP10 Details :- Phone: 01.1-26588980 | CPIO Details :- Phonis: 011-26588980
 | From: U11-20065980 | FTIOTIE: UL1-1/2008/000 | CHOOSE WAS A CONSTRUCTION OF THE CONSTRUCTION | The same of the sa | T TROUBLE WAS A WOODSHIP TO THE TOTAL OF THE | THOUSE WAR PARAMETERS | Phone: 011-26585980 | CPIO Details :-
 | THE RESERVE OF THE PROPERTY OF | | 75000 MC 7500 MC | 125 (A) A (175 (A) (A) | | CONTRACTOR OF THE PROPERTY OF | CONTRACTOR OF THE PROPERTY OF |
 | | 1880 A A CONTROL OF A CONTROL O | 0000000000 | 2000/700/00000 | 16500 Address 207/1 | 553.00 (10.00)
 | | | CONO Districts | CP10 Details :- Phone: 011-26588980 | CPIO Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011-26588980 |
| Dr Nivedita Gupta | | De Mine Standard | | - CTR (CLR (CLR (CLR (CLR (CLR (CLR (CLR (CL | | D100740000000000000000000000000000000000
 | 11 Table 2 State 1 Sta | CRIO Datable : | CPIO Details :- | CPIO Details :- Phone: 011.74556990 | CP10 Details :- Phone: 013-26585980 | CP10 Details :- Phone 01.1.76588880
 | CPIO Details :- | CBMO Data Res | The state of the s | 120000000000000000000000000000000000000 | or means super | or reveals dupts
 | Dr Nivecitis dupts | | | | 0.000.000
 | of meeting stapes | Of Nivedita dupta | Of Nivedita Gupta | or reveals dupts | Dr Nivedita Gupta
 | NEW 2007 (1997) | 0.0000000000000000000000000000000000000 | 0.000,000,000,000,000 | | The second of th | The state of the s | F2200000000000000000000000000000000000
 |
| | | client reaction (x1-r-x1), electron microscopy and next-generation sequencing (wos). | Dr Nivedita Guota | Dr Nivedita Gupta | |
 | | | | |
 | | | | | Or Nivedita Gupta
 | Dr. Mineritte County | | | Dr Nivedita Gupta | Dr Nivedita Gupta
 | Dr Nivedita Gupta | Dr Nivedita Gupta | To Minedite Guete | |
 | | The Market State S | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta
 | | | |
| | | chain reaction (x1-7-x4), electron microscopy and next-generation sequencing twist). | | | Dr Nivedita Gupta | Or Nivedita Gupta
 | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta |
 | | | | |
 | | | | |
 | | | | |
 | | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta |
| | | chain reaction [k1-7-k1], electron microscopy and next-generation sequencing [woo]; | | | Dr Nivedita Gupta | Or Nivedita Gupta
 | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta | | |
 | | | | |
 | | | | |
 | | | | |
 | | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta |
| | | Main reaction (cit-r-cit), election increasely) and max-generation sequencing (reco). | Dr Nivedita Gueta | Dr Nieedita Gupta | |
 | | | | |
 | | | | | Dr Nivedita Gupta
 | Dr Nigeritte Guerte | | | Dr Nivedita Gupta | Dr Nivedita Gupta
 | Dr Nivedita Gupta | Dr Nivedita Gupta | Dr Manufille Durch | The second second |
 | The second secon | W. M. W. W. W. W. | Dr Nivedita Gueta | Dr Nieedita Gupta | Dr Nivedita Gupta | Dr Nivedita Gupta
 | | | | | | |
| Dr Nivedita Gupta | | chain reaction (n.1-1-ch), electron intruscopy and next-generation sequencing (next). | | | |
 | | | | |
 | | | | |
 | Of means supe | Dr Nivedita Gupta | Dr Nivedita Gupta | | 250000000000000000000000000000000000000
 | 7.000.000.000.000.000 | | or meeting suggest | Dr Nivedita Gupta | Dr Nivedita Gupta
 | Dr Nivedita Gupta | Dr Nivedita Gupta | and the same and t | | | 200000000000000000000000000000000000000
 | | | | | | |
| Parking the Parking | 25.50 | | Of Nivedita Guota | Of Nivedita Gupta | |
 | | | | |
 | | | | | Dr Milledita Gupta
 | | The Million of the Change of t | The Million of the Principle | Dr Nivedita Gupta | Of Nivedita Outra | or nivedita dupta
 | Of Nivedita dupta | | | The Million of the Distriction |
 | | Of Nivedita Gudes | Of Nivedia dupta | or revenue dupos | Of Nivedita Cupta
 | | | |
| | | Dr Niverlite Gueta | | 25.00 (25.00) | |
 | | CRIO Datales | CPIO Details :- | CPIO Details :- | CP10 Details :- Phone: 011-26588980
 | CP10 Details :- Phone: 011,74538980 | CPIO Details :- Phone (11) Missenson | Chica beautics | CONTRACTOR OF THE PROPERTY OF | [1888 B188 B188 B188 B188 B188 B188 B188 | of different supple
 | or meeting support | or means supe | | 100 Maria 200 Ma | TO AND THE PARTY OF THE PARTY O | | ST THESIA SUPE
 | or meeting suppor | of director supple | or mesms signs | Si different sugar | No. of the control of |
 | 25.00 (25.00) | DOMESTICAL CONTROL OF THE PROPERTY OF THE PROP | | | |


https://rtionline.gov.in/request/status.php

1/1

Yash, el solicitante del FOI anterior al ICMR, apeló la respuesta del ICMR, señalando que el estudio citado por ICMR era exactamente lo que había especificado que **no** estaba solicitando (porque no tiene nada que ver con aislar/perpurar un supuesto virus). La respuesta del 12 de julio de 2021 a su apelación: La *respuesta proporcionada al solicitante está en orden y satisfactoria*.

El llamamiento y la respuesta de Yashés:

$\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/08/ICMR-first-APPEAL-package.pdf}$



https://rtionline.gov.in/request/status.php

1/1

fraude de la **empresa**, esta vez a través su . Observe el logotipo de la Organización Mundial de la Salud y la referencia en el pie de la letra. Aquí está la URL de la imagen:



आई सी एम आर - राष्ट्रीय विषाणु विज्ञान संस्थान

भारतीय आयुर्विज्ञान अनुसंघान परिषद श्वास्त्र्य अनुसंघान विभान स्यास्त्र्य एवं परिवार कान्याण मंत्रालय, मारत सरकार

I C M R - NATIONAL INSTITUTE OF VIROLOGY

Indian Council of Medical Research

Ministry of Health & Family Welfare, Govt. of India

20 - ए. डा. आंबेडकर मार्ग, पोस्ट बॉक्स संस्था 11, पुणे - 411 001, मारत. 20-A. Dr. Ambedkar Road, Post Box No. 11, Pune 411 001, India. ii.: NIV Camp +91-020-26127301, 26006290, Fax : 26122669, 26126643 / NIV Pashan +91-020-26006390 Fax : No. 25871895 / 25870640 E-mail : director.niv@icmr.gov.in Website : www.niv.co.in

No. 1/8/2005/RTI/Admn./XVII- 671

28th June 2021




Sub.: Online Application under Right to Information Act 2005
Ref.: Registration No. NIOVP/R/T/21/00005 dated 12/06/2021

Sir,

This is in reference to your above online application no. NIOVP/R/T/21/00005 dated 12th June 2021 forwarded by ICMR with reference no. INCMR/R/T/21/00577 dated 12/06/2021, seeking information under Right to Information Act 2005. Please find the below mentioned publications for the SARS-CoV-2 isolations by ICMR-National Institute of Virology.

- a. Sarkale P., Patil, S., Yadav, P.D., Nyayanit, D.A., Sapkal, G., Baradkar, S., Lakra, R., Shete-Aich, A., Prasad, S., Basu, A. and Dar, L., 2020. First isolation of SARS-CoV-2 form clinical samples in India. The *Indian Journal of Medical Research*, 11(2-3), p.244.
- b. Yadav, P., Sarkale, P., Razdan, A., Gupta, N., Nyayanit, D., Sahay, R., Potdar, V., Patil, D., Baradkar, S., Kumar, A. and Aggarwal, N., 2021. Isolation and characterization of SARS-CoV-2 VOC. 20H/501Y. V2, from UAE travelers, bioRxiv.
- c. Yadav, P.D., Nyayanit, D.A., Sahay, R.R., Sarkale, P., Pethani, J., Patil, S., Baradkar, S., Potdar, V. and Patil, D.Y., 2021. Isolation and characterization of the new SARS-CoV-2 variant in travelers from the United Kingdom to India: VUI-202012/01 of the B. 1.1. 7 lieage. Journal of Travel Medicine, 28(2), p.taab009.
- d. Yadav, P.D., Nyayanit, D.A., Sahay, R.R., Shete, A.M., Majumdar, T., Patil, S., Patil, D.Y., Gupta, N., Kaur, H., Aggarwal, N. and Vijay, N., 2021. Imported SARS-CoV-2 V501Y. V2 variant (B. 1.351) detected in travelers from South Africa and Tanzania to India. Travel Medicine and Infectious Disease.



पोलिओ, खसरा एवं रुबेला के लिए रेफरल प्रयोगशाला

(4)

Collaborating Centre for Emerging Viral Infections National Influenza Centre Referral Lab for Polio, Measles and Rubella La siguiente es una segunda respuesta de la FOI de 28 de junio de 2021 del **Consejo Indio de Investigación Médica** que no proporciona/cita de nuevo ningún registro de la purificación de la ORA-COV-2 y citando los mismos documentos anti-ciencia, esta vez en respuesta a la solicitante Trinayan Das. A ICMR también se le hicieron preguntas adicionales de PCR, y respondió que es el estándar de oro para la detección (conmuy exactamente. Respuesta completa:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/07/ICMR-June-28-2.pdf

What are the methods used for isolation/purification of SARS-CoV-2 virus?	Virus isolation is being performed in Vero cell lines using the tissue culture techniques.
Is the RT-PCR test approved for diagnostic of infectious disease like SARS-CoV-2 (COVID-19) virus?	Yes, Real Time Reverse Transcription Polymerase Chain Reaction (Real Time RT-PCR) is the gold standard test for detection of SARS-CoV-2. For more details on molecular testing of SARS-CoV-2 please refer to ICMR advisory available at https://www.icmr.gov.in/pdf/covid/labs/ICMR Advisory Testing System v 10112 020.pdf and the WHO guidelines available at https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf
4. Was the RT-PCR test used earlier to diagnose any infectious disease? What is the accuracy of the test?	Yes, RT-PCR test is a widely used test to detect many infectious diseases such as Influenza viruses, Hepatitis viruses, HIV, Dengue chikungunya etc. it is widely used in biomedical science research. The test is highly sensitive and detects specific targets very accurately.

Abril / Junio 2021:

El Consejo de Investigación Médica de la India no proporcionó o citó en dos ocasiones ningún registro que probara el contagio de la causa por el virus, para el solicitante: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/ICMR-contagion-causation-PACKAGE-redacted.pdf

Citizenship	Indian
Is the Requester Below Poverty Line ?	No
Ground For Appeal	Provided Incomplete, Misleading or False Information
CPIO of Public Authority approached	Dr Nivedita Gupta
CPIO's Order/Decision Number	Details not provided
CPIO's Order/Decision Date	
Description of Information sought (upto 500 charact	ters)
Prayer or Relief Sought	
Distriction and an interest an	
The lockdowns due to Covid-19 has pushed million Covid-19 is contagious and spreads from person to	
Covid-19 is contagious and spreads from person to	ns of people into poverty and inconvenienced many people. The reason given for lockdowns was that person. Proving that Covid-19 is contagious and spreads from person to person. However the reply given in RT
Covid-19 is contagious and spreads from person to	person. proving that Covid-19 is contagious and spreads from person to person. However the reply given in RT
Covid-19 is contagious and spreads from person to In the RTI I had asked ICMR for research material p is that this information can be obtained from googl	person. Proving that Covid-19 is contagious and spreads from person to person. However the reply given in RT le. e its own research on the infectiousness of Covid-19 then it has to share the same. Otherwise it has to

Agosto / Septiembre 2021:

El Consejo de Investigación Médica de la India (ICMR, el organismo de ápice en la India para la formulación, coordinación y promoción de la investigación biomédica) no proporcionó o citó ningún registro de la versión de la variante de la .Delta para el

$solicitante: \underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/ICMR-Delta-Pelurification-2x-PACKAGE-redacted.pdf}$

Enter Registration Number	INCMR/R/T/21/01016
Name	
Date of filing	23/08/2021
Public Authority	Indian Council of Medical Research
Status	RTI REQUEST APPLICATION RETURNED TO APPLICANT
Date of action	23/08/2021
already available at public doma	ted ICMR guidelines, advisories, publications etc, that can be disseminated, a in icmr.gov.in. Please follow the ICMR website for updation. Interrogative, ons are not covered under the RTI Act 2005.
personal and hypothetical quest There is no provision under the	ted ICMR guidelines, advisories, publications etc, that can be disseminated, a in icmr.gov.in. Please follow the ICMR website for updation. Interrogative,
already available at public doma	ted ICMR guidelines, advisories, publications etc, that can be disseminated, a in icmr.gov.in. Please follow the ICMR website for updation. Interrogative, ons are not covered under the RTI Act 2005.
personal and hypothetical quest There is no provision under the	ted ICMR guidelines, advisories, publications etc, that can be disseminated, a in icmr.gov.in. Please follow the ICMR website for updation. Interrogative, ons are not covered under the RTI Act 2005.
already available at public doma personal and hypothetical quest There is no provision under the Regards.	ted ICMR guidelines, advisories, publications etc, that can be disseminated, a in icmr.gov.in. Please follow the ICMR website for updation. Interrogative, ons are not covered under the RTI Act 2005. ITI Act 2005 to seek explanation. (Nodal Officer Details :-)

Home | National Portal of India | Complaint & Second Appeal to CIC | FAQ

Copyright © 2013. All rights reserved. Designed, Developed and Hosted by National Informatics Centre, New Delhi

14 de septiembre de 2021:

Instituto de Química Orgánica y Bioquímica de la Academia Checa de Ciencias (Estav organické chemie a biochemie AV .R, v. i. (Praga) aconseje que nunca han purificado el supuesto virus COVID-19 de cualquier muestra de pacientes, pero se convenció de que tenían una muestra de "it" al fabricar un genio de secuencias de ARN encontradas en su cultivo de células monos.



Prague, 14 September 2021

Re: Information Provided in Response to a Request for Information Filed in accordance with Act No. 106/1999 Coll.

On 1 September 2021, the following request for information was delivered to the Institute of Organic Chemistry and Blochemistry of the Czech Academy of Sciences, (bitzer organicale chemier a blochemier AVCR, v, v, ℓ) ("Institute"). The request was filed by David Sublik ("Applicant") in accordance with ACR, to, 106/1999 Coll., the *Freedom of Information Act, as in effect ("Precodom of Information act) as in effect of the color of Information act, as in effect of the color of Information act, as in effect of the color of Information act, as in effect of the color of Information act and Information

- What method was used by the Institute to carry out the full purification and isolation of the virus referred to as SARS- CoV-2? Provide a citation referring to a scientific paper or contribute authorities.
- Provide electron microscope imagery demonstrating the full purification and isolation of viral particles of the virus referred to as SARS-CoV-2.
- 3) What method was used to identify the fully purified and isolated viral particles to be part of the virus referred to as SARS-CoV-2? Provide a citation referring to a scientific paper or a methodology.

The Institute has fully complied with the request and hereby provides the following information to the Applicant in accordance with Section 14/5Vd) of the Freedom of Information Act:

Re 1)

- A nasopharyngeal swab specimen in a collection tube with a transport medium was agitated briefly five times.
- b) The medium was filtered using a 0.22 µm filter and added to Vero cells in a 25 cm2 cultivation bottle and incubated in an incubator at 37 °C, 5% CO2.
- c) Outpositive effect on the cells was monitored on a daily basis
- d) After three days, the cultivation bottle containing the cells was twice frosted and defrosted.
- e) The culture containing Vero cells was centrifuged for five minutes at 1,000 g.
- f) The supernatant was filtered using a 0.45 µm filter, and 0.5 ml was transferred to fresh Vero cells in a 25c m2 cultivation bottle and incubated in an incubator at 37°C, 5% CO2.
- g) After three days, the cultivation bottle containing the cells was frosted and defrosted twice.
- b) The culture containing Vero cells was centrifuged for five minutes at 1,000 g.
- The supernatant was filtered using a 0.45 µm filter, and 1.5 ml was transferred to fresh Vero cells in a 75cm2cultivation bottle and incubated in an incubator at 37°C, 5% CO2.
- i) After three days, the cultivation bottle containing the cells was twice frosted and defrosted.
- ii) The culture containing Vero cells was centrifuged for five minutes at 1,000 g.

| Paminique miles. 2 | 400 (20 180 333 | ID. 61369603 | 166 10 Patric 6 | Uschib-Specialbuse cz | DIC- CZ6136963 | Czech-Respolito | Warw. cschibutz |

- 1) The supernatant was filtered using a 0.45 µm filter, aliquoted, and frozen to -80 °C.
- m) Thus obtained supernatant contained purified, infectious particles of SARS CoV-2 with a 10e6 IU/ml titer, capable of infecting fresh cells.

Re 2)

SARS-CoV-2 was not examined by means of electron microscopy in the Institute's laboratory; however, imagery obtained this way has been described in numerous instances in literature, such as

- e) Turonova, B.; Sikora, M.; Schurmann, C.; Hagen, W.J.H.; Weisch, S.; Bianc, F.E.C.; von Bulow, S.; Gecht, M.; Bagola, K.; Horner, C., et al. In situ structural analysis of SARS-COV-2 spike reveals Bisivibity mediated by those binoses. Science 2020, 372. 203-208. doi:10.1156/science.abd5233.
- b) Ke, Z.; Oton, J.; Qu, K.; Cortese, M.; Zila, V.; McKeane, L.; Nakane, T.; Zivanov, J.; Neufeldt, C.J.; Cerikan, B., et al. Structures and distributions of SARS-CoV-2 spike proteins on intect virions. Nature 2020, 588, 498-522, doi:10.1038/41558-020-2655-2.

Pa 31

- a) The virus aliquot was defrosted, and 70 µl was used to isolate RNA using a QIAamp Viral RNA kit (Qiagen).
- b) cDNA was prepared using a LunaScript RT SuperMix kit (New England Biolabs).
- cDNA was amplified by means of multiplex PCR using an Artic nCov-2019 V3 panel (IDT) with a Q5
 HotStart High Fidelity 2x master mix.
- t) The products of the PCR procedure were purified, quantified, and fragmented using a NEB Next Ultra II FS DNA module (New England Biolabs).
- a) Adaptors for Illumina sequencing were added using NEBNext® Ultra™ II DNA Library Prep and indexation was carried out using NEBNext® Multiplex Oligos for Illumina (New England Biolabs).
- f) Virus sequencing was performed using an Illumina Miniseq device, and the sequence was analyzed using the DNASTAR Lasergene software.
- g) The sequences were entered into the GISAID database, specifically an isolate designated as hCoV-19/Crach Republic/NRL 6632 2/2020 under the code EPI_ISL_3050767. The sequence corresponds to SARS-CoV-2 line B.I.
- ii) The isolated virus contained the described viral proteins (demonstrated by means of specific antibodies using immunofluorescence and the Western Blot method) and was able to infect sensitive mammelian cells, which subsequently produced viral particles.

Notice

The Applicant may file a complaint against the manner in which the request has been processed in accordance with Section 16a(1/a) of Act No. 106/1999 Coll., the Freedom of Information Act, as in effect. A complaint must be filled with the Institute within 30 days of the delivery of this document. Complaints are reviewed by the supervisory authority, specifically the Office for Personal Data Protection.

..... i prostorovoti

Institute of Organic Chemistry and Biochemistry RNDr. PhDr. Zdeněk Hostomský, CSc.

Univerzita Karlova: Esto de la universidad número 1 en Czech R. Como respuesta, nos informan, que hay un amplio **consenso** en la comunidad científica internacional sobre la secuencia precisa de ARN de SARS-Cov2, sobre su estructura química y proteica y que causa COVID19.

Así, Univerzita Karlova no proporcionó ningún registro que demostrara la purificación o la existencia del virus: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/05/checo-university.pdf

Existuje široký vědecký konsensus o tom, že chorobu COVID-19 způsobuje virus SARS-CoV-2, že tento virus lze specificky a citlivě detekovat pomocí řady biochemických metod včetně polymetázové řetězové reakce, je známa detailní chemická i prostorová struktura všech proteinů, z nichž se virus SARS-CoV-2 skládá, i struktura viru samotného a je známa přesná sekvence jeho dědičné informace, RNA. To vše může poučená, kvalifikovaná osoba snadno nemůže sdělit odpovědi na předmětné dotazy žadatele, které by mohly sloužit jako konečné, autoritativní a nesporné pravdy, resp. konečné vědecké informace.

Z těchto všech důvodů nelze žadateli vyhovět a Univerzitě Karlově nezbývá než žádost odmítnout.

Poučení: Proti tomuto rozhodnutí lze podat odvolání nejpozději do 15 dnů ode dne jeho doručení podáním u rektorátu Univerzity Karlovy (ust. § 16 odst. 1 zák. č. 106/1999 Sb.).

JUDr. Tomáš Horáček, Ph.D. kvestor Univerzity Karlovy Ministerio de Salud checo: Esta es la respuesta del Ministerio de Salud checo. Cuando se solicitó una prueba de existencia del virus SARS-Cov2....

Las referencias citadas por el Ministerio están en inglés y no describen la purificación de un supuesto virus, y mucho menos el estudio científico de tal. Carta completa: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/05/Cádulo-ministry-of-health.pdf





Váš dopis ze dne 26. prosince 2020

V Praze dne 30. prosince 2020 Č. j.: MZDR 55403/2020-11/MIN/KAN MZDRX010QV5W

Sdělení Ministerstva zdravotnictví ke stížnosti – poskytnutí požadovaných informací


K Vámi podané stížnosti, doručené Ministerstvu zdravotnictví dne 26. prosince 2020, evidované pod č. j.: MZDR 55403/2020-8/MIN/KAN, Vám níže zasílám požadované informace.

Publikace potvrzující existenci viru SARS-CoV-2:

- Ludwig S., Zarbock A. Coronaviruses and SARS-CoV-2: A Brief Overview. 2020 International Anaesthesia Research Society, www.anesthesia-analgesia.org Dostupné na: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173023/
- Na Zhu et al., A novel coronavirus from patients with pneumonia in China, 2019, N Engl J MED 382;8, February 20, 2020 (pdf ke stažení zde: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092803/pdf/NEJMoa2001017. pdf)
- 3. SZÚ WEB:
 - http://www.szu.cz/uploads/Epidemiologie/Coronavirus/Zakladni info/2020 08 07
 Covid 19 zakladni informace.pdf
- Sharma et.al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a <u>global pandemic and treatment strategies</u>. Int J Antimicrob Agents. 2020 Aug; 56(2): 106054. Published online 2020 Jun 10. doi: 10.1016/j.ijantimicag.2020.106054
- Junejo Y, Ozaslan M, Safdar M, et al. Novel SARS-CoV-2/COVID-19: Origin, pathogenesis, genes and genetic variations, immune responses and phylogenetic analysis. Gene Rep. 2020;20:100752. doi:10.1016/j.genrep.2020.100752
- 6. https://viralzone.expasy.org/9056



Personalmente no puedo leer este próximo documento del **Ministerio de Salud de Ucrania** del 15 **de** marzo de 2021, pero se me dijo que el Ministerio declaró aquí que no tienen ningún aislamiento de la SARS-COV-2, ni tienen la intención de obtener ninguno.



24 de agosto de 2021: **La Autoridad de Salud Pública** de **Suecia** también puede encontrar el virus. <u>John Blaid</u> presentó una solicitud formal de FOI para registros que describen la purificación del virus de cualquier muestra de paciente (no adulterada con

material genético, es decir, células de mono, suero bovino fetal) en el planeta, por cualquier persona, en cualquier lugar. La respuesta: No, *no existen tales documentos*. Correspondeción completa:

Begäran om allmän handling John Blaid 2021-08-20



18 de octubre de 2021: **El Instituto Karolinska** de **Suecia** no pudo proporcionar o citar ningún registro de aislamiento/purificación SARS-CoV-2 para <u>John Blaid</u>. Según John: Esta

- Hola John.

El registrador y el departamento de comunicaciones del Instituto Karolinska han respondido ahora que no tienen acceso a esta información. En la actualidad, la biblioteca universitaria no tiene la oportunidad de realizar tareas de búsqueda para clientes externos. Una sugerencia es hacer una búsqueda en la base de datos de libre acceso PubMed. Si tienes la oportunidad de visitarnos, también puedes utilizar otras bases de datos.

PubMed contiene el término MeSH SARS-CoV-2 / aislamiento y purificación, que actualmente proporciona 5251

referencias. https://pubmed.ncbi.nlm.nih.gov/?term=%22SARS-CoV-2%2Fisolation-and-purification%22&sort=relevance.

Respuesta del Instituto Karolinska:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/10/Karolinska-Institute-2021-10-18-3.pdf}{}$

REFID: KIB0123839 - VB: Sv: Tillgång till dokumentation gällande isolering och rening av SARS-COV-2

From: kib@ki.se <kib@ki.se>
To: John Blaid

Cc: KI Registrator < registrator@ki.se>, KI Communicationsoffice < communicationsoffice@ki.se>

Date: 2021-10-18 11:45

Hej John!

Registrator och kommunikationsavdelningen på Karolinska Institutet har nu svarat att de inte har tillgång till dessa uppgifter.

För närvarande har universitetsbiblioteket inte möjlighet att utföra sökuppdrag åt externa kunder. Ett förslag är att göra en sökning i den fritt tillgängliga databasen PubMed. Om du har möjlighet att besöka oss kan du använda även andra databaser. https://kib.ki.se/om-kib/kontakt-oppettider

I PubMed finns MeSH-termen SARS-CoV-2/isolation and purification, som fn ger 5251 referenser. https://pubmed.ncbi.nlm.nih.gov/?term=%22SARS-CoV-2%2Fisolation+and+purification%22&sort=relevance

Vill du se vilka som arbetar med frågan på Karolinska Institutet eller Karolinska Universitetssjukhuset kan du lägga till Karolinska. Då blir det just nu 29 artiklar, Du hittar kontaktuppgifter till varje.

https://pubmed.ncbi.nlm.nih.gov/?term=%28%22SARS-CoV-

2%2Fisolation+and+purification%22%29+AND+%28karolinska%29&size=50

Med vänlig hälsning

Johnny Carlsson 1:e bibliotekarie

Universitetsbiblioteket | Karolinska Institutet

https://kib.ki.se

Från: KI Communicationsoffice (communicationsoffice@ki.se)

Skickat: 2021-10-14 16:34:33

Ämne: VB: Sv: Tillgång till dokumentation gällande isolering och rening av SARS-COV-2

Meddelande:

Hej!

Detta meddelande har kommit till Karolinska Institutets e-postbrevlåda. Vi är tacksamma för hjälp med handläggning av

Med vänlig hälsning/Best regards

Anki Israelsson

Kommunikationsavdelningen/Communications and Public Relations Office Karolinska Institutet | ki.se Karolinska Institutet – a medical university

El Ministerio de Salud, Bienestar y Deporte de los Países Bajos (Países Bajos) no proporcionó/citado al solicitante ningún registro de los experimentos reales de purificación y control para demostrar la existencia de la Ley de la República Árabe Rojas-CoV-2:

26 de abril de 2021: Una vez más, el **Ministro holandés de Salud, Bienestar y Deportes (Países Bajos)** respondió a una FOI enviada a su agencia RIVM (Instituto Nacional de Salud Pública y Medio Ambiente) de la repuración del virus; el Ministro proporcionó/citaba cero registros de este tipo para Gabrille Rutten, y citó en su lugar a

la cultura celular anti-ciencia. Correspondeción completa: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/07/Wob-verzoek-no-records-package.pdf

(English Translation of response from the Dutch) Ministry of Health, Well-being and Sport

> Return address PO Box 20350 2500 EJ The Hague

BY E-MAIL ONLY Mr G. Rutten info@official-eft.nl

Date 26 april 2021 Subject Request for information

Dear Mr Rutten,

On March 16, 2021, I received your email. I confirmed receipt of this letter of 29 March 2021 with characteristic 2021.063/001.

By invoking the Public Administration Act (hereinafter: Wob), you request all scientific peerreviewed publications that promote the isolation of the SARSCOV 2. You have also requested scientific publications that prove that the aforementioned virus is the cause of the disease 'Covid-19'.

In accordance with Article 6(1), the Wob only applies to information documented in documents which are not already public. The requested information concerns public information. Next I will indicate where you can find the relevant information.

The coronavirus Sars-Cov-2 is the virus that can cause the disease COVID-19. More information about this can be found on the website of the Government Institute for Public Health and the Environment (hereinafter: RIVM) under the heading 'virus' (www.rivm.nl/coronavirus-covid-19/virus). For the scientific reports about the existence of Sars-Cov2 I refer you to the following websites:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159086/ and https://pubmed.ncbi.nlm.nih.gov/31978945/.

In addition to the website of the RIVM mentioned above, you might also like to visit the following RIVM website: https://lci.rivm.nl/richtlijnen/covid-19. On this website you will find relevant literature.

If you have any questions about this letter, please feel free to contact the Wob cluster. The contact details are at the top of this letter.

Sincerely,

the Minister for Health,
Well-being and Sport,
on behalf of this,
the Director of Legislation and Legal Affairs,
Mr. M.M. den Boer

15 de marzo de 2022:

El **Ministro holandés de Salud, Bienestar y Deportes (Países Bajos)** respondió a una solicitud de *evidencia confiable de que el SARS-CoV-2 (o cualquier otro supuesto virus)*

ha sido aislado de una muestra "una persona enferma) y que ese supuesto virus puede transmitirse a otra persona (o animal) y luego causar la misma llamada enfermedad allí.en el cultivo celular (oximoron).https://www.fluoridefreepeel.ca/wp-content/uploads/2022/1 Netherlands-Min-Health-Welfare-Sport-PACKAGE-redacted-updated-Nov-2022.pdf



19 de enero de 2022:

El Departamento de Salud y Atención Social de la Isla de Man (Islas Británicas) confirmó para Courtenay Adam-Lawrence que no tienen registro de los siguientes, ni para los presuntos "Omicron" ni para el imaginario de la "Equitro" de la imaginación. Secuencia única del genoma entera

- procedimientos de ensayo
- aislamiento/purificación
- contagio
- la confirmación de que no se trata simplemente de un modelo de maquillaje de una cepa de un virus:

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/Isle-of-Man-DHSC.pdf

While our aim is to provide information whenever possible, in this instance the Department of Health and Social Care ('the Department') is unable to provide the information that you have requested. This is in line with Section 11(3)a of the Act, as a practical refusal reason applies; namely we do not hold or cannot, after taking reasonable steps to do so, find the information that you have requested as it may be held by **Manx Care**.

Feb 18, 2021: El **Departamento de Salud y Atención Social de** la **Isla de Mano** admitido en una respuesta del FOI al Sr. Steven Gardner que:

El virus no está aislado/purificado;

45 ciclos de PCR.

Clarification received:

Has the SarsCov2 been isolated and purified. To be proven scientifically and proven the virus causes disease.

Question 1:

Has Covid 19/21 been isolated?

Regarding SARS-CoV-2 the virus is not isolated.

Question 2:

Has covid 19/21 been purified?

Regarding SARS-CoV-2 it is not purified.

Question 3:

Has there been a risk assessment on masks?

The Department has and does risk assessments on masks.

Question 4:

Have all places of business who have mandatory masks done a risk assessment or should they do a risk assessment, in regards to masks? For their employees and customers.

While our aim is to provide information whenever possible, in this instance the Department of Health and Social Care ("the Department") is unable to provide the information that you have requested. This is in line with Section 11(3)a of the Act, as a practical refusal reason applies; namely we do not hold or cannot, after taking reasonable steps to do so, find the information that you have requested.

Places of business are responsible for undertaking their own risk assessments and setting their own policies for wearing masks.

To provide further advice and assistance guidance on face coverings, including 'face coverings at work' is available within the public domain at:

https://covid19.gov.im/general-information/guidance-on-face-coverings/

Ouestion 5:

Is the sequence in the PCR test SarsCov2?

Yes, the sequence in the PCR test is SARsCov2

Ouestion 6:

What amplifications has the PCR test been run at?

The amplification is 45 cycles.

19 de agosto de 2022:

Claire O-Connell, actuando como Oficial de Cumplimiento de Información de la Universidad de Canterbury, Nueva Zelanda, confesó a Michael S. que no tienen pruebas científicas de la existencia de SARS-COV-2:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/09/2022-08-19-University-of-Canterbury-SARS-COV-2-Proof-of-Existance-Redacted-1.pdf$



Official Information Act request 22.45 SARS -COV -2 Proof of Existence

I refer to the Official information Act [the Act] request dated 3 August 2022 for information relating to the existence of SARS-COV-2. You have requested the following:

All records in the possession, custody or control of The University of Canterbury that scientifically proves the existence of SARS-COV-2 virus.

Scientific proof is NOT

- Experiments that follow the scientific method
 Repeatable experiments that produce identical results
 Experiments all have valid control groups

The scientific method is a process used to prove or disprove hypotheses. My request requires the hypothesis to include the claim of existence of SARS-COV-2 particles. If the records do not have a hypothesis or do not have a hypothesis that claims the existence of SARS-COV-2, then these records are disqualifyed from my request.

I om requesting records that only use the scientific method and where the experiments have been repeated multiple times where the results were 100% the same. For any of the SARS-COV-2 Genome Sequences, multiple times where the results were 100% the same. For any of the SARS-COV-2 Genome sequences, the speniments must have been conducted and produced a 100% match for the SARS-COV-2 genome sequence t researchers found. Records that have not been repeated with 100% matches for the SARS-COV-2 genome and alquiofiled from my request.

A control experiment is an experiment that has exactly the same parameters of the experimental ground the variable being tested. For cell culture experiments, the control group should have exactly the same composition sans the SARS-COV-2 viruses. Experiments that do not have a valid control as defined are disqualified from my request.

Please provide all records that scientifically prove the existence of SARS-COV-2 as defined in this request

If any records match the above description of requested records and accurrently available to the public ehewhere, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access st). Please provide UNLs where possible.

Record Search
I do not expect the University to search students' computers, labs' computers, or even researchers' computer
sepect the University to direct this request to the appropriate department who have COVID experts such as
Professor Michael Plank.

Format: Pdf documents sent to me via email; I do not wish for anything to be shipped to me

Please note that the University of Canterbury (UC) does not have a Faculty of Medicine. No one at UC has undertaken any experiments in relation to SARS-COV-2. UC does not hold the requested information Therefore, the request is refused under s 18(e), as the document alleged to contain the information does not

You have the right to seek an investigation and review by the Ombudsman of this decision. Information about

Yours sincerely

CMO Carela Claire O'Connell Information Compliance Officer

9 de agosto de 2022:

Jan Torres, en calidad de Gerente de Servicios de la OIA, Ministerio de Salud de Nueva Zelanda, ha confesado a mi colega Michael S. que nadie en el Ministerio tiene ningún registro que demuestre científicamente la existencia de SARS-COV-2 o que causa "COVID-19".

Además, no ven ninguna razón en la Tierra para pensar que cualquier agencia del gobierno lo hace, y así naturalmente esto hace que Michaels sea un ejemplo de vez en cuando vuelva a saber de él.

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/08/NZ-MOH-no-science-re-Existance-and-Causation-PACKAGE-redacted.pdf



133 Molesworth Street PO Box 5013 Wellington 6140 New Zealand T+64 4 496 2000

9 August 2022

Ref: H2022007956

H2022009478

Response to your request for official information

Thank you for your requests under the Official Information Act 1982 (the Act) to Manatū Hauora (Ministry of Health) on 19 July 2022 and 4 August 2022 for information about the SARS-CoV-2 virus and COVID-19 disease. Rather than repeat your requests in full, they are attached as Appendix 1 to this response.

On 23 May 2022, in response to the latest in a series of requests about the existence of viruses and whether they caused disease, you were advised:

"As you have been advised previously, particularly in the context of the SARS-COV-2 virus, Poliovirus and Marburg viruses, the Ministry does not hold this information. There is no requirement under the Act for the agencies subject to it to create new information or compile information they do not hold. Your request is therefore refused under section 18(g)(i) as the information requested is not held by the Ministry and there are no grounds for believing it is held by another agency subject to the Act. Please note the Ministry does not conduct scientific research or studies. Please refer to online scientific studies for further information: https://pubmed.ncbi.nlm.nih.gov. You have been advised that should you make further requests for the same information the Ministry may refuse your requests under section 18(h) of the Act, as they may be considered frivolous or vexatious."

As you have continued to ask for information to which the Ministry has previously provided a response, these requests are refused under section 18(h) as vexatious.

Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any decisions made under this request. The Ombudsman may be contacted by email at: info@ombudsman.parliament.nz or by calling 0800 802 602.

Nāku noa, nā

Jan Torles
Acting Manager OIA Services
Government and Executive Services

29 de julio de 2022:

En julio, algún hombre o mujer anónimo que trabajaba para Servicios Ministeriales, Trabajo, Ciencia y Empresa, **Ministerio de Negocios, Innovación y Empleo, Nueva Zelanda** confesó a mi colega Michael S. que, a pesar de su política de cuarentena, sería demasiado trabajo para cualquiera de los que en MBIE buscara sus registros por cualquiera que probara científicamente la existencia de SARS-COV-2. Rechazaban el FOI de Michael sobre esta base, y también afirmaban que los registros requeridos están disponibles públicamente, y que entienden que el virus existe basado en pruebas de rumores. Michael siguió con una queja, buscando reparación mediante la provisión de los supuestos registros o una retractación de la afirmación de MBIA-s de que existe.

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/08/NZ-Min-Business-Innovd-Employ-no-science-re-existence.pdf

MBIE is not an institution that is used for scientific experiments or testing, and has not generated information along the lines of what you request. While MBIE will hold information that relates to scientific work that has been undertaken about COVID-19, identifying which of these records relate specifically to the existence of COVID-19 per the parameters you set out would require a considerable amount of work to collate. Your request is therefore subject to a technical refusal in reliance on section 18(f) of the OIA, as the information requested cannot be made available without substantial collation or research.

Information about the existence of COVID-19 is available through publicly available resources. Your request is therefore also subject to refusal in reliance on section 18(d) of the Act, as the information requested is publicly available. Please note that MBIE is not required to create information in order to respond to a request under the Act, per your request for MBIE to identify and list where to access specific publicly available records.

Agosto/septiembre actualización de 2022:

Una carta anónima de respuesta a las quejas indica que el MBIE formó parte de toda la respuesta del gobierno al COVID-19 (sic) y la gente de MBIE se mantuvo firme en su confianza en las pruebas de rumores. Además, admitieron a Michael que, sin embargo, tienes razón de que no podemos identificar una información específica que entra dentro de los parámetros específicos de tu solicitud, pero continuó rechazando su FOI en base a sus suposiciones de que ellos 1) tienen registros científicos y 2) se necesitaría demasiado trabajo para encontrarlos. Concluyeron sugiriendo que Michael se rielió y hable con el Ministerio de Salud en su lugar... como si ya hubiera hecho eso repetidamente desde 2020. Michael siguió esta loca con otra queja, buscando de nuevo remedio a través de la provisión de los supuestos registros científicos o una admisión de que no existen tales registros. La última carta de respuesta a la queja anónima de MBIE indica que están a un lado 1) su confianza en los rumores, 2) su suposición de que tienen registros científicos, y 3) su negativa a la FOI con el argumento de que intentar confirmar su asunción sería demasiado trabajo y afectaría injustificadamente a su Raqueta criminal operaciones.https://www.fluoridefreepeel.ca/wpcontent/uploads/2022/09/NZ-MBIE-complaint-responses-PACKAGE-redacted.pdf

MBIE's response under the OIA

MBIE formed part of the all of government response to COVID-19 and therefore holds general information about scientific work that has been undertaken about COVID-19. However, if MBIE holds information that meets your criteria then it will not have been produced by MBIE (MBIE does not undertake this type of scientific research).

MBIE has not undertaken work to determine which of its records relating to the existence of COVID-19 meet the detailed parameters set out in your email. As noted, this would require a considerable amount of work to collate. Therefore, your request has been refused under section 18(f) of the OIA (the information requested cannot be made available without substantial collation or research). If such collation work was undertaken and it was found that MBIE did not hold such information then your request would be declined in reliance on section 18(e) of the OIA.

As noted above we did identify that much of the information falling within the broad topic of your request was already publicly available. This resulted in your request also being declined under section 18(d) of the Act. You are however correct that we cannot identify a specific piece of information which falls within the specific parameters of your request. To that end your request should not have been refused on this ground; the refusal grounds under 18(f) remain.

MBIE would again emphasise that other public agencies such as the Ministry of Health may be better placed to address your request and provide you with information meeting the specific criteria in your original request.

8 de abril de 2022:

La (que rechazó una queja de nuevo el fraude convivíso) admitió a Michael S. que no tienen registro de que el supuesto SARS-COV-2 sea encontrado y purificado de cualquier enfermedad humana en el planeta, por cualquier persona, en cualquier lugar, nunca: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/05/SFO-SARS-COV-2-v3-Redacted-2022-04-08-.pdf



28 de enero de 2022:

El Servicio de Inteligencia de Seguridad de Nueva Zelanda confirmó que no tienen registro de nadie en el planeta habiendo encontrado el supuesto "SARS-COV-2" en los fluidos tomados de cualquier humano enfermo, de modo que podría secuenciarse, caracterizar y estudiar con experimentos controlados... para ver si realmente existe como se afirma:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/2022-01-28-NZ-SIS-SARS-COV-2-v3-redacted.pdf$



New Zealand Security Intelligence Service PO Box 900, Wellington

> P +64 4 472 6170 F +64 4 472 8209

28 January 2022

Dear

Official information request

Thank you for your Official Information Act 1982 (OIA) request of 13 December 2021 seeking information describing the purification of the Covid-19 virus.

You have specifically asked for: "All studies and/or reports in the possession, custody or control of The New Zealand Security Intelligence Service (NZSIS) describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), directly from a sample taken from a diseased human where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum)."

In response, I can advise that we have searched our records and we do not hold the information you are seeking. Your request therefore falls under section 18(e) of the OIA – the information you have asked for does not exist.

Review

If you wish to discuss this decision with us, please feel free to contact oia.privacy@nzsis.govt.nz.

You have the right to seek an investigation and review by the Ombudsman of this decision. Information about how to make a complaint is available at www.ombudsman.parliament.nz or freephone 0800 802 602.

Yours sincerely

Rebecca Kitteridge

Te Tumu Whakarae mō Te Pā Whakamarumaru

Director-General of Security

admitió que no tienen registro de nadie en el planeta habiendo encontrado el supuesto "SARS-COV-2" en los fluidos tomados de cualquier humano enfermo, de modo que podría secuenciarse, caracterizarse y estudiarse con experimentos controlados... para ver si realmente existe como se afirma:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/2022-01-28-NZ-GCSB-SARS-COV-2-v3-redacted.pdf}{}$



PO Box 12-209 Wellington 6144 P+64 4 472 6881 F+64 4 499 3701 www.gcsb.govt.nz

28 January 2022

Dear

Official information request

I refer to your Official Information Act 1982 (OIA) request of 13 December 2021, in which you ask for:

"All studies and/or reports in the possession, custody or control of The Government Communications Security Bureau (GCSB) describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), directly from a sample taken from a diseased human where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum)."

We have searched our records and we do not hold studies or reports described in your request. I am therefore refusing your request under section 18(e) of the OIA, as the information you have asked for does not exist.

You have the right to seek an investigation and review by the Ombudsman of this decision. Information about how to make a complaint is available at www.ombudsman.parliament.nz or freephone 0800 802 602.

Yours sincerely

Andrew Hampton

Te Tumu Whakarae mõ Te Tira Tiaki

Director-General, Government Communications Security Bureau

25 de enero de 2022:

El Ministerio de Justicia de Nueva Zelanda admitió que no tiene registro de nadie en el planeta habiendo encontrado el supuesto "SARS-COV-2" en los fluidos tomados de cualquier humano enfermo, de modo que podría secuenciarse, caracterizar y estudiar

con experimentos controlados... para ver si realmente existe como se afirma: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/2022-01-25-NZ-MoJ-SARS-COV-2-v3-redacted.pdf



Justice Centre | 19 Aitken Street

DX SX10088 | Wellington

T 04 918 8800 | F 04 918 8820

contactus@justice.govt.nz | www.justice.govt.nz

25 January 2022



Our ref: OIA 92901

Dear

Official Information Act request: Purification of COVID-19

Thank you for your email of 22 December 2021 requesting, under the Official Information Act 1982 (the Act), records describing the purification of the COVID-19 virus. Specifically, you have requested:

"...As the Ministry of Justice is making rulings on the COVID-19 Public Health Response Act, the Ministry of Justice MUST have records for the purification of SARS-COV-2 viruses directly from humans as these records would prove there is a weapon in every person said to cause murder in other people. Without this evidence, the Ministry of Justice would not be able to rule in favor of the COVID-19 Public Health Response act as the Ministry has been, so I am assuming the Ministry has the records that I am requesting (which no other organization that I have requested has such as MOH, ESR, NZ Defence Force, University of Otago, and many more).

All studies and/or reports in the possession, custody or control of Ministry of Justice describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), directly from a sample taken from a diseased human where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum)."

I am refusing your request under s18(g)(i) of the Act, as the Ministry of Justice does not hold the information requested. I have no grounds for believing the information is held by another department (beyond any responses you have received from other agencies you have specified).

The Ministry of Justice does not decide whether a new law comes into force nor does it interpret or make decisions on existing laws. The role of the Ministry, as a part of the Executive, is to provide advice on any new policy or bill to Ministers. On issues relating to

13 de diciembre de 2021:

Las Fuerzas de Defensa de Nueva Zelanda confirmaron para Michael S. en Nueva

Zelanda que no tienen registro describiendo la purificación de la muestra de pacientes en el planeta, por cualquiera, nunca: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/NZ-Defence-Force-SARS-COV-2-v3-Redacted-2021-12-13-.pdf



Headquarters
New Zealand Defence Force
Defence House
Private Bag 39997
Wellington Mail Centre
Lower Hutt 5045
New Zealand

OIA-2021-4275

/3 December 2021

I refer to your request of 25 November 2021, under the Official Information Act 1982 (OIA), for the following:

All studies and/or reports in the possession, custody or control of The New Zealand Defence Force (NZDF) describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), directly from a sample taken from a diseased human where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum).

Noting you have asked that this request not be transferred, the response only addresses information held by the New Zealand Defence Force (NZDF). Your request is declined in accordance with section 18(e) of the OIA as no relevant studies or reports are held by the NZDF.

You have the right, under section 28(3) of the OIA, to ask an Ombudsman to review this response to your request.

Yours sincerely

AJ WOODS
Air Commodore
Chief of Staff HONZDF

registro describiendo la purificación de ninguna muestra de pacientes de cualquier muestra de pacientes, por cualquier persona, en cualquier lugar... ...sin embargo, toman muestras compuestas de aguas residuales de 24 horas, las envían a ESR para el análisis sin sentido y los tests sin sentido (que no tienen un estándar de oro y por lo tanto son imposibles de validar) que luego son reenviados al Ministerio de Salud. Porque la ciencia. Pdf:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/Tauranga-City-Council-SARS-COV-2-V3-redacted-2021-11-19-pdf}{}$



17 de agosto de 2022:

<u>Michael S</u>. ha estado ocupado de nuevo, esta vez obteniendo una admisión del **Instituto** de Ciencias e Investigación Ambientales de Nueva Zelanda (ESR) que no tienen ningún registro que demuestre que el insólito de silico "virus" causa el supuesto "COVID-19" .https://www.fluoridefreepeel.ca/wp-content/uploads/2022/09/2022-08-29-ESR-SARS-COV-2-Proof-of-Causation-Redacted.pdf

Our response to your request:

ESR has not performed any experiments to scientifically prove that SARS-COV-2 virus causes COVID-19 and can therefore not provide you with any records.


We are therefore not able to release any information relating to this request under Section 18(e) of the Official Information Act 1982 as the information requested does not exist.

19 de julio de 2022:

Jill Vintiner, en calidad de Directora General Conjunta, Grupo de Salud y Medio Ambiente del Instituto de Ciencias e Investigación Ambiental (ESR, instituto de investigación de la corona), Nueva Zelanda ha emitido otra confesión en nombre de

todos en ESR, esta vez afirmando que... no tienen constancia de que demuestre científicamente la existencia de la supuesta "SARS-COV-2":

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/08/NZ-ESR-No-Proof-Of-Existence.pdf}$



12 de julio de 2022:

Jill Vintiner, directora general conjunta del Grupo de Salud y Medio Ambiente del **Instituto de Ciencias e Investigaciones Ambientales (ESR, instituto de investigación de la corona), Nueva Zelandia** ha emitido otra confesión en nombre de todos en ESR en el sentido de que:

no tienen registro de que el fantasma **SARS-COV-2** (incluyendo a los "variantes) sea encontrado y purificado de la fluididad corporal/tejido de cualquier persona en el planeta, por cualquiera, en cualquier lugar, nunca. Jill también proporcionó enlaces inútiles e irrelevantes a la documentación en kits de aislamiento de ácido nucleico, afirmando que han sido utilizados para purificar el ARN de dicho fantasma nunca se muestra a virus.

(Jill equivale irracionalmente a la purificación del ARN tomado de sopas heterogélasas, es decir, mono/cow/human/bacteria/fungi mezclas con purificación de ARN a partir de un virus puramente teórico.)

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/NZ-ESR-julio-2022-PACKAGE-redacted.pdf}{}$



12 July 2022

By email:

Official Information Act Request: OIA: Isolation and Purification of the SARS-COV-2

On 13 June 2022 you sent a request for information under the Official Information Act 1982 (Act) to ESR as follows:

This is a formal request for access to general records under the Freedom Of Information Act.

Description Of Requested Records

All studies and/or reports in the possession, custody or control describing the purification and isolation of the alleged SARS-COV-2 or COVID-19 virus including any alleged variants of relevance directly from a sample taken from a human specimen where the patient was not first combined with any other sources other genetic material (aka monkey kidney cells)

Clarification Of Request

Please note I am not requesting studies/reports of failed purification of the alleged SARS-COV-2 virus. I simply request records that describe **purification** (separation of the alleged virus from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things).

If any records match the above description stated

please provide enough information about each record so that I may identify and access each one with certainty (i.e., title, author(s), date, journal, where the public can access it). Please provide URLs where possible.

Our response to your request:

ESR does not have any studies and/or reports in the possession, custody or control of ESR describing the purification and isolation of SARS-COV-2 or COVID-19 virus including any variants of relevance directly from a sample taken from a human specimen where the patient was not first combined with any other sources or other genetic material. Accordingly we rely on section 18(e) of the Act – the information requested does not exist in ESR's files.

At ESR, we use the Thermo Fisher MagMAX Viral and Pathogen Nucleic Acid Isolation Kits on the KingFisher sample purification system kits and reagents to purify SARS-CoV-2 RNA from swab samples collected from human patients and direct you to these links below:

(MagMAX Viral and Pathogen Nucleic Acid Isolation Kits (RUO) | Thermo Fisher Scientific - NZ)

KingFisher Sample Purification System Kits & Reagents | Thermo Fisher Scientific - NZ

INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH LIMITED

Kenepuru Science Centre: 34 Kenepuru Drive, Kenepuru, Porirua S022 | PO Box 50348, Porirua 5240, New Zealand T: +64 4 914 0700 | P: +64 4 914 0770

₹ www.esr.ori.nz

23 de agosto de 2021:

Una vez más **el Ministerio de Salud de Nueva Zelanda** confirmó para mi colega en Nueva Zelanda que ni ellos ni el instituto de investigación de la corona de Nueva Zelanda, el **Instituto de Ciencias Ambientales e Investigación (ESR)**, tienen ningún

registro del fantasma "SARS-COV-2" (incluyendo cualquier "variantes") purificado de cualquier muestra de pacientes en el planeta, por cualquier persona, en cualquier lugar. https://www.fluoridefreepeel.ca/wp-content/uploads/2021/08/NZ-MOH-2021-08-23-SARS-COV-2-Variants-Purification-Request-Response-Redacted-1.pdf

> to work done at/by the NZ Ministry of Health. Rather, my request includes any record matching the above description, for example (but not limited to): any published peer-reviewed study authored by anyone, anywhere, ever that has been downloaded or printed by the NZ Ministry of Health and relied on as evidence of a disease-causing "virus"."

The Ministry does not hold any information, authored by any party, in relation to your request. The Ministry has also confirmed that Institute of Environmental Science and Research (ESR) does not hold any information relating to your request.

Therefore, your request is refused under section 18(g)(i) as the information requested is not held by the Ministry and there are no grounds for believing it is held by another agency subject to the Act.

Please be aware that should you make further requests for the same information the Ministry may refuse your requests under section 18(h) of the Act, as they may be considered frivolous or vexatious.

Under section 28(3) of the Act you have the right to ask the Ombudsman to review any decisions made under this request. The Ombudsman may be contacted by email at: info@ombudsman.parliament.nz or by calling 0800 802 602.

Ngā mihi,

Nick Allan

Manager OIA Services Statement of confidentiality: This e-mail message and any accompanying attachments may contain information that is IN-CONFIDENCE and subject to

If you are not the intended recipient, do not read, use, disseminate,

distribute or copy this message or attachments.

If you have received this message in error, please notify the sender

If you have received this message.

This e-mail message has been scanned for Viruses and Content and cleared by the Ministry of Health's Content and Virus Filtering Gateway

26 de agosto de 2021:

Una vez másNew Zealand's, el Instituto de Ciencias e Investigación Ambiental (ESR), confirma que no tienen constancia del fantasma .SARS-COV-2 (incluyendo cualquier variedad) purificado de cualquier muestra de pacientes en el planeta, por cualquier persona, en cualquier lugar:



Please also note that my request is not limited to records that were authored by ESR or that pertain to work done at/by ESR. Rather, my request includes any record matching the above description, for example (but not limited to): any published peer-reviewed study authored by anyone, anywhere, ever that has been downloaded or printed by ESR and relied on as evidence of a disease-causing "virus".

If any records match the above description of requested records and are currently available to the public elsewhere, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible."

Our response to your request:

Using the definition of 'purification' that you refer to in your request, ESR does not hold any records describing 'purification' of SARS-CoV-2.

We cannot provide papers that staff in ESR have downloaded or printed which may apply to your request using your definition of 'purification' as the information cannot be made available without substantial collation or research pursuant to section 18(f) of the Act. We have considered section 18A of the Act and consider that even if we were to charge you for the time to check and collate any relevant materials and extend the timeframe of the request, this would still unduly affect our team who are supporting New Zealand's COVID-19 response work.

Your right to seek a review

You have the right to seek an investigation and review by the Ombudsman of this decision. Information about how to make a complaint is available at www.ombudsman.parliament.nz or freephone 0800 802 602.

Thank you for your request.

Yours sincerely

Jill Vintiner

Joint General Manager health and Environment Group - Health

ESR

INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH LIMITED

Kenepuru Science Centre: 34 Kenepuru Drive, Kenepuru, Portrus 5022 | P0 Box 50348, Portrus 5240, New Zealand

T: +64 4 934 0700 P: +64 4 934 0770

₹ www.esr.orl.nz

El theInstituto de Ciencias Ambientales e Investigación del Instituto de Ciencias Ambientales e Investigación del Ministerio de admitió que no tienen registros de aislamiento de .SARS-COV-2:

Aquí hay 5 páginas de oro puro, evidenciando evasión magistral más incompetencia impresionante y / o fraude del **Ministerio de Salud de Nueva Zelanda**. En lugar de proporcionar los registros de solicitudes de aislamiento/purificación de SARS-COV-2 y


prueba de pruebas diagnósticas precisas, hablaron sobre genomas y cultivos del virus imaginario nunca aislado; declararon que las pruebas de PCR han sido validadas en todo el mundo y son el estándar de oro; y citaron un informe preliminar de febrero de 2020 (La patogenicidad del SARS-CoV-2 en hACE2 Transgenic Mice) que usó la cepa llamada "SARS-COV-2" que había sido concotada por Zhu et al.y afirmó que se habían cumplido los Postulados de Kos.

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/01/NZ-Min-Health-2nd-FOI-no-records.pdf$

In relation to COVID-19, the RT-qPCR test for viral RNA is considered as 'gold standard'. This test has been validated by several means including as a purified virus. However, the most definitive comparison is when PCR's are sequenced as they are mapped to the SARS-CoV-2 viral genome. This mapping is definitive proof that the test is picking up the target SARS-CoV-2 and no other samples.

No hay registros que describan el aislamiento de SARS-COV-2 de una muestra no ya adulterada con otro material genético, admite el **Departamento de Nueva Zelanda del Primer Ministro y Gabinete:**

22 de marzo de 2021, el Ministerio de Heath de **Nueva Zelanda** confirma que todavía no tienen registro describiendo la purificación del virus y por lo tanto cero pruebas de su existencia, y eligen citar estudios fraudulentos en su lugar (el infame estudio Harcourt et al. mencionado anteriormente y el documento australiano citado en la parte superior de esta página). Respuesta completa pdf: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/04/2021-22-NZ-MOH-Purification-SARS-COV-2-redacted.pdf



Response to your request for official information

Thank you for your request under the Official Information Act 1982 (the Act) transferred to the Ministry of Health (the Ministry) on 12 March 2021 for:

"All studies and/or reports in the possession, custody or control of The Department of the Prime Minister and Cabinet describing the purification of "SARS-COV-2" said to have caused disease in humans (via maceration, filtration and use of an ultracentrifuge; also referred to at times by some people as "isolation"), directly from a sample taken from a diseased human, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum)."

The Ministry does not hold any information relating to your request. Therefore, your request is refused under section 18(g) of the Act, as the information requested is not held by the Ministry, and I have no reason to believe that this information is held by another agency subject to the Act. However, further information that may be of use has been previously provided to you below (refers H202100057 & H202100059):

19 de abril de 2021, respondiendo a una solicitud que les había sido enviada por la Oficina del Primer Ministro Jacinda Ardern, el Ministerio de Heath de Nueva Zelandia confirma que ningún registro que describa la depuración de la depuración de la SARS-COV-2 está en manos del Ministerio o de cualquier agencia sujeta a la Ley. Respuesta completa en pdf:

23 de abril de 2021 **La Primera ministra Jacinda Ardern, Nueva Zelanda**, confirma de nuevo que no tienen antecedentes que describan la purificación de la SARS-COV-2 por parte de cualquier persona, en cualquier lugar, nunca. Respuesta completa pdf: https://www.www.fluoridefreepeel.ca/wp-content/uploads/2021/05/NZ-PMO-23.04.2021-2021-068-Redacted.pdf

22 de junio de 2022:

Kelsey Kennard, en la Oficina del Registrador de **la Universidad de Otago de Nueva Zelanda**, confesó a Michael S. que el trabajo titulado "Caracterización del Primer SARS-CoV-2 Aislable de Aotearoa Nueva Zelanda como parte de una respuesta rápida a la pandemica COVID-19 por elvirólogo **Miguel Quiñones-Mateu** es simplemente un papel descriptivo sin hipótesis y nada que probar o refutar... en otras palabras Miguel no empleó ningún método científico y su trabajo no puede llamarse con precisión "ciencia".- Sí.

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/2022-22-University-of-Otago-Scientific-Method-Response-Redacted-Complete.pdf}{}$

3 de agosto de 2022:

Kelsey Kennard, en la Oficina del Registrador de la Universidad de Otago de Nueva

Zelanda, insistió a Michael S. en que el documento titulado "Caracterización del Primer SARS-CoV-2 Aislable de Aotearoa Nueva Zelanda como parte de una respuesta rápida al pandémica COVID-19 por elvirólogo <u>Miguel Quiñones-Mateu</u> (que Kelsey <u>ya confesó</u> es simplemente un documento descriptivo sin hipótesis y nada que demostrar o refutar, como se ha indicado anteriormente) prueba la existencia de la RAE.S-COV-2 en Nueva Zelandia:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/08/NZ-U-of-Otago-no-scientific-proof-existence-PACKAGE-redacted.pdf$



3 August 2022

OFFICIAL INFORMATION REQUEST FOR ALL RECORDS IN THE POSSESSION, CUSTODY OR CONTROL OF THE UNIVERSITY OF OTAGO THAT SCIENTIFICALLY PROVES THE EXISTENCE OF SARS-COV-2 VIRUS

I refer to your official information request dated 10 July 2022 for "all records in the possession, custody or control of the University of Otago that scientifically proves the existence of SARS-COV-2 virus."

We have liaised with the Department of Microbiology and Immunology in respect of your request. Research by the University of Otago proving the existence of the SARS-COV-2 virus in New Zealand has been completed and is currently in the public domain. This includes Professor Quiñones-Mateu's paper "Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic.' This study was published using validated and internationally accepted processes. The Department does not agree that this paper is "not scientific" simply because it does not have a hypothesis.

19 de julio de 2022:

Landon Watt, actuando como Asesor Jurídico de la **Universidad de Auckland, Nueva Zelanda** proporcionó a mi colega <u>Michael S.</u> una nueva excusa sin sentido para proporcionar/citar cero registros que demuestran científicamente la existencia del **teórico SARS-COV-2**:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/08/University-of-Auckland-SARS-COV-2-No-science-re-existence.pdf}{}$




Octubre 2020 / actualizado marzo de 2022:

La Universidad de Auckland de Nueva Zelanda fue decepcionantemente no cooperativa, optando por una escueta "refusal" de mi colega. Si la Universidad realmente tuviera algún registro de este tipo (que nadie más en el planeta parece) y están a disposición del público, la Universidad de Auckland habría proporcionado con orgullo enlaces/citas. Pero no lo hicieron. https://www.fluoridefreepeel.ca/wp-content/uploads/2022/03/Auckland-redacted-FOI-emails-updated-2022.pdf

30 de marzo de 2021 Universidad de Otago de **Nueva Zelanda** confirma que todavía no tienen registro de aislamiento/purificación de la SARS-COV-2, por cualquier persona en ninguna parte. Respuesta completa pdf aquí:



30 March 2021



source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum)".

Thank you for clarifying in your email precisely what is out of scope for this request.

I can confirm that the University holds no records which fall within the scope of your request. Accordingly, we decline your request pursuant to section 18(g) of the Act on the basis that the information requested is not held by the University.

22 de septiembre de 2021:

La Universidad de Otago, donde los investigadores afirmaron el año pasado que el año pasado se había aislado el virus, confirmó una vez más que no tienen registro de aislamiento/purificación de la SARS-COV-2, por cualquier persona, en cualquier lugar: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/Otago-Sept-22-2021-03-30-University-of-Otago-SARS-COV-2-v3-Redacted.pdf

13 de octubre de 2021:

La Universidad neozelandesa de Waikato confirmó al solicitante que no tienen antecedentes describiendo la depuración del presunto virus COVID-19 de cualquier muestra de pacientes en el planeta:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/10/University-of-Waikato-2021-10-13-SARS-COV-2-v3-redacted.pdf

Office of the Vice-Chancellor The University of Waikato Private Bag 3105 Hamilton 3240 Phone +64 7 858 9472 www.waikato.ac.nz



13 October 2021

New Zealand



Official Information request - SARS-COV-2 and Variants purification by any method

I refer to your information request of 22 September 2021. The University of Waikato (University) has given due consideration to your request as follows:

"All studies and/or reports in the possession, custody or control of The University of Waikato describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), directly from a sample taken from a diseased human where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; foetal bovine serum)".

The University advises that there is no research being conducted on the COVID-19 virus by any staff member or student of the University, therefore under section 18 (e) of the Official Information Act 1982 the University refuses the request on the basis that the information requested is not held.

You have the right to seek an investigation and review by the Ombudsman of this decision. Information about how to make a complaint is available at www.ombudsman.parliament.nz or freephone 0800 802 602.

Yours sincerely

Jim Mercer

Chief Operating Officer

1 de agosto de 2022:

Jim Mercer actúa como director de operaciones de la Universidad de Waikato en Nueva Zelanda. La universidad publicó un blog en abril de 2021 titulado "Sam Bailey" sobre el aislante de virus, y por qué se equivoca. El blog todavía se publica en el sitio web de la universidad.

Jim confesó a Michael S. que no hay registros que contengan pruebas científicas de la existencia del supuesto SARS-COV-2 en U de Waikato.

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/08/U-of-Waikato-no-SARS-COV-2-Existance-PACKAGE-redacted.pdf}$

Office of the Vice-Chancellor The University of Waikato

Private Bag 3105 Hamilton 3240 New Zealand Phone +64 7 837 9472 www.waikato.ac.nz



1 August 2022



Official Information request - SARS-COV-2 Proof of Existence

I refer to your request for official information of 19 July 2022 requesting all records in the possession, custody or control of the University that scientifically proves the existence of SARS-COV-2 virus.

The University of Waikato (University) has given due consideration to your request and advises that there is no research being conducted on the COVID-19 virus by any staff member of the University.

On that basis, the University refuses your request under section 18(e) of the Official Information Act 1982 as the information requested does not exist or, despite reasonable efforts to locate it, cannot be found.

You have the right to seek an investigation and review by the Ombudsman of this decision. Information about how to make a complaint is available at www.ombudsman.parliament.nz or freephone 0800 802 602.

Yours sincerely

Jim Mercer

Chief Operating Officer

9 de noviembre 2021

La Policía de Nueva Zelandia confirmó al solicitante que no tenía antecedentes (pruebas) describiendo el aislamiento/purificación del presunto virus Sars-Cov-2 o de cualquier variante alegada:

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/11/NZ-Police-2021-11-09-SARS-COV-2-v3-redacted.pdf}$



9 November 2021

Reference: IR-01-21-30354

I am writing in response to your request dated 9 October 2021. Your request has been considered pursuant to the Official Information Act 1982 (OIA). Specifically, you requested:

All studies and/or reports in the possession, custody or control of The New Zealand Police describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), directly from a sample taken from a diseased human where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum).

Police do not hold any information in relation to your request. Therefore, your request is refused pursuant to section 18(g) of the OIA as the information requested is not held.

You have a right under section 28(3) of the OIA to ask the Ombudsman to seek an investigation and review of my decision.

Yours sincerely

Superintendent Barry Taylor Director: Major Events 9 de marzo de 2021: El Instituto de Ciencias e Investigación Ambiental de Nueva Zelanda admite que todavía no tienen registro de aislamiento/purificación de la SARS-COV-2 (realizado por cualquier persona en el planeta, en cualquier lugar, nunca): https://www.fluoridefreepeel.ca/wp-content/uploads/2021/03/ESR-SARS-CO-COV-2-Purification-Redacted.pdf

Una de las **ministras de Salud Asociadas de Nueva Zelanda, Jenny Salesa**, tiene registros del No:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2020/10/NZ-Ass-Min-Health-Hon-Jenny-Salesa-Response-scrubbeded.pdf}{}$

Hon Jenny Salesa

MP for Manukau East

Minister for Building and Construction Minister of Oustoms Minister for Ethnic Communities

Associate Minister of Education Associate Minister of Health



20 October 2020

20-317

Response to your request for official information

Thank you for your request under the Official Information Act 1982 (the Act) to the office of the Associate Minister of Health on 15 October 2020 for:

"All records in the possession, custody or control of the Associate Minister of Health Hon Jenny Salesa describing the isolation of a SARS-COV-2 virus, directly from a sample taken from a diseased patient, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka vero cells; lung cells from a lung cancer patient).

Please note that I am using "isolation" in the every-day sense of the word: the act of separating a thing(s) from everything else. I am not requesting records where "isolation of SARS-COV-2" refers instead to:

- the culturing of something, or
- the performance of an amplification test (i.e. a PCR test), or
- the sequencing of something.

Please also note that my request is not limited to records that were authored by the Associate Minister of Health Hon Jenny Salesa or that pertain to work done by the Associate Minister of Health Hon Jenny Salesa. My request includes any sort of record, for example (but not limited to) any published peer-reviewed study that the Associate Minister of Health Hon Jenny Salesa has downloaded or printed.

If any records match the above description of requested records and are currently available to the public elsewhere, please provide enough information about each record so that I may identify and access each record with certainty (i.e. title, author(s), date, journal, where the public may access it)."

This office does not hold any information pertaining to your request. For this reason, I am refusing your request under section 18(e) of the Act, as the information requested does not exist.

Under section 28(3) of the Act you have the right to ask the Ombudsman to review my decision to refuse your request.

Yours sincerely

Hon Jenny Sales Associate Minister of Health

+64 4 817 8714

Private Bag 1804I, Parliament Buildings, Wellington 6160, New Zeeland

Jaaleseigiministers.govt.nz

Otra de las ministras de Salud Asociadas de Nueva Zelanda, Julie Anne Genter, tiene registros del No:

https://www.fluoridefreepeel.ca/wp-content/uploads/2020/10/Hon-Julie-Anne-Genter-Response-scrubbeded.pdf

Y otra de las ministras de Salud Asociadas de Nueva Zelanda, Peeni Henare, tiene registros:

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2020/10/Hon-Peeni-Henare-Response-scrubbed.pdf}$

18 de octubre de 2022:

Mi colega Michael S. exigió a Ayesha Verrall, que juega como "Miestro de Salud" de Nueva Zelanda, que le proporcionara pruebas científicas de la existencia de SARS-COV-2. En cambio, Ayesha le envió enlaces a la transcripción estrictamente en silico llamada MN908947 que no corresponde a nada en el reino físico (discutido aquí), y varias otras páginas web inútiles. Michael respondió señalando la inutilidad de la respuesta de Ayeshas y expuso el remedio que él requiere de ella: https://www.fluoridefreepeel.ca/wp-content/uploads/2023/02/NZ-Health-Min-Ayehsa-Verrall-PACKAGE-redacted-Oct-2022.pdf

Igual, no records dice **Bay of Plenty District Health Board, Tauranga Hospital, Nueva Zelanda:**

https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/Bay-Of-Plenty-District-Health-Board-response-scrubbeded.pdf

29 de abril de 2022:

El Departamento de Asuntos Internos de Nueva Zelanda requiere una vacunación falsa de sus visitantes, pero confirmó para Michael S. que no tienen registro de que el supuesto SARS-COV-2 sea encontrado y purificado de cualquier humano enfermo en el planeta por alguien, nunca, y por lo tanto no tienen idea de si el supuesto virus realmente existe:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/05/NZ-Dept-Internal-Affairs-PACKAGE-redacted.pdf$

3 de mayo de 2022:

Ministra del Interior de Nueva Zelandia, Ministra de la Mujer y Ass. La ministra de Educación, Jan Tinetti, confirmó para Michael S. que no tiene constancia de que el supuesto SARS-COV-2 sea encontrado y purificado de cualquier humano enfermo en el planeta, por cualquiera, en cualquier lugar, jamás:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/05/2022-05-03-Tinetti-SARS-COV-2-v3-Redacted.pdf}{}$

Hon Jan Tinetti

Minister of Internal Affairs Minister for Women Associate Minister of Education



Michael Speth conzar@gmail.com

Dear Michael Speth

Official information request for records on SARS-COV-2 Purification and Variants

I refer to your official information request dated 26 April for:

"All studies and/or reports in the possession, custody or control of Jan Tinnetti describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), directly from a sample taken from a diseased human where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum). "

The document you requested does not exist.

I am therefore refusing your request under section 18(e) of the OIA because the requested document does not exist.

You have the right to seek an investigation and review by the Ombudsman of this decision. Information about how to make a complaint is available at www.ombudsman.parliament.nz or freephone 0800 802 602.

Yours sincerely

Hon Jan Tinetti

Minister of Internal Affairs

Minister for Women

Associate Minister of Education

Private Bag 18041, Parliament Buildings, Wellington 6160, New Zealand +6448178730 | j.tinetti@ministers.govt.nz | beehive.govt.nz

18 de agosto de 2022:

Annabel Kent, en su calidad de Asesoría Jurídica de **la Agencia Nacional** de **Investigación Científica de Australia, Commonwealth Scientific and Industrial Research Organisation** aka CSIRO ha confesado a mi colega Michael S. que nadie en CSIRO tiene ningún registro que demuestre científicamente la existencia de **SARS-COV-2**. Nos parece especialmente interesante dado que CSIRO cuenta con un equipo de investigación de patógenos peligrosos (https://sciencejobs.org/posting/7089260) y

que las personas de CSIRO son cómplices de los llamados ensayos de la llamada vacuna COVID-19. utilizando el falso aislado de Doherty Institute.

Pdf:https://www.fluoridefreepeel.ca/wp-content/uploads/2022/08/Ago-18-CSIRO-SARS-COV-2-Proof-of-Existance-Redacted.pdf

Decision

I am an authorised decision maker under section 23 of the FOI Act. This letter sets out my decision and reasons for the decision in response to your request.

CSIRO does not hold any documents that fall within the scope of your specific request. I am therefore required to refuse access, pursuant to section 24A of the FOI Act, on the basis that the document[s] sought do not exist or cannot be found.

I have come to this conclusion following consultation with relevant CSIRO officers. These officers have advised me that CSIRO has not been involved in any research aimed at proving the existence of SARS COV-2 or any research that conforms with the scope of your request.

Rights of Review

In accordance with section 26(1)(c) of the FOI Act, a statement setting out your rights of review under the Act is at **Attachment A**. Since my decision is that no documents exist, an application for review would be limited to a situation where you consider that I have not identified all the documents in the CSIRO's possession that are relevant to your request.

Yours sincerely,

Went

Annabel Kent Legal Counsel CSIRO

17 de noviembre de 2023:

El hombre Greg Hunt en Australia, que se hace llamar **"El Honorable Greg Hunt Ministro de Salud y Cuidado de Aged"** - confesó que no tiene registro de nadie en la Tierra "aislarando COVID-19" (sic). Y se refirió al ridículo estudio de aislamiento falso del Instituto Doherty.

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2023/06/EN3213-Min-response-Health-and-Aged-Care.pdf}$

Info res el estudio falso de Caly et al.:

fluoridefreepeel.ca/australian-dept-of-health-has-no-record-of-covid-19-virus-aislación/



1 de agosto de 2022:

Darius Everett, actuando como A/g Subsecretario, Subdivisión de Enfermedades Transmisibles, **Departamento de Salud y Atención a Aged, el Gobierno australiano** insistió a Michael S. en que el supuesto **SARS-COV-2** es real, pero confesó que no hay registros que contengan pruebas científicas de su existencia en el departamento. https://www.fluoridefreepeel.ca/wp-content/uploads/2022/08/Australian-govt-DOHAC-no-scientific-proof-existence-PACKAGE-redacted.pdf

SARS-CoV-2, the virus which causes COVID-19, is real. Multiple scientific studies across the world demonstrate that highly reputable laboratory medicine experts have isolated and sequenced the virus that causes COVID-19, demonstrating that the virus exists, that it exists in variant forms, that it is different from the influenza virus, and that it causes a disease that has resulted in over 6.3 million deaths worldwide.

While the department is not the custodian of the scientific studies establishing the existence of SARS-CoV-2 and the effectiveness of vaccines, this research has informed the Australian Government's response to the pandemic. You can find those scientific studies in the public domain.

The department is a government agency and does not conduct scientific studies or laboratory testing for the SARS-CoV-2 in a laboratory. Diagnostic assays using reverse transcriptase polymerase chain reaction (RT-PCR) are conducted by testing laboratories throughout Australia. For more information, please see the Public

5 de octubre de 2021: Universidad de Nueva Gales del Sur, Australia, aconseje que todavía no tienen registro de ningún virus/variante de COVID-19 que haya sido purificado de cualquier muestra de pacientes en el planeta, por cualquier persona, en cualquier lugar:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/10/University-of-New-South-Wales-PACKAGE.pdf



UNSW Ref. ND7149

5 October 2021

By email: cmssyc@gmail.com

Dear Ms Massey

Notice of decision in relation to access applications under the Govern Information (Public Access) Act 2009 (NSW) (GIPA Act)

I refer to your information access application under the GIPA Act dated 1 August 2021 and received as a valid application by the University on 12 August 2021. scope of your applications was as follows:

All studies and/or reports _ describing the purification (i.e. vis filtration and use of an ultracentritique) of any "SARS-COV2" sha "DOVID-19 vitus" (including any "variants"), directly from a sample taken from a diseased human, where the patient sample was no first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; feel bovine serum).

- Vero ceix; tetal powine setum).

 Please note that I am not requesting any private health information, or studies/reports where researchers failed to purify the suspected "virus" and instead:
 cultured an papient sample or other unpurified substance, and/or
 performed an amplification test (i. e. a PCR test) on all the RNA from a patient sample or from a cell culture, or on genetic material form or any unpurified substance, and/or sequenced the total RNA from a patient sample or from a cell culture or nor any unpurified substance, and/or produced electron microscopy images of unpurified things.

inicroscopy images of unpurified things.

For further clarity, phase a note I am already aware that according to virus theory a Virus' requires host cells in order to replicate, and I am not requesting records describing the replication of a Virus' without host cells. Further, I am not requesting records that describe a suspected virus' floating in a vecuount, I am alreafy requesting records that describe purification of Virus Virus' (expansion from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things).

Please also note that my request is not limited to records that were authored by someone at University of New South Wales or that pertain to work done at/by University of New South Wales. Rather, my request includes any record matching the above description, for example (but not limited to); any published peer-reviewed study authored by anyone, anywhere that has been downloaded or printed — and relied on as relidence of a disease—causing vitus: "If any records match the above description of requested records and are currently available to the public elsewhere, please provide enough information about each record so that I may identify and access each one with containty (i.e. title, author(s), date, journal, where the public may access (i). Please provide IRLs where possible.

I have liaised with the University's Faculty of Medicine and Research Office to attempt to identify information that is held by the University and within the scope of your request. Based on the specific requirements of your request I have not been able to identify any information that is within the scope of your request

Authorisation

I am authorised by the Vice-Chancellor (acting as principal officer for the purposes of s 9(3) of the GIPA Act) to make the decision of your access application

I have decided, in accordance with s 58(1)(b) of the GIPA Act, that the information requested is not held by the University

Your rights of review

If you are aggrieved by my decision, you may seek review under Part 5 of the GIPA Act. Your rights for review are outlined in the attached fact sheet from the Information Commissioner – Your review rights under the GIPA Act.

If you have any queries about this notice or require further information on your

Yours sincerely

Right to Information Officer, UNSW

16 de junio de 2021: La Universidad de Australia Occidental, hogar de la investigadora Christine Carson, financiada por Gates, que ha pasado innumerables horas en las redes sociales el año pasado insistiendo en que sí, el virus COVID-19 ha sido aislado. Proveno/citado cero registros de aislamiento/purificación de una muestra de pacientes, por cualquier persona en cualquier lugar:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/06/UWA-Carson-norecords-redacted.pdf

DECISION

In consideration of the above, I, Jay Guyver, Manager - Information Governance, Governance Directorate have today made the decision that:

In relation to part (A) of your application,

- despite reasonable steps, such as searches and enquiries being made, no documents have been found or surrendered which meet the specific and precise requirements of your scope.
- Enquiries of Dr Carson have yielded no such documents relating to the precise and exact isolation or purification of the virus you talk about, and research she has and is engaged in does not meet the criteria, indeed is specifically excluded by your criteria.

En este siguiente enlace encontrará múltiples respuestas de FOI del **Departamento de Salud** de **Australia**, tan reciente como octubre de 2021:

https://www.fluoridefreepeel.ca/australian-dept-of-health-has-no-record-of-covid-19-virus-isolation/



Department Reference: FOI 3054



I refer to your request of 11 September 2021 to the Department of Health (the department) seeking access under the *Freedom of Information Act 1982* (Cth) (the FOI Act) to documents related to COVID-19. Your request is in the following terms:

 All studies and/or reports in the possession, custody or control of The Australian Department of Health describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), directly from a sample taken from a diseased human where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum)

Information about COVID-19

SARS-CoV-2, the virus which causes COVID-19, is real. Multiple scientific studies across the world demonstrate that highly reputable laboratory medicine experts have isolated and sequenced the virus that causes COVID-19, demonstrating that the virus exists, that it exists in variant forms, that it is different from the influenza virus, and that it causes a disease that has resulted in more than 4.8 million deaths worldwide in just over 21 months.

While the department is not the custodian of the scientific studies establishing the existence of SARS-CoV-2, this research has informed the Australian Government's response to the pandemic. You can find those scientific studies in the public domain.

The department is a government agency and does not conduct scientific studies or laboratory testing for the SARS-CoV-2 in a laboratory. Diagnostic assays using reverse transcriptase polymerase chain reaction (RT-PCR) are conducted by testing laboratories throughout Australia. For more information, please see the Public Health Laboratory Network (PHLN) guidance on laboratory testing for

La misma admisión en **el <u>Instituto de Infección e Inmunidad</u> de Australia**, que había afirmado públicamente que había aislajado el virus).

Y, en febrero de 2022, los llamados científicos del **Instituto Doherty de Australia** confesaron a Marvin Haberland (a través de Eugene Toh, actuando como Oficial de Regulación de la Información, Universidad de Melbourne) que descuidaron el uso de controles adecuados cuando se equilibraban o consiguiendo su in silico .SARS-COV-2 genome, por lo que admitieron que su resultado es anti-científico: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/11/Doherty-Inst-no-controls-Marvin-PACKAGE-redacted.pdf

Von: Gesendet: An: Cc:	foi-officer <foi-officer@u Dienstag, 22. Februar 20 @berke foi-officer</foi-officer@u 		
Betreff:	RE: [EXT] Request under	FOI Act	
Dear ,			
I have followed up	with the Doherty Institute in re	sponse to your final question. The answer below was provided:	
sequencing reads	for nCoV-2019 (named at the tin	requencing SARS-CoV-2. In order to maximise the number of me) we elected to dedicate an entire flow cell to the positive ral reads and not spend reads on sequencing a negative sample.	
I trust this is of as	I trust this is of assistance and wish you well.		
Kind regards,			
Eugene			
To: foi-officer <fo< th=""><th> @berkeley.edu <r February 2022 7:57 PM i-officer@unimelb.edu.au>] Request under FOI Act</r </th><th>@berkeley.edu></th></fo<>	@berkeley.edu <r February 2022 7:57 PM i-officer@unimelb.edu.au>] Request under FOI Act</r 	@berkeley.edu>	
External email: Pl	ease exercise caution		
Dear Eugene,			
Thank you very m	uch.		
Your answer fully	satisfies my request.		
Is there any speci- sequencing metho		e study did not perform negative controls for all the genome	
Many thanks		Screenpresso.com	

La misma admisión de **Australia-Comunidad de Investigación Científica e Industrial de** Australia . CSIRO (-Australias, agencia nacional de investigación científica), que <u>participa en ensayos de vacunas COVID-19 utilizando</u> el llamado aislamiento .SARS-COV-2 del Instituto Doherty: https://www.fluoridefreepeel.ca/wp-content/uploads/2020/10/CSIRO-Isolation-Response-scrubbed.pdf

22 de marzo de 2021, Australia-Sidita La Organización de Investigación Científica e Industrial de Australia todavía no tiene registro de ningún tipo de SARS-COV-2

purificado de un paciente, por cualquier persona, en cualquier lugar:



7 October 2020

Our ref: FOI 2020/50



FREEDOM OF INFORMATION REQUEST - DECISION FOI2020/50

I refer to your request of 7 September 2020, under which you sought access under the Freedom of Information Act 1982 (FOI Act) to:

"All records in the possession, custody or control of CSIRO describing the isolation of a SARS-COV-2 virus, directly from a sample taken from a diseased patient, where the patient sample was <u>not</u> first combined with any other source of genetic material (i.e. monkey kidney cells aka vero cells; lung cells from a lung cancer patient).

CSIRO has been unable to identify any document relevant to your request. I must therefore refuse access, pursuant to section 24A of the FOI Act on the basis that the document[s] sought do not exist or cannot be found.

27 de septiembre de 2021:

Australias Commonwealth Scientific and Industrial Research Organisation - CSIRO (Australia-s national science research agency-) que participa en ensayos de vacunas contra la llamada ASAR-COV-2, con el llamado aislamiento SARS-COV-2 del Instituto Doherty, confirmó que todavía no tienen registro de la purificación de la SARS-COV-2 (incluyendo los "variantes), por cualquier persona, en cualquier lugar: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/2021-09-27-CSIRO-SARS-COV-2-v3-Redacted.pdf

Decision maker

I am an authorised decision maker under section 23 of the FOI Act. This letter sets out my decision and reasons for the decision in relation to your request.

Decision

Despite an extensive search, CSIRO has been unable to identify any document relevant to your request. I must therefore refuse access, pursuant to section 24A of the FOI Act on the basis that the document[s] sought do not exist or cannot be found.

Searches conducted

Searches were conducted by the Australian Centre for Disease Preparedness (formerly the Australian Animal Health Laboratory) and by other relevant staff and it was confirmed that CSIRO does not hold any documents relevant to the scope of your request. In this regard, CSIRO's research involves virus already isolated from human samples by a non-CSIRO institute.

(27 de enero de 2022:

Australias Commonwealth Scientific and Industrial Research Organisation - CSIRO (-Australia-s national science research agency) también ha confirmado que no tienen ningún registro que contenga detalles de cualquier "controls" utilizado en procedimientos de cultivo anti-cientítico, el llamado aislamiento de los virus, o

procedimientos de secuenciación del genoma completo: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/2022-01-27-CSIRO-SARS-COV-2-Controls-redacted.pdf)


La siguiente carta de la FOI mostrada en la captura de pantalla a continuación es en respuesta a una solicitud que fue presentada **por consejo del Departamento de Salud de Australia**, y ha venido a nosotros a través de <u>John Blaid</u>. Dirigida a Mary-Jane Liddicoat, la carta formal pero sin fecha fue escrita en algún momento después del 9 de marzo **de** 2021 por **el Dr. Nick Coatsworth**, Director Ejecutivo de Servicios Médicos de <u>Canberra</u> **Health** <u>Services</u> (CHS), Australiana).

[Al revisar la respuesta de Coatsworth, tenga en cuenta los siguientes hechos proporcionados por Darren Christison, un periodista en Sydney, Australia: Este es el mismo Dr. Nick Coatsworth que es el chico de los "poster" para el empujón del gobierno australiano para vacunar a todos hasta que orinan el veneno, y ha sido un accesorio permanente en la televisión y en línea en los últimos meses (https://www.youtube.com/watch?v=Aep-RKawTWc). También el mismo Dr. Nick Coatsworth que recientemente, según The Sydney Morning Herald, apareció un grupa de médicos activistas que propagaba la desinformación y socavaba la confianza de las vacunas (]]

Coatsworth admitió que Canberra Health Services no tiene registros relevantes para el tema de aislar (también conocido como purificar) el supuesto "SARS-COV-2". Toda su carta está aquí:

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/04/Australian-Dept-of-Health-March-2021.pdf}$

Our reference: FOI21-10



Dear Ms Liddicoat

DECISION ON YOUR ACCESS APPLICATION

I refer to your application under section 30 of the Freedom of Information Act 2016 (FOI Act), received by ACT Health Directorate (ACTHD) and transferred to Canberra Health Services (CHS) on **Tuesday 9 March 2021.** In accordance with section 57 of the FOI Act, the information you are seeking is in their possession.

This application requested access to:

'I am writing to you on advice from the Australian Department of Health (the Department) to seek clarification on information requested in a Freedom of Information (FOI) request that was sent to the Department.

I am therefore writing to you to on initial advice by the Department of Health to confirm whether you do hold the information requested in the original request to the Department, as shown in attachment "FOI 1937" and pasted again below:

"All records in the possession, custody or control of The Department of Health describing the isolation of a SARS-COV-2 virus, directly from a sample taken from a diseased patient, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka vero cells; lung cells from a lung cancer patient). Please note that I am using "isolation" in the every-day sense of the word: the act of separating a thing(s) from everything else. I am not requesting records where "isolation of SARS-COV-2" refers instead to:

- the culturing of something,
- or the performance of an amplification test (i.e. a PCR test),
- or the sequencing of something.

Please also note that my request is not limited to records that were authored by The Department of Health or that pertain to work done by The Department of Health. My request includes any sort of record, for example (but not limited to) any published peer reviewed study that The Department of Health has downloaded or printed."

I am an Information Officer appointed by the Chief Executive Officer of Canberra Health Services (CHS) under section 18 of the FOI Act to deal with access applications made under Part 5 of the Act. CHS was required to provide a decision on your access application by Thursday 8 April 2021.

Decisions

ACT Pathology does not have the ability to isolate the virus from patient samples. I am therefore satisfied that in accordance with section 35(1)(b), CHS does not hold any documents relevant to the scope of your request.

Marzo 19, 2021: Territorio de Capital Australiano / Servicios de Salud de Canberra una vez más no proporcionó / citar ningún registro de la purificación de .SARS-COV-2 de cualquier muestra de pacientes en el planeta (demupándose así que todavía tienen cero pruebas de que el virus realmente existe). Comunicaciones completas: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/07/ACT-Canberra-Health-Services-no-reco rds-package.pdf

Mar 16 de 2021: **El Ministro y el Departamento de Salud de Australia Occidental** confirman que no tienen registro de la purificación de cualquier muestra de pacientes en el planeta (y por lo tanto cero pruebas de que existe el virus), y que la Medicina de Laboratorio de Senderismo sólo hace la versión de aislamiento del virus. Comunicaciones completas:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/07/Western-Australia-no-records-package.pdf

28 de abril de 2021: **El Ministro de Salud y Bienestar** de **Australia del Sur** confirmó que no tienen registro de la purificación de un paciente de cualquier muestra de pacientes en el planeta (y por lo tanto cero pruebas de que el virus existe realmente). Comunicaciones completas: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/07/South-Australia-package-no-records.pdf

Mayo 25 de mayo de 2021: **El Ministerio de Salud de Nueva Gales del Sur, Australia**, confirmó que no tienen registro de la purificación de un paciente de cualquier muestra de pacientes en el planeta (y por lo tanto cero pruebas de que el virus existe realmente). Comunicaciones completas:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/07/NSW-no-records-May-25-2021.pdf}{}$

Junio de 2013:

La Universidad de Sheffield y (profesor) Carl Smythe (que se han asociado con Paraytec Limited para desarrollar una prueba de código falso que "obrea" en 5 minutos) afirman tener registros que describan la "purificación" del "virus" imaginario, pero también:

- 1) definir como un mero *proceso* en el que se *enriquecen progresivamente* sustancias biológicas (presuntos), , no que necesariamente resulta en la separación de las partículas supuestas de virus de todo lo demás en una muestra de fluido corporal/tejido/excremento, y que podría implicar la adición de material genético a la muestra del paciente,
- 2) negarse a publicar los registros para el escrutinio público porque hacerlo pondría en peligro sus intereses comerciales:

 $\frac{https://www.fluoridefreepeel.ca/fake-covid-test-developers-carl-smythe-u-of-sheffield-paraytec-limited-and-a-virus-foi/}{}$

Artículo:

Los desarrolladores de pruebas de código cómpliso Carl Smythe, U de Sheffield, Paraytec Limited, y un FOI de virus:

https://christinemasseyfois.substack.com/p/fake-covid-test-developers-carl-smythe

24 de octubre de 2023 actualización:

Universidad de Sheffield p rotts desarrolladores de pruebas falsos Paraytec Ltd & Carl Smythe... otra vez. Difamaciones a lame ofrecidas para negarse a la nueva FOI:

https://christinemasseyfois.substack.com/p/university-of-sheffield-protects



23 de junio de 2022:

Una vez más, la gente (o tal vez sólo una plataforma de IA) en la **Agencia** de **Seguridad de la Salud** eufemísticamente nombrada por no proporcionó/cita ningún registro en HSA o **Salud Pública de Inglaterra** describiendo la purificación del imaginario **de** la muestra clínica, ya que no existe tal registro, en cualquier lugar de la Tierra, porque la virología es pseudociencia: https://www.fluoridefreepeel.ca/wp-content/uploads/2023/03/UK-HSA-and-PHE-2022-06-23.jpg



By email

@googlemail.com

Our ref: 06/06/22/HD/319

23 June 2022

Re: Freedom of Information Request

Thank you for your request received on 6 June 2022 addressed to the UK Health Security Agency (UKHSA). In accordance with Section 1(1)(a) of the Freedom of Information Act 2000 (the Act), we can confirm that UKHSA does not hold the information you have specified.

Pursuant to the Freedom of Information Act 2000, please respond to/disclose the following:

Description of Requested Records:

All studies and/or reports in the possession, custody or control of the UKHSA describing the purification of the alleged "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants") directly from a sample taken from a diseased human, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal

Clarification of Request:

Please note that I am not requesting studies/reports where researchers failed to purify the suspected "virus" and instead:

cultured something, and/or
performed an amplification test (i.e. PCR), and/or
fabricated a genome from sequences (allegedly) detected in an impure

- fabricated a genome from sequences (allegedly) detected in an impure substance, and/or produced electron microscopy images of unpurified things.

 I am already aware that according to virus theory a "virus" requires host cells in order to replicate, and am not requesting records that describe replication of a 'virus' without host cells. Nor am I requesting records that describe a strict fulfillment of Koch's Postulates, or records where researchers conflate extraction of genetic material from a patient sample or cell culture with "virus

isolation", or records that describe a suspected "virus" floating in a vacuum, or private patient information.

I simply request records that describe purification (separation of the alleged virus from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things). Please note that my request includes any study/report matching the above description, authored by anyone, anywhere.

If any records match the above description of requested records and are currently available in the public domain, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible.

I am grateful for your assistance in this matter and look forward to hearing from you in due course.

There are no documents authored by The UK Health Security Agency (UKHSA) or Public Health England (PHE) which relate to the purification of virus directly from clinical samples as described, as we did not attempt this. If you would like a purification protocol we would suggest a peer reviewed biomedical literature. citations can be found at PubMed (nih.gov).

Please see the following suggested links:

https://publichealthmatters.blog.gov.uk/2020/01/23/wuhan-novel-coronavirus-what-

COVID-19 human challenge study reveals detailed insights into infection | Imperial

https://www.researchsquare.com/article/rs-1121993/v1

Human challenge trial launches to study immune response to COVID-19 | University

https://acmedsci.ac.uk/file-download/55062331

If you have any queries regarding the information that has been supplied to you, please refer your query to the Information Rights Team in writing in the first instance. If you remain dissatisfied and would like to request an internal review, then please contact us at the address above or by emailing InformationRights@UKHSA.gov.uk.

27 de octubre de 2021:

La nueva Agencia de Seguridad Sanitaria, llamada eufemística del , confirmó que no tienen registros de reaislamiento/purificación del presunto virus COVID-19. El solicitante respondió con una respuesta

encantadora:https://www.fluoridefreepeel.ca/wp-content/uploads/2021/11/UKHSA-2021-10-27-Replicaes-redacted.pdf

Case ref: 1409 - FOI Purification of SARS-COV-2 and Variants (CF)

2 messages

Information Rights < InformationRights@ukhsa.gov.uk>

Wed, Oct 27, 2021 at 3:49 AM

The UK Health Security Agency (UKHSA) has taken responsibility for requests previously addressed to Public Health England (PHE), your request was assessed based on the information held by PHE at the time of receipt.

In accordance with Section 1(1)(a) of the Freedom of Information Act 2000 (the Act), I can confirm that UKHSA does not hold the information as specified by your request.

We have provided information regarding the isolation of Sars-Cov2 that we hold, you may be able to find further sources from other organisations.

Under Section 16 of the Act, a public authority has a duty to provide advice and assistance. Accordingly, we have provided further information below that you may wish to view.

The SARS-CoV-2 virus has been identified by electron microscopy, which uses high resolution to visualise virus particles directly in specimen, as well as culturing in a laboratory. Evidence of the Electron Micrograph is available at the following link: https://publichealthmatters.blog.gov.uk/2021/02/05/what-do-we-know-about-the-new-covid-19-variants/

Viruses are not independent living entities. They require a host cell substrate to replicate. Isolation of any virus without any medium therefore is not possible. The medium provides suitable growing environment for the virus in the absence of a human or other host animal. These media and any products added are all sterile and do not contain additional genetic material.

You may be interested in the following information on the COVID-19 variants: https://github.com/phe-genomics/variant_definitions https://www.gov.uk/government/collections/new-sars-cov-2-variant

A Novel Coronavirus from Patients with Pneumonia in China, 2019: https://www.nejm.org/doi/full/10.1056/nejmoa2001017

Yours sincerely.

Information Rights Team UK Health Security Agency InformationRights@UKHSA.gov.uk www.gov.uk/ukhsa Follow us on Twitter @UKHSA



30 de junio de 2022:

La Agencia de Seguridad Sanitaria del Reino Unido y Salud Pública de Inglaterra han confesado una vez más que nunca han encontrado y purificado ningún supuesto virus conviviente de muestras clínicas (pero evitó admitir que no tienen registro de nadie en el planeta haciendo esto)... y proporcionaron vínculos inútiles desperdiciar el tiempo a páginas web inútiles de desperdiciamiento de tiempo... https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/UK-HSA-and-PHE-julio-

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/UK-HSA-and-PHE-julio-2022-PACKAGE-redacted.pdf

Response

There are no documents authored by The UK Health Security Agency (UKHSA) or Public Health England (PHE) which relate to the purification of virus directly from clinical samples as described, as we did not attempt this. If you would like a purification protocol we would suggest a peer reviewed biomedical literature, citations can be found at PubMed (nih.gov).

No hay registros de aislamiento de SARS-COV-2, admite el **Reino Unido. Departamento de Salud y Asistencia Social** (nota: no hay 1, ni 2, ni 3, ni 4, sino 5 de estas respuestas de DHSC, la más reciente fechada del 11 de octubre de 2021):



Freedom of Information Team
Department of Health and Social Care
39 Victoria Street
London SW1H 0EU

www.gov.uk/dhsc

DHSC does not hold the information you have requested.

[Nota **el Reino Unido. El Departamento de Salud y Atención Social** nos ha mantenido esperando durante casi 1 año una solicitud de FOI para (a lo sumo) 3 días de análisis sobre la supuesta variante de "alfa" anunciada por Matt Hancock el 14 de diciembre de 2020:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/02/UK-DHSC-handling-of-Dec14-FOI-re-so-so-variant.pdf]$

La Oficina de Ciencia del Gobierno del Reino Unido no tiene constancia de que el aisladamiento/purificación .SARS-COV-2:



Government Office for Science 10 Victoria Street London SW1H 0NN

+44 (0)20 7215 5000 - Public enquiries +44 (0)20 7215 6740 - Textphone (for those with hearing impairment)



Date 2/10/20

Ref no: GOS-COV-040920-0068

Thank you for your email of 4/9/20 where you requested the following information:

"All records in the possession, custody or control of the Government Office for Science describing the isolation of a SARS-COV-2 virus, directly from a sample taken from a diseased patient, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka vero cells; lung cells from a lung cancer patient).

Response

We do not hold the information you have requested. This information may be available from DHSC

20 de septiembre de 2021: **La Oficina de Ciencia del Gobierno del Reino Unido** confirmó una vez más que no tenemos la información que ha solicitado, re-SARS-COV-2 (incluyendo cualquier "variantes") aislamiento/purificación, por cualquier persona, en cualquier lugar:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/2021-09-21-Government-Office-of-Science-SARS-COV-2-v3-Redacted.pdf

(25 de enero de 2022:

La Oficina Gubernamental para la Ciencia (Go-Science) del Reino Unido confirmó que tampoco tienen registros que contengan detalles de cualquier "controls" utilizado en procedimientos de cultivo celular de la anticiencia, el llamado aislamiento de los virus o procedimientos de secuenciación del genoma completo:

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/2022-01-26-Government-Office-Office-of-SSARS-COV-2-controls-Redacted.pdf)

9 de abril de 2022:

Esta respuesta de la FOI de **la Policía Metropolitana, Reino Unido**, sugiere muy fuertemente que las personas involucradas en su **investigación de delitos COVID-19** (número de referencia 6029679/21) son:

- 1) Desorganizado salvajemente e incompetente, o
- 2) participar en un encubramiento de fraudes y crímenes de lesa humanidad en todo el mundo.

Exitamos que las personas que actuaban para la Policía Metropolitana proporcionaran registros que deberían haber buscado como parte de su investigación, registros que describían el primer y absolutamente esencial (pero no suficiente) paso para probar la existencia del supuesto virus (**purificación del fluido corporal/tejido**), O, si no tienen tales registros (ya que ninguno existe en ningún lugar del mundo) **estudios que en su opinión prueban la existencia de la** supuesta "virus-"SARS-COV-2".

Las personas de la **Policía Metropolitana** afirman que necesitarían más de 18 horas para buscar dichos registros, y esconderse detrás de una exención basada en dicha afirmación.

Véase la página 22:

DARCISION

La presente carta le debe informar que no será posible responder a su solicitud dentro del umbral de costo...Tenga en cuenta también que cuando una parte de una solicitud es denegada porque el costo de completar esa parte de la solicitud excedería el límite apropiado, esto resulta en la denegación de la solicitud en su totalidad....

REASON PARA DECISION

Sección 12(2) Exención cuando el costo del cumplimiento excede el límite apropiado La exención de la Sección 12 se aplica porque cualquier intento de cumplir con esta solicitud requeriría una extensa búsqueda manual para determinar si se mantiene alguna de las informaciones solicitadas...

El límite adecuado se ha especificado en la normativa y para los organismos fuera del Gobierno central, que se fija en 450,00 libras esterlinas. Esto representa el costo estimado de una persona que pasa 18 horas [a una tarifa de 25 libras por hora] para determinar si el MPS tiene la información y luego localizar, recuperar y extraer la información.

(Como señaló en mi respuesta: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/London-MOPAC-and-MPS-final-PACKAGE-redacted.pdf

8 de marzo de 2022:

La Oficina de Policía y Crimen de Londres (MOPAC) confirmó que no tienen registro de que el supuesto SARS-COV-2 sea encontrado y purificado de cualquier humano enfermo en el planeta, por cualquier persona, nunca, y que los hombres a cargo de la investigación criminal COVID-19 de la Policía Metropolitana (archivo número 6029679/21) que se cerraron injustamente tampoco tienen antecedentes que demuestren que se alegara existe. Véase la página 8:https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/London-MOPAC-and-MPS-final-PACKAGE-redacted.pdf

FOI response 445 Christine Massey "SARS-COV-2" purification 08.03.2022

MOPAC FOI <FOI@mopac.london.gov.uk>
To: "cmssyc@gmail.com" <cmssyc@gmail.com>
Cc: MOPAC FOI <FOI@mopac.london.gov.uk>

Tue, Mar 8, 2022 at 9:40 AM

Dear Christine

Thank you for your Freedom of Information (FOI) request of 8 March to the Mayor's Office for Policing And Crime (MOPAC). I confirm that your request has been handled under the Freedom of Information Act 2000 and that MOPAC does not hold the requested information.

The Metropolitan Police Service (MPS) may be able to assist you and you can send your request to them, here:

https://www.met.police.uk/rgo/request/ri/request-information/rip/request-information-police/

Lo mismo, de la **Oficina del Gabinete del Reino Unido** y de la **Oficina del Primer Ministro del Reino Unido**, en respuesta a una consulta de Marc Horn. Véase aquí:

https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/Prime-Ministers-Office-FOI-reply-isolation-SARS-COV-2pdf

14 de enero de 2022:

La **Oficina del Gabinete del Reino Unido** confirmó una vez más para Marc Horn que no tienen constancia de:

- el supuesto virus que se encontró en los fluidos corporales de cualquier paciente en la Tierra y purificado para que pudiera secuenciarse, caracterizarse y estudiarse con experimentos controlados;
- una secuencia única de ARN que se prueba por cualquier método de prueba que identifique la presencia del virus imaginario y ningún otro material genético;
- un daño único causado por el virus imaginario;

Evidencia experimental de la transmisión del virus imaginario:

 $\frac{https://www.whatdotheyknow.com/request/817480/response/1951835/attach/3/CO\%\,20}{FOI\%\,20response\%\,20FOI2021\%\,2023894.pdf?cookie.passthrough=1}$

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/UK-Cabinet-Office-Jan-2022.pdf}$

We are writing to advise you that following a search of our paper and electronic records, we have established that the information you requested is not held by the Cabinet Office.

You may wish to try contacting the UK Health Security Agency at this link: https://www.gov.uk/government/organisations/uk-health-security-agency who may be able to help you with your request.

Aquí hay una escueta respuesta de la FOI del **Reino Unido. Medicamentos y productos de salud Agencia Reguladora** (obtenida por Mr. Athanasios Kandias). La agencia no proporcionó/no se publicó ningún registro de aislamiento. Su respuesta incluye una afirmación (aparentemente fraudulenta) de que dichos registros están disponibles en el dominio público, pero proporcionaron cero enlaces/citas a pesar de haber sido solicitados para la ubicación de tales registros. A continuación se muestran extractos. Respuesta completa:

 $\frac{https://www.whatdotheyknow.com/request/documents.held.showing.sars.cov 2--2-incoming-1670059}{}$

Pdf: https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/UK-Medicines-and-Healthcare-products-Regulatory-Agency-no-aislation-records.pdf


4 de mayo de 2021: **La Universidad de Warwick** (Reino Unido) admite que no tienen antecedentes describiendo la purificación de un paciente de una muestra de pacientes, por cualquier persona, en cualquier lugar, jamás:


 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/05/University-of-Warwick-F352.20.20-21-May-4-2021.pdf}$

En cuanto al principio del ARNm en la vacuna Pfizer-BioNTech .Covid-19, que se transcribe de una plantilla genética que supuestamente codifica la proteína supuestamente viral (S) del supuesto pico (S) del presunto virus SARS-COV-2, **Reino Unido. Medicines & Healthcare products La Agencia Reguladora** admitió al periodista de investigación Frances Leader que: la plantilla genética en la que se basa (BNT162b2") no proviene directamente de un virus aislado de una persona infectada, sino que se generó a través de una combinación de síntesis de genes y tecnología de ADN recombinante. El intercambio de correo electrónico está disponible aquí: https://hive.blog/proofebbrain/-francesleader/email-exchange-with-mhra-sarscov2-genomic-sequence-is-synthetic-3edition

y en un pdf aquí:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/01/UK-MHRA-emails-w-FL.pdf.





Sin fotos EM de purificados "SARS-COV-2", ningún artículo revisado por pares con el genoma de la SARS-COV-2 purificado, sin pruebas de que el virus causa -COVID-19, etc. dice la Oficina del Gabinete del Reino Unido en respuesta a las preguntas que se muestran a continuación de Bartolomeus Lakeman; carta completa aquí: https://www.whatdotheyknow.com/request/666330/response/1589609/attach/3/FOI20206205%2Draft%201.pdf?cookie.passthrough=1 y preservado aquí:

22/06/2020

Dear Bartholomeus Lakeman

I refer to your request where you asked:

- "1) Is there an electron micrograph of the pure and fully characterised virus (SARS-CoV-2)?
- 2. What is the name of the primary specialist peer reviewed paper in which said virus is illustrated and its full genetic information described?
- 3. What is the name of the primary specialist peer reviewed paper which provides unequivocal proof that the 'Covid-19' virus is the sole cause of a particular disease?
- 4. Where is (if there is proof of SARS-CoV-2) its antibody test that fulfils the Koch postulates and has a false positive below 30%; that can confirm being infected by SARS-CoV-2?"

I am writing to advise you that following a search of our paper and electronic records, I have established that the information you requested is not held by the Cabinet Office.

No hay registros de aislamiento de la muestra no adulterada de una muestra no adulterada, dice la **Cámara de los Comunes** del **Reino Unido**, en respuesta a una consulta de Marc Horn:

Lo mismo, desde la **Cámara de los Lores del Reino Unido**, en respuesta a una consulta de Marc Horn: https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/House-of-Lords-FOI-reply-isolation-SARS-COV-2.pdf

31 de enero de 2022:

West Sussex, Reino Unido respondió a una serie de FOI de Oro de Holbbs para los registros de varios supuestos/viruses que fueron encontrados y purificados a partir de fluidos corporales/estrellados/excrementos por cualquier persona, en cualquier lugar del planeta, y/o probando un vínculo causal entre dicho supuesto virus y la desasoporte relevante. La Autoridad respondió que ahora habían completado una búsqueda de la información y "podá" ostentar los registros relevantes (lol), sin embargo, en lugar de entregar los registros imaginarios que ellos pueden tener, estaban eligiendo aplicar una exención basada en peticiones o repetidas.

Los "virus" enumerados en los "anillos" rechazados incluyen el virus del ébola.

Comunicaciones:(En la última página, el remitente de la respuesta parece haber olvidado eliminar algún proyecto de redacción que terminaron eligiendo no usar.)https://www.fluoridefreepeel.ca/wp-content/uploads/2023/11/West-Sussex-many-PACKAGE-redacted.pdf

Reports and records held by the council regarding the purification of Zika and other Viruses

We have now completed a search for the information which you requested and confirm that this Authority may hold data relevant to your request.

However the Authority is applying the exemption in section 14(1) of the Act.

Although the Authority does not regard the request as patently vexatious, the likelihood of complying would be burdensome and cause a significant burden and impact, resulting in a disproportionate or unjustified level of disruption and we are therefore applying the exemption under section 14 of the Act. Under the terms of the Act, the statutory wording we are required to use for this exemption is: 'Vexatious or repeated requests'.

18 de noviembre de 2021:

Las personas no identificadas que trabajan en el Equipo de Divulgación, Relaciones con el Cliente e Información, Cheshire West y Chester Council, Reino Unido confesaron a nuestro dedicado FOI-filer en Inglaterra que no tienen antecedentes describiendo cualquier supuesto virus Zika, VIH, Ebolavirus, Virus Polio, virus MERS, virus del VPH, VPH, Influenza virus o SARSCOV-2 - siendo encontrado en el fluido/tejido corporal de cualquier persona en la Tierra y purificado, por cualquier persona, en cualquier lugar, siempre con el fin de que se caracterizó, yestudiado con experimentos controlados (también conocidos como ciencia).

Subject: RFI 4618 Freedom of Information Request

X-Pm-Spam: OyeiAlic37iBOIJChpR3Y2bi4AiOiuHVZb8miiACLWbfxNvc2imUcOBi7BJCIIQFR QiU1xiAOLACiWVERjlgocgMjgSwflNnyiQWaiOiAE5Nj2jANYI MBys0NXaWZgQ4gaWu2wdbFWpwNHbWalt5iLmcF1db0iwgAjL1UGBhFX0fE9TUFETTByUEU6YhFIE gE8TbFW0ih2YycTBYgUEjmVcbJ3kt4GXCMw4NQI h52ZHdyVBmZ5tm9cX4Gg0VXYGay9MgJ3tG9ZYIWug4GXCMx4RLIEfU1SUI0HEVKTEII1Nhc3g2UZ aFGzgEGIERUtBvTSEiBcSByzudWaXY1RUscmvG5IdBC HIpN5hZ2yHVdZBSmt9mcGXg452ZWvWxZcUGtvJnZSbkB1hb2cW5ab0iwgAjLIRPJ9HTVf1ZTRtEJ B9VTSVGB9tcmvEdIdVmyl1mbnbgQRkYWzmVccByhg X-Pm-Origin: external

X-Pm-Transfer-Encryption: TLSv1.2 with cipher ECDHE-RSA-AES256-GCM-SHA384 (256/256 bits)

X-Pm-Content-Encryption: on-delivery

X-Pm-Spamscore: 0

X-Pm-Spam-Action: dunno

)ear

Thank you for your requests for information dated 21st October 2021 which have been logged as RFI 4618 and dealt with under the Freedom of Information Act 2000.

Your requests related to purification studies/reports/records regarding Zika Virus, HIV, Ebolavirus, Polio, MERS, Virus, Measles, HPV, Influenza and SARS-COV-2.

We confirm that Cheshire West and Chester Council does not hold information relating to your request. We suggest the UK Health Security Agency is the authority most likely to hold information. The contact details for the UK Health Security Agency are available on the following link: UK Health Security

Agency - GOV.UK (www.gov.uk) or: Public Information Access Office Wellington House 133-155 Waterloo Road London SE1 8UG United Kingdom

InformationRights@UKHSA.gov.uk

The Council considers that your request has been answered in full by either confirming that information is not held, providing you with the information requested, or explaining why any information has been withheld and the reasons for any redaction. Where applicable, the Council has also told you the reasons for the delay in responding to your request.

If you are unhappy with the way your request for information has been handled you can request a review by writing to the Disclosures Team within 40 working days from the date of the Council's response.

You are entitled to a review by the Council if:

- · You are dissatisfied with the Council's explanation of why the application was not dealt with within the 20 working day time limit.
- All the information requested is not being disclosed and you have not received an explanation why some information is not being disclosed.
- A reason for the disclosures under the request being refused is not received.
 You consider that exemptions have been wrongly applied, and/or
- · You consider that a fee has been wrongly applied.

Please set out your grounds for seeking a review together with what specific part of your request those grounds apply to and the outcome you are seeking. The Council reserves the right to ask you for clarification of the grounds for your review request if the grounds are not clear, and to delay commencing the review if such grounds are not provided.

The Disclosures Team can be contacted by email via: foi@cheshirewestandchester.gov.uk or at the following address:

Disclosures Team Cheshire West and Chester Council 4 Civic Way Ellesmere Port CH64 0BE

The Disclosures Team will acknowledge a request for an internal review within 5 working days and complete the review as soon as possible and no later than 40 working days from receipt of the request.

More information about the Council's internal review process can be found via:

http://www.cheshirewestandchester.gov.uk/your_council/policies_and_performance/council_plans_and_strategies/freedom_of_information_policy /foi_internal_review_process.aspx

If you remain dissatisfied following the outcome of your review, you have a right of appeal to the Information Commissioner at:

The Information Commissioner's Offic Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Telephone: 08456 30 60 60 or 01625 54 57 45

22 de octubre de 2021:

Alguien en **el Consejo del Condado de Somerset, Reino Unido** confesó a nuestro dedicado amigo de la FOI en Inglaterra que nadie tiene ningún registro que describa a ningún supuesto **SARS-COV-2** - siendo encontrado en el fluido corporal / tejido de cualquier persona en la Tierra y purificado, por cualquier persona, en cualquier lugar, siempre... para que se secuenciar, se cara a ser secuenciado, caracterizado y estudiado

con experimentos controlados (también conocido como ciencia): https://www.fluoridefreepeel.ca/wp-content/uploads/2022/08/Somerset-County-Council-PACKAGE-redacted.pdf

Our Response:

The information you requested is not held by Somerset County Council.

Please quote the reference number 8589749 in any future communications.

28 de octubre de 2021:

Steve Hanratty, que actúa como Gerente de Negocios, confesó a nuestro dedicado FOI-filer en Inglaterra que la gente del Ayuntamiento de Sunderland no tiene registro de ningún supuesto que **se** encuentre en el fluido/tejinó corporal de un humano y purificado... para que se secuenciar, se caracterizara y estudiara con experimentos controlados (también conocido como ciencia):https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/Sunderland-City-Council-PACKAGE-redacted.pdf

Sunderland [NE England] Fw: FOI_4269 - Covid-19 Virus roundcube C christinem@fluoridefreepeel.ca <christinem@fluoridefreepeel.ca> Date 2022-06-03 05:35 PM . North East Sunderland - Gerry Taylor.pdf (~492 KB) Is this FOI any good to you considering the format is not what was requested? Sent with Proton Mail secure email. ------ Original Message ------ On Thursday, October 28th, 2021 at 15:03, OCEFOI <OCEFOI@sunderland.gov.uk> wrote: Dear I refer to your recent request for information under the Freedom of Information Act 2000. I can confirm that the Council does not hold this information, as detailed below All studies and/or reports and/or records in the possession, custody or control of the addressed body corporate describing the purification (i.e. via filtration and ultracentrifugation and chromatography) of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", B.1.351", "P.1") directly from a sample taken from a diseased man, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum, liver cancer cells) and also studies and/or reports and/or records in the possession, custody or control of the addressed body corporate proving a causal link between Sars-Cov-2 and the suspected infectious disease Sunderland City Council does not hold any of the requested records This information has been provided in response to a Freedom of Information request and this must be acknowledged in any subsequent use of the information. In addition, the authority must be notified of any proposed re-use of this information for commercial or other purposes. I hope this is satisfactory. If, however, you are dissatisfied with our response to your request for information, you can ask for the decision to be reviewed in reply to this letter, however any request for review must be submitted within 40 days of the date of this freedom of information response. The review will be removed from the Directorate and coordinated by the Council's team of Solicitors. A request for review should be directed, by email to freedom.information@sunderland.gov.uk by post or by hand addressed to Business Support, Sunderland City Council, Civic Centre, Burdon Road, Sunderland. SR2 If this fails to resolve your concerns, then you have the right to apply to the Information Commissioner for a Kind Regards

1 de noviembre de 2021:

El Concejo de Wiltshire, Reino Unido, confesó a nuestro dedicado FOI-filer en Inglaterra que no tienen antecedentes describiendo que cualquier supuesto "SARS-COV-2" (o "variante) se encuentra en el fluido corporal/tejido de cualquier persona en la Tierra y purificado... por cualquier persona, en cualquier lugar, siempre... para que se secuencia, se caracterizara y estudiara con experimentos controlados (también conocido como ciencia):

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/Wiltshire-PACKAGE-redacted.pdf}$

Under the Freedom of Information Act 2000 (the Act) the Council is obliged to:

- Let you know whether we hold the information you have requested
- Provide you with the requested information, if held, (subject to any exemptions to disclosure that may apply)

I can confirm that following searches the council does not hold the information you requested; this may be something that the <u>World Health Organisation</u> or <u>UK Health Security Agency</u> could help with.

If you are dissatisfied with the response to your request you can ask for a review of the handling of your request for information. Details of the complaints procedure are below

Best wishes.

Daniella Heard

Information Governance Officer
Wiltshire Council | County Hall | Bythesea Road | Trowbridge | BA14 8JN
Email: <u>InformationGovernance@wiltshire.gov.uk</u> | Web: <u>www.wiltshire.gov.uk</u>
Tel: 0300 456 0100 (Customer Services)

4 de noviembre de 2021:

El Equipo de Gestión de la Información de **Londres en el distrito de Hackney** confesó a nuestro dedicado FOI-collector en Inglaterra que no tienen ningún registro que describa cualquier supuesto **que** se encuentre en el fluido corporal/tejido de alguien en la Tierra y purificado... por cualquier persona, en cualquier lugar, siempre... para que sea secuenciado, se caracteriza y estudia con experimentos controlados (también conocido como ciencia):

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/LONDON-HACKNEY-PACKAGE-redacted.pdf

The Council's Response

We have detailed below the information that is being released to you.

Public Health for the City and Hackney do not hold the information requested. This

21 de octubre de 2021:

Kirklees Council confesó a nuestro dedicado FOI-collector en Inglaterra que no tienen registro describiendo cualquier supuesto "SARS-COV-2" (o "variante") siendo encontrado en el fluido corporal/tejido de cualquier persona en la Tierra y purificado... por cualquier persona, en cualquier lugar, siempre... para que se secuenciar, se cara a la secuenciación, se caracterizó y estudiara con experimentos controlados (también

conocido como ciencia): https://www.fluoridefreepeel.ca/wp-content/uploads/2022/06/Kirklees--PACKAGE-redacted.pdf





Red Doles Lane Huddersfield HD2 1YF

Tel: 01484 221000 (when calling please ask for freedom of information)

freedom.info@kirklees.gov.uk

Our ref: 26188 Date: 21/10/2021



I am writing in response to your request dated 19/10/2021. This has been dealt with under the Freedom of Information Act 2000.

You asked for the following information:

All studies and/or reports and/or records in the possession, custody or control of the addressed body corporate describing the purification (i.e. via filtration and ultracentrifugation and chromatography) of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") directly from a sample taken from a diseased man, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum, liver cancer cells) and also studies and/or reports and/or records in the possession, custody or control of the addressed body corporate proving a causal link between Sars-Cov-2 and the suspected infectious disease Covid-19.

Please note that I am not requesting studies/reports where researchers failed to purify the suspected "virus" (separate the alleged "virus" from everything thing else in the patient sample) and instead:

■ cultured an unpurified sample or other unpurified substance, and/or
■ performed an amplification test (i.e. a PCR test) on the total RNA from a
patient sample or from a cell culture, or on genetic material from any
unpurified substance, and/or

fabricated a genome based on PCR-detected sequences in the total RNA from a patient sample or from a cell culture or from any unpurified substance, and/or

mages of unpurified things in a cell culture.

The Council's response to your specific questions is set out below:

Kirklees Council do not hold any information relating to your request.

If you are not content with the handling of your request, you have the right to ask for an internal review. Requests for internal reviews should be submitted within 2 months of

www.kirklees.gov.uk

28 de mayo de 2021:

Royal Borough de Kensington y Chelsea confesó a nuestro dedicado FOI-collector en Inglaterra que no tienen ningún registro que describa cualquier supuesto "SARS-COV-2" (o "variante) siendo encontrado en el fluido corporal/tejido de alguien en la Tierra y

purificado por cualquiera, en cualquier lugar, nunca... para que se secuencia, se cara a ser secuenciado, caracterizado y estudiado con experimentos controlados (también conocido como ciencia):

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/06/Royal-Borough-Kensington-and-Chelsea-PACKAGE-redacted.pdf}$

21 de octubre de 2021:

El Ayuntamiento de Derby (Reino Unido) confirmó para el solicitante de la FOI que no tienen evidencia científica de que el SARS-COV-2 haya sido aislado y exista en cualquier parte del mundo.

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/Derby-City-Council.pdf

FOI211565413 - Response & Internal Review Decision Inbox foi@derby.gov.uk Tue, Oct 12, 2021, 11:30 AM

The Council does not hold the information requested - please see attached response template for more information.

13 de enero de 2022:

Dear

Hospitales Universitarios de Derby y Burton, del Servicio Nacional de Salud (Reino Unido), confirmaron para el solicitante del FOI que no tienen evidencia científica de que el SARS-COV-2 haya sido aislado y realmente exista en cualquier

parte del mundo.

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/02/University-Hospitals-of-Derby-and-Burton.jpg

From:

Sent: 10 January 2022 17:24

To: FOI (UNIVERSITY HOSPITALS OF DERBY AND BURTON NHS FOUNDATION TRUST)

uhdb.foi@nhs.net>Subject: SARS covid

Hi

As a matter of information I would request an answer to the following question. Could you please supply me with any scientific evidence that you have to say that SARS covid 2 and SARS covid 19 has been isolated and actually exists anywhere in the world?

Regards

FOI.22.015

Inbox

FOI (UNIVERSITY HOSPITALS OF DERBY AND

BURTON NHS FOUNDATION TRUST)

Thu, Jan 13, 1:45 PM (22 hours ago)

Dear Mr

Further to your enquiry below, I can confirm that our Trust, as an independent NHS organisation, does not hold this information.

May we would refer you to the World Health Organisation (WHO), who would be best placed to answer a globally orientated question.

https://www.who.int/about/contact-us

Kind regards

Jane Haywood

FREEDOM OF INFORMATION MANAGER

14 de diciembre de 2021:

El distrito de Londres de Bromley confirmó al solicitante que tampoco tienen registro de que CUALQUIER de los siguientes supuestos virus ha sido purificado de

cualquier muestra de pacientes, por cualquier persona, en cualquier parte del planeta, o cualquier estudio que demuestre un vínculo causal con las sospechas de enfermedades infecciosas:

- * SARS-COV-2
- * SARS-COV-1
- * Cualquier coronavirus frío común
- * Ebola
- * VIH
- * HPV
- * Influenza
- * Meas
- * Polio
- * Zika
- * MERS
- * CUALQUIER VIRUS en el calendario de inmunización infantil: https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/BOROUGH-OF-BROMLEY-many-PACKAGE-redacted.pdf

LONDON BOROUGH OF BROMLEY

FREEDOM OF INFORMATION ENQUIRY - RESPONSE

Date: 14 December 2021
Request ID: \$29JF44R94

Subject: Virus Information/Infectious Disease

Request Type: Freedom of Information Request

Subject Type: FOI/EIR

Which department do you require information from?

Adult Services FOI/SAR and Housing FOI

Please see below responses to your enquiry (highlighted in Green)

Response: We can confirm that London Borough of Bromley (LBB) does not hold the

information requested in your FOI enquiry.

NB: For future reference, please be aware that LBB does not hold any data pertaining to the purification/causation of sickness in living man

regarding any viruses known to man.

Request:

Please address my request in full * and respond in kind on letter head notepaper with a reference number, referencing the information requests made-a separate response letter for each request made that is dated and signed by whomever is responsible for the decision contained within the response letter 'claims of 'virus' isolation/sickness causation' for the sake of clarity and transparency to the publick. I do not wish to create accounts and passwords and all manner of other property to prolong the delivery of evidences/publick records and further attempts to obtain my property will be posted in the publick domain.

I have included link to Public Health England's response letter by way of example as to how it is usual to respond and lay out the response also a response link from Derby to purification of the polio virus. Should you require a copy of PHE's response or further help on how to respond to requests please let me know soonest.

As evidences/publick record these communications will be placed in the public domain rendering them live. For further clarity as i have submitted more than 1 request to the Director of Public Health for Bromley – Nada Lemic, including SARS-CoV-1 'virus' purification/causation of sickness in living man, for HPV, INFLUENZA 'virus' and so forth in the last few weeks would they please indicate what request is referred to.

Page 1 of 1

29 de octubre de 2021:

El Consejo del Condado de Norfolk, Este de Inglaterra (Cubrir Gran Yarmouth) confirmó para que el solicitante no tenga registro de ningún supuesto "SARS-COV-2" (incluyendo ningún escarián) que haya sido encontrado y purificado del fluido corporal/tejido/excremento de cualquier fantasma enfermo en el planeta (para que sea

secuenciado, caracterizado y estudiado con experimentos controlados) por cualquier persona, en cualquier lugar, nunca. https://www.fluoridefreepeel.ca/wp-content/uploads/2022/05/Norfolk-UK-PACKAGE-redacted.pdf

Our response:

Information relating to the medical and scientific analysis of the Covid-19 virus is not held by Norfolk County Council. The Council's Public Health remit extends only to those measures and activities required in discharge of responsibilities as directed by the Secretary of State, and our response to the covid-19 pandemic is predicated on guidance issued by Public Health England (now The UK Health Security Agency).

Under section 11 of the Health and Social Care Act 2012, the Secretary of State for Health has a duty to "take such steps as the Secretary of State considers appropriate for the purpose of protecting the public in England from disease or other dangers to health". By virtue of the Local Authorities (Public Health Functions and Entry to Premises by Local Healthwatch Representatives) Regulations 2013 local authorities have a statutory duty to carry out certain aspects of the Secretary of State's duty to protect the public.

30 de diciembre de 2021:

El Ayuntamiento de Leicester confirmó que no tiene registro de ningún ejemplo de que haya sido purificado de cualquier muestra de pacientes, por cualquier persona, en cualquier parte del planeta, o cualquier estudio que sugiera un vínculo causal entre el caso y el sospechoso infeccioso "COVID-19": https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/Leicester-City-Council-PACKAGE-redacted.pdf

Response:

Leicester City Council does not hold the information requested. It is not a laboratory and does not undertake any of the procedures listed in the request. This is therefore a refusal notice under section 17.1 of the FOI Act: Information Not Held.

You may re-use the information under an Open Government Licence.

If you are dissatisfied with the handling of your request, please write, explaining your grounds of appeal, to:

Internal Review
Information Governance & Risk
Email: info.requests@leicester.gov.uk

Yours sincerely

Pravina Chandarana Information Governance Officer

10 de noviembre de 2021:

El distrito de Londres de Lambeth confirmó que el solicitante no tiene registro de ningún ejemplo de que haya sido purificado de cualquier muestra de pacientes, por cualquier persona, en cualquier parte del planeta, o cualquier estudio que sugiera un vínculo causal entre el caso y el presunto infeccioso "COVID-

19":https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/London-Borough-of-Lambeth-PACKAGE-redacted.pdf



10 November 2021 Our ref: IRN6651758

Freedom of Information Act 2000

This request is being handled under the Freedom of Information Act 2000.

Request

Please note that I am using 'purification' in the every-day sense of the word: the act of separating a thing(s) from everything else. Please note that I am not requesting records/studies/reports where researchers failed to purify the suspected "virus" (separate the alleged 'virus' from everything thing else in the patient sample) and instead:-

- cultured an unpurified sample or other unpurified substance, and/or
- performed an amplification test (i.e. a PCR test) on the total RNA from a patient sample or from a cell culture, or on genetic material from any unpurified substance, and/or
- fabricated a genome based on PCR-detected sequences in the total RNA from a patient sample or from a cell culture or from any unpurified substance, and/or.
- produced electron microscopy images of unpurified things in a cell culture.

Response

We do not hold the information requested. Lambeth council does not own or operate any clinical laboratory facilities.

Right to review

If you are dissatisfied with the way in which your Freedom of Information request has been dealt with you can request an internal review. Tell us why you are unhappy with our response within 40 working days, and it will be looked at afresh. We will aim to provide you with our review response within 20 working days.

By email: foi@lambeth.gov.uk (Please quote the reference number above) or by writing to:

London Borough of Lambeth Freedom of Information P.O. Box 734 Winchester S023 5DG

If you remain dissatisfied with the outcome of the review you have a further right to appeal to the Information Commissioner, who regulates the implementation of the Freedom of Information Act. The Commissioner can be contacted at the following address:

22 de octubre de 2021:

El Consejo del Condado de Lincolnshire confirmó al solicitante que no tiene registro de ningún hecho de que haya "SARS-COV-2" sido purificado de cualquier muestra de un paciente, por cualquier persona, en cualquier parte del planeta, o cualquier estudio que sugiera un vínculo causal entre el caso y el sospechoso infeccioso COVID-19:https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/Lincolnshire-PACKAGE-redacted.pdf

purification (separation from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things). Please note that my request includes any study/report matching the above description, for example (but not limited to) any published peer-reviewed study authored by anyone, anywhere. This includes your own website which claims to have the virus isolated; given your body corporate/politick receives public treasure, the worldwide 'interest' and that more than 100 institutions other have no virus isolate this is for public record/evidence.

If any records match the above description of requested records and are currently available in the public domain, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible.

Response:

Lincolnshire County Council does not hold this information


Please quote the reference number 2634405 in any future communications.

25 de octubre de 2021:

El Consejo del Condado de Nottinghamshire en el Reino Unido confirmó para Yvonne Hobbs que no tienen registro de ningún "SARS-COV-2" que haya sido purificado de una muestra de pacientes, por cualquier persona, en cualquier parte del planeta, o cualquier registro que demuestre un vínculo causal entre la enfermedad infecciosa y la sospecha de enfermedad infecciosa .

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/Nottinghamshire-1.pdf

This matter is being dealt with by: Freedom of Information Team Reference: FOI/167 T 0115 977 2788 E complaints@nottscc.gov.uk W nottinghamshire.gov.uk



25/10/2021 07:19:24

Dear Von

Request FOI/167

I write further to your request for information received on 20/10/2021 in which you requested the following information:

Covid

Your request has been given careful consideration under the Freedom of Information Act 2000/Environmental Information Regulations 2004 however we have established that the information you requested is not held by Council.

If you have any queries about this email please do not hesitate to contact us directly, quoting the reference number listed at the top of this email in all communications.

If you are unhappy with the Council's response to your request and wish to make a complaint, please write to us or complete the on-line complaint form that can be found on our website

In addition to this and for future reference, Nottingham County Council regularly publishes previous FOIR, s and answers on its website, under Disclosure logs, that may provide details relating to your query. (see link)

http://site.nottinghamshire.gov.uk/thecouncil/democracy/freedom-of-information/disclosure-

You can use the search facility using keywords i.e. 'funerals.

If you wish to raise any concerns about the way your request was dealt with, then please write to the Team Manager, Complaints and Information, County Hall, West Bridgford, Nottingham, NG2 7QP or e-mail foi@nottscc.gov.uk quoting the reference number above.

If after going through the Council's Internal Review process you are still not satisfied, you can contact the Information Commissioner direct.

Information Commissioner

Helpline:

0303 123 1113

Wycliffe House

01625 545 745

Water Lane

casework@ico.org.uk Email:

Wilmslow

Website:

www.ico.org.uk

Cheshire SK9 5AF

13 de diciembre de 2021:

El Consejo del Condado de Rutland en el Reino Unido confirmó para Yvonne Hobbs que no tienen registro de que ningún SARS-COV-2 haya sido purificado de una muestra de paciente, por cualquier persona, en cualquier parte del planeta, o cualquier registro que demuestre un vínculo causal entre el SARS-COV-2 y la sospecha de

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/Rutland-sc2.pdf

If any records match the above description of requested records and are currently available in the public domain, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible.

Response:

Rutland County Council does not hold this information.

You are free to use any documents supplied for your own use, including for non-commercial research purposes. The documents may also be used for news reporting. However, any other type of re-use, for example by publishing the documents or issuing copies to the public will require the permission of the copyright owner, where copyright

El Consejo Central de Bedfordshire confirmó para Yvonne Hobbs que no tienen registro que describa la purificación de la "SARS-COV-2" de cualquier muestra de pacientes en el planeta, por cualquiera, nunca:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/Central-Bedfordshire-Council-PACKAGE-redacted.pdf



Von Hobbs Email: accesstoinfo@centralbedfordshire.gov.uk

Our ref: 4982869

Date: 27 October 2021

Dear Von Hobbs

Freedom of Information Act 2000

Request regarding Covid studies/reports

I am writing to advise you that, following a search of our paper and electronic records, I have established that the information you requested is not held by Central Bedfordshire Council.

Please quote the reference number 4982869 in any future communications.

Croydon Council confirmó para Yvonne Hobbs que no tienen registro de la purificación de la muestra de pacientes en el planeta, por cualquier persona, y ningún registro que demuestre un vínculo causal entre la "Sars-Cov-2" y la sospecha de enfermedad infecciosa Covid-19:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/Croydon-Council-PACKAGE-redacted.pdf}{PACKAGE-redacted.pdf}$

El Concejo Municipal de Derby en el Reino Unido confirmó para Yvonne Hobbs que no tienen registro de que ningún .SARS-COV-2 haya sido purificado de una muestra de paciente, por alguien en el planeta:

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/Derby-City-Council-PACKAGE-redacted.pdf

El Consejo del Condado de Hertfordshire en el Reino Unido confirmó para Yvonne Hobbs que no tienen registro de ningún tipo de SARS-COV-2 que haya sido purificado de una muestra de paciente, por cualquiera en el planeta:

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/Hertfordshire-County-Council-PACKAGE-redacted.pdf

19 de octubre de 2021: **East Midlands - El Consejo del Condado de Leicestershire** en el Reino Unido confirmó al solicitante que no tienen registro de ningún virus COVID-19/variante purificado de cualquier muestra de pacientes, por cualquier persona, en cualquier parte del planeta - y por lo tanto cero evidencia de la existencia de "su":

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/East-Midlands-Leicestershire-\%E2\%80\%93-Mike-Sandys-SARS-CoV-2-PURIFICATION-FOI-RESPONSE-v2.pdf$



Response:

Unfortunately, we do not hold the information you have requested

With regards to reports published in medical journals / databases, we would suggest searching for the relevant reports online.

Your request has been handled under the Freedom of Information Act 2000.

If you are not happy with how we've dealt with your request, you can complain and ask us to review our decision. If this is the case, please email foi@leics.gov.uk or write to us at the above address, quoting the FOI Request Number. We will usually only be able to consider complaints about requests if they are submitted to us within two months (from the date of this letter).

Further information about your rights to information is available from the Information Commissioner's Office at:

Address: Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF

Telephone: 0303 123 1113 Website: www.ico.org.uk

Kind regards,

FOI Team Leicestershire County Council

Corporate Resources

Leicestershire County Council, County Hall, Glenfield, Leicestershire LE3 8RE Telephone: 0116 3057830 Email: resources@leics.gov.uk
Chris Tambini, Director of Corporate Resources

www.leics.gov.uk

25 de octubre de 2021: **Bedford Borough Council** en Inglaterra confirmó para Yvonne Hobbs que no tienen registro de la purificación de la SARS-COV-2, por parte de nadie en el planeta:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/Bedford-Borough-Council-PACKAGE-redacted.pdf}{}$

25 de octubre de 2021: **El Concilio Brent** en Inglaterra confirmó para Yvonne Hobbs que no tienen registro de la purificación de la SARS-COV-2, por nadie en el planeta, y sin registros que prueben un vínculo causal entre el virus imaginario y el virus .covid-19:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/Brent-Council-PACKAGE-redacted.pdf}{PACKAGE-redacted.pdf}$

30 de octubre de 2021:

El Concejo del Condado de Suffolk en Inglaterra confirmó para Yvonne Hobbs que no tienen registro de la purificación de la SARS-COV-2, por parte de nadie en el planeta, y ningún registro que demuestre un vínculo causal entre el virus imaginario y (resultados de la RCP envasado como)

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/11/Suffolk-County-Council-PACKAGE-redacted.pdf}{PACKAGE-redacted.pdf}$



Freedom of Information - Response - 21103

Description of Requested Records:

All studies and/or reports and/or records in the possession, custody or control of the addressed body corporate describing the purification (i.e. via filtration and ultra- centrifugation and chromatography) of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") directly from a sample taken from a diseased man, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum, liver cancer cells) and also studies and/or reports and/or records in the possession, custody or control of the addressed body corporate proving a causal link between Sars-Cov-2 and the suspected infectious disease Covid-19.

Please note that I am <u>not</u> requesting studies/reports <u>where</u> researchers <u>failed</u> to <u>purify</u> the suspected "virus" (separate the alleged "virus" from everything thing else in the patient sample) and instead:

- cultured an unpurified sample or other unpurified substance, and/or
- performed an amplification test (i.e. a PCR test) on the total RNA from a patient sample or from a cell culture, or on genetic material from any unpurified substance, and/or
- fabricated a genome based on PCR-detected sequences in the total RNA from a patient sample or from a cell culture or from any unpurified substance, and/or
- · produced electron microscopy images of unpurified things in a cell culture.

Clarification of Request

For further clarity, please note I am already aware that according to virus theory a "virus" requires host cells in order to replicate, and I am not requesting records describing

the replication of a "virus" without host cells.

Further, I am not requesting private patient information, or records that describe a suspected "virus" floating in a vacuum; I am simply requesting records that describe

its <u>purification</u> (separation from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things). Please note that my request includes any study/report matching the above description, for example (but not limited to) any published peer-reviewed study authored by anyone, anywhere. This includes your own website which claims to have the virus isolated; given your body corporate/politick receives publick treasure, the worldwide 'interest' and that more than 100 institutions other have no virus isolate this is for publick record/evidence.

If any records match the above description of requested records and are currently available in the public domain, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible.

Suffolk County Council do not hold this information.

Octubre 2021:

Salud Pública London Hammersmith y Fulham en el Reino Unido confirmaron al solicitante que no tienen registro de ningún virus/variante de la Comisión de Salud purificado de cualquier muestra de paciente por cualquier persona, en cualquier parte del planeta, y ningún registro que demuestre un vínculo causal entre el presunto virus y

el "COVID-19" y, por lo tanto, cero evidencia de la existencia: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/10/London-Hammersmith-and-Fulham-PACKAGE-redacted.pdf



Assessment and care coordination

Hammersmith & Fulham Council Town Hall, King Street Hammersmith London W6 9JU

Reference: 2029609 Email: icaseworkinformation@lbhf.gov.uk Date: 20 October 2021



Dear

Freedom of Information Act 2000

This request is being handled under the Freedom of Information Act 2000.

I am writing to advise you that, following a search of our paper and electronic records, I have established that the information you requested is not held by London Borough of Hammersmith and Fulham.

All studies and/or reports and/or records in the possession, custody or control of the addressed body corporate describing the purification (i.e. via filtration and ultracentrifugation and chromatography) of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") directly from a sample taken from a diseased man, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum, liver cancer cells) and also studies and/or reports and/or records in the possession, custody or control of the addressed body corporate proving a causal link between Sars-Cov-2 and the suspected infectious disease Covid-19. We do not have any records that relate to your query

Please quote the reference number 2029609 in any future communications.

If you aren't happy with the council's response, please contact H&F within 40 working days of us sending you our response, with details of why you're unhappy. You can do this by:

- visiting H&F's website: https://www.lbhf.gov.uk/councillors-and-democracy/complaints
- · emailing handfintouch@lbhf.gov.uk
- writing to the Resident Experience team, Hammersmith Town Hall, King Street, London, W6 9JU

Your concerns will be passed to H&F's Information Management Team to consider as an internal review. There's no charge for requesting an internal review.

28 de octubre de 2021:

El Ayuntamiento de Brighton y Hove en Inglaterra confirmó para Yvonne Hobbs que no tienen registro de la purificación de la SARS-COV-2 por parte de nadie en el planeta:

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/11/Brighton-SARS-COV-2-PACKAGE-redacted.pdf}$

Our response:

In processing your request we liaised with colleagues within Public Health as they would hold the information in relation to your request were this information to be held by the council.

We can confirm that the information you have requested is not held by the council.

The council does not hold any documents describing the purification of any Covid-19 virus, including variants.

(Haga clic aquí para ver una serie de solicitudes de FOI de COVID-19 presentadas por Marc Horn a varias agencias: https://www.whatdotheyknow.com/user/marc-horn)

Lo mismo, de **Public Health Scotland** en respuesta a Athanasios Kandias: https://www.fluoridefreepeel.ca/wp-content/uploads/2020/10/PH-Scotland-RESPONSE-2020-000133.pdf



Date 7 October 2020] Our Ref 2020-000133 Enquiries to phs.foi@nhs.net

Dear Athanasios Kandias

Freedom of Information Reference: 2020-000133

I refer to your request of 9 September 2020 under the above legislation for information about:

All records in the possession, custody or control of Public Health Scotland, describing the isolation of a SARS-COV-2 virus, directly from a sample taken from a diseased patient, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka vero cells; liver cancer cells).

Please note that I am using "isolation" in the every-day sense of the word: the act of separating a thing(s) from everything else. I am not requesting records where "isolation of SARS-COV-2" refers *instead* to:

- · the culturing of something, or
- . the performance of an amplification test (i.e. a PCR test), or
- · the sequencing of something.

Please also note that my request is not limited to records that were authored by the PHS or that pertain to work done by the PHS. My request includes any sort of record, for example (but not limited to) any published peer-reviewed study that the PHS has downloaded or printed.

I am writing to advise you that following a search of our records, I have established that under Section 17(1) of the Freedom of Information (Scotland) Act 2002, Public Health Scotland (PHS) does not hold the information you requested.

PHS has not been involved in any studies where methods of isolation described have been performed. Such studies may have been performed in a number of Universities but PHS is not aware of any specific studies to be able to direct you to them for more information.

If you have any questions please contact me on phs.foi@nhs.net.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this correspondence, and we will reply within 20 working days of receipt.

1 South Gyle Crescent, Edinburgh EH12 9EB

Glasgow office: 5 Cadogan Street, Glasgow G2 6QE

Lo mismo, por segunda vez de **Public Health Scotland** en respuesta a mi colega en NZ: https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/Public-Health-Scotland-Response-2020-000158.pdf

10 de septiembre de 2021: **Salud Pública Escocia** confirmó una vez más, esta vez para Richard Anthony, que no tienen una muestra purificada del supuesto virus/variantes de

COVID=19 y no conocen a nadie en Escocia que lo hace, y equipararon el aislamiento/purificación con la matanza de células monos sin sentido y poco científica. Pdf:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/10/Scotland-PH-FOI-2021-000848-2.pdf}{}$



15 de febrero y 9 de marzo, 2022:

Escocia: La **Dirección de Salud Pública COVID del COVID, COVID: COVID Ready Society** dice que tener una ruta clara para sintetizar evidencia científica y presentarlo al Gobierno es importante.

Sin embargo, Jason Carroll también confirmó que el gobierno escocés no tiene registro de que el gobierno escocés no tenga registro de que se encuentre en los fluidos corporales de cualquier hombre enfermo en la Tierra y purificado... lo que sería necesario para que se pueda secuenciar, caracterizar, estudiar con experimentos controlados y demostrar que existen.

En marzo de 2022, una respuesta a una apelación resultó la confirmación anterior. https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/Scottish-govt-w-appeal-2022-PACKAGE.pdf

Response to your request

This is a formal notice under **Section 17(1)** of FOISA that the Scottish Government does not have the information you have requested.

Throughout the epidemic, having a clear route for synthesising scientific evidence and presenting that to Government is important. To do this, scientific advice is provided by the <u>Scottish Government COVID-19 Advisory Group</u>. In addition, the Scottish Government is informed by SAGE, and its sub groups of which further details can be found on the <u>UK Government website</u>.

11 de abril de 2023:

3 años más tarde y aún así la gente de **Public Health Wales** tuvo que confesar a Tim que no tiene registro de nadie en la Tierra encontrando y purificando el imaginario . **SARS-COV-2** . de cualquier fluido corporal / tejido/excremento:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2023/06/PH-Wales-2023-PACKAGE-redacted.pdf}{PACKAGE-redacted.pdf}$

Sus confesiones/incumplidas anteriores se pueden encontrar aquí.

From: FOI (Public Health Wales) <phw.foi@wales.nhs.uk></phw.foi@wales.nhs.uk>
Sent: 11 April 2023 14:10
To: Tim Subject: RE: FOI request CORRECTION
Dear Tim
Thank you for your recent request. Public Health Wales has not produced any of the below mentioned material.
Please refer to the Public Health Wales disclosure log for previous FOI responses (FOI 850 - SARS-COV-2 virus records)
https://www2.nphs.wales.nhs.uk/DisclosureLog.nsf/byMonthPage?OpenPage
Thanks,
Alex

de mayo de 2023:

Algaño hombre/mujer (o tal vez AI) en **Cardiff y Vale University Health Board, Gales** confesó a Tim que no tienen ningún registro de nadie en la Tierra encontrando y purificando el imaginario **de la SARS-COV-2** de cualquier fluido corporal/tejido/excremento y sugirió que le **preguntara** a **Salud Pública Gales** (ver arriba); https://www.fluoridefreepeel.ca/wp-content/uploads/2023/06/Cardiff-and-Vale-University-Health-Board-Wales-PACKAGE-redacted.pdf



Freedom of Information Act 2000 - Request Reference Fol/23/160 Covid-19 Studies

Information Requested:

Description of Requested Records:

All studies and/or reports in the possession, custody or control of NHS Wales describing the purification of the alleged "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants") directly from a sample taken from a diseased human, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum).

Clarification of Request:

Please note that I am not requesting studies/reports where researchers failed to purify the suspected "virus" and instead:

- · cultured something, and/or
- · performed an amplification test (i.e. PCR), and/or
- · fabricated a genome from sequences (allegedly) detected in an impure substance, and/or
- · produced electron microscopy images of unpurified things.

I am already aware that according to virus theory a "virus" requires host cells in order to replicate, and am not requesting records that describe replication of a 'virus' without host cells.

Nor am I requesting records that describe a strict fulfillment of Koch's Postulates, or records where researchers conflate extraction of genetic material from a patient sample or cell culture with "virus isolation", or records that describe a suspected "virus" floating in a vacuum, or private patient information. I simply request records that describe purification (separation of the alleged virus from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things). Please note that my request includes any study/report matching the above description, authored by anyone, anywhere.

If any records match the above description of requested records and are currently available in the public domain, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible.

Response details:

Cardiff and Vale University Health Board (the UHB) does not hold this information. Under Section 16 of the FOIA, which provides us with the duty to advise and assist, the UHB can inform you that Public Health Wales may be able to assist you with your query, please see their contact details below,

foi.phw@wales.nhs.uk



Salud Pública de Gales proporcionó al Dr. Dr. Janet Menage una excusa escueta para no ayudar adecuadamente con su petición (Dr. Menage ha presentado una queja al equipo de PHW -Corporate Complaints); véase la respuesta de PHW.s aquí:

https://www.fluoridefreepeel.ca/wp-content/uploads/2020/10/Puplic-Health-Wales-453-Isolation-of-Sars-COV-2.pdf



Freedom of Information request to Public Health Wales FOI Reference: FOI 453 Date request received 06 October 2020

Thank you for your recent request. Public Health Wales has not produced any of the above mentioned material. Any records that may be in possession of Public Health Wales would be material that is already in the public domain, which we would decline to supply under Section 21 of the Freedom of Information Act.

Under our duty to assist, we would ordinarily be willing to provide links or advise where you may be able to find such documentation if we held it within our systems, however the information above would prove to be too wide in terms of search parameters for us to identify any records with certainty that we hold.

Aquí hay una respuesta esquiva segunda y más reciente de **Public Health Wales** sin que no haya registrado ningún registro, o cita de ningún registro, de aislamiento/purificación de la SARS-COV-2 hecha por cualquier persona, en cualquier lugar, jamás. https://www.fluoridefreepeel.ca/wp-content/uploads/2020/12/PHWales.pdf

A continuación se presenta una captura de pantalla de una respuesta de Libertad de Información al Sr. James McCumiskey, autor de The Latest Conspiracy: The Biomedical Paradigm, del University College Dublin, explicando que el Laboratorio Nacional de Referencia de Virus de Irlanda no tiene registros que describan cómo se purificó el Coronavirus de la Novela. Haz clic en el enlace para más detalles.



Oifig Dli UCD

UCD Legal Office

Caisleán an Ruabhoic, An Coláiste Ollscoile, Baile Átha Cliath, Belfield, Baile Átha Cliath 4, Eire

Roebuck Castle. University College Dublin, Belfield, Dublin 4, Ireland

corporate.legal@ucd.ie www.ucd.ie/corpsec T +353 1 716 8708

Mr James McCumiskey

By email: il mccumiskey@yahoo.ie

22 June 2020

Reference: FOI12_1_544 Internal Review

Dear Mr McCumiskey,

I refer to your application for an internal review under the Freedom of Information Act 2014 of a decision by Ms Debbie Scanlan, dated 22 May 2020, concerning item 1 of your request for access to records of the National Virus Reference Laboratory (NVRL), as follows: "1) I am looking for a scientific paper, which demonstrates how the Novel Coronavirus was purified? Surely, if the NVRL is able to detect the Novel Coronavirus, it should also be able to demonstrate how it is purified?"

In the original decision, Ms Scanlan refused part 1 of your request on grounds that the University do not hold records to answer your request (Section 15 (1) (a)).

I have now conducted an internal review in accordance with Section 21 of the Act. I wish to inform you that I affirm the original decision.

The University's position is that matters of academic debate cannot be conducted under FOI and we would not regard academic research material as administrative records of an FOI body that would make them available for release under the legislation. The NVRL have advised that they do not culture live SARS-CoV-2 or purify SARS CoV 2 antigens. They detect SARS-CoV-2 RNA in diagnostic samples, as per the PCR assay that was shared with you previously. As such, there are no relevant records held and no further searches that may be taken for records that would provide an answer to your query. Section 15 (1) (a) of the FOI applies.

The University is committed to its obligations under the Act to provide requesters with access to records held by it and with reasons for its decisions that affect them. In this case, we regret that we cannot assist you further.

Under the Act, the University is required to advise you of your right, following receipt of your internal review decision, to make a further review application by writing to the Information Commissioner, 18 Lower Leeson Street, Dublin 2.

Yours sincerely,

K

Mr Julian Bostridge Director of Legal Services

23 de diciembre de 2020:

Irlandas El Ejecutivo de Servicios de Salud (HSE) informó al Sr. Robert Pye que no tienen registro describiendo aislamiento/purificación de la muestra de un paciente, por cualquier persona, en cualquier lugar (creo que esta es la respuesta reportada por Gemma O-Doherty el año pasado. Finalmente obtuve una copia): https://www.fluoridefreepeel.ca/wp-content/uploads/2021/12/Irlanda-HSE-PACKAGE.pdf

Following consultation with my colleagues, both from the scientific and medical areas of HPSC can confirm that we would hold no records in relation to your request. These are the reasonable steps I have taken to ascertain the whereabouts or existence of such records and unfortunately I must inform you that having undertaken these searches we were unable to locate the records in question. I am satisfied that all reasonable steps have taken to locate the records you have requested and must refuse therefore your request under Section 15.1(a) of the FOI Act 2014.

15 de septiembre de 2022:

El Laboratorio Nacional de Referencia contra el Virus de Irlanda en el University College de Dublín confesó, en 2 respuestas separadas de la FOI, que no tienen estudios firmados, documentados y verificados sobre el agente causal de los estudios de validación verificados para la adquisición de equipos de verificación de PCR: https://www.www.fluoridefreepeel.ca/wp-content/uploads/2022/11/NVRL-UCDublin-causative-agent-and-PCR-validation-PACKAGE-redacted.pdf



UCD Records Management and Freedom of Information Unit Aonad Bainistíochta Taifead & Saoráil Faisnéise UCD

An Coláiste Ollscoile, Baile Átha Cliath,

Roebuck Castle. University College Dublin, Belfield, Dublin 4, Ireland

Belfield, Baile Átha Cliath 4, Eire

Caisleán an Ruabhoic,

T +353 1 716 8786/8722

foi@ucd.ie www.ucd.ie/foi

By Email:

15 September 2022

Reference: FOI 12 1 988

Dear

I refer to your request under the Freedom of Information Act 2014 for access to records held by the University. You requested the following:

"as the named laboratory for my daughter's PCR test, please provide to us the signed, documented and verified studies for the causative agent of Covid-19."

Having considered the provisions of the Acts, I have decided to deny access to the requested records on the grounds that the records do not exist.

As no records exist, I therefore invoke Section 15(a) of the FOI Act which states:

15. (1) "A head to whom an FOI request is made may refuse to grant the request where) the record concerned does not exist or cannot be found after all reasonable steps to ascertain its whereabouts have been taken"

The NVRL is a diagnostic laboratory that performs diagnostics investigations on patient samples using validated assays. The NVRL has advised our office that the following website - https://pubmed.ncbi.nlm.nih.gov/ - is for the NIH's National Library of Medicine, where one could search for peer-reviewed articles on SARS-CoV-2 and Covid-19.

If you are dissatisfied with this reply to your FOI request, you may have it reviewed. You must make your application for internal review in writing to this office within four weeks of receiving this letter. The making of a late application for internal review may be permitted in appropriate circumstances.

Where you are dissatisfied with the outcome of the internal review, you can appeal in writing to the Information Commissioner, 18 Lower Leeson Street, Dublin 2. You have six months to make such a request, but in certain circumstances, late reviews may be permitted.

Yours sincerely,

SOM

PP. Dee Synnott - Information Compliance Officer

Debbie Scanlan Information Compliance Manager

Agosto/septiembre de 2022:

Danni y Tonny en **Dinamarca** presentaron FOIs para los registros de **cualquier**

"virus" que las autoridades recomiendan que los niños sean vacunados contra ser aislados/purificados. Danni describió las respuestas:

Un médico de **Sundhedsstyrelsen** dice que no tienen evidencia científica. Basan las recomendaciones en el hecho de que han estado vacunando a los niños durante décadas.

Y un abogado de **Statens Serum Institut** buscó en la base de datos de la revista y no se le ocurrió nada. No pudo encontrar nada que coincidiiera con mi petición. Había usado la plantilla de uno de sus FOIs en SARS COV 2.

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2023/03/Dinamarca-Statens-Serum-Institut-PACKAGE-redacted.pdf}{}$



J. nr.: 22/03077 20. september 2022

Anmodnin	ng om aktindsigt
Kære Danı	& Tonny
	-mail af 7. september 2022 præciseret i forbindelse med tidligere sendt anmodning af 16. august modningen omfatter følgende:
	(M. Sana)
	Vi anmoder om alle studier som ligger bag jeres anbefalinger af børnevaccinationsprogrammet, som overholder de listede kriterier.
	Dvs bevis for eksistensen af de vira man immuniserer børn imod her i Danmark.
	"

Statens Serum Institut har på den baggrund foretaget en række søgninger i journaliseringssystem med henblik på at identificere dokumenter omfattet af anmodningen. Statens Serum Institut har på den baggrund ikke identificeret dokumenter omfattet af aktindsigtsanmodningen. Instituttet kan derfor ikke imødekomme jeres anmodning om aktindsigt, jf. offentlighedslovens § 7, stk. 1, modsætningsvis.

1. KLAGEVEJLEDNING

Klage over denne afgørelse om aktindsigt kan ske til Sundhedsministeriet. Du skal dog indledningsvis sende din klage til Statens Serum Institut, Direktionssekretaria@ssi.dk. Hvis din klage ikke giver Statens Serum Institut anledning til at ændre afgørelsen, sender Statens Serum Institut klagen samt sagens dokumenter og herunder afgørelsen til Sundhedsministeriet snarest og som udgangspunkt senest syv arbejdsdage efter modtagelsen af klagen ved Statens Serum Institut, jf. offentlighedslovens § 37, stk. 1 og

Med venlig hilsen

Ayan

Jurist

Direktionssekretariatet

Adresse: Artillerivej 5 | 2300 København S

Statens Serum Institut, Dinamarca le dijo a Alex Holmsted que (traducción): *El Statens Serum Institut puede afirmar que ahora hemos llevado a cabo una búsqueda de la revista para la documentación que ha convencido a los establos Institut sobre la existencia real de SARS-CoV-2, la supuesta causa de COVID19 y, además, hemos*

tratado de alguna otra manera de localizar documentos relevantes. Los Estados.- El Instituto del Suero puede notar que no estamos en posesión de los documentos solicitados...

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/04/Dinamarca-The-Statens-Serum-Instituttet-Alex-Holmstedt-w-English.pdf}{}$

Alex Holmstedt alex@panteon.dk



J. no.: 20/08162 10 September 2020

Request for access to documents

Dear Alex Holmstedt

By email on 10 August 2020, you requested to documents as follows:

"In continuation of the reply of Statens Serum Institut of 8 July 2020 as to the request for access to bibliographies, to which the Administration has Informed that it "is not in possession" of:

Bibliography, ... showing articles on SARS-CoV-2 having been isolated and purified.

"Purified" is to be understood according to the principles described here: https://www.news-medical.net/life-sciences/Virus-Purification-Methods.aspx "

In accordance with the Public Access to Information Act, full access to documents is sought as to the following:

Documentation that has convinced Statens Serum Institut about the real existence of SARS-CoV-2, the alleged cause of COVID-19 - since it must be assumed that indisputably evidence for the real existence of SARS-CoV-2 must lie behind the actions that have been imposed on the Danish society."

On 11 August 2020, Statens Serum Institut* acknowledged receipt of your request, stating that due to the special circumstances applied to Statens Serum Institut, we were unable to inform you as to when a final answer to your request would be made.

On 25 August 2020, Statens Serum Institut stated that we expected to be able to respond to your inquiry within 14 work days.

We regret to inform you that due to the special circumstances that apply to Statens Serum Institut, we were unable to answer your request until now.

Statens Serum Institut has now reviewed the case.

1. DECISION

Statens Serum Institut hereby states that we have now carried out a journal search for documentation that has convinced Statens Serum Institut about the real existence of SARS-CoV-2, the alleged cause of COVID 19, and in addition, we have tried in other ways to locate relevant documents. Statens Serum Institut ascertain that we are not in the possession of the requested documents.

* The Danish Central Health Laboratory

Vídeo relacionado: **Los funcionarios de salud de Dinamarca** se indignaron y se defensivaron durante una conferencia de prensa cuando le preguntó por la periodista Kristofer Krarup sobre las respuestas del FOI de sus propias instituciones que indican

que tienen cero pruebas de "el virus": https://www.bitchute.com/video/AiwB5h4VCnTH/



Abril 2020: En respuesta a una consulta del Dr. Kevin Corbett, de Salud Pública de **Inglaterra**, admitió haber usado material falso para evaluar las pruebas de la norma de oro, que el patrón oro no es un virus aislado, y más:

https://www.fluoridefreepeel.ca/public-health-englands-answers-to-covid-19testing-questions/

Subject: OFFICIAL: RE: Data request

From: WNCoV.virology < WNCoV.virology@phe.gov.uk>

Date: 28-Apr-20, 17:45

CC: Maria Zambon <Maria.Zambon@phe.gov.uk>, WNCoV.virology <WNCoV.virology@phe.gov.uk>

OFFICIAL

Professor Zambon asked that we respond to your request for data, as below.

i) RT-PCR tests -

- the gold standard for PCR tests is not virus isolation
- · PCR tests are developed using synthetic transcripts; field use data are not widely available yet

No hay registros de aislamiento de la muestra no adulterada, dijo a Andrew Johnson, un tutor de tecnología de una Universidad de Reino Unido:

https://www.whatdotheynow.com/request/679566/response/1625332/attach/html/2/ 8762FOI%20All%20records%20de%20de%20de%20of%20S%20of%20S%20C 0%202.pdf.html. Este es el escrito de Andrews sobre su solicitud de FOI: https://cvpandemicinvestigation.com/2020/08/phe-has-no-real-evidence-that-sars2-

cov2-causes-covid-19-chromosome-8-blood-plasma-treatment-and-more/.

Meses atrás, el Comité de Ciencia de StandUpX publicó una carta abierta fechada el 22 de junio de 2020 al primer ministro británico, Boris Johnson. A continuación se presenta una captura de pantalla de su carta, exigiendo pruebas científicas del supuesto virus COVID-19. (Su carta completa se puede ver y/o descargar aquí: https://kevinpcorbett.com/onewebmedia/Firmado%20StandUpX%20definitive.pdf Therefore, we demand that by July 22nd 2020, Public Health England must:

- Produce independently peer reviewed scientific evidence proving that the Covid-19 virus has been isolated and purified in the reference laboratories run by Public Health England under the leadership of Professor Zambon (Imperial College London/SAGE member) ignoring the instructions not to do so issued by the World Health Organisation.
- Produce independently peer reviewed scientific evidence proving that Covid-19 virus causes disease using all of the Koch Postulates.

If the United Kingdom Government's own health agency - Public Health England – CANNOT show independent and peer-reviewed proof that a virus exists which causes COVID-19 then the Government must DECLARE THERE IS NO SUCH VIRUS AND CEASE MEASURES AGAINST SOMETHING WHICH DOES NOT EXIST, including producing a vaccine and the Government's Track+Trace policy.

El miembro del Comité de StandUpX también hizo la demanda verbalmente fuera de la sede del gobierno del Reino Unido; imágenes de vídeo de la demanda están disponibles en este url (el video incrustado de abajo - que es un video diferente con Peirs Corbyn; WordPress no el pie de la demanda de alguna razón, así que por favor haga clic en este url para ver la demanda, no en la imagen de abajo):

A continuación se muestra el video de Piers Corbyn llamando al gobierno del Reino Unido por el no aislamiento de su virus teórico "SARS-COV-2". https://www.bitchute.com/embed/1eDDh3eqFPAJ/?feature=oembed?secret=SiAIVe09 M ERRATUM: En la descripción debajo del video (en la página del bitchute) los autores de la publicación en la prueba de Drosten PCR se refieren a tiene "Drosten et al" cuando deberíaLea "Croman et al".

StandUpX tiene una petición titulada "Si no hay pruebas de que exista el virus terminan con todas las acciones de Lockdowns/Masks/Trax/Vax". Si puedes decir la diferencia entre el aislamiento y el negocio fraudulento de monos, por favor considera firmarlo, aquí: https://www.gopetition.com/petitions/if-theres-no-proof-the-virus-exists-end-all-lockdownsmaskstraxvax-actions-2.html

En abril, el miembro del comité de StandUpX Dr. Kevin Corbett MSc PhD publicó <a href="Mexicology-color: Mexicology-color: Mexicology-colo

https://kevinpcorbett.com/onewebmedia/WHERE%20IS%20THE%20TELDENC E%20FOR%20THE%20E%20OF%20THE%20THE%20CORONAVIRUS%20F INAL2.pdf Ogenstad et al (2020) are clearly admitting that no purified infectious 'novel Coronavirus' ('SARS-Cov-2') has ever been adequately demonstrated as coming from patients (e.g. see Huang et al 2020). The implication is that the 'novel Coronavirus' RNA/antibodies whose veracity are assumed by PHE/FDA may not actually prove to be 'viral' but could represent other phenomena. For example some scientists like Andrew Kaufman (Kaufman, 2020) suggest these may be 'exosomes', whilst others point to numerous confounding process artefacts (Schierwater et al 2009), or due to the laboratory 'quality processes' which appear remarkably open to errors and misinterpretation (Bustin and Nolan 2017). Until the proper research is suitably undertaken (and reproduced) regulators cannot scientifically claim that the tests are accurate.

Adígase que la OMS aconsejó a Salud Pública de Inglaterra (y al resto del mundo) no aislar el virus como un procedimiento de diagnóstico rutinario, y la OMS fomenta la confluencia de aislamiento con la cultivación. Vea las imágenes de la siguiente manera de la página 4 del documento de Orientación Provisional de fecha 2 de marzo de 2020 . Pruebas de laboratorio para la enfermedad coronavirus 2019 (COVID-19) en casos sospechosos de ser humano. Corbett de StandUpX: https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/WHO-COVID-19-laboratory-2020.4-eng.pdf y página 8 de las pruebas diagnósticas para la guía provisional SARS-CoV-2 11 de septiembre

Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases

Laboratories with limited experience in testing for COVID-19 virus are encouraged to work with laboratories with more experience with this pathogen to have their initial test results confirmed and to improve their own performance.

Viral culture

Virus isolation is not recommended as a routine diagnostic procedure.

Viral isolation

Virus isolation is not recommended as a routine diagnostic procedure. All procedures involving viral isolation in cell culture require trained staff and BSL-3 facilities. A thorough risk assessment should be carried out when culturing specimens from potential SARS-CoV-2 patients for other respiratory viruses because SARS-CoV-2 has been shown to grow on a variety of cell lines [183].

Actualización, 1 de octubre de 2020: Mi colega en Nueva Zelanda recibió recientemente una respuesta de No Records de Public Health England - idéntica a la respuesta de "no records" anterior que ya fue proporcionada a Andrew Johnson. Puede acceder a esta segunda respuesta de PHE aquí: https://www.fluoridefreepeel.ca/wp-content/uploads/2020/10/Public-Health-England-scrubbeded.pdf

Actualización 1 de noviembre de 2020: Marc Horn también cuestó a Public Health England para que los registros descenteran el aislamiento de la categoría de una muestra que no está sin adulterar con material genético adicional. Respuesta: no records. https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/PHE-FOI-re-re-SARS-COV-2-isolation.pdf

Otra respuesta de la FOI de Public Health England de fecha 3 de noviembre de 2020, en respuesta a una solicitud de Athanasios Kandias para registros (reprosor aislamiento

SARS-COV-2) en poder de la **Junta Nacional** de **Normas Biológicas**.https://www.whatdotheyknow.com/request/701311/response/1669071/attach/2/1740%20FOI%20NIBSC%20cords%20on%20on%20SARS%20COV%202.pdf?cookie.passthrough=1">https://www.whatdotheyknow.com/request/701311/response/1669071/attach/2/1740%20FOI%20NIBSC%20cords%20on%20on%20SARS%20COV%202.pdf?cookie.passthrough=1">https://www.whatdotheyknow.com/request/701311/response/1669071/attach/2/1740%20FOI%20NIBSC%20cords%20on%20on%20SARS%20COV%202.pdf?cookie.passthrough=1">https://www.whatdotheyknow.com/request/701311/response/1669071/attach/2/1740%20FOI%20NIBSC%20cords%20on%20on%20SARS%20COV%202.pdf?cookie.passthrough=1">https://www.whatdotheyknow.com/request/701311/response/1669071/attach/2/1740%20FOI%20NIBSC%20cords%20on%20on%20SARS%20COV%202.pdf?cookie.passthrough=1">https://www.whatdotheyknow.com/request/701311/response/1669071/attach/2/1740%20FOI%20NIBSC%20cords%20on%20on%20on%20SARS%20COV%202.pdf?cookie.passthrough=1">https://www.whatdotheyknow.com/request/701311/response/1669071/attach/2/1740%20FOI%20NIBSC%20cords%20on%20on%20SARS%20COV%202.pdf?cookie.passthrough=1">https://www.whatdotheyknow.com/request/701311/response/1669071/attach/2/1740%20FOI%20NIBSC%20COV%202.pdf

No hay registros que respalden la afirmación de que el presunto virus de la "SARS-COV-2" causa síntomas de COVID-19", dice **Public Health England**, en respuesta a una consulta de Marc Horn. Tenga en cuenta que PHE citó 3 estudios disponibles al público, ninguno que implique el aislamiento de una muestra no no adulterada con material genético adicional. https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/PHE-FOI-re-re-SARS-COV-2-isolation-and-causation-de-COVID-19.pdf

7 de septiembre de 2021:

Salud Pública de Inglaterra no volvió a citar ningún registro de la purificación de la SARS-COV-2:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/PHE-Sept-7-2021-PACKAGE.pdf

Done 1028 - FOI Isolation of SARS-CoV...





Protecting and improving the nation's health

Public Accountability Uni Wellington House 133-155 Waterloo Road London SE1 BUG

www.gov.uk/phe

By email

lewie.mm@outlook.com

Our ref: 11/08/21/ag/1028

07 September 2021

Dear Lewis Murphy-Munroe,

Re: FOI request

Thank you for your request received on 11 August 2021 addressed to Public Health England (PHE). In accordance with Section 1(1)(a) of the Freedom of Information Act 2000 (the Act), I can confirm that PHE does not hold the information you have specified.

Request

I am filing a challenge to my public health act by writing to request information of the isolation of a SARS-CoV-2 virus directly from a sample taken from a diseased patient, where the patient sample was not first combined with any other source of genetic material (ie. money kidney cells aka vero cells; liver cancer cells).

I am using "isolation" in the everyday sense of the word: the act of separating a thing(s) from everything else. I am not requesting records where "isolation of SARS-CoV-2" refers instead to:

- -the culturing of something, or
- -the performance of an amplification test (i.e a PCR test), or -the sequencing of something.

To conclude, I am requesting all such records that are in the possession, custody or control of Public Health England (for example: downloaded to a computer, printed in hard copy, etc.).

Response

In accordance with Section 1(1)(a) of the FOI Act, PHE can confirm that it does not hold the information you have requested.

Viruses are not independent living entities. They require a host cell substrate to replicate.

1

PHE's microbiology teams use the term "isolation" to mean culture in the laboratory. It is used sometimes interchangeably to mean isolation from a patient or clinical material – but usually implies that the organism has been grown in culture. An organism is identified by looking for its unique genetic material in a clinical sample and further identification is refined and confirmed by whole genome sequencing.

The Virus Reference Laboratory at PHE, Colindale, London has grown the virus, SARS-CoV-2. The virus culture method has been published in the following peer-reviewed paper: https://www.eurosurveillance.org/content/10.2807/1560-



20 de septiembre: **Salud Pública de Inglaterra** confirmó para Yvonne Hobbs que no contiene ninguna información de purificación de ningún virus de COVID-19 o de los "variantes".

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/10/PH-England-PACKAGE-redacted.pdf}$



Protecting and improving the nation's health

Public Accountability Unit Wellington House 133-155 Waterloo Road London SE1 8UG

www.gov.uk/phe

By email

Our ref: 18/09/21/ag/1345

20 September 2021

Dear Yvonne Hobbs.

Re: Covid-19

Thank you for your request received on 18 September 2021 addressed to Public Health England (PHE). In accordance with Section 1(1)(a) of the Freedom of Information Act 2000 (the Act), I can confirm that PHE does not hold the information you have specified.

Request

All studies and/or reports and/or records in the possession, custody or control of the addressed body corporate describing the purification (i.e. via filtration and ultra-centrifugation and chromatography) of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") directly from a sample taken from a diseased man, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum, liver cancer cells) and also studies and/or reports and/or records in the possession, custody or control of the addressed body corporate proving a causal link between Sars-Cov-2 and the suspected infectious disease Covid-19.

Please note that I am not requesting studies/reports where researchers failed to purify the suspected "virus" (separate the alleged "virus" from everything thing else in the patient sample) and instead:

- · cultured an unpurified sample or other unpurified substance, and/or
- performed an amplification test (i.e. a PCR test) on the total RNA from a patient sample or from a cell culture, or on genetic material from any unpurified substance, and/or
- fabricated a genome based on PCR-detected sequences in the total RNA from a patient sample or from a cell culture or from any unpurified substance, and/or

produced electron microscopy images of unpurified things in a cell culture

In accordance with Section 1(1)(a) of the FOI Act, PHE can confirm that it does not holds the information you have requested.

Viruses are not independent living entities. They require a host cell substrate to replicate.

1

28 de septiembre de 2021:

Salud Pública de Inglaterra confirmó que todavía no tienen registro de la purificación de la SARS-COV-2 (incluyendo los "variantes), por cualquier persona, en cualquier

lugar:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/09/Public-Health-England-SARS-COV-2-v3-Redacted-2021-09-28.pdf$

5 de enero de 2023:

NHS Grampian confesó a Kevin McKenzie que no tienen registro de que el imaginario **SARS-COV-2** sea encontrado y purificado desde cualquier lugar, en cualquier lugar, nunca:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2023/03/NHS-Grampian-PACKAGE-redacted.pdf$

El canal de bitchute de Kevin está aquí:

https://www.bitchute.com/channel/mckenzie123456789/

purification of other very small things).

Please note that my request includes any study/report matching the above description authored by anyone, anywhere.

If any records match the above description of requested records and are currently available in the public domain, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible."

I can now respond as follows:

Description of Requested Records:

All studies and /or reports from anywhere in the world describing the purification of the alleged "COVID-19 virus" (aka "SARS-COV-2" including any alleged "variants") directly from a sample taken from a diseased human, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum).

Clarification of Request

Please note I am not requesting studies/reports where researchers failed to purify the suspected "virus" and instead:

- * cultured something, and/or
- * performed an amplification test (i.e. PCR), and/or
- * fabricated a "genome" from millions of sequences (alledgedly) detected in an impure substance, and/or
 - * produced electron microscopy images of unpurified things.

I am already aware that according to virus theory a "virus" requires host cells in order to replicate, and am not requesting records that describe replication of a "virus" without host cells. Nor am I requesting records that describe a strict fulfillment of Koch's Postulates, or records that describe a suspected "virus" floating in a vacuum, or private patient information.

I simply require records that describe purification (separation of the alleged virus from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things).

Please note that my request includes any study/report matching the above description authored by anyone, anywhere.

If any records match the above description of requested records and are currently available in the public domain, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible. In relation to all of the above NHS Grampian can advise it does not hold any studies or reports into what is requested; s.17 of the Act refers – Information not held.

27 de julio de 2021: En Inglaterra, el **Pennine Acute National Service Trust** y el **Salford Royal National Health Service Foundation Trust** revelaron en las respuestas del FOI:

Que tienen en total cero registros re .SARSCov2 (y sí, sabemos que una aplicación estricta de Kochs no sería posible, incluso si existiera realmente el imaginariovirus; tenga en cuenta que estas instituciones proporcionaron un montón de datos no solicitados, pero no hay registros en absoluto de aislamiento/purificación de virus);

- Se han realizado pruebas de PCR con hasta 42 ciclos;
- 10 niños murieron en los 28 días siguientes a dar positivo en una prueba de convije;

Debido a la muerte no se registra en nuestros sistemas clínicos. Respuesta completa: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/07/NCA-FOI-11135-package.pdf

Response - Salford Royal Foundation Trust

 I would like to know the number of cycles you have been using on PCR (Polymerase Chain Reaction) test as standard and if that number has ever been changed at anytime for whatever reason.

The Trust uses the following Commercial CE IVD assays - Hologic Panther, Cepheid, BD Max, Abbott Alinity, Abbott M2000 and AusDiagnostics Hi-Plex. The number of thermal cycles across all the platforms in use varies slightly and the maximum is 42; the parameters for all these assays are available from the commercial suppliers. The Trust does not alter them for any reason.

I would also like to know how many children under the age of 16 have been logged as a death from SARSCov2 without any underlying health issues.

There were no children under the age of 16 who died within 28 days of a positive COVID-19 test result.

And can you tell me if you have any records of SARSCov2 going through Koch's Postulates.

The Trust has not recorded any cases going through Koch's Postulates.

No hay registros que respalden la afirmación de que el presunto virus "SARS-COV-2" causa síntomas de la **Cámara de los Comunes** del **Reino Unido**, en respuesta a una pregunta de Marc Horn:

No hay registros que respalden la afirmación de que el presunto virus de la SARS-COV-2 causa los síntomas de la **Cámara de los Lores** del **Reino Unido**, en respuesta a una pregunta de Marc Horn:

El Ejecutivo británico de Salud y Seguridad confirmó para Athanasios Kandias el 3 de noviembre de 2020 que no tienen información relacionada con el aislamiento de la SARS-COV-2.

https://www.whatwhattheyknow.com/request/documents.held-held-showing.sars.cov2-3 (Como aquí: https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/Health-and-Safety-Executive.pdf).

He aquí un exasperante intercambio de correos electrónicos entre yo y **el Imperial College de Londres**, hogar del deshonrado director de la categoría de Salud Pública Neil Ferguson y el Director Adjunto de Servicio Nacional de Infección de Inglaterra y Director de Servicios de Microbiología de Referencia, virólogo británico, la **profesora Maria Zambon** FMedSci FRCPath. Es evidente que la Universidad no tiene registros que describan el aislamiento/depurificación de la SARS-COV-2, pero no está dispuesto a admitirlo:

https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/Imperial-College-London-FOI-exchange-SARS-COV-2-isolation-updated.pdf

We explained in our response to you that we do not keep records of what material has been printed or downloaded by our staff and students. In order for us to deal with your request in its present form we would need to ask all staff and students at the College whether they had downloaded or printed information on the isolation of the virus and ask them to provide details. As the college has about 20,000 students and 8,000 members of staff that approach is not practical. The exemption at Section 12 of the Freedom of Information Act, which provides that organisations need not respond to Freedom of Information Act requests if it would take more than 18 hours to extract and compile the information requested, would apply.

Kepa Ormazabal presentó una solicitud de libertad de información al **Ministerio de Salud de España** para registros bibliográficos de estudios que describen el aislamiento/purificación de la Real *Academia* Española; la respuesta del Ministerio no arrojó registros:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/03/Spain-Ministry-of-Health-de-Health-request-request-w-translation.pdf

8 de septiembre de 2021: **El Ministerio de Salud de España** dio una respuesta uberevasiva a una organización llamada Liberum, reisado aislamiento/purificación, caracterización, cultivo, etc. del presunto virus COVID-19. Estas son las preguntas reales planteadas por Liberum (proporporegado por un miembro), con una traducción al inglés (automizada) y las respuestas también con una traducción al inglés (automizada). El Ministerio de la evasión total de la repuración, y su admisión de que ni siquiera se molestan con las culturas falsas de células monstruosas, habla mucho: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/10/España-Ministry-of-Health-Liberum-request-PACKAGE.pdf

On genomic sequencing of the virus you can consult the following link:

https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Integracion de la secuenciacion genomica-en la vigilancia del SARS-CoV-2.pdf

The Ministry of Health does not have a SARS-CoV-2 culture for testing, and it does not have a registry of laboratories with culture and isolation capacity for testing.

In relation to the SARS-COV-2 diagnostic tests, and in general, with issues related to the SARS-Cov-2 pandemic, the Ministry of Health works with the aforementioned documents, which are updated according to epidemiological need, to enable decision-making in relation to the management of the pandemic, and the dissemination of information to third parties that can use it in their specific environments. In this sense, the most conceptual and definitional issues remain more in academic and teaching environments, with the Ministry of Health playing a more secondary role and not acting on these issues in its power.

Finally, the evaluation of patients in relation to their state of health, be it COVID-19 or another disease or pathology, is the responsibility of the reference health professionals. The tests, by themselves, are not usually sufficient to determine disease, requiring an expert evaluation of the person who has been tested. Either way, the case definition can be found at the following link:

15 de septiembre de 2021: aquí está un informe de España discutiendo una demanda de acción colectiva aparente exigiendo pruebas del virus, en forma de una muestra para ser sometido a verificación independiente:

https://digitalwarriors.uk/great-news-out-of-

$\frac{spain/?fbclid=IwAR376xHErLyVCZRCruY-60spufsBPnb0a-}{4GknQluYE4cqZwVhdelZo}$

7 de marzo de 2023:
Los CDC europeos confesaron que no tenía registro de la supuesta proteína de pico
SARS-COV-2 - encontrada y purificada de cualquier persona que fuera diagnosticada
con cómplis falsas o que recibiera una llamada vacuna contra ARNA.
La solicitud descartó estudios en los que los investigadores hicieron algo con proteína
de ápoda de á
Gracias Barbara.
https://www.fluoridefreepeel.ca/wp-content/uploads/2023/03/Eurpoean-CDC-spike-
protein-PACKAGE-redacted-03-2023.pdf





Francesco Cantele



Stoccolma, 7 Marzo 2023

N.ref.: PHF-2023-OUT-0479-VLEIKh

Egregio Signore,

Oggetto: La sua domanda di accesso a documenti - Ref 23-0957

Le scrivo in riferimento alla sua email del 26 Febbraio 2023, contenente una domanda di accesso, registrata con il numero indicato in oggetto.

La sua richiesta concerneva:

"un qualsiasi studio o documento prodotto direttamente o possesso di ECDC che descriva il ritrovamento della proteina Spike riconducibile al virus SARS-CoV-2 in una persona (ad esempio nei fluidi corporei, tessuti o escrementi) a cuì sia stata diagnosticata la presunta COVID-19 o che abbia ricevuto una o più dasi di uno o più dei cosiddetti vaccini COVID disponibili.

Tale ritrovamento deve essere avvenuto mediante purificazione delle particelle e confermato con immagini al microscopio elettronico EM.

Vi chiedo di non inviarmi studi in cui i ricercatori siano ricorsi all'uso di proteina Spike ricombinante (creata in laboratorio) o in cui tale proteina sia stata rilevata indirettamente (cioé senza uno specifico test anticorpale)*.

Siamo spiacenti di informarLa che il Centro europeo per la prevenzione ed il controllo delle malattie (ECDC) non possiede nessun documento corrispondente alla descrizione tale e come contenuta nella Sua domanda.

Il regolamento (CE) n. 1049/2001 specifica al suo articolo 2, paragrafo 3, che il diritto d'accesso come definito dallo stesso regolamento si applica solo a documenti esistenti e in possesso dell'istituzione.

Non possedendo documenti di questo tipo corrispondenti alla descrizione tale e come contenuta nella Sua domanda, l' ECDC non è nelle condizioni di darvi seguito.

1/2

European Centre for Disease Prevention and Control (ECDC) Gustav den Ill:s Boulevard 40, 169 73 Soina, Sweden Phone: +46 (0)8 58 60 10 00 - Fax; +46 (0)8 58 60 10 01

www.ecdr.europa.eu

El director del Centro Europeo para la Prevención y el Control de Enfermedades, Andrea Ammon, ha admitido no tener documentación, incluso para la metodología ECDC para demostrar que existe un virus, y mucho menos prueba de SARS-COV-2: https://www.fluoridefreepeel.ca/wp-content/uploads/2020/11/DOCUMENT-REREQUEST-ECDC-AND-RESPONSE.pdf





Stockholm, 16 September 2020 Our ref.: DPR-2020-OUT-3176-KEEIKh

Dear Mr ,

Re: Your application for access to documents - Ref 20-3696

We refer to your email dated 31 August 2020 in which you make a request for access to documents, registered on 1 September 2020 under the above mentioned reference number, and your follow up email on 2 September 2020 that has been handled under the same reference number as well.

We regret to inform you that no documents were found that would correspond to the description given in your application.

Indeed, as specified in Article 2(3) of Regulation 1049/2001, the right of access as defined in that Regulation applies only to existing documents in the possession of the institution.

Según el sitio web de **la Universidad de Liubliana**, su **Facultad de Medicina** ha participado <u>en</u> *la implementación de los últimos procedimientos de diagnóstico molecular; un intento de aislar el virus en cultivos celulares* [oximoron], *que es una condición previa para probar agentes antivirales y vacunas...* La Facultad admitió formalmente el 30 de noviembre de 2020 a no tener registro (incluso obtenido de otros) de aislamiento SARS-COV-2 o probar un vínculo causal con el COVID-19; también que se han utilizado 40 ciclos de PCR en toda Eslovenia desde el comienzo de las pruebas. La respuesta original de la Facultad y una traducción al inglés están disponibles aquí:

https://www.fluoridefreepeel.ca/wp-content/uploads/2021/01/FOI-reply-Slovenia-University-of-Ljubljana-re-islation.pdf

Prosilka v 3. točki zahteva posredovanje znanstvenih dokazov o izolaciji virusa Sars-Cov-2 v skladu s Kochovimi postulati ter posredovanje študije, ki bi dokazala vzročno zvezo med Sars-Cov-2 in domnevno nalezljivo boleznijo Covid-19. UL MF Inštitut za mikrobiologijo in imunologijo znanstvene študije, ki bi izpeljala dokaz o izolaciji virusa Sars-Cov-2 v skladu s Kochovimi postulati, ni izvajal. UL MF Inštitut za mikrobiologijo in imunologijo prav tako ni izvedel znanstvene študije, ki bi dokazovala vzročno zvezo med Sars-Cov-2 in domnevno nalezljivo boleznijo Covid-19. Organ tako z zahtevanim dokumentom ne razpolaga, zaradi česar je bilo potrebno glede 3. točke zahteve odločiti, kot izhaja iz izreka tega sklepa.

Más recientemente, **el Ministerio de Salud de Eslovenia** declaró que no tenían registros de purificación, pruebas de PCR, etc. y transfirieron una solicitud de FOI al **Instituto de Microbiología e Inmunología (IMI) en la Univerisy de Liubliana**. El IMI finalmente admitió en febrero de 2021 que no tienen registros de purificación de virus y que las pruebas de PCR se han realizado con hasta 40 ciclos. Las letras más molestas están aquí: https://www.fluoridefreepeel.ca/wp-

<u>content/uploads/2021/05/Slovenian-Dept-Health-transfers-to-IMI-at-U-de-</u> <u>Ljubljana-no-isolation-40-PCR-CT.pdf</u>

Y más recientemente, el Laboratorio Nacional de Salud, Medio Ambiente y Alimentación de Eslovenia (Ocatoriano de Necionalnega za zdravje, okolje in hrano, NLZOH -) no proporcionó o no cita ningún registro de la purificación prueba de existencia de la empresa de protección salud a pesar de una intervención del Comisionado Información. NLZOH también citó un secreto de negocios en las consultas de respuestas re PCR testing. https://www.fluoridefreepeel.ca/wpcontent/uploads/2021/06/Slovenia-Lab-package-w-translations.pdf

9 de julio de 2021: **Centro** médico principal **de Eslovenia** - **Univerzitetni centro Ljubljana**, **UKCLJ** (**Centro Médico de la Universidad Ljubliana**) Propropor:/clics cero registros de aislamiento/purificación de SARS-COV-2, pero sin embargo afirma que se cumplen los postulados de Koch.s, y cita los documentos típicos de los negocios de Mono: https://www.fluoridefreepeel.ca/wp-content/uploads/2021/07/Slovenia-UKCLJ-request-response-redacted.pdf

K vprašanju pod zaporedno številko 3 se posreduje povezavo:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184405/pdf/ciaa325.pdf
In pojasnilo; podajamo referenco, iz katere je razvidno, da SARS-CoV-2 izpolnjuje Kochove postulate. Vlagatelju ob tem pojasnjujemo, da je Koch s svojim sodelavcem Henlejem postulate objavil, precej preden so bili odkriti virusi. Kasneje so, predvsem v luči spoznanj virologije, Kochovi postulati bili prilagojeni novim odkritjem. Ne vemo sicer, kaj vlagatelj pojmuje pod pojmom "papir", domnevamo, da gre za neposrečen prevod angleškega izraza "paper", ki v tem primeru pomeni članek.

22 de diciembre de 2021:

Argentina. Administración Nacional de Laboratorios e Institutos de Salud .Dr. Carlos Malbrán es descrito como *un organismo público descentralizado dependiente del Ministerio de Salud*, y es un <u>Centro Colaborador de Vigilancia de la Resistencia Antimicrobiana</u> con adivinanzas.

Monica Tous (-Virology Department Head-) respondió a Edgar Horacio Russo-s request para registros que describen la purificación de la .SARS-COV-2 con una carta sobre PCR .tests, "secuenciación" de sopas de ARN, aislamiento oximorónico de virus, intentos de cultivos de células monos, y esta gema: La *LNR no maneja el uso del microscopio de electrones*.

En caso de apelación, no *hay registros de lo que se solicitó en las condiciones especificadas, ya que no se realiza la purificación viral* (véase la página 16, 21): https://www.fluoridefreepeel.ca/wp-content/uploads/2022/01/Argentina-Natl-Admin-of-Labs-and-Health-Institutes-PACKAGE-not-redacted.pdf

2.pdf), a partir de confirmar el resultado derecuble, dependiendo del vulor de CT, se llevia a cubo la extracción de deidos muclicos y el RNA extraído es emisido a la Planaforma de Gentónica donde se realiza el intento de senesvicación de gentoma completo en utilizado presencios es enablecidos y exanderizados. Los reanidados obrendos no matinizado presentos y exadie disponibles en la pigina del Ministerio de Salda (https://henw.arpentina.gola.nicvosonavirua/informs-aluminivigilancia-gentonicos, la Inciencia de ministerio de Salda (https://henw.arpentina.gola.nicvosonavirua/informs-aluminivigilancia-gentonicos, la Inciencia de ministerio de Salda (https://henw.arpentina.gola.nicvosonavirua/informs-aluminivigilancia-gentonicos, la Inciencia de ministerio del Salda (https://henw.arpentina.gola.nicvosonavirua/informs-aluminivigilancia-gentonicos, el Indonatorio Blevia a cube el inserno de alataminio vortal on cultimos aperal per moderio del controlo del con

AUTO-TRANSLATION (Reviewed)

result". By virtue of this, on December 7, 2021, he presented before this AAIP a claim under the terms of article 15 of Law No. 27.275, which gave rise to these proceedings.

In compilance with Resolution AAIP 4-E/2018, through NO-2021-119677532-APN-DPIPMAAIP, the obliged subject was required to submit the background of the case and all other documentation and / or information that is considered relevant to the resolution of the claim.

In response to said request, through NO-2021-122264216-APN-INEIABANLIS the obliged subject expanded its answer in which it clarified "[...] there are NO records of what was requested under the specified conditions since viral purification is not performed. The methodologies used are those cited in note NO-2021-117551442-APNINEIABANLS of December 3 of the current year".

In view of the foregoing, it is appropriate to comply with the provisions of Criterion No. 3 approved by AAIP Resolution No. 48 of July 27, 2018, according to which all claims will be filled when "1. b-The claim had been initiated due to incomplete or unsatisfactory response and the agency expands the information previously provided, or it duly substantiates the denial".

If the applicant does not agree with the information received, he may initiate a new claim because of being different the reasons that originated the present.

In the absence of the head of the AAIP and in order to ensure the normal functioning of the agency, in accordance with the provisions of AAIP Resolution No. 30 of May 14, 2018, the

National Director of Personal Data Protection, Dr. Eduardo Hernán CIMATO, has been e

18 de junio de 2021: **El Ministerio de Salud de Argentina** sugirió fuertemente en una respuesta de la FOI a Ana María Daverede (resulta las pruebas sin sentido de la PCR COVID-19) que ellos también no tienen registro de que el virus haya sido purificado. En el punto 4 se mencionan *por no tener aislados virales disponibles* (También en el punto 9: *Los* no *sirven para discriminar el transporte, la infección, la enfermedad, la contagio, la transmisibilidad* ...

 $\underline{https://www.fluoridefreepeel.ca/wp-content/uploads/2021/07/Argentina-no-aislamiento-\underline{del-sarscov.pdf}}$

VIDEO: Admite que no existe el coronavirus: Develan la gran farsa https://canal7salta.com/2021/06/24/argentina-video-admiten-que-no-existe-el-coronavirus-develan-la-gran-farsa/

Salón de la Verga Conmoción

El 15 de febrero de 2021, Kepa Ormazabal presentó una solicitud de FOI reislamiento/depuración del FOI de la Oficina del **País Vasco (España)** a la **Presidencia y el Departamento de Salud** y a todas las instituciones dependientes. Meses después Kepa escribió: *De acuerdo con la ley, tienen 30 días para responder; 60 si la pregunta es especialmente compleja. Hoy es el 2 de mayo y no he sabido nada de ellos.*



of 1 5/4/2021, 8:00 PM

El 30 de marzo de 2021 Kepa Ormazabal presentó otra solicitud de FOI reislándose/purificación del fantasma "virus" al **buque insignia de la investigación española, Consejo Superior de Investigaciones Científicas /Consejo Superior de Investigación Científica** (la siguiente indica la recepción de la solicitud por parte de la institución). Meses más tarde Kepa escribe: "De nuevo, no han respondido y, por lo

tanto, su silencio es negarse a acceder a la información que pueden tener con respecto a mi pregunta.

El CSIC y el Gobierno vasco son instituciones públicas y, por tanto, deben cumplir con la Ley de Transparencia, buen gobierno y acceso a la información pública/Ley de transparencia, buen gobierno y acceso a la información pública. El artículo 20.4 de esta ley establece que, si después de 30 días no ha habido respuesta de la administración pública, este silencio debe entenderse en el sentido de que la solicitud de acceso a la información pública solicitada ha sido denegada.

REGISTRO ELECTRONICO

Estimado/a Sr./Sra. KEPA MIRENA ORMAZABAL

Su solicitud de registro con número de registro REGAGE21e00003676931 en fecha 31/03/2021 12:37:05, va a ser tramitada por la oficina de registro Registro General del Consejo Superior de Investigaciones Científicas.

Puede consultar el estado de su solicitud en Carpeta Ciudadana en https://sede.administracion.gob.es/carpeta/recAre/consulta.htm[1]

La Carpeta Ciudadana es un portal web que le permite, de una forma sencilla y sin tener que registrarse, conocer los asuntos que sean de su interés en relación con las Administraciones Públicas, por ejemplo el estado de sus expedientes, las notificaciones y comunicaciones que reciba o las solicitudes presentadas a través del Registro electrónico. Puede acceder a Carpeta ciudadana en la dirección https://sede.administracion.gob.es/carpeta.

Links:

[1]https://sede.administracion.gob.es/carpeta/recAre/consulta.htma

Te gustaría ayudar? Plantilla FOI

Si desea enviar su propia solicitud de FOI a otra institución, u obtener una respuesta actualizada de una institución que ya ha sido FOI-d, aquí hay una plantilla sugerida y algunos consejos:

https://www.fluoridefreepeel.ca/template-for-foi-requests/. VERSI-N EN ESPA-OL, HAGA CLIC AQU.

Por favor, comparta conmigo las respuestas que recibas.)

Terrain: la película El fin de la teoría de Germ? de Andrew Kaufman. y Marcelina Cravat



Así que, qué diablos va?

En este punto podrías estar rascándote la cabeza y preguntarte qué diablos está pasando. Si es así, la recopilación de recursos en la página siguiente se revelará el fraude detrás de la pandemia falsa conocida como "COVID-19", según han explicado varios expertos. Aquí se centra en la cuestión del aislamiento/purificación, las pruebas falsas de PCR y PCR sin sentido que están en el corazón de todo.

El Desafío de Virus:

 $\frac{https://www.fluoridefreepeel.ca/wp-content/uploads/2022/07/SETTLING-THE-VIRUS-DEBATE-Source-document.pdf}{}$

Creciente colección de respuestas de la FOI re **otros virus imaginarios** (VIH, gripe aviar, VPH, Influenza, Measles, etc., etc.):

https://www.fluoridefreepeel.ca/fois-reveal-que-health-science-institutions-have-no-record-of-any-virus-hab-ais-isolated-purified-virology-isnt-a-science/

FOIs resecivas y anticientíficamente células infectadas (también con controles inválidos) y fabricadas engeniosos:

 $\frac{https://www.fluoridefreepeel.ca/do-virologists-perform-valid-control-experiments-is-virology-a-science/\\$

Las instituciones de salud y ciencias tienen estudios que prueban que la enfermedad de la bacteria CAUSE?

https://www.fluoridefreepeel.ca/do-health-authorities-have-studies-proving-that-bacteria-cause-causease-lets-find-out-vía-freedom-of-information/

Y finalmente, algunas entrevistas y discursos de mi propia...

13 de junio de 2023:

Mi última entrevista con **Jimuphy Masters de PLannedilLusion** https://www.plannedillusion.com/news-weekly/episode101



10 de junio de 2023:

He aquí una presentación que hice por mí mismo, mostrando mis páginas web que contienen las respuestas de los FOI:

Evidencia oficial de que Virología es Pseudociencia . Christine Massey 10 de junio de 2023, Video:

https://www.bitchute.com/video/gvu4NbieSuVb/



A finales de abril de 2023, me sentí honrada de ser invitado para una entrevista con la encantadora y muy talentosa **Kate Sugak**, naturópata, cineasta, profesora. Aquí está la

entrevista en inglés, y otra versión apodada en ruso. Kate añadió muchas diapositivas al video para ilustrar de lo que estábamos hablando.

Español:

https://odysee.com/-katie.su:7/theofficialevidencethatvirusesnotexist:7 Ruso:

https://odysee.com/-katie.su:7/christinemasseykatesugakrussian:3



28 de abril de 2023: Hablé con mi buen amigo y increíble reportero de investigación / presentador de radio **Eric Francis Coppolino** (nuestro amigo <u>Jeffrey Strahl</u> también tuvo una fascinante discusión con Eric durante el mismo programa): https://planetwaves.fm/health-freedom-movement-sells-out-cheap-to-rfk-jr-the-alleged-alien-threat-is-about-about-power/



Christine Massey sobre la perspectiva con Jesse Zurawell 13 de abril de 2023 https://tntradiolive.podbean.com/e/christine-massey-on-perspective-with-jesse-zurawell-13-april-2023/



Curtis Costo: Sin censura - Entrevista con Christine Massey COVID.....

.....https://curtiscost.substack.
Mejor audio, aquí:https://www.bitchute.com/video/XGFuuJNjHofB/



Christine Massey **en Perspective con Jesse Zurawell** - registrado el 15 de marzo de 2023:

 $\underline{\text{https://tntradiolive.podbean.com/e/christine-massey-on-perspective-with-jesse-zurawell-16-march-2023/}$



Mi 9 de marzo de 2023 con **Ab en Fkeólogo**, después de Tim Truth, a partir de 33:35 (disculpas por la bomba f):


 $\underline{https://fakeotube.com/video/5780/thu-mar-9-2023-fak686-timtruth-christine-massey-and-frank}$



9 de marzo de 2023: Mi entrevista con **Jeremy Nell de Germ Warfare**. https://jermwarfare.com/conversations/christine-massey-on-sars-cov-2-virus-isolation

TNT RADIO

Christine Massey on (SARS-CoV-2) virus isolation



8 de marzo de 2023: Mi entrevista con **Patrick Timpone** <a href="https://oneradionetwork.com/all-shows/christine-massey-freedom-of-information-requests-to-agencies-aking-to-see-the-virus-results-yield-nothing-march-8-2023/https://www.bitchute.com/video/PqrdkAhRnb1W/



7 de marzo de 2023:

Michael Wallach, director de la increíble serie de docu-serie Viral Delusion y yo hablamos con el Dr. Rima Laibow y Ralph Fucetola

https://www.brighteon.com/d8088302-1073-4deb-9e7e-26d313460bfd Viral Deimento:

http://www.theviraldelusion.com



Más tarde, en enero de 2023 (23o?):

Eric Coppolino, Michael Bryant y Christine Massey discuten sobre RFK Jr. y Childrens Health Defense's gatekeeping re virology

(Nota: este no es el mismo Michael Bryant que actuó como General de Ontario, <u>asesinó</u> a <u>Darcy Allen Sheppard</u> en un ataque de rabia en la carretera y se puso en marcha con ella) https://www.bitchute.com/embed/xmDzPAPzHR26/



Enero de 2023:

ALEC ZECK, TOM COWAN, ANDREW KAUFMAN, MARK BAILEY AND CHRISTINE MASSEY RESPOND TO (CHILDREN-S HEALTH DEFENCE - SCIENCE- ADVISOR) JJ COUEY

https://www.bitchute.com/video/JCFqG9vaEiEE/



4 de enero de 2023:

Todo lo que sabemos sobre la Virología se equivoca?

Mi entrevista con

https://rumble.com/v23wjmw-is-everything-we-know-about-virology-wrong.html



30 de diciembre de 2022:

Hablando con mi amigo, el veterano periodista de investigación Eric Coppolino, en **Planet Waves FM:**

https://planetwavesfm.substack.com/p/pwfm-daniel-giamario-shamanic-astrologer

Planet Waves FM from Chiron Return

PWFM:: Daniel Giamario, shamanic astrologer; Christine Massey, shamanic letter writer

The new program is posted. My quests are astrologer Daniel Giamario and statistician Christine Massey. The program is always free to everyone — no login required, back shows available.








3 de noviembre de 2022:

Mi entrevista con Jimuphy Masters de Illuision planificada

(Nota: Cometí un error durante esta entrevista, al referirme al Dr. Kevin McKernan cuando en realidad estaba hablando de Kevin McCairn (un supuesto científico con un doctorado).

https://www.plannedillusion.com/news-weekly/episode84



8 de septiembre de 2022, con Regis Tremblay: https://www.bitchute.com/video/OKkhJIRGwkss/

El Dr. Kevin Corbett, el Dr. Mark Bailey y yo pasamos 2 horas revisando la naturaleza anticientífica de la virología y el Dr. Dolores Cahill en su programa de radio 9 de julio de 2022.:

Parte 1: https://tntradiolive.podbean.com/e/christine-massey-dr-kevin-corbett-dr-mark-bailey-part-1-on-dolores-cahill-show-09-july-2022/

Parte 2:



TNTRADIOLIVE.PODBEAN.COM

Christine Massey, Dr Kevin Corbett & Dr Mark Bailey (Part 2) on Dolores Cahill Show - 09 July 2022 | TNT Radio

Descubriendo la Virología a través de FOI con Christine Massey

V de julio de 2022, por El podcast de la resistencia colectiva con Leo y Fabiola Audio aquí:

https://thecollectiveresistance.podbean.com/e/uncovering-virology-through-foi-with-christine-massey/

Video: https://rumble.com/v1b78cr-tcr-tcrp-episode-57-uncovering-virology-through-foi-with-christine-massey.html



Mi entrevista con Frances Marc Gray de CoronaX-Files: se pueden encontrar los registros de aislamiento CV19?

(algún de mis colegas piensan que esta es una de mis mejores entrevistas)

(Los subtítulos franceses se añadirán eventualmente): https://odysee.com/-

FREEDOMUFOS:8/Christine-Massey-on-DTV-05-05-2022:3

https://www.bitchute.com/video/HDRYo0P0LOFB/

 $\underline{https://rumble.com/v144m25\text{-}christine\text{-}massey\text{-}can\text{-}cv19\text{-}isolation\text{-}records\text{-}be\text{-}founds\text{-}}{coronax\text{-}files.html}$

https://crowdbunker.com/v/EqWrLGafFt

2 **de** febrero de 2022:

Entrevista del 21 de enero de 2022 con Maggie de <u>People for Justice</u> <u>https://peopleforjusticecanada.com/</u>



20 de enero de 2022:

Discutando el arresto ilegal de esta mujer de carne y sangre con el profesor de common law **Christopher James** de <u>A Warrior Calls</u>:

19 de enero de 2022:

Mi primera entrevista con la encantadora **Ramola D**.: https://www.bitchute.com/video/gLxaibKhNWFc/



6 de enero de 2022:

Esta fue mi primera conversación con mi gran héroe e inspiración, **Dr. Tom Cowan**. **Conversaciones con el Dr. EP de Cowan & Friends 44: Christine Massey** https://www.bitchute.com/video/fBN2S8mR6ipP/



Mi entrevista con **Mike Adams - el Ranger de la Salud** de <u>NaturalNews</u> y fundador de <u>Brighteon.com</u>:

https://www.brighteon.com/cdf766f0-15a2-4502-911c-946e6c6dd



Video: Jueves 26 de agosto de 2021: **Mi entrevista con el profesor de common law** Christopher James de <u>A Warrior Calls</u> https://www.bitchute.com/video/u0Y75lQGlPvo/



Video: 20 de octubre de 2021: **Christine Massey y <u>Dr. Kevin Corbett</u> discute la prueba que falta de la existencia de la existencia de .SARS-CoV-2:** https://rumble.com/vo1evl-where-is-the-evidence-for-the-existence-of-sars-cov-2-covid-virus.html



Audio: 1 de octubre de 2021: La Caza Mundial para SARS-CoV-2: Christine Massey Entrevista sobre sus respuestas a la Ley de Libertad de Información . Eric F. Coppolino de Planet Waves FM:

https://planetwaves.fm/worldwide-hunt-for-sars-cov-2/

The Worldwide Hunt for SARS-CoV-2: Christine Massey Interview about her Freedom of Information Law responses

ERIC FRANCIS / JANUARY 15, 2022 / NEW PROGRAM, PACIFICA / 3 COMMENTS

Originally published Oct. 1, 2021

<u>Visit Covid19 News - Daily since March 3, 2020</u>

describe the isolation of the [alleged] genetic variant of the [causes [the alleged disease reterred to as] COVID-19 [alleged] Kingdom, directly from a sample taken from a diseased patient was not first combined with any other source of genetic materials are cells; fetal bovine serum).

Please note that I am using "isolation" in the every-day sense separating a thing(s) from everything else. I am not requestin refers instead to:



Octubre 2021: Dr. Bill Smith y yo nos unímos a Brian Lupo de Cann Con Community para discutir el tema de aislamiento/purificación, y las inyecciones de Covid:

 $\frac{https://canncon.locals.com/post/1203533/some-incredible-information-on-covid-and-the-vaccines$



20 de agosto de 2021: **Atlantic Underground con los invitados Patrick King y Christine Massey**

 $\frac{https://odysee.com/AtlanticUndergroundPodcast:6/Atlantic-Undeerground-Podcast-Episode-64-zoom-0:9}{Episode-64-zoom-0:9}$



10 de Agosto de 2021: **ES EL EXISTO VIRUS? HAS SARS-COV-2 BEEN ISOLATED?** Con el profesor Michel Chossudovsky de **Global Research** (y **aquí está** con subtítulos holandeses)

En abril de 2021 hice una breve entrevista improvisada con <u>Lockdown Radio</u>, en una protesta en mi nueva ciudad natal de Peterborough Ontario (7 minutos, sólo audio): https://www.youtube.com/watch?v=FHi1pofmCkO

A principios de diciembre de 2020, Kevin J. Johnston me invitó a discutir los documentos del FOI en su podcast semanal:

https://www.bitchute.com/video/ruvRPMZtSCTI/



El 28 de noviembre de 2020 di un discurso en <u>la</u> protesta antibloqueo de <u>The Line</u> Canada; comienza en la marca de 19 minutos en este video:

El 26 de noviembre de 2020 en una protesta en Toronto, se me dio una oportunidad para lanzar **un mensaje al gobierno canadiense que les entregara el mensaje de la mano de la Comisión de** Medios **de** Comunicación. Disfrúta: https://www.youtube.com/watch?v=5k-iWZTvB-U

Un amigo ha estado reuniendo todas mis entrevistas de audio/vídeo y un espejo de este sitio web (un trabajo en curso) aquí: http://TinyURL.com/BHChristineMasseyArchive

Si desea recibir actualizaciones por correo electrónico de las nuevas respuestas de la FOI, házmelo saber en christinem.fluoridefreepeel.ca o cmssyc.gmail.com o inscríbase en mi boletín gratuito Substack: https://christinemasseyfois.substack.com/.

Twitter me ha prohibido. Así que conéctate conmigo en FB:

Why Many Don't Buy the Theory That Viruses CAUSE Disease

The problem is with HOW virologists do lab work...

- Virologists take samples of stuff (like snot) from a sick patient. Then...
- They add it to monkey, cow or even aborted baby cells. Then...
- They starve and poison the cell mixture. Then...
- They see cells dying and take still life photos with an electron microscope and conclude that a virus killed the cells. The problem?

They (1) **ASSUME** that there were viruses in the patients' sample and (2) they **BELIEVE** that the virus (which they only assume was there) CAUSES the cells to die.

In reality, the infected cells and tissues die BECAUSE they were starved and poisoned by the virologists themselves because of the method they used to do the experiment in their lab.

"The death of the tissue and cells takes place in the exact same manner when no "infected" genetic material is added at all. Virologists have apparently not noticed this fact." 1- Stefan Lanka

1. https://thefreedomarticles.com/dr-stefan-lanka-2020-article-reveals-virus-misconception/

David Icke resume la virología tan perfectamente, en 11 minutos: https://www.facebook.com/dualsport/videos/702133147838709



La fascinante nueva serie documental, **The Viral Delusion** del cineasta de Hollywood Mike Wallach, es gratuita por un tiempo limitado y cuenta con el creciente grupo de médicos y científicos desmantelando la ilusión de la teoría del virus para entender las causas reales de la enfermedad, desde La Gran Plaga a Polio, el SIDA hasta el COVID.

Ahora puedes ver **Episodio On** e de forma gratuita, haciendo clic **AQUI**



Absolutamente increíble e increíblemente importante Dr. Sam Bailey. Inmundamente importante y bellamente hecho. John Bevin-Smith. - Increíble. Debería traducirse a todos los idiomas del mundo. Vinnie Costa.

Cualquiera puede entender los problemas con la virología, esto no es ciencia de cohetes. Sin embargo, para que conste en caso de que alguien quiera saber, mis títulos se muestran a continuación.

Honours BA de la Universidad de Toronto, 11 de junio de 2007 (le hice un especialista en sociología y una especialidad en estadísticas):



Y a continuación se encuentra mi maestría en bioestadística, de la Escuela de Salud Pública Dalla Lana, Universidad de Toronto, 13 de noviembre de 2008:



Me prohibieron en Twitter en el verano de 2021, pero se me puede encontrar en Facebook:

https://www.facebook.com/profile.php?id=100084768107639